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Abstract 
 
This study presents evidence supporting heparan sulfate proteoglycans (HSPGs) as 
novel markers and key mediators of human neural stem cell (hNSC) maintenance 
and lineage specification. NSCs are multipotent cells of the central nervous system 
(CNS) capable of self-renewal and differentiation toward neurons and glial cells 
(astrocytes and oligodendrocytes). NSCs can be isolated from the brain or derived 
from pluripotent stem cells, including embryonic stem cells (ESCs). Due to their 
self-renewing and multipotent differentiation properties, NSCs provide an excellent 
model to study neurogenesis and gliogenesis in vitro and they have therapeutic 
potential in cell transplantation based treatments of brain injury. However, the use of 
NSCs, specifically human NSCs, is challenged by limitations associated with their 
expansion potential, lineage differentiation control and transplantation efficiency, 
thus a better understanding of how these cells are regulated is crucial to improve 
their use in downstream applications.   
 
The NSC microenvironment, also termed the “niche”, regulates NSC behaviour, 
including self-renewal and differentiation. The niche is composed of surrounding 
cells, extracellular signalling molecules and the extracellular matrix (ECM). Major 
constituents of the ECM include proteoglycans (PGs), composed of a core protein to 
which one or more sulfated glycosaminoglycan (GAG) side chains attach at specific 
sites. One superfamily of PGs is formed by the HSPGs, which includes the syndecan 
(SDC) and glypican (GPC) family members. HSPGs carry sulfated HS GAG side 
chains, through which HSPGs bind and mediate the activity of a wide variety of 
extracellular signalling molecules, including growth factors. Many of the signalling 
molecules bound by HSPGs regulate NSC behaviour and are ubiquitously expressed 
in the CNS, suggesting HSPGs are likely key mediators of NSC fate. With HSPGs 
likely having central roles within the neural niche, this study aimed to identify key 
HSPGs mediating self-renewing hNSCs and lineage-committed neural cells (neurons 
and glia) during hNSC lineage specificity. In addition, with HS-growth factor 
interactions occurring in the extracellular space, this study examined the potential to 
exploit these interactions for enhanced hNSC lineage commitment. As a model of 
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self-renewing and multipotent hNSCs, human embryonic stem cell-derived NSCs 
(hNSC H9 cells) were utilised in this study.  
 
Self-renewal and multi-lineage potential of hNSC H9 cells was examined during 
long-term (approximately 100 days) in vitro expansion through examination of 
expression of self-renewal and multilineage (neuron, astrocyte and oligodendrocyte) 
markers as well as HSPG pathway members. Results demonstrated that during 
extended basal expansion hNSC H9 cells maintained self-renewal and multilineage 
potential. In addition, hNSC H9 cultures expressed HS biosynthesis enzymes 
indicative of active HS production and modification. Several HSPG core protein 
SDCs and GPCs were shown to be expressed in hNSC H9 cells at a high level with 
altered expression observed during extended culture. When comparing the HSPG 
profile of hNSC H9 cells to the more lineage-restricted human neural progenitor cells 
(hNPCs) significant differences between the two cell types were observed. In 
particular, a variety of HS chain modulatory enzymes as well as a number of HSPG 
core proteins demonstrated upregulated expression in the more lineage-restricted 
hNPCs when compared to hNSC H9 cells. This data suggests an important role for 
HSPGs and HS chain modifications during neural lineage specification.  
 
hNSC H9 cells were then examined during neuronal and astrocyte differentiating 
culture conditions in 14-18 day and 40 day cultures. hNSC H9 cells exhibited high 
neuronal differentiation potential in both cultures, with significantly upregulated 
expression of neuronal lineage markers when compared to basal hNSC H9 cells. 
Neuronal lineage differentiation significantly increased the expression of multiple 
HS side chain modification enzymes, suggesting increased HS modification during 
neuronal differentiation. Neuronal differentiation of hNSC H9 cells continued for 40 
days specifically upregulated the expression of SDC1, SDC3, SDC4, GPC1, GPC3, 
GPC4 and GPC6. Astrocyte differentiation of hNSC H9 cells was achieved at a 
lower efficiency, however, day 40 astrocyte differentiation cultures demonstrated 
enhanced astrocyte lineage specificity, indicated by upregulated astrocyte marker 
expression when compared to basal hNSC H9 cells. Fewer changes were observed in 
the hNSC H9 cell HSPG profile following astrocyte lineage differentiation, however, 
GPC4 demonstrated high astrocyte lineage specificity. When the expression of GPC1 
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and GPC4 was downregulated in basal hNSC H9 cells using RNA-interference 
(RNAi) an altered neuronal and glial lineage potential was observed. Interestingly, 
HSPG expression changes in hNSC H9 cells following neural lineage commitment 
correlated with the observed differences between the HSPG profile of hNSC H9 cells 
and hNPCs further supporting the key roles of HSPGs and HS chain modifications 
during hNSC lineage commitment. In addition, these results also proposed several 
HSPGs as novel markers of hNSCs and neural lineage cell characterisation. 
 
The effect of HS and key growth factor interactions on hNSC lineage commitment 
was explored during enhanced lineage differentiation. Day 40 day neuronal and 
astrocyte differentiation cultures were modulated with exogenous HS in the form of 
heparin along with key HS-binding neuroregulatory growth factors. Brain-derived 
neurotrophic factor (BDNF) was added to neuronal differentiating cultures with 
platelet-derived growth factor (PDGF) added to astrocyte differentiation cultures. 
Morphological changes along with lineage marker and HSPG profiles were 
examined to determine if these in vitro modulations influenced lineage specificity 
and culture heterogeneity. Changes in marker and HSPG expression following 
heparin and growth factor modulated neuronal and astrocyte cultures indicated cell 
responsiveness to the altered microenvironment. In addition, heparin in combination 
with BDNF or PDGF further induced these effects, suggesting cooperation between 
these growth factor signalling pathways during human neurogenesis. 
 
To identify potential mechanisms of HSPG-mediated control of human neurogenesis, 
hNSC H9 cells were cultured under neuronal differentiating conditions in the 
presence of heparin, BDNF, PDGF and the combination BDNF+PDGF, with growth 
factor conditions also co-stimulated with heparin. The effect of the treatments on 
neuronal lineage specificity were monitored via differences in cell morphology, 
viability, proliferation, neuronal lineage marker expression along with functional 
characteristics of the cultures following 40 and 60 days of culture when compared to 
untreated neuronal cultures. The addition of heparin and BDNF stimulated cell 
viability and proliferation with the combination of heparin and BDNF enhancing the 
effects observed with BDNF. Treatment of neuronal cultures with PDGF maintained 
neuronal lineage specificity and induced spontaneous calcium signals in cells when 
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compared to untreated neuronal cultures, indicative of modulated neuronal 
functionality. With BDNF and PDGF eliciting specific effects on hNSC neuronal 
lineage specificity, the potential roles of HSPGs GPC1 and GPC4 in mediating 
BDNF and PDGF signalling during hNSC neuronal lineage commitment was 
examined. Localised expression within hNSC H9-derived neuronal cultures 
following 40 and 60 days of culture was observed for GPC1 and GPC4 along with 
the BDNF and PDGF receptors Trkb and PDGFRβ. Downregulation of GPC1 and 
GPC4 gene expression in hNSC H9 cells during neuronal differentiation utilising 
RNAi demonstrated an altered ability of the cells to respond to BDNF and PDGF. 
The altered response of the cells was demonstrated by decreased neuronal marker 
expression, suggesting GPC1 and GPC4 may be regulators of BDNF/PDGF-
mediated hNSC lineage commitment.  
 
The results of this project demonstrate that hNSC H9 cells provide an excellent in 
vitro model of self-renewing and multipotent NSCs. In addition, HSPGs function as 
novel markers of basal hNSCs and lineage-specific neural cells with these cell types 
distinguishable from each other based on their marker and HSPG profiles. This study 
demonstrated modulation of hNSC H9 neuronal differentiation through exogenous 
HS in the form of heparin and key neuroregulatory signalling molecules, including 
BDNF and PDGF with the effects of BDNF enhanced by heparin. BDNF and PDGF 
with and without heparin supplementation had positive effects on neuronal survival 
and lineage specificity, respectively, with the sequential administration of these 
growth factors likely beneficial for optimal neurogenesis. The results of this study 
demonstrate that GPC1 and GPC4 are human neuronal proteins expressed along the 
neurites and cell bodies of developing human neurons with both HSPGs 
demonstrating an associative relationship with neuronal lineage markers, and are 
likely required for neuronal differentiation of hNSCs, potentially mediating BDNF 
and PDGF signalling efficacy. The findings of this study provide an improved 
understanding human neural cell regulation with this knowledge of benefit to the 
field of human stem cell research and our understanding of human neurogenesis for 
use in downstream applications.  
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Chapter 1: Introduction 
 
1.1 INTRODUCTION 
 
Neural stem cells (NSCs) are multipotent stem cells of the central nervous system 
(CNS) capable of differentiating into neurons and glial cells: astrocytes and 
oligodendrocytes. Due to their multipotent neuronal differentiation capacity, NSCs 
have an important role in the regeneration of the brain and these cells also provide a 
model to investigate the processes of neurogenesis and gliogenesis in vitro. However, 
our understanding of human NSC (hNSC) function is limited, hindering the efficient 
use of these cells in downstream applications.  
 
NSC behaviour, including maintenance of self-renewal as well as lineage-specific 
differentiation is largely regulated by the NSC microenvironment or the “niche”, in 
which NSCs reside. Proteoglycans (PGs) are ubiquitous components of the neural 
niche localising either to the extracellular matrix (ECM) or to the cell membrane. 
PGs consist of several superfamilies with one being the heparan sulfate 
proteoglycans (HSPGs), consisting of a core protein and attached heparan sulfate 
(HS) side chains. HSPGs have multiple regulatory roles in various cellular functions, 
including proliferation, migration and differentiation. HSPGs are also known to be 
important in mediating the activity of numerous extracellular signalling molecules, 
including growth factors and morphogens.  Furthermore, HSPGs are expressed in the 
CNS and several roles for HS and HSPGs in neural cell function has been reported.  
 
As such HSPGs likely have importance in NSC regulation, however, our 
understanding of the roles of HSPGs in hNSCs is largely unknown and reliant upon 
rodent studies, despite the known differences in NSC function and brain structure 
between these models. Identification of key HSPGs regulating hNSC function would 
provide novel markers for improved isolation or characterisation of the cells or 
targets for better control of hNSC fate. This study aimed to investigate the roles of 
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HSPGs in the maintenance and lineage specification of hNSCs to elucidate the 
mechanisms behind HSPG-mediated regulation of hNSC lineage commitment.  The 
results of this study are the first to propose HSPGs as novel markers of hNSCs and 
human lineage-specific neural cells. In addition, this study demonstrates the potential 
to mediate hNSC lineage fate through HS and key HS-binding growth factors for 
enhanced lineage specificity.  
 
1.2 THESIS OUTLINE 
 
This Thesis is comprised of eight Chapters, which are followed by a Bibliography 
and Appendices. Following this Chapter (Chapter 1: Introduction), the Thesis outline 
is as follows: 
 
Chapter 2: Literature Review. This Chapter provides a thorough review of the current 
literature encompassing NSC biology, HSPGs and the potential to use NSCs as cell 
therapy.  In this Chapter nervous system biology, including neural cell types, key 
neuroregulatory signalling pathways and the NSC niche is discussed. An introduction 
to HSPGs and their known roles in the CNS will is also described. The Literature 
Review will also discuss the potential to use NSCs as therapy in brain damage 
treatment and the potential to use HSPGs as novel markers or targets for enhanced 
use of NSCs as therapy. At the end of Chapter 2 the Hypothesis, Aims and Research 
Design will be presented. An important focus of the Literature Review is the 
comparison of the similarities and differences between human and rodent NSC 
models, published as a review article as outlined below: 
 
Oikari LE, Griffiths LR, Haupt LM (2014) The current state of play in human 
neural stem cell models – what we have learnt from the rodent. OA Stem Cells Apr 
08;2(1):7. 
 
Chapter 3: Materials and Methods. This Chapter describes the cell types and 
methodologies used throughout the study. The basal expansion and differentiation 
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protocols of the cell types are described along with a description of in vitro 
modulations of cell culture conditions. The methodologies used for RNA and protein 
expression studies and microscopy techniques are then described along with the 
protocol for the detection of calcium signals in neuronal differentiating cultures. The 
final section of Chapter 3 explains the statistical analysis of results as well as ethic 
requirements and resources of the study.  
 
This Thesis consists of four Results Chapters (Chapter 4, Chapter 5, Chapter 6 and 
Chapter 7). These Chapters are structured as research publications. Each Chapter 
consists of a brief overview, followed by an Introduction, description of Methods, 
Results, a Discussion and a Summary. The outline of the Results Chapters is as 
follows: 
 
Chapter 4: Characterisation of HSPGs during human neural stem cell expansion. 
This Chapter examined HSPGs in basal hNSCs during long-term expansion.  During 
expansion expression of markers defining pluripotency, NSC self-renewal and neural 
lineages (neuron, astrocyte and oligodendrocyte) were examined in hNSCs. 
Following confirmation of self-renewal and multipotency, expression of HSPG 
biosynthesis enzymes and core proteins were examined to identify potential key 
HSPGs of hNSC maintenance in hNSCs cultures. The expression profile of hNSCs 
was then compared to more lineage-restricted human neural progenitor cells (hNPCs) 
to identify potential key HSPGs of lineage specificity. The results of this chapter 
have been published in Stem Cell Research and in the supplementary data journal 
Data in Brief as follows: 
 
Oikari LE, Okolicsanyi RK, Qin A, Yu C, Griffiths LR, Haupt LM (2016) Cell 
surface heparan sulfate proteoglycans as novel markers of human neural stem cell 
fate determination. Stem Cell Research Jan;16(1): 92 – 104.  
 
Oikari LE, Okolicsanyi RK, Griffiths LR, Haupt LM (2016) Data defining markers 
of human neural stem cell lineage potential. Data Brief Feb 19;7:206-215. 
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Chapter 5: HSPGs during human neural stem cell lineage commitment.  In this 
Chapter hNSCs were examined during lineage-specific differentiation culture 
conditions to identify key markers and HSPGs associated with lineage specificity. 
This Chapter encompasses results following 14 to 18 days of neuronal and astrocyte 
differentiation of hNSCs and the results of this Chapter identified markers and 
HSPGs associated with neuronal and astrocyte lineage specification. The results of 
this Chapter have been published in Stem Cell Research.  
 
Oikari LE, Okolicsanyi RK, Qin A, Yu C, Griffiths LR, Haupt LM (2016) Cell 
surface heparan sulfate proteoglycans as novel markers of human neural stem cell 
fate determination. Stem Cell Research Jan;16(1): 92 – 104. 
 
Chapter 6: Heparan sulfate-mediated lineage specification of human neural stem 
cells. Following examination of hNSCs during neuronal and astrocyte differentiating 
culture conditions in Chapter 5, the differentiation time of the cells was extended to 
40 days to enhance lineage specification of the cells. Following the establishment of 
day 40 differentiation cultures, the neuronal and astrocyte cultures were examined 
for changes in their marker and HSPG profile similar to Chapter 5. With the 
confirmation that extended differentiation time enhanced lineage specificity, hNSCs 
were then examined in the presence of exogenous HS (heparin) and key HS-binding 
growth factors (BDNF and PDGF) to assess the effect of these treatments on lineage 
specification. With these treatments altering lineage-specific marker expression and 
the HSPG profile of the cells, it was concluded that hNSCs respond to exogenous HS 
and growth factors, which have the potential to be exploited to modulate hNSC 
differentiation. 
 
Chapter 7: Unravelling mechanisms of HSPG-mediated control of human 
neurogenesis.  In the final results Chapter, the potential roles of HSPGs in mediating 
human neurogenesis were examined. In the first part of this Chapter (Part A) hNSCs 
were examined under neuronal differentiating culture conditions for 40 to 60 days 
during HS, BDNF, PDGF and BDNF+PDGF modulatory culture conditions with or 
without heparin co-stimulation. The effects of these treatments on cell morphology, 
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cell viability, cell proliferation and neural lineage specificity along with functional 
characteristics of the cultures was examined. The results demonstrated that heparin 
and BDNF promoted cell survival and proliferation with heparin in combination with 
BDNF further stimulating the effects of BDNF alone. PDGF supplementation with or 
without heparin appeared to stimulate neuronal lineage specificity and promoted the 
generation of spontaneous calcium spikes within the cultures, indicative of neuronal 
functionality. In the second part of this Chapter (Part B), the potential roles of GPC1 
and GPC4 as mediators of hNSC neuronal lineage commitment were investigated. 
GPC1 and GPC4 were identified previously in this study (Chapters 4 to 6) to be key 
markers of lineage-specific neural cells. The neuronal differentiating hNSC H9 
cultures examined in Part A were first examined for the expression of GPC1 and 
GPC4 along with BDNF and PDGF receptors, Trkb and PDGFRβ, respectively.  To 
investigate if GPC1 or GPC4 play a role in mediating BDNF and PDGF signalling, 
GPC1 and GPC4 gene expression was downregulated in hNSC H9 cells using RNAi 
and following downregulation the response of the cells to BDNF and PDGF 
examined. In addition, Trkb and PDGFRβ specific inhibitors were used to examine 
any correlations between the GPC1 and GPC4 downregulated cultures. This Chapter 
demonstrated that GPC1 and GPC4 along with Trkb and PDGFRβ are expressed 
within differentiating human neurons, suggesting they are proteins of neuronal 
specification. The downregulation of GPC1 and GPC4 expression resulted in an 
altered response to BDNF and PDGF, suggesting GPC1/4 may be involved in 
modulating the activity of these pathways during hNSC neuronal differentiation.  
 
Chapter 8: Discussion.  
The Discussion Chapter discusses the key findings and implications of this study in 
the context of previous and recent studies in the literature. At the end of the 
Discussion Chapter, suggested Future Directions emerging from this study along 
with a Summary of the impact of the key findings from this study is presented. 
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Bibliography and Appendices.  
Following the main Chapters of this Thesis, the Bibliography of scientific 
publications/web pages etc. cited in this study is presented. This Thesis ends in a list 
of Appendices, which are as follows:  
Appendix A: Cell culture media recipes 
Appendix B: RNA Extraction and in-column DNase treatment protocol 
Appendix C: Primer sequences 
Appendix D: Western blotting buffers and assay protocol 
Appendix E: Immunofluorescence and confocal microscopy protocol and negative 
controls 
Appendix F: Fluo-4 calcium assay protocol 
Appendix G: Phase-contrast images of hNSC H9 neuronal differentiating cultures 
Appendix H: USB Drive containing digital attachments  
 
1.3 SIGNIFICANCE OF STUDY 
 
Due to their multi-lineage differentiation ability, NSCs provide an excellent in vitro 
model for neurogenesis research and they hold tremendous potential in the 
regenerative treatment of brain damage. NSC research is, however, limited by 
challenges associated with cell characterisation, expansion and lineage fate control. 
The transplantation efficiency of NSCs is challenged by poor survival, integration 
and differentiation of transplanted cells. Thus, a better understanding of how NSC 
self-renewal and differentiation is regulated is crucial to enable the improved use of 
these cells for various applications. The extracellular microenvironment, or niche, is 
known to be important in regulating NSC lineage fate decisions. HSPGs are 
ubiquitous proteins of the ECM bound to the cell surface with roles for several 
HSPGs in NSC regulation and within the CNS reported. HSPGs also interact with a 
large number of extracellular signalling molecules, many of which mediate NSC 
maintenance or differentiation. This suggests that HSPGs are key regulatory proteins 
of NSCs, however, their roles in NSCs have to date, not been extensively studied. 
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With much of the NSC research conducted to date performed in model organisms, 
including the mouse or rat, there is a crucial need to improve our understanding of 
the human NSC (hNSC) model.  This study has aimed to identify key HSPGs of 
hNSC regulation and explore the potential roles of HSPGs in meditating hNSC self-
renewal or lineage differentiation. The results presented in this Thesis propose 
several HSPGs as novel markers of hNSCs and lineage-specific neural cells and 
suggest that HSPGs may have potential roles in mediating hNSC self-renewal and 
lineage fate decisions. In addition, the results of this Thesis demonstrate the ability to 
mediate hNSC neural differentiation through exogenous HS and key HS-binding 
growth factors to influence neural lineage specification of the cells. The results of 
this study contribute to our understanding of nervous system biology and 
specifically, to how hNSCs are regulated. Importantly, the findings of this research 
have potential to be applied to other human stem cell types with neuronal 
differentiation potential to enable the development of stem cell based applications for 
the treatment of brain damage.  
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Chapter 2: Literature Review 
 
This Chapter begins with an introduction to neural stem cells (section 2.1), followed 
by literature reviews on neurogenesis (section 2.2) and neural stem cell expansion 
and derivation (section 2.3). Important signalling mechanisms regulating neural stem 
cell function (section 2.4) and the properties of the neural stem cell niche (section 5) 
will then be discussed. Following this, an introduction to proteoglycans will be given 
(section 2.6) focussing specifically on heparan sulfate proteoglycans (HSPGs) and 
the known roles of HSPGs in the central nervous system (CNS) (section 2.7). 
Advances in stem cell therapy for brain damage treatment will be reviewed  (section 
2.8) combined with a discussion of the potential of proteoglycans as a target for 
neural stem cell based brain damage treatment (section 2.8.4). Following review of 
the literature, the hypothesis (section 2.10), aims (2.11) and research design (section 
2.12) of this study will be presented. This chapter has been published in part in OA 
Stem Cells: 
 
Oikari LE, Griffiths LR, Haupt LM (2014) The current state of play in human 
neural stem cell models – what we have learnt from the rodent. OA Stem Cells Apr 
08;2(1):7. 
 
2.1 NEURAL STEM CELLS 
 
2.1.1 Stem cell classification 
 
Stem cells are undifferentiated cells, which have the capacity to self-renew and 
differentiate into specialised cell types (Fuchs & Chen, 2013). According to their 
ability to generate different tissue types, stem cells are classified into distinct groups. 
Embryonic stem cells (ESCs) derived from the inner cell mass of a developing 
blastocyst are pluripotent, capable of differentiating into any of the three embryonic 
layers, the endoderm, mesoderm or ectoderm, and thus create all tissues in the body 
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(Thomson et al., 1998; Trounson, 2006). A central characteristic of ESCs is their 
capacity for unlimited proliferation in vitro in an undifferentiated state, which is 
reflected by high telomerase expression when detected using a Telomeric Repeat 
Amplification Protocol - assay (Thomson et al., 1998). In contrast, adult stem cells 
are multipotent with the ability to differentiate into a limited number of cell types. 
Adult stem cells reside in specific tissues, where they generate tissue-specific cells, 
thus being responsible for the regeneration of various tissues, such as the 
hematopoietic system, skin and neural tissue (Calvi & Link, 2015; Gregoire et al., 
2015; Ojeh et al., 2015). Generally it is considered that stem cells give rise to 
progenitor cells, which have a restricted proliferation, self-renewal and 
differentiation capacity, often giving rise to only a single cell lineage (Fuchs & Chen, 
2013; Homem et al., 2015; Seaberg & van der Kooy, 2003). The life-long self-
renewal ability harboured by stem cells versus the restricted self-renewal ability 
exhibited by progenitor cells is a central characteristic distinguishing these cell types 
from each other (Fuchs & Chen, 2013). 
 
2.1.2 Neural stem cell characterisation 
 
Neural stem cells (NSCs) are multipotent stem cells of the central nervous system 
(CNS) that have the ability through asymmetric division to generate neurons and 
glial cells, including astrocytes and oligodendrocytes (Gage, 2000). During 
development NSCs arise from neuroepithelial (NEP) cells, which are formed from 
the neuroectoderm and throughout life NSCs are maintained in the brain where they 
are localised in specific niches, including the subventricular zone (SVZ) and the 
subgranular zone (SGZ) (Alvarez-Buylla & Lim, 2004; Decimo et al., 2012). The 
SVZ and SGZ NSCs are derived from radial glial cells (RGCs) and phenotypically 
resemble astrocytes (Codega et al., 2014; Gengatharan et al., 2016). NSCs are 
characterised by the expression of specific markers that determine intracellular, cell 
surface and behavioural characteristics. Commonly used intracellular markers for the 
identification of NSCs include nestin, vimentin, SRY-box 1 and 2 (SOX1 and SOX2) 
and Musashi 1 (MSI1) (Christie et al., 2013; Okano et al., 2005; Ramasamy et al., 
2013). Nestin belongs to the class VI and vimentin to the class III of intermediate 
filaments, SOX1 and SOX2 are members of the high mobility group (HMG)-box 
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family of transcription factors and MSI1 is an RNA-binding protein with all of these 
markers mediating NSC self-renewal and thus playing a role in the maintenance of 
the NSC pool (Christie et al., 2013; Ellis et al., 2004; Okano et al., 2005; Park et al., 
2010). Furthermore, due to their astrocytic characteristics NSCs in the brain have 
also been shown to express the astrocyte marker glial fibrillary acidic protein 
(GFAP) (Codega et al., 2014). Finally, the cell surface marker CD133 is also a 
common marker used for the isolation of NSCs (Corti et al., 2007). In the adult both 
quiescent and actively dividing NSCs co-exist. The importance of quiescent NSCs is 
that in contrast to their actively dividing counterparts, they can survive anti-mitotic 
drugs and irradiation. Thus the presence of quiescent NSCs is crucial for maintaining 
the regenerative potential of the CNS (Codega et al., 2014; Daynac et al., 2016). 
Quiescent NSCs are generally characterised through their long-term retention of the 
thymidine analogue bromodeoxyuridine (BrdU) with actively proliferating NSCs 
expressing the proliferation marker Ki67 (Decimo et al., 2012; Rao et al., 2006). In 
addition to identifying these markers of stemness, NSC behaviour, including self-
renewal and multi-lineage differentiation potential is also an important characteristic 
to be monitored when identifying NSCs (Ramasamy et al., 2013). NSCs give rise to 
neural progenitor cells (NPCs), which are considered to have a more restricted self-
renewing and lineage-differentiation capacity than NSCs (Seaberg & van der Kooy, 
2003). Although many NSC markers are well established, it should be noted that 
difficulties still remain e.g. in differentiating between an NSC and a more lineage-
restricted NPC (De Filippis & Binda, 2012).  
 
2.2 NEUROGENESIS 
 
Neurogenesis is the process during which neural cells, including neurons and glial 
cells are produced. Neurogenesis consists of distinct cellular behaviours, including 
cell proliferation, followed by cell migration and finally cell differentiation (Vinci 
2016). The characteristics of mammalian embryonic and adult neurogenesis are 
discussed below.  
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2.2.1 Human embryonic neurogenesis 
 
The NSCs during embryogenesis are the neuroepithelial (NEP) cells, which form the 
neural tube (Yamashita, 2013). All cells of the CNS, including neurons, astrocytes, 
oligodendrocytes and ependymal cells are produced from NEP cells (Vinci et al., 
2016). In humans the neocortex forms in the rostral end of the neural tube, with 
neural tube closing at embryonic day 30 (gestational week 5), which initiates rapid 
brain growth (Budday et al., 2015; Silbereis et al., 2016). Between gestational weeks 
4 and 5 NEP cells proliferate rapidly with gestational week 5 marking the onset of 
neurogenesis, during which RGCs in the ventricular zone switch from symmetric 
division to asymmetric division (Budday et al., 2015). The asymmetric division 
generates one RGC with the other daughter cell becoming either a postmitotic neuron 
or an intermediate progenitor, which eventually also generate pairs of postmitotic 
neurons (Budday et al., 2015; Silbereis et al., 2016). The neocortex develops and 
thickens until gestational week 18 when the six characteristic layers of the neocortex 
can be detected (Budday et al., 2015). The first half of gestation consists mainly of 
neuron production with glial cell production beginning in the second half of gestation 
when RGCs switch from generating only neurons to also generating astrocyte and 
oligodendrocyte precursors (Budday et al., 2015; Silbereis et al., 2016). 
Oligodendrocytes are continuously generated until approximately the third year of 
life with significant myelination of axons also occurring during this period (Budday 
et al., 2015; Silbereis et al., 2016). During the second half of gestation neuronal 
connectivity develops, during which axons extend and each neuron connects with 
thousands of other neurons (Budday et al., 2015; Silbereis et al., 2016). The 
formation of synaptic connections, also known as synaptogenesis, begins around 
gestational week 27, but occurs mainly after birth (Budday et al., 2015). While the 
number of neurons does not increase after birth, axonal myelination and formation of 
new synaptic connections are characteristics of postnatal brain growth (Budday et al., 
2015; Silbereis et al., 2016). 
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2.2.2 Adult neurogenesis 
 
Adult neurogenesis is a relatively recently accepted occurrence with neurogenesis 
previously thought to be confined only to the developing brain and ceasing after 
birth. Much of our understanding of the biology of neurogenesis has relied on studies 
in rodent models, which have enabled adult neurogenesis research.  The initial 
ground breaking work on adult neurogenesis done by Altman & Das in the 1960s 
demonstrated the presence of neurogenesis in the postnatal rat brain (Altman & Das, 
1965) (Fig. 2-1). This work was initially controversial until further work by Kaplan 
and colleagues in the 1970s and 1980s demonstrated that new neurons were indeed 
produced in the adult rat and mouse brain, confirming the findings of Altman and 
Das (Kaplan & Bell, 1984; Kaplan & Hinds, 1977) (Fig. 2-1). Following this, after 
elaborate research into adult neurogenesis in rodents, a breakthrough in 
understanding human neurogenesis occurred in the late 1990s, when Eriksson and 
colleagues demonstrated the presence of dividing and differentiating cells in the adult 
human brain. Neurogenesis was detected in a 72-year-old subject, demonstrating the 
persistence of neurogenesis throughout life and giving new understanding of nervous 
system biology (Eriksson et al., 1998) (Fig. 2-1). In both rodent and human models 
adult neurogenesis is now commonly accepted and the biology of adult rodent 
neurogenesis is well understood. Adult neurogenesis is confined to areas where 
NSCs reside, including the SVZ lining the walls of the lateral ventricles and the SGZ 
of the dentate gyrus (DG) in the hippocampus (Eriksson et al., 1998; Sanai et al., 
2004). NSCs give rise to lineage-restricted neural and glial -progenitor cells that 
produce either neurons or astroglial and oligodendroglial cells, respectively (Okano, 
2002). The significant milestones in neurogenesis research are summarised in Figure 
2-1.  
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Figure 2-1: A timeline illustrating advances in rodent and human adult neurogenesis and neural 
stem cell research. Rodent model systems (rat and mouse) have provided significant advances in 
adult neurogenesis research as well as in the identification, isolation and propagation of NSCs 
enabling the identification and use of human NSC models. The timeline demonstrates and compares 
the advances between rodent and human adult neurogenesis research along with the development of 
models of NSC isolation and expansion. Figure adapted from Oikari et al. 2014 (Oikari et al., 2014) 
 
2.2.2.1 Adult rodent neurogenesis 
 
NSCs in the rodent SVZ and the SGZ resemble astrocytes and give rise to 
neuroblasts that migrate to their target sites where they mature into neurons and 
interestingly, NSCs from both the neurogenic niches have been shown to resemble 
astrocytes (Doetsch et al., 1999; Seri et al., 2001). The current view suggests that 
primary NSCs of the SVZ are slowly dividing RGCs that express GFAP and nestin 
(type B cells) (Ming & Song, 2011) (Fig. 2-2A). These cells give rise to rapidly 
proliferating type C cells, which in turn give rise to type A neuroblasts (Alvarez-
Buylla & Lim, 2004) (Fig 2-2A). Type A cells migrate a long distance to the 
olfactory bulb (OB) in chain formation through the rostral migratory stream (RMS), 
giving rise to OB neurons (Alvarez-Buylla & Lim, 2004; Lois et al., 1996) (Fig. 2-
2A). Type B cells also generate oligodendrocytes in the corpus callosum (Menn et 
al., 2006). As with SVZ NSCs, also SGZ NSCs are RGCs that express nestin, GFAP 
and SOX2 (Ming & Song, 2011) (Fig. 2-2B). SGZ RGCs (type I cells) in the 
hippocampus give rise to progenitor cells, which generate neuroblasts that migrate 
only locally maturing into hippocampal dentate granule cell neurons (Ming & Song, 
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2011) (Fig. 2-2B). There is also evidence of another NSC population existing in the 
SGZ. These type II cells are non-radial and express SOX2 but not GFAP and have 
self-renewal and multipotent capacities (Suh et al., 2007). However, it is not known 
whether type II cells arise from type I cells or if they represent a distinct population 
of cells (Suh et al., 2007).  
 
 
Figure 2-2: Schematic representation of rodent SVZ and SGZ neurogenesis. A) NSCs in the SVZ 
are radial glial-like (RGL) cells, also known as type B cells that express nestin and GFAP. They give 
rise to type C transient amplifying progenitor cells, which in turn give rise to type A neuroblasts. Type 
A cells migrate through the rostral migratory stream (RMS) to the olfactory bulb (OB) where they 
become OB neurons. B) NSCs of the SGZ are also radial glial-like (RGL), also known as type I cells 
that express nestin, GFAP and SOX2. Type I cells give rise to proliferating progenitor cells. 
Progenitor cells give rise to neuroblasts that mature into dentate granule cell neurons (Figure adapted 
from Ming and Song 2011 (Ming & Song, 2011)). 
 
2.2.2.2 Adult human neurogenesis 
 
Identification of the neurogenic areas in the rodent brain led to the discovery of 
neurogenic areas in the adult human CNS. Neurogenesis in the adult human 
hippocampal DG was demonstrated in the late 1990s through the detection of 
proliferating cells within this area (Eriksson et al., 1998). Comparison of the 
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expression of neurogenesis-associated markers between the human and rat 
hippocampus revealed similar characteristics in the two species, including the co-
expression of the proliferation marker BrdU along with neuronal markers calbidin 
and neuronal nuclear protein (NeuN) (Eriksson et al., 1998; Suh et al., 2007). The 
presence of proliferating cells in the adult human SVZ was demonstrated in the early 
2000s with these cells, similarly to the rodent, also resembling astrocytes (Sanai et 
al., 2004) (Fig. 2-1). The RMS that was discovered in the rodent was not initially 
identified in the human, requiring further research leading to its characterisation. It 
was then discovered that the human RMS exists, and contains migrating neuroblasts, 
but it differs structurally from the rodent RMS (Curtis et al., 2007) (Fig. 2-1). 
Continued investigations have shown that, as with the rodent RMS, neuroblasts in 
the human foetal RMS form chains, however, due to the small number of migratory 
neuroblasts in the adult RMS, no evidence of chain migration in the adult human 
RMS has been observed (Wang et al., 2011). While in the human infant SVZ (under 
6 months of age) migrating neuronal progenitors are detected, neuroblast migration 
to the adult human OB does not exist, or only exists at a minimal level (Lim & 
Alvarez-Buylla, 2016; Wang et al., 2011). Interestingly, there are an increasing 
number of reports showing that neurons arising from the SVZ are incorporated into 
the striatum in the adult human (Inta et al., 2015; Ernst et al., 2014). In contrast to 
rodents, it appears that striatal neurogenesis has more importance than OB 
neurogenesis in the adult human (Inta et al., 2016). A key element of adult human 
neurogenesis is that it vastly decreases during age and despite some similarities 
between human and rodent adult neurogenesis, the exact mechanisms regulating 
adult human neurogenesis remain largely unknown (Lim & Alvarez-Buylla, 2016). 
 
2.2.2.3 Similarities and differences in adult rodent and human neurogenesis 
 
Neurogenesis is conserved amongst mammalian species, supported by similar 
neurogenesis-associated marker expression between rodents and humans. 
Interestingly, the spatial as well as temporal expression of these markers is also 
similar between the two models (Knoth et al., 2010). A common characteristic to 
both rodent and human neurogenesis is its decrease with age, however the relative 
decrease is higher in rodents than in humans (Knoth et al., 2010; Spalding et al., 
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2013). Other reported differences between rodent and human neurogenesis include 
hippocampal neuron turnover, i.e. the number of new neurons added to the DG to 
replace missing neurons, reported to be higher in humans than in rodents (Spalding et 
al., 2013). In contrast, neuron turnover in the human OB is vastly slower than in 
rodents with reports that in humans less than 1% of OB neurons are exchanged over 
100 years while in rodents over 50% of OB neurons are exchanged annually 
(Bergmann et al., 2012). In addition, a distinct and unique attribute of the human 
SVZ is a structure termed the astrocyte ribbon, which has not been observed in any 
other species (Sanai et al., 2004). The human SVZ also contains a unique “gap” 
region, which is an area that does not contain cells (Quinones-Hinojosa et al., 2006). 
Finally, the lack of chain migration in the adult human RMS demonstrates that 
human neurogenesis contains features that differ from the rodent (Wang et al., 2011). 
An overview of differences between adult rodent and human neurogenesis is 
presented in Table 2-1.   
 
Table 2-1: Adult neurogenesis in rodents and humans differs by physiological and structural 
differences. Table adapted from Oikari et al. 2014(Oikari et al., 2014) 
Location       Differences Ref. 
   
   
   
Hippocampus/ 
Olfactory 
bulb (OB) 
• Hippocampal neuronal turnover higher in 
humans than rodents 
(Spalding et al., 2013) 
 • OB neuronal turnover higher in rodents than 
humans 
(Bergmann et al., 
2012) 
 • Relative age-related decrease of neurogenesis 
higher in rodents than humans 
(Spalding et al., 2013) 
   
SVZ • Presence of astrocyte ribbon in humans (Sanai et al., 2011; 
Sanai et al., 2004) 
 • Presence of “gap “region in humans (Quinones-Hinojosa 
et al., 2006; Sanai et 
al., 2011) 
 • No chain migration in adult human RMS (Quinones-Hinojosa 
et al., 2006; Wang et 
al., 2011) 
 • No neuroblasts detected in human OB (Lim & Alvarez-
Buylla, 2016; Wang 
et al., 2011) 
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2.3 NEURAL CELL TYPES 
 
Neural cells, including neurons and glial cells are produced from NSCs during the 
process of neurogenesis and gliogenesis, respectively. As previously described 
(section 2.1.2) self-renewing NSCs in the SGZ and SVZ are characterised through 
the expression of markers including CD133, nestin, SOX1 and 2, MSI1, VIM and 
GFAP (Table 2.) (Conti et al., 2005; Corti et al., 2007; Knoth et al., 2010; Sun et al., 
2008). NSC self-renewal and differentiation is associated with active cell 
proliferation, which can be detected through the expression of proliferation markers 
including BrdU, Ki67, minichromosome maintenance complex component 2 (Mcm2) 
and proliferating cell nuclear antigen (PCNA) (Table 2.) (Curtis et al., 2007; 
Eriksson et al., 1998; Knoth et al., 2010; Wang et al., 2011)  During the process of 
differentiation, expression of markers associated with NSC self-renewal switches to 
the expression of lineage-specific markers, including neuronal, astrocyte and 
oligodendrocyte markers. Lineage-specific markers are summarised in Table 2-2. and 
lineage-specific neural cells are discussed in detail below. 
 
Table 2-2: A summary of the markers currently used for the characterisation of rodent and 
human NSCs and neural cell lineages. Table adapted from Oikari et al. 2014 (Oikari et al., 2014) 
Neural Stem Cell Proliferation Neuronal Astrocyte Oligodendrocyte 
     
CD133 (Prominin-1) BrdU Dcx GFAP GalC 
Nestin Ki67 MAP2 S100B O1 
SOX1 Mcm2 NeuN GS O4 
SOX2 PCNA Neurofilament AldhlL1 Olig1 
Musashi 1  NSE  Olig2 
Vimentin  PSA-NCAM   
GFAP  TuJ1 (βIII-
tubulin) 
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2.3.1 Neurons 
 
Neurons are the electrically excitable cells of the CNS that fire action potentials and 
are responsible for signal transduction in the CNS (Lodish et al., 2000). 
Morphologically neurons consist of a cell body, dendrites and a single axon with the 
axon ending at an axon terminal known as a synapse. Neurons maintain a voltage 
gradient across their membranes via ion pumps with change in the voltage gradient 
resulting in the generation of one or many action potentials, which travel along the 
axon resulting in the activation of synaptic connections (Lodish et al., 2000). The 
majority of synapses are chemical synapses with an action potential resulting in the 
release of neurotransmitters (Lodish et al., 2000). The post-synaptic cell can be a 
dendrite or cell body of a neuron or it can be a non-neuronal cell and a single axon 
can synapse with multiple cells and stimulate them simultaneously.  (Lodish et al., 
2000). In complex organisms, including mammals, neurons are organised in circuits 
that consists of different neuron types, such as sensory and motor neurons (Lodish et 
al., 2000). In the brain there are hundreds of neuron types, however, a general term 
for a neuron that projects its axon out of the area where the cell body is located, is 
‘projection neuron’ (Masland, 2004). In contrast, ‘intrinsic neurons’, also known as 
interneurons, form synaptic connections with cells located in the same area as the 
cell body of the neuron (Masland, 2004). An important characteristic of neurons is 
membrane trafficking, which plays an important role in providing lipids and 
membrane proteins for the extending axons and dendrites (Wojnacki et al., 2016).  
 
Common neuronal cell markers characterised both in the rodent and human include 
doublecortin (DCX), microtubule-associated protein 2 (MAP2), NeuN, 
neurofilament (NEF), neuron-specific enolase (NSE), polysialylated-neural cell 
adhesion molecule (PSA-NCAM) and βIII-tubulin (TUBB3) also known as Tuj1 
(Conti et al., 2005; Doetsch et al., 1999; Eriksson et al., 1998; Sanai et al., 2004; Sun 
et al., 2008) (Table 2-2.). Different neuron subtypes also express their specific 
markers, i.e. γ-aminobutyric acid (GABA)ergic, dopaminergic and cholinergic-like 
motor neurons express GABA, tyrosine hydroxylase and ISL1/2, which are markers 
of these neurons, respectively (Belinsky et al., 2013; Teratani-Ota et al., 2016). 
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2.3.2 Glial cells 
 
2.3.2.1 Astrocytes 
 
The majority of “electrically silent or non-spiking” brain cells are classified as glial 
cells, which include at least 50% of all brain cells with the majority of these cells 
consisting of astrocytes and oligodendrocytes (Khakh & Sofroniew, 2015; Rowitch 
& Kriegstein, 2010). Glial cells exist in higher numbers than neurons in the brain and 
20 – 40 % of all glial cells are comprised of astrocytes (Khakh & Sofroniew, 2015; 
Shigetomi et al., 2016). In some areas, such as the cerebral cortex, astrocyte numbers 
are higher than neurons, whereas areas containing high numbers of neuronal bodies, 
including the cerebellar granule and hippocampal pyramidal cell layers, contain a 
low number of astrocytes (Khakh & Sofroniew, 2015).   Mature astrocytes can be 
divided in to two main categories: the ‘star-shaped’ white matter populating fibrous 
astrocytes; and the highly branched grey matter population protoplasmic astrocytes 
(Rowitch & Kriegstein, 2010; Sofroniew & Vinters, 2010). Common markers 
expressed by astrocytes include GFAP, calcium binding protein S100B, glutamine 
synthetase (GS) and Aldh1L1 (Table 2-2.), however, as astrocytes are a 
heterogeneous population of cells, some of these markers, including GFAP are not 
expressed by all astrocytes (Donato, 2001; Reeves et al.,  1989; Sofroniew & Vinters, 
2010; Sosunov et al., 2014). Astrocytes have multiple regulatory roles in the CNS, 
including the regulation of CNS blood flow and metabolism; regulation of synaptic 
transmission through the release of multiple synaptically active molecules; regulation 
of synaptic interstitial fluid homeostasis; with astrocytes also indicated to be 
important in the maintenance of the blood-brain barrier (Rowitch & Kriegstein, 
2010; Sofroniew & Vinters, 2010). In response to CNS damage and disease 
astrocytes can undergo functional, morphological and proliferative changes, a 
process known as reactive astrogliosis. This process is responsible for the formation 
of the glial scar, an area high in extracellular matrix proteins blocking further axonal 
growth in the area (Fernandez-Castaneda & Gaultier, 2016; Khakh & Sofroniew, 
2015). 
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2.3.2.2 Oligodendrocytes 
 
Oligodendrocytes are myelin producing cells of the CNS and they are generated from 
highly proliferative oligodendrocyte precursor cells (OPCs), which remain in 
abundant numbers in the adult CNS capable of generating adult oligodendrocytes 
when needed (Bergles & Richardson, 2015).  OPCs express amongst others the 
platelet-derived growth factor receptor-α (PDGFRα), ganglioside A2B5 and 
proteoglycan NG2 with OPCs also known as NG2 cells (Barateiro & Fernandes, 
2014). Once OPCs begin to mature towards oligodendrocytes, they start to express 
lineage-specific markers including galactosylceramidase (GalC), surface markers O1 
and O4 and oligodendrocyte transcription factors Olig 1 and Olig 2 (Table 2-2.) 
(Barateiro & Fernandes, 2014; Tracy et al. 2011; Wegner, 2008). Structurally 
oligodendrocytes have multiple extended processes that allow them to form contacts 
with axons and produce a myelin sheath along the axon (Barateiro & Fernandes, 
2014). In the process of myelination, oligodendrocytes produce myelin and grow 
their plasma membranes to allow them to wrap around neuronal axons to form a 
myelin sheath (Barateiro & Fernandes, 2014; Fernandez-Castaneda & Gaultier, 
2016). In peak periods of myelination oligodendrocytes can produce up to three 
times their body weight in myelin and grow their plasma membrane up to hundred 
times its weight a day, making them sensitive and vulnerable to environmental 
damage pathways (Barateiro & Fernandes, 2014). Following CNS injury, OPCs 
along with reactive astrocytes contribute to the formation of the glial scar 
(Fernandez-Castaneda & Gaultier, 2016). 
 
2.4 NEURAL STEM CELL EXPANSION AND DERIVATION  
 
The discovery that neurogenesis persists in the adult mammalian brain resulted in the 
search of finding a common precursor cell that generates neurons and glial cells in 
the CNS. This was finally achieved in the early 1990s when neural precursor cells 
with multilineage differentiation capacity were isolated from adult mouse and rat 
brains (Palmer et al., 1995; Reynolds & Weiss, 1992). Following this discovery in 
the rodent, identification and isolation of human NSCs was achieved in the late 
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1990s, a significant breakthrough in human NSC research (Kukekov et al., 1999). 
The discovery of NSCs resulted in the establishment of rodent and human NSC in 
vitro isolation and culturing protocols and today multiple rodent and human NSC 
lines are routinely expanded and commercially available. The culture conditions for 
the in vitro propagation of both rodent and human NSCs are similar, using serum-
free conditions along with the presence of key growth factors, EGF and FGF-2, to 
maintain cells in an undifferentiated and multipotential state (Sun et al., 2008). The 
two main methods of expanding NSCs in culture are the neurosphere assay and the 
adherent monolayer culturing system. Advances in NSC isolation and the 
development of in vitro culturing methods are summarised in Figure 2-1. 
 
2.4.1 Neurosphere assay 
 
The neurosphere assay (NSA) developed by Reynolds and Weiss in 1992 is a well-
established assay for the identification, isolation and in vitro propagation of NSCs 
(Reynolds & Weiss, 1992). A neurosphere is a free-floating cluster of cells 
composed of NSCs, progenitor cells and differentiated cells. During primary 
neurosphere culture, using serum-free culture conditions in the presence of EGF and 
FGF-2, the majority of cells die, leaving the NSCs, which are responsive to these 
culture conditions (Reynolds & Rietze, 2005). The primary neurosphere can then be 
dissociated and passaged to form secondary spheres, which can be further propagated 
or induced to differentiate toward the neural lineages (Reynolds & Rietze, 2005). The 
formation of secondary spheres and their subsequent differentiation represents the 
self-renewal and multipotent differentiation capacity of NSCs (Reynolds & Rietze, 
2005). The NSA is well established and has been successfully applied to the isolation 
and propagation of NSCs from the foetal and adult human brain (Kukekov et al., 
1999; Svendsen et al., 1998) with both SVZ- and SGZ-derived NSCs successfully 
expanded and differentiated in vitro (Kukekov et al., 1999). Although the NSA has 
been successfully applied to the isolation and in vitro expansion of NSCs, the 
limitation of this assay is that neurospheres can also be generated by non-stem cells. 
Thus, to prove the presence of NSCs, neurospheres must be extensively passaged and 
accurately characterised to demonstrate the long-term self-renewal ability of the 
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spheres and their capacity to generate a large number of neuronal progeny (Reynolds 
& Rietze, 2005). 
 
2.4.2 Adherent monolayer 
 
Adherent monolayer culturing of NSCs offers an alternative to the neurosphere 
assay, which is challenged by high cell heterogeneity and the low number of NSCs 
within a neurosphere (Conti et al., 2005). In adherent long-term culturing, the 
presence of both EGF and FGF-2 is required to support symmetrical division of 
NSCs and their multilineage differentiation potential (Conti et al., 2005). Protocols 
for the stable adherent culture of rodent and human NSCs are now well established 
with differentiation of adherent NSC cultures achieved through plating of the cells on 
extracellular matrix substances such as laminin (Conti et al., 2005). An advantage of 
these methods includes maintaining high levels of homogeneity, reduced 
spontaneous differentiation and the potential to expand the cells over 40 passages 
(Sun et al., 2008). Adherent NSC cultures can be derived from induced pluripotent 
stem cells (iPSCs), mesenchymal stem cells (MSCs) and embryonic stem cells 
(ESCs), which are discussed in more detail below. 
 
2.4.3 Induced pluripotent stem cell –derived NSCs 
 
NSCs can be derived from pluripotent iPSCs. iPSCs were first generated by 
Takahashi and Yamanaka in 2006 when they reported that fibroblasts can be 
reprogrammed into pluripotent stem cells through the introduction of defined factors, 
including Oct3/4, SOX2, c-Myc and Kfl4 (Takahashi & Yamanaka, 2006). Since 
then, techniques for the derivation of NSCs or neural cells from iPSCs have been 
described and their potential as a tool of cell therapy for CNS injuries has been 
demonstrated (Lopez-Serrano et al., 2016; Nizzardo et al., 2010). The advantage of 
using iPSCs is that they can be generated from easy-to-access cells, such as 
fibroblasts, and due to their pluripotency, they have the ability to generate all 
neuronal cell lineages (Lopez-Serrano et al., 2016; Nizzardo et al., 2010). In 2008 
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Dimos et al. generated iPSCs from a patient with amyotrophic lateral sclerosis (ALS) 
and successfully differentiated these cells to motor neurons, which are destroyed in 
ALS (Dimos et al., 2008). This demonstrated the potential iPSC technology holds in 
patient-specific therapies. However, as oncogenic genes are targeted to achieve cell 
reprogramming, more research is required for the use of iPSC-derived NSCs for 
therapeutic applications to ensure the safety of treatments to recipients (Dimos et al., 
2008; Lopez-Serrano et al., 2016).  
 
2.4.4 Mesenchymal stem cell –derived neural cells 
 
MSCs are multipotent stem cells, mainly isolated from the bone marrow and adipose 
tissue that have the ability to differentiate to cells of mesodermal, endodermal and 
ectodermal origin such as fat, cartilage, bone and neurons (Alexanian, 2010; 
Okolicsanyi et al., 2015). Undifferentiated MSCs express neuronal and glial markers 
and due to this they have raised interest as an alternative for NSCs (Foudah et al., 
2013). Multiple in vitro protocols for neural induction of MSCs have been reported 
including exposing MSCs to neurotrophic factors, transfecting the cells with the 
Notch or noggin transcription factors or co-culturing them with NSCs (Alexanian, 
2010). In addition, epigenetic mechanisms, such as exposing MSCs simultaneously 
to DNA methylation and histone deacetylation inhibitors combined with cAMP 
elevating pharmacological agents, results in neural induction (Alexanian, 2010). 
However, expression of neural markers in MSCs does not indicate that MSCs are 
functional neurons and this needs to be further investigated (Foudah et al., 2013).  
 
2.4.5 Embryonic stem cell –derived NSCs 
 
Pluripotent ESCs have a high expansive potential, thus ESC-derived NSCs provide 
an advantageous additional mechanism to generate NSCs (Zhang et al., 2001). In 
defined culture-conditions it is possible to generate tissue-restricted stem cells from 
ESCs and in appropriate conditions ESCs readily acquire a neural identity by default 
(Tropepe et al., 2001). Several protocols for the derivation of NSCs from ESCs have 
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been described, with one method involving the aggregation of ESCs into embryoid 
bodies (EB), which in the presence of FGF-2 differentiate to neural precursor cells 
(Okabe et al., 1996; Zhang et al., 2001).  Another method involves exposing ESCs to 
the bone morphogenetic protein antagonist, Noggin, which promotes neural 
differentiation resulting in the enrichment of neural precursors that can differentiate 
into the three neural cell lineages (Itsykson et al., 2005; Pera et al., 2004). Other 
methods involve direct differentiation of adherent ESCs in a defined culture medium, 
such as in the presence of growth factors, morphogens or their inhibitors (Shin et al., 
2006; Ying et al., 2003). The transcriptome of human ESC-derived NSCs has been 
found to closely resemble that of primary human NPCs isolated from human foetal 
brain tissue (Stein et al., 2014). In addition, when differentiated for the same period 
of time, human ESC-derived NSCs and NPCs maintained a high level of similarity 
(Stein et al., 2014). While many of the same genes are expressed between ESC-
derived NSCs and primary NPCs, differences in the expression levels of some genes, 
including signalling pathway receptors and downstream molecules, have been 
detected between these cell types (Shin et al., 2007). 
 
2.5 KEY SIGNALLING MECHANISMS OF NSC FATE 
 
The balance between NSC maintenance and lineage differentiation is crucial for 
maintenance of the NSC pool as well as sufficient neurogenesis and gliogenesis. 
Several signalling molecules in the CNS, including growth factors, neurotrophins 
and morphogens are known to be important in mediating these processes (Fig. 2-3) 
and will be discussed in more detail below. 
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Figure 2-3: A schematic summary of key signalling pathways involved in the regulation of 
neural stem cell maintenance and differentiation. A) Growth factors (GF), including fibroblast 
growth factor-2 (FGF2, epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) 
bind to receptors of the receptor tyrosine kinase family (RTK). GF binding results in RTK 
dimerisation and in the activation of downstream signalling cascades (MAPK and PI3K) that regulate 
neural stem cell (NSC) maintenance, proliferation and differentiation. B) Brain-derived neurotrophic 
factor (BDNF) belongs to the family of neurotrophins. Binding of BDNF to tropomyosin-related 
kinase receptor B (TrkB) triggers dimerisation and autophosphorylation of the receptor and the 
activation of downstream signalling cascades that promote neuron survival and differentiation. C)  In 
the canonical Wnt/β-catenin pathway, binding of extracellular Wnt to its receptor Frizzled results in 
the inactivation of glycogen-synthase-kinase-beta-3 (GSKβ), which results in the increase of 
intracellular β-catenin. This in turn results in the activation of Wnt target genes, some involved in 
promoting neurogenesis. D) Extracellular Sonic hedgehog (Shh) binds to its receptor Patched (Ptc) 
and the co-receptor Smoothened (Smo). This releases Ptc inhibition of Smo and results in the 
activation of Shh target genes promoting NSC proliferation. E) Notch is a single-pass transmembrane 
receptor and is activated by its ligands Delta or Jagged bound to the surface of a neighbouring cell. 
Upon ligand binding the intracellular domain of Notch (NICD) is cleaved and it travels to the nucleus 
triggering the expression of Notch target genes stimulating NSC self-renewal. F) Bone morphogenetic 
proteins (BMPs) bind to their type I and type II receptors (BMPRI and BMPRII), which belong to the 
class of serine-threonine kinase receptors. Ligand binding results in the phosphorylation of the 
receptor and activation of SMAD proteins that translocate to the nucleus regulating target gene 
transcription. The BMP pathway promotes specifically astrogliosis.  (Schematics adapted from Ables 
et al., 2011; Hirota et al., 2016; Islam et al., 2009; Liu et al., 2005; Ruiz I Altaba et al., 2002 and 
Schlessinger et al., 2002) 
 
2.5.1 FGF-2 and EGF 
 
Growth factors are a large group of molecules that promote numerous cellular 
functions including cell growth, proliferation and maintenance. Several growth 
factors play an important role in NSC function, with fibroblast growth factors (FGFs) 
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and epidermal growth factor (EGF) known to be required for supporting NSC 
maintenance (Decimo et al., 2012). These growth factors bind to their specific 
receptors, which belong to the receptor tyrosine kinase (RTK) family, resulting in the 
activation of downstream signalling cascades, such as phosphoinositide 3-kinase 
(PI3K)/Akt or mitogen-activated protein kinase (MAPK) (Schlessinger, 2000) (Fig. 
2-3A).  
 
The importance of FGFs in the development of the nervous system is well 
documented (Guillemot & Zimmer, 2011). The FGFs, which are comprised of 22 
family members, bind four FGF-specific receptors (FGFR1-4), with this binding 
largely regulated by cell surface proteins such as the heparan sulfate proteoglycans 
(HSPGs) (Iwata & Hevner, 2009; Li et al., 2016b). The MAPK pathway is one of the 
major signalling pathways activated by FGFs leading to increased cell proliferation 
(Iwata & Hevner, 2009). FGFs are required for the survival and expansion of NSCs 
with FGF-2 a known potent mitogen for NSCs increasing the cells’ responsiveness to 
EGF, which also promotes NSC/NPC proliferation (Aguirre et al., 2010; Guillemot 
& Zimmer, 2011). As a result, the combination of FGF-2 and EGF is commonly used 
for the in vitro culturing of NSCs (Guillemot & Zimmer, 2011). In addition, the 
influence of FGF-2 and EGF on NSC maintenance and proliferation has been 
demonstrated in vivo where infusion of these growth factors into the adult mouse 
SVZ resulted in increased proliferation of SVZ NSCs (Ochi et al., 2016). 
 
2.5.2 Neurotrophins 
 
Neurotrophins are a group of growth factors that regulate survival, differentiation 
and migration of neurons in the CNS. The members of the neurotrophin family are 
the nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin 3 (NT-3) and 4/5 (NT-4/5) (Islam et al., 2009; Wei et al., 2015). 
Neurotrophins exert their effects through binding a specific tropomyosin-related 
kinase (Trk) receptor. NGF binds specifically to TrkA, BDNF and NT-4/5 to TrkB 
and NT-3 to TrkC (Islam et al., 2009) (Fig. 2-3B). Binding of the ligand triggers 
dimerization and autophosphorylation of the Trk receptor, resulting in the activation 
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of downstream signalling cascades and regulation of neuronal cell functions 
including survival, proliferation and differentiation (Islam et al., 2009) (Fig. 2-3B). 
Neurotrophins also bind to a neurotrophin receptor p75 (p75NTR) (Islam et al., 
2009; Wei et al., 2015). BDNF has been widely studied and has been shown to 
promote NPC survival and proliferation resulting in larger neurosphere diameter in 
vitro and importantly, promote neuronal differentiation (Li et al., 2009; Wei et al., 
2015). BDNF expression is linked to neurogenesis in the adult rodent SGZ and 
although this effect is not observed in the rodent SVZ, BDNF injection to SVZ 
increases the migration of SVZ cells enhancing neuroregeneration (Galvao et al., 
2008; Rossi et al., 2006; Yu et al., 2013). 
 
2.5.3 PDGF 
 
The platelet-derived growth factor (PDGF) family consists of PDGF-A, -B, -C and –
D that can as homo- or heterodimers (AA, BB, AB, CC or DD) bind to the PDGF 
receptors (PDGFRs) (Shim et al., 2010). The two PDGFR types, PDGFRα and 
PDGFRβ, can dimerise in the -αα, -ββ or -αβ forms. Similar to FGFR, PDGFR 
belongs to the RTK family and upon ligand binding can activate the MAPK and 
PI3K pathways (Li et al., 2015; Shim et al., 2010) (Fig. 2-3A). In the CNS 
oligodendrocyte progenitor cells (OPCs) express PDGFRα and thus, PDGF 
signalling is considered important in driving oligodendrocyte production (Jackson et 
al., 2006; Rakic & Zecevic, 2003). The PDGFRα is also expressed in another subset 
of cells in the CNS, namely the PDGF-responsive neural precursors (PRPs). These 
cells have multi-lineage differentiation potential but representing a distinct 
subpopulation from the GFAP expression NSCs (Chojnacki et al., 2011; Chojnacki 
& Weiss, 2004). The PRPs in the adult SVZ have been shown to be multipotent with 
PDGFAA supplementation in vitro inducing them to differentiate toward 
oligodendrocytes, astrocytes and neurons (Moore et al., 2014). In addition, PDGFRα 
expressing B cells in the SVZ can differentiate towards neurons and 
oligodendrocytes highlighting the importance of the PDGF pathways in numerous 
neural differentiation processes (Jackson et al., 2006). In vitro studies have also 
shown that PDGFBB administration stimulates the proliferation of rat astrocytes and 
overexpression of PDGFB in mouse GFAP-positive astrocytes results in significantly 
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increased proliferation (Dai et al., 2001; Luo & Miller, 1999). PDGF together with 
FGF-2 and EGF has also been used to induce neuronal differentiation of hMSCs 
(Tao et al., 2005). 
 
2.5.4 Wnt/ β-catenin pathway 
 
The Wnt/β-catenin pathway, also known as the canonical Wnt pathway, plays a key 
role in NSC proliferation as well as in promoting neurogenesis (Ikeya et al., 1997; 
Lie et al., 2005). In the canonical Wnt pathway, when the Wnt ligand is absent, 
intracellular β-catenin is phosphorylated by the active glycogen-synthase-kinase-beta 
3 (GSKβ3), which leads to the degradation of β-catenin and to the repression of Wnt 
target genes (Chen et al., 2000). When extracellular Wnt is present, it binds to its 
receptor Frizzled leading to the activation of downstream molecules that inactivate 
GSKβ3, resulting in the accumulation of β-catenin and transcription of Wnt target 
genes (Chen et al., 2000) (Fig. 2-3C). In vivo overexpression of β-catenin or the 
inhibition of GSKβ3 studies in the adult mouse SVZ have been shown to increased 
type B cell proliferation resulting in an increased number of OB neurons (Adachi et 
al., 2007). In the adult rat hippocampus enhanced Wnt signalling has been shown to 
increase neurogenesis while inhibition of this pathway leads to decreased 
neurogenesis (Lie et al., 2005). These findings have been further confirmed in vitro 
with overexpression of Wnt3 in adult rat hippocampal NS/NPCs resulting in 
increased neurogenesis (Lie et al., 2005). Wnt-mediated neurogenesis is regulated by 
the transcription factor NeuroD1, which is crucial in mediating survival and 
differentiation of neurons (Gao et al., 2009; Kuwabara et al., 2009). The stabilisation 
of β-catenin through activation of the Wnt pathway or GSKβ3 inhibition has also 
been shown to have a neuroprotective effect on human cortical NPCs (Skardelly et 
al., 2011). In addition GSKβ3 inhibition and exposure to Wnt ligands induces the 
differentiation of human pluripotent stem cells (hPSCs) towards dopaminergic 
neurons (Kriks et al., 2011). 
 
 
 30 Chapter 2: Literature Review 
2.5.5 Sonic hedgehog pathway 
 
Sonic hedgehog (Shh) is a member of the hedgehog (Hh) family of signalling 
molecules central to regulating many developmental processes, including the 
formation of the nervous system (De Luca et al., 2016; Ruiz i Altaba et al., 2002). 
Shh is a soluble molecule that binds and forms a complex with its receptor Patched 
(Ptc) and the co-receptor Smoothened (Smo). In the absence of Shh, Ptc represses 
signal transduction from Smo resulting in inhibition of Shh target genes with binding 
of Shh releasing this inhibition and leading to the activation of Shh target genes (De 
Luca et al., 2016; Ruiz i Altaba et al., 2002) (Fig. 2-3D). Shh has been shown to act 
as mitogen for adult rat hippocampus-derived NPCs both in vitro and in vivo (Lai et 
al., 2003). Overexpression of Shh increased rat hippocampal NPC proliferation with 
inhibition of the Shh pathway resulting in reduced adult rat hippocampal progenitor 
cell proliferation (Lai et al., 2003). Interestingly, Shh has been shown to be a direct 
target of SOX2 with deletion of SOX2 in the mouse brain leading to a loss of Shh 
expression with in vitro cultured SOX2-deficient NSCs failing to express Shh 
(Favaro et al., 2009). Shh signalling has also been found to be central to the 
regulation of cellular migration in the adult mammalian brain (Balordi & Fishell, 
2007). Together with Wnt signalling, activation of the Shh pathway has been shown 
to induce dopaminergic neuron differentiation of hPSCs (Kriks et al., 2011).  The 
supplementation of Shh or its agonist has also been shown to efficiently generate 
cholinergic neurons from hESCs and hiPSCs highlighting the importance of Shh 
signalling in neuronal differentiation (Hu et al., 2016).  
 
2.5.6 Notch pathway 
 
The Notch pathway is evolutionarily conserved and it has an important role in CNS 
development (Ables et al., 2011). The Notch protein is a single-pass transmembrane 
receptor consisting of four members in mammals (Notch1-4) and is activated by its 
ligands Delta and Jagged bound to the surface of the neighbouring cell (Ables et al., 
2011) (Fig. 2-3E). Upon ligand binding the intracellular domain of the Notch (NICD) 
receptor is cleaved, after which the NICD travels to the nucleus where it forms a 
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complex with the DNA-binding protein RBPj, with this complex inducing the 
expression of Notch target genes (Ables et al., 2011; Artavanis-Tsakonas et al., 
1999) (Fig. 2-3E). Notch has been demonstrated to play a role in NSC maintenance 
in various animal models, including the zebrafish and the mouse (Chapouton et al., 
2010; Hitoshi et al., 2002). In particular Notch1 has been shown to be required for 
the self-renewal of nestin-positive cells in the mouse hippocampus (Ables et al., 
2010). The overexpression of Notch1 signalling resulted in increased proliferation of 
the adult hippocampal stem cells with the absence of Notch1 disrupting self-renewal 
of these cells as indicated by a decrease in the stem cell pool (Ables et al., 2010; 
Breunig et al., 2007). Interestingly, SOX2, which is critical for NSC self-renewal, 
has been found to be one of the downstream targets of Notch signalling, suggesting 
Notch signalling during NSC maintenance is mediated at least partially by SOX2 
(Ehm et al., 2010). Notch signalling has also been shown to be important in hESC 
motor neuron differentiation (Ben-Shushan et al., 2015). 
 
2.5.7 Bone morphogenetic proteins and their antagonists 
 
Bone morphogenetic proteins (BMPs) are members of the transforming growth 
factor-β (TGFβ) family, highly expressed in the nervous system, which act in 
conjunction with other important pathways including Wnt and Shh to regulate 
embryonic and postnatal CNS development (Liu & Niswander, 2005; Tong et al., 
2015). BMPs bind to their type I and type II receptors (BMPRs), which belong to the 
class of serine-threonine kinase receptors. Ligand binding results in phosphorylation 
and activation of SMAD proteins that translocate to the nucleus and regulate the 
transcription of target genes (Liu & Niswander, 2005; Tong et al., 2015) (Fig. 2-3F). 
In the mouse model, BMP signalling has been demonstrated to reduce NPC 
proliferation and self-renewal and inhibit neurogenesis and oligodendrocyte 
differentiation, while inducing astrogliosis (Bonaguidi et al., 2005; Lim et al., 2000; 
Samanta & Kessler, 2004). BMP signalling is inhibited through antagonists including 
Noggin, chordin, follistatin and neurogenesin, with these molecules, in particular 
Noggin, shown to induce neurogenesis (Bonaguidi et al., 2008). Noggin is highly 
expressed in the mouse hippocampal SGZ where it promotes NSC self-renewal and 
proliferation, thus it is required for NSC maintenance (Bonaguidi et al., 2008; Lim et 
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al., 2000). Due to its positive effect on NSC self-renewal, proliferation and neuronal 
differentiation, Noggin and other BMP signalling inhibitors have been successfully 
used to generate NSCs from human ESCs (Itsykson et al., 2005; Noisa et al.,  2015; 
Pera et al., 2004).  
 
2.6 NEURAL STEM CELL NICHE 
 
Stem cells are localised in specific microenvironments, or “niches” that regulate 
stemness, specifically, cell maintenance, self-renewal and lineage fate specification 
(Morrison & Spradling, 2008). The microenvironment in which NSCs reside is also 
known as the NSC niche with the two neurogenic NSC niche areas in the brain 
located in the SVZ and SGZ (Alvarez-Buylla & Lim, 2004). Multiple extrinsic 
factors in the NSC niche mediate NSC function, including the previously discussed 
signalling molecules. In addition, neighbouring mature cells and proteins located in 
the extracellular matrix (ECM) have important regulatory roles influencing NSC 
behaviour and will be discussed in the following sections 
 
2.6.1 Cellular components of the NSC niche 
 
Cellular components of the NSC niche include mature cells, such as astrocytes, 
ependymal cells, vascular cells and mature neurons. The cell-cell contacts between 
these cells and NSCs contribute to the regulation of NSC self-renewal and lineage 
specification. Astrocytes express secreted and membrane-bound factors that regulate 
proliferation and differentiation of NSCs as well as neurogenesis and synaptic 
plasticity (Barkho et al., 2006; Parpura et al., 2012).  Astrocyte processes are also 
important in connecting cells of different compartments to each other, such as 
connecting neurons to the vasculature (Barkho et al., 2006; Parpura et al., 2012).  
Ependymal cells are ciliated cells that line the lateral ventricles and are in close 
contact with SVZ NSCs (Ramirez-Castillejo et al., 2006; Sawamoto et al., 2006). 
Ependymal cells are thought to regulate NSC maintenance and differentiation by 
secreting soluble factors such as pigment-epithelium derived factor and Noggin, 
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which promote NSC self-renewal and neurogenesis, respectively (Lim et al., 2000; 
Ramirez-Castillejo et al., 2006). Furthermore, ependymal cell cilia beating influences 
cerebrospinal fluid flow, which is required for neuroblast migration through the RMS 
(Sawamoto et al., 2006). A link between the vasculature and NSC maintenance has 
been established as NSCs in the SGZ and SVZ are located close to blood vessels 
with soluble factors secreted by endothelial cells shown to promote NSC self-
renewal and neurogenesis (Shen et al., 2004). Endothelial cells and NSCs secrete 
vascular endothelial growth factor (VEGF), with endothelial cell-derived VEGF 
promoting NSC proliferation and maintenance, and NSC-derived VEGF promoting 
endothelial cell proliferation and angiogenesis (Mackenzie & Ruhrberg, 2012). 
Mature neurons also play a role in the NSC niche through secretion of 
neurotransmitters and other factors that predominantly promote neurogenesis (Ma et 
al., 2009). Combined, neighbouring cells surrounding the NSC niche provide 
structural and nutritional support to the NSC pool. 
 
2.6.2 The extracellular matrix (ECM) 
 
The ECM is described as the substance between and around cells and is produced by 
the cells that reside within in it, thus it has a highly tissue-specific structure 
(Hubmacher & Apte, 2013). The ECM is composed of multiple proteins with 
structural or enzymatic properties including collagens, fibronectin, elastin, fibrillins, 
matrix metalloproteinases (MMPs) and proteoglycans (PGs) (Ahmed & Ffrench-
Constant, 2016; Hubmacher & Apte, 2013). The ECM has diverse roles including 
providing support, acting as a basement membrane and a source of polarity for 
epithelial cells and it also provides tissues elasticity and stiffness (Hubmacher & 
Apte, 2013). Importantly, the ECM plays a role in modulating cell signalling activity 
by mediating local concentrations of extracellular signalling molecules, including 
morphogens and growth factors (Ahmed & Ffrench-Constant, 2016; Hubmacher & 
Apte, 2013).  
 
The brain ECM is produced by the cells of the nervous system, specifically, neurons, 
glial cells and non-neural cells types and it provides an environment for neural cell 
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development and plasticity (Howell & Gottschall, 2012; Soleman et al., 2013). 
Approximately 20 % of the brain is extracellular space and is composed of proteins 
and soluble factors (Howell & Gottschall, 2012; Soleman et al., 2013). Some of the 
most abundant proteins found in the brain ECM are the chondroitin sulfate 
proteoglycans (CSPGs), in particular the lectican family of CSPGs that form the 
majority of the brain ECM (Howell & Gottschall, 2012; Soleman et al., 2013). 
During development the brain ECM supports the formation of neurons and glial cells 
as well as cell migration, axonal outgrowth and synapse development while in the 
adult it mediates brain structure and plasticity e.g. during or after injury or disease 
(Howell & Gottschall, 2012; Soleman et al., 2013).  The brain ECM also has an 
important role in mediating brain plasticity in response to environmental changes and 
altered neural activity (Howell & Gottschall, 2012; Soleman et al., 2013). 
Importantly, the brain ECM is also responsible for formation of perineuronal nets 
(PNNs), aggregates of the ECM found in particular in the cortex, hippocampus, brain 
stem and cerebellum, which play a central role in synapse structure and function and 
neuronal activity (Howell & Gottschall, 2012; Soleman et al., 2013).  
 
2.6.3 Role of brain ECM proteins in NSC regulation 
 
The ECM forms a physical compartment in which NSCs reside with the 
heterogeneous properties of the NSC niche ECM promoting either the self-renewal 
or differentiation of NSCs (Reinhard et al., 2016). Several ECM proteins, including 
proteoglycans, collagens, laminin and integrins have been implicated to promote 
NPC self-renewal in the human SVZ (Fietz et al., 2012). This data suggests that cell 
adhesion and cell-ECM interactions are crucial in regulating NSC maintenance (Fietz 
et al., 2012). In the adult mouse hippocampus the ECM glycoproteins reelin and 
tenascin-R have been reported to mediate neurogenesis reinforcing the role of ECM 
proteins in mediating NSC lineage commitment (Xu et al., 2014; Zhao et al., 2007).  
Not only providing a structural environment for cell attachment and cell-matrix 
interaction, the ECM also sequesters growth factors, morphogens and cytokines to 
the NSC niche providing a permissive environment for self-renewal or differentiation 
to occur (Faissner & Reinhard, 2015). In the larger context, the brain ECM plays a 
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crucial role in brain plasticity and homeostasis allowing for larger functions, 
including the development of memory and learning (Dityatev et al., 2010).  
 
2.7 PROTEOGLYCANS 
 
Proteoglycans (PGs) are ubiquitous members of the ECM. They are expressed 
throughout the body and are a major component of several tissues including bone, 
cartilage and the brain (Couchman & Pataki, 2012). Several PGs are localised in the 
ECM, with other PGs being membrane-bound or localised in intracellular 
compartments (Couchman & Pataki, 2012; Cui et al., 2013). PGs have a variety of 
functions, including having a structural role to mediating enzymatic activity to acting 
as cell surface receptors (Couchman & Pataki, 2012). Due to these diverse functions, 
PGs play central roles in development, homeostasis and also in diseases such as 
cancer (Couchman & Pataki, 2012; Dreyfuss et al., 2009). On the cellular level PGs 
mediate multiple cellular behaviours including proliferation, adhesion, migration and 
differentiation (Dreyfuss et al., 2009). The effects of PGs are achieved through their 
interactions with numerous extracellular and cell surface proteins as well as 
signalling molecules, including, morphogens, cytokines and growth factors, a well-
noted characteristic of PGs  (Dreyfuss et al., 2009).  
 
Structurally, PGs consist of a core protein to which one or more sulfated unbranched 
glycosaminoglycan (GAG) side chains attach at specific sites. According to 
structure, GAGs are classified into groups including heparin or heparan sulfate (HS), 
chondroitin sulfate (CS), dermatan sulfate (DS), keratan sulfate (KS) and hyaluronic 
acid (HA) and it is through these side chains that PGs are able to interact with other 
molecules (Kjellen & Lindahl, 1991; Maeda et al., 2011). The focus of this Thesis is 
on HSPGs, thus their biosynthesis, known functions and potential roles in the neural 
niche will be discussed in the following sections.  
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2.7.1 Heparan sulfate proteoglycans 
 
HSPGs are bound to the cell surface or localised in the ECM.  Membrane-bound 
HSPGs include the transmembrane syndecans and the glycosylphosphatidylinositol- 
(GPI-) anchored glypicans with ECM localised HSPGs including perlecan, agrin, 
type XVIII collagen and testican family members (Dreyfuss et al., 2009). HSPGs 
modulate the activity of various signalling pathways by binding and interacting with 
these signalling molecules and their receptors through their HS side chains (Haupt et 
al., 2009). The HS chain/signalling molecule interactions are mainly dependent on 
the sulfation pattern of the chains with the ability of molecules to bind to specific 
sulfation sites also described as the sulfation code (Gama et al., 2006; Haupt et al., 
2009).  
 
2.7.1.1 HSPG Biosynthesis 
 
The biosynthesis of HSPGs is a complex process with HS chains assembled to the 
core protein post-translationally in the Golgi apparatus via the co-ordinated temporal 
action of multiple biosynthesis enzymes (Kjellen & Lindahl, 1991). Structurally HS 
chains consist of repeating disaccharide units of N-acetylglucosamine (GlcNAc) and 
glucoronic acid (GlcA) (Maeda et al., 2011). The chain synthesis on the core protein 
begins by the assembly of a linkage tetrasaccharide structure, which consists of a 
xylose residue, incorporated by xylosyltransferase, and two galactose residues and a 
GlcA residue, incorporated by galactosyltransferases-I and –II and 
glucuronyltransferase-I, respectively (Tone et al., 2008) (Fig. 2-4).  When the linkage 
tetrasaccharide is completed, the HS chains are polymerised by the hetero-complex 
of exostosin glycosyltransferases 1 and 2 (EXT1 and EXT2 (Busse et al., 2007) (Fig. 
2-4). Following chain polymerisation the HS GAG chains are extensively modified 
resulting in side chains highly heterogeneous in structure. These modifications, are 
strictly regulated and include N-deacetylation and N-sulfation of GlcNAc residues, 
epimerisation of GlcA to iduronic acid (IdoA) followed by O-sulfation of GlcA, 
IdoA, GlcNAc, GlcNS and GlcN residues with the enzymes catalysing these 
reactions located in the lumen of the Golgi apparatus (Esko & Lindahl, 2001; Gama 
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et al., 2006) (Fig. 2-4). The N-deacetylase/N-sulfotransferases (NDSTs), a family of 
four enzymes, catalyse N-deacetylation/N-sulfation and following their action, GAG 
chains are committed to becoming HS chains (Esko & Lindahl, 2001) (Fig. 2-4). 
NDSTs function by removing acetyl groups from some of the GlcNAc residues and 
replacing them with sulfate groups after which some GlcA residues located near the 
N-sulfated areas are C5 epimerised by HS C5 epimerase (C5-EP) converting them to 
iduronic acid (IdoA) (Grobe et al., 2002) (Fig 2-4.). After these modifications O-
sulfation occurs: heparan sulfate 2-O-sulfotransferase (HS2ST) performs 2-O 
sulfation of GlcA/IdoA residues and three heparan sulfate 6-O-sulfotransferases 
(HS6ST1, HS6ST2 and HS6ST3) and seven heparan sulfate 3-O sulfotransferases 
(HS3ST) perform 6-O sulfation and 3-O-sulfation, respectively, of the GlcNAc and 
GlcNS residues (Kreuger & Kjellen, 2012) (Fig 2-4). HS chain length along with the 
N- and O-sulfation pattern subsequently determine the binding abilities of HSPGs 
(Esko & Selleck, 2002). 
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Figure 2-4: Biosynthesis and modification of HSPGs. The synthesis of heparan sulfate (HS) chains 
begins with the assembly of a tetrasaccharide linkage region, which is linked to serine residue on the 
proteoglycan core protein and is composed of one xylose residue, two galactose residues and one 
glucoronic acid (GlcA) residue. The HS chains are composed of repeating disaccharide units of N-
acetylglucosamine (GlcNAc) and GlcA and HS chain modifications begin with the action of N-
deacetylase/N-sulfotransferases (NDSTs), after which GAG chains are committed to becoming HS 
chains. C5 epimerase converts GlcA residues to IdoA and HS sulfotransferases catalyse 2-O-sulfation, 
6-O-sulfation and 3-O-sulfation of saccharide units in HS chains. Figure adapted from Hacker et al. 
2005 (Hacker et al., 2005). 
 
2.7.1.2 Syndecans 
 
Syndecans are a family of PGs that carry both HS and CS chains although 
predominantly HS chains. Structurally syndecans are type I transmembrane proteins 
that consist of an extracellular N-terminal domain, a transmembrane domain and a C-
terminal intracellular domain (Choi et al.,  2011). The extracellular domain contains 
GAG attachment and protease cleavage sites and it interacts with a variety of soluble 
and insoluble molecules within the ECM (Couchman et al., 2015; Couchman & 
Pataki, 2012) (Fig. 2-5). The transmembrane domain is formed by 25 hydrophobic 
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amino acids and it influences syndecan core protein dimerisation/oligomerisation 
(Couchman et al., 2015; Couchman & Pataki, 2012).  The intracellular domain of 
syndecans consists of two conserved regions, termed C1 and C2, which are common 
to all syndecan family members (Couchman et al., 2015; Couchman & Pataki, 2012) 
(Fig. 2-5). The C1 region interacts with the actin cytoskeleton and contains a 
sequence that is required for syndecan endocytosis and the C2 region contains a 
motif that interacts with PDZ-proteins that mediate downstream effects (Couchman 
et al., 2015). The conserved regions are separated by a variable (V) region, which 
varies between syndecan family members resulting in syndecan-specific functions 
(Couchman et al., 2015; Couchman & Pataki, 2012) (Fig. 2-5). Syndecans interact 
with a large number of extracellular ligands including growth factors, cytokines, 
chemokines, morphogens and ECM proteins. Importantly, the extracellular domain 
of syndecans is able to interact with integrins while cytoplasmic domain of 
syndecans interacts with the actin cytoskeleton supporting cell adhesion (Couchman 
et al., 2015; Couchman & Pataki, 2012). Due to their interaction with the 
cytoskeleton, syndecans play multiple roles in mediating cellular behaviours 
including cell adhesion and migration, cytoskeletal organisation as well as 
differentiation (Couchman et al., 2015). 
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Figure 2-5: A schematic representation of the structure of syndecan (SDC1-SDC4) proteins. 
Syndecans are type 1 transmembrane proteins that carry heparan sulfate (HS) chains on their 
extracellular domain. The intracellular domain of syndecans has two conserved regions (C1 and C2), 
which are separated by a variable (V) region. SDC1 and SDC3 sometimes carry chondroitin sulfate 
(CS), thus belonging to the same subfamily with SDC2 and SDC4 forming another subfamily. Figure 
adapted and modified from Couchman et al. (2015) (Couchman et al., 2015). 
 
In the mammal there are four syndecan family members, namely syndecan-1 
(SDC1), syndecan-2 (SDC2), syndecan-3 (SDC3) and syndecan-4 (SDC4) with all of 
these representing tissue-specific expression and playing multiple roles in cellular 
processes (Couchman et al., 2015). SDC1 and SDC3 show homology and sometimes 
carry chondroitin sulfate (CS) chains, thus belonging to the same subfamily 
(Couchman et al., 2015). The other syndecan subfamily is formed by SDC2 and 
SDC4 (Couchman et al., 2015.) SDC1 is highly expressed in epithelial tissue with 
SDC1 knockout (KO) mice demonstrating reduced epithelial repair (Pal-Ghosh et al., 
2008). High SDC1 expression has also been linked to invasive epithelial ovarian 
carcinoma, poorer prognosis in lung cancer and myeloma as well as higher tumour 
aggressiveness in breast cancers (Guo et al., 2012). Conversely, however, high SDC1 
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expression in head and neck squamous cell carcinoma has been shown to reduce 
invasiveness of the cancer cells demonstrating the cancer type-specific roles of SDC1 
(Ishikawa & Kramer, 2010). SDC2 is highly expressed in mesenchymal tissue and 
also enriched in the liver and neuronal cells (Couchman, 2003). Similar to SDC1, 
also SDC2 plays a role in tumourigenesis, acting as a tumour promoter (colon 
cancer) or a tumour suppressor (Lewis lung carcinoma) (Iozzo & Sanderson, 2011).  
Furthermore, in neurons SDC2 is clustered at synapses and it plays a central role in 
dendritic spine development (Ethell & Yamaguchi, 1999). SDC3 shows mainly 
neural tissue specific expression with the depletion of this protein in the mouse 
resulting in impaired neural migration (Hienola et al., 2006). SDC3 is also expressed 
in the musculoskeletal system and has been shown to have proinflammatory effects 
in the joint (Kehoe et al., 2014).  Although it is expressed at a low level, SDC4 is 
broadly expressed across many cell types, including mesenchymal, epithelial, 
endothelial and immune cells (Couchman et al., 2015).  Interestingly, SDC4 
expression is commonly upregulated in response to inflammation and anti-
inflammatory effects of SDC4 have been reported (Strand et al., 2013; Tanino et al., 
2012; Xie et al., 2012). Differential SDC4 expression has been linked to cancers, 
including breast, melanoma and hepatocellular carcinoma (Couchman et al., 2015). 
Interestingly, in breast cancer SDC4 is expressed in oestrogen and progesterone 
receptor tumours, in which SDC1 is not expressed (Lendorf et al., 2011); in 
melanoma SDC4 may function as a good prognostic marker as it reduces cell 
motility (Chalkiadaki et al., 2009).  
 
2.7.1.3 Glypicans 
 
Glypicans are HSPGs bound to the cell membrane via a GPI-anchor and are 
structurally composed of a globular N-terminal domain and a C-terminal domain, 
which contains attachment sites for HS side chains and the GPI-anchor (Song & 
Filmus, 2002) (Fig. 2-6). In the globular N-terminal domain there is a cysteine-rich 
domain (CRD) that contains 14 conserved cysteine residues, which are preserved in 
all family members and determine the three dimensional structure of glypicans 
(Filmus et al., 2002). The N-terminal structure of glypicans is further stabilised by 
disulphide bridges (Fico et al., 2011) (Fig. 2-6). In contrast to syndecans, which have 
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HS chains bound throughout the core protein, glypicans carry HS chains in the C-
terminus near the GPI-anchor attachment site indicating that glypicans are able to 
bind molecules located on the cell surface, including receptors (Filmus et al., 2008; 
Song & Filmus, 2002) (Fig. 2-6). As glypicans are not transmembrane proteins, they 
are not implicated in cell adhesion, but rather play a larger role in binding and 
mediating the activity of extracellular ligands. Several key signalling molecules 
bound by glypicans include FGFs, Wnts, Hhs and BMPs (Couchman et al., 2015; 
Filmus et al., 2008). 
 
 
Figure 2-6: A schematic representation of the structure of glypican proteins. Glypicans (GPCs) 
are globular proteins bound to the cell surface via a glycosylphosphatidylinositol (GPI) anchor. GPCs 
carry heparan sulfate (HS) chains in the C-terminus close to the GPI-anchor attachment site.  The 
globular structures of GPCs is stabilised by disulphide bridges. Figure adapted and modified from 
Fico et al. 2011 (Fico et al., 2011). 
 
The mammalian genome contains six glypican family members (GPC1, GPC2, 
GPC3, GPC4, GPC5 and GPC6), with 25% amino-acid homology found between the 
two subgroups, of which one is formed by glypicans 1, 2, 4 and 6 and the other by 
glypicans 3 and 5 (Filmus et al., 2008; Song & Filmus, 2002). As with the 
syndecans, the glypicans also demonstrate tissue-specific expression and have been 
shown to play roles in various diseases. GPC1 has been demonstrated to be 
expressed in neuroepithelium, post-mitotic neurons, osteoblasts, muscle tissue, the 
 Chapter 2: Literature Review 43 
skin, kidney, and is highly expressed in pancreatic cancer cells (Melo et al., 2015; 
Song & Filmus, 2002). As such, GPC1 has been defined as a sensitive biomarker of 
pancreatic cancer (Melo et al., 2015). GPC2 is highly expressed in developing 
neuronal tissue, localising specifically to growing axons and mitotic neurons 
however in adult neuronal tissue this expression is diminished (Ivins et al., 1997; 
Song & Filmus, 2002). Reports of GPC2 expression in non-neuronal tissue are 
limited. GPC3 is expressed in many tissues during development but in the adult its 
expression is localised mainly to the lung, ovaries and mammary epithelium (Song & 
Filmus, 2002). GPC3 is upregulated in hepatocellular carcinoma (HCC) and it drives 
HCC cell proliferation through the Wnt/β-catenin pathway (Yao et al., 2014).  A 
loss-of-function mutation in the GPC3 gene results in the tissue over-growth 
syndrome Simpson-Golabi-Behmel syndrome (Pilia et al., 1996). GPC4 is expressed 
during development in the kidney, adrenal glands and in the smooth muscle of the 
endothelium and intestines and its expression has also been detected in the 
developing brain localising to areas rich in neural precursor cells (Song & Filmus, 
2002). Interestingly, GPC4 also regulates adipocyte differentiation and functions as a 
biomarker for high BMI (Ussar et al., 2012). The positive effect of GPC4 on 
adipocyte differentiation is achieved through its interaction with the insulin receptor 
(Ussar et al., 2012). GPC5 is expressed in a more limited number of tissues when 
compared to the other glypicans, however, during development its expression is 
upregulated in areas of mesenchymal proliferation and condensation, such as in 
developing digits (Song & Filmus, 2002). GPC5 is also expressed in the developing 
kidney, with this expression diminishing during maturation (Song & Filmus, 2002). 
Overexpression of GPC5 has been associated with rhabdomyosarcoma, a paediatric 
cancer arising from skeletal muscle cells, although conversely GPC5 seems to 
function as a tumour suppressor in lung adenocarcinoma (Williamson et al., 2007; 
Zhao et al., 2014). Similar to GPC5, GPC6 is detected during development in areas 
of condensing mesenchyme and in embryonic and adult tissues GPC6 expression 
pattern is similar to the structurally related GPC4 (Song & Filmus, 2002; Veugelers 
et al., 1999). In the mouse embryo GPC6 expression is localised in the developing 
gastrointestinal tract, the neuroectoderm and smooth muscle tissue of blood vessels 
(Veugelers et al., 1999). In the human GPC6 expression is enriched in the foetal 
kidney and in the adult ovary with GPC6 also shown to be involved in promoting 
human breast cancer cell invasiveness (Veugelers et al., 1999; Yiu et al.,  2011).  
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2.7.1.4 Other HSPGs 
 
Other HSPGs include the ECM-localised proteins perlecan, agrin, type XVIII 
collagen and testican family members (Dreyfuss et al., 2009; Whitelock & Melrose, 
2011). Perlecan is a large ECM protein synthesised by vascular endothelial cells and 
smooth muscle cells and it has the ability to bind and cross-links multiple ECM 
proteins, including integrins, collagen, laminin and fibronectin (Giros et al., 2007; 
Whitelock & Melrose, 2011). Perlecan also interacts with multiple extracellular 
signalling molecules and, thus plays a role in critical developmental processes, such 
as neurogenesis (Giros et al., 2007). Agrin is a large HSPG and it plays roles in 
synaptic function and in the maintenance of neuromuscular junctions (Jury & 
Kabouridis, 2010). Agrin is expressed by T cells, thus immunomodulatory roles for 
agrin have been implicated (Jury & Kabouridis, 2010). Type XVIII collagen is the 
only collagen type that carries HS chains and it is expressed in various basement 
membranes, cartilage and fibrocartilage (Whitelock & Melrose, 2011).  Depleted or 
disrupted collagen XVIII expression results in abnormalities in the eye and defects in 
the basement membrane structure in multiple organs (Iozzo, 2005). Finally, testicans 
are a family of three proteins demonstrating high expression in the brain with testican 
2 also expressed in the lung and testis (Hartmann & Maurer, 2001; Schnepp et al., 
2005). Testicans play a role in mediating neuronal migration and axonal growth and 
they have also been shown to regulate the activity of extracellular proteases 
(Hartmann & Maurer, 2001; Schnepp et al., 2005). 
 
2.7.1.5 HSPG-mediated signalling pathways 
 
HS chains bind a vast number of signalling proteins and their receptors and in this 
way regulate multiple biological functions. Soluble proteins bound by HS chains 
include growth factors such as, FGFs, EGF, VEGF, PDGF and TGF-β; morphogens 
such as BMP, Hh (Shh) and Wnts (Fig. 2-7); and cytokines and chemokines such as 
interleukins, CCL-2 and TNF-α (Dreyfuss et al., 2009). Along with ECM 
components, HS chains are also able to bind various cell surface receptors (FGFR) 
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(Fig. 2-7) and intracellular and extracellular enzymes (Dreyfuss et al., 2009; Esko & 
Selleck, 2002). The specificity of these interactions is dependent on the length of the 
HS chain, distribution of saccharide residues (GlcA vs. IdoA) as well as the number 
of N-acetyl and N-sulfation groups and the number and position of O-sulfated areas 
along the chain (Dreyfuss et al., 2009; Esko & Selleck, 2002).  
 
 
Figure 2-7: Syndecans and glypicans interact with extracellular signalling molecules and cell 
surface receptors mediating their downstream signalling. Through their HS side chains syndecans 
and glypicans interact with signalling molecules, including growth factors (FGF) and morphogens 
(Wnt) along with their receptors (FGFR) and regulate their downstream signalling. Figure adapted 
and modified from Vainio and Lin (2002) (Vainio & Lin, 2002). 
 
One of the most well characterised pathways mediated by HSPGs is the FGF 
signalling pathway where it has been established that HS and FGF interaction is 
required for fully activated FGF signalling to occur (Dreyfuss et al., 2009) (Fig. 2-7). 
Ashikari-Hada et al. demonstrated that FGF molecules bind to distinct sulfation 
patterns on HS chains and based on their binding site preferences FGFs could be 
divided roughly into five groups (Ashikari-Hada et al., 2004). Group 1 (FGF-2) binds 
to 2-O sulfated but not 6-O sulfated areas; group 2 (FGF-10) binds to 6-O sulfated 
but not 2-O sulfated areas; group 3 (FGF-18) has affinity for both 2-O and 6-O 
sulfated residues but preferring 2-O sulfation sites; group 4 (FGF-4 and FGF-7) 
requires both 2-O and 6-O sulfation sites for binding; and finally group 5 (FGF-8) 
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has no significant affinity for any of the sulfation sites (Ashikari-Hada et al., 2004). 
As such, HSPGs enhance the activity of FGF signalling through increasing the 
affinity of FGF binding to their receptors (FGFRs) and for complete activation to 
occur, HS chains also need to bind to the FGFRs (Chan et al., 2015; Harmer, 2006). 
 
Multiple roles for HSPGs in regulating morphogen signalling have also been 
reported predominantly based on studies in the model organisms Drosophila 
melanogaster, Xenopus laevis, zebrafish and rodents (Hacker et al., 2005). The 
regulatory roles of glypicans in Hh signalling were initially identified in the 
Drosophila where it was found the Drosophila glypican, Dally-like (Dlp), was 
required for Hh signal transduction (Desbordes & Sanson, 2003). It has since been 
demonstrated that the mammalian GPC3 has high affinity for Shh and Hh, but not for 
the receptor Ptc, and thus competes with Ptc for Hh binding (Capurro et al., 2008). 
The binding of GPC3 to Hh results in endocytosis of the GPC3/Hh complex, 
resulting in the inhibition of Hh signalling (Capurro et al., 2008). Interestingly, this 
effect of GPC3 on Hh signalling is not completely due to GPC3 HS chains with the 
GPC3 core protein also binding Shh with high affinity (Capurro et al., 2008). In 
contrast to GPC3, GPC5 has been shown to induce Hh signalling through increasing 
binding of Shh to Ptc instead of competing with the receptor (Li et al., 2011). In 
addition GPC5 binds to Hh and Ptc via its HS GAG chains (Li et al., 2011). Finally, 
GPC1 has been linked to playing a role in Shh-mediated axon guidance of 
commissural neuron (Wilson & Stoeckli, 2013).  
 
A role for glypicans in mediating Wnt and BMP signalling was also initially 
demonstrated through studies utilising the Drosophila glypicans Dally and Dlp. Both 
of these glypicans mediate Wg and Decapentaplegic (Dpp) signalling, homologues of 
mammalian Wnt and BMP, respectively (Jackson et al., 1997; Lin & Perrimon, 
1999). In human cells in vitro GPC3 has been found to stimulate Wnt signalling with 
GPC6 inhibiting this signalling pathway (Capurro et al., 2014). Membrane-bound 
GPC4 activates both β-catenin dependent and independent Wnt pathways but 
interestingly cleaved GPC4 has been shown to have an inhibitory effect on Wnt 
signalling (Sakane et al., 2012). In the rodent, HS chains are required for BMP 
signalling with HS promoting dimerisation of BMP type II receptors, thus acting as a 
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co-receptor (Kuo et al., 2010). Multiple other signalling molecules, including TGF-β, 
PDGF, insulin-like growth factor and members of the hepatocyte growth factor 
family have been reported to bind to extracellular proteins or HS chains, suggesting a 
high importance for PGs in mediating numerous signalling pathways (Taipale & 
Keski-Oja, 1997).  
 
2.8 HSPGS IN THE CENTRAL NERVOUS SYSTEM 
 
PGs are ubiquitous constituents of the ECM that regulate multiple cellular processes. 
Due to their diverse regulatory functions, they also mediate CNS development and 
function. 
 
2.8.1 HSPGs and the nervous system – studies in KO mice 
 
The role of HSPGs in nervous system development has been examined in vivo 
through knockout (KO) mice lacking specific enzymes involved in HSPG 
biosynthesis. EXT1 KO mice produced by Lin et al. lacked HS expression 
completely but were also embryonic lethal and thus, not suitable for further 
investigation (Lin et al., 2000). To overcome embryonic lethality, conditional KO 
mice of EXT1 were generated using a nestin-Cre line (nestin-EXT1 null mice), 
which lacked expression of EXT1 in the nervous system (Inatani et al., 2003). These 
mice were not viable and died within the first day of life with major abnormalities 
observed in the brain, including malformations in the caudal midbrain-cerebellum 
region, an abnormally small cerebral cortex and the absence of commissural tracts 
and the OB (Inatani et al., 2003). The phenotypes observed in nestin-EXT1 null mice 
also indicated disrupted FGF-8 signalling with the results demonstrating that HS is 
essential for normal brain development (Inatani et al., 2003).  
 
KO mice lacking the expression of other HS biosynthesis enzymes, including 
NDST1 and HS sulfation enzymes, HS2ST and HS6ST1, have also been generated 
and examined. NDST1 null mice were generated by Grobe et al. with these mice 
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showing decreased HS sulfation and abnormalities in their CNS development (Grobe 
et al., 2005). Developmental abnormalities detected in the embryos were of various 
severities with some embryos having only mild developmental defects in the eye, 
with other embryos demonstrating severe defects such as the lack of a defined skull 
and eyes (Grobe et al., 2005). In addition, neural precursor cells in the cortex of 
NDST1 null mice showed increased apoptosis (Grobe et al., 2005). Both HS2ST and 
HS6ST1 KO mice developed a normal brain phenotype, however the HS2ST KO 
mice exhibited reduced proliferation of neural precursor cells in the cortex 
(McLaughlin et al., 2003; Pratt et al., 2006). In both models, axon guidance defects 
were observed in retinal ganglion cells suggesting expression of HS2ST and HS6ST1 
is required to retinal axon guidance (Pratt et al., 2006). Taken together, studies in KO 
mice have demonstrated the HS expression is required for normal CNS development 
and neural cell function.  
 
In the regulation of nervous system development and NSC function various roles for 
HSPGs have been implicated. These include a role for HS chains in the stimulation 
of axon growth and acting as axon guidance cues, suggesting that HS chains may be 
involved in neural regeneration (Van Vactor et al., 2006). In addition, HSPGs are 
responsible for sequestering FGF-2 to the NSC niche, supporting NSC maintenance 
(Kerever et al., 2007). Individual HSPGs demonstrate their own specific expression 
patterns and roles in the CNS with these being discussed in detail below. 
 
2.8.2 HSPGs in axon growth and guidance 
 
A role for HSPGs in axon growth and guidance has been previously demonstrated 
(Van Vactor et al., 2006). Initial experiments in insects and amphibians revealed that 
the addition or depletion of HS chains affected axon guidance or growth, respectively 
(Walz et al., 1997; Wang & Denburg, 1992). HSPGs bind several axon growth and 
guidance molecules and mediate their activity, regulating axon growth. The 
regenerative effect of HSPGs on axon growth is achieved in part through the binding 
of HSPGs to receptor protein tyrosine phosphatase sigma (RPTPσ), a central protein 
to axonal development (Coles et al., 2011). Binding of HSPGs to RPTPσ induces 
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RPTPσ clustering on the axon growth cone promoting axon growth (Coles et al., 
2011). The axon guiding effects of HS are thought to occur due to the interaction of 
HS with axon guidance molecules, including Slit2 and Semaphorin 5A (Sema5A). 
Slit2 is an axon growth repelling protein that requires HS for binding to its receptor 
(Hu, 2001). Sema5A can either stimulate or inhibit axon growth with CSPGs shown 
to induce the inhibitory functions of Sema5A, while HSPGs are thought to induce the 
attractive properties of Sema5A (Kantor et al., 2004).  
 
2.8.3 Syndecans in neural tissue 
 
Studies in mouse and rat models have demonstrated that all four syndecans are 
expressed in the mammalian brain, each with their own specific expression pattern 
during embryonic development as well as in the adult CNS (Ford-Perriss et al., 2003; 
Hsueh & Sheng, 1999). In the developing mouse brain SDC1 is associated with 
proliferating and undifferentiated neural precursor cells as its expression is localised 
to NEP cells in areas of increased proliferation (Ford-Perriss et al., 2003; Hsueh & 
Sheng, 1999). In the adult rat forebrain SDC1 expression is almost undetectable but 
its expression can be detected in the cerebellum (Hsueh & Sheng, 1999). In vivo and 
in vitro studies have further demonstrated that SDC1 plays a role in the maintenance 
and proliferation of mouse NPCs through a Wnt-pathway mediated mechanism 
(Wang et al., 2012). In the developing mouse brain, the expression of SDC2 and 
SDC3 is restricted almost exclusively to neurons (Ford-Perriss et al., 2003). In the 
developing rodent brain SDC2 expression can be detected in the hind brain in 
neuronal cells and during brain maturation it is localised specifically to synapses and 
required for dendritic maturation of hippocampal neurons (Ethell & Yamaguchi, 
1999; Ford-Perriss et al., 2003; Hsueh & Sheng, 1999) SDC3 expression in the adult 
rat brain is concentrated in granule cells and cerebellar Purkinje cells and it is 
moderately expressed in the cerebellar cortex, hippocampus, cortex and thalamus 
(Hsueh & Sheng, 1999). With SDC3 expression strongly concentrated in rodent 
axons, a role for SDC3 in neural cell migration has been implicated (Hienola et al., 
2006; Hsueh & Sheng, 1999). Interestingly, in the rodent model SDC3 has been 
demonstrated to function as a receptor for the matrix-bound glial cell-derived 
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neurotrophic factor (GDNF), which stimulates neurite outgrowth and neuronal 
migration (Bespalov et al., 2011). Finally, similar to SDC1, also SDC4 is expressed 
in the neuroepithelium during mouse development, but at a markedly lower level 
than SDC1 (Ford-Perriss et al., 2003). In the adult rodent brain SDC4 is expressed in 
white matter, thus demonstrating glial-specific expression and its involvement in 
glial cell function is further confirmed by its role in mediating rat astrocyte adhesion 
(Avalos et al., 2009; Hsueh & Sheng, 1999).  
 
2.8.4 Glypicans in neural tissue 
 
Glypicans also demonstrate specific expression patterns in the mammalian CNS and 
are implicated to have various roles in regulating neural cell functions. In the 
developing rat brain GPC1 is expressed in areas of proliferating precursor cells, such 
as the ventricular zone, and in the adult brain GPC1 expression localises to mature 
neurons, specifically to the axons (Litwack et al., 1998). One of the major ligands of 
GPC1 are the Slit axon guidance proteins, thus GPC1 is thought to be a regulator of 
axonal guidance and branching as well as neural cell migration (Ronca et al., 2001). 
Mice lacking GPC1 expression are viable and fertile, however, they exhibit a 
significantly smaller brain when compared to control mice, which is thought to result 
from impaired FGF signalling resulting from GPC1 deficiency (Jen et al., 2009). 
GPC1 is also expressed in mouse ESC-derived NSCs, demonstrating its potential 
importance in these cells (Abaskharoun et al., 2010).  
 
GPC2, also known as cerebroglycan, is predominantly expressed in neurons, 
specifically in mitotic neurons in the developing mouse brain (Ford-Perriss et al., 
2003; Stipp et al., 1994). GPC2 localises to actively growing axons and when GPC2 
is ligated to midkine, a heparin binding neuroregulatory factor, it promotes neurite 
outgrowth and cell adhesion implying an important regulatory role for GPC2 in 
neuron function (Kurosawa et al., 2001). GPC3 is expressed in several specific 
regions of the developing mouse brain (Luxardi et al., 2007), however, currently 
there is limited data on the role of this HSPG in nervous system function. In contrast, 
GPC4 is highly expressed in the nervous system with multiple functions in regulating 
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nervous system and neural cell function identified. In the mouse brain, GPC4 
expression correlates with areas containing NSC pools, such as the ventricular zone 
in the developing brain and the DG in the adult hippocampus (Hagihara et al., 2000), 
Thus, a role for GPC4 in regulating in particular NSC maintenance and function has 
been implicated (Hagihara et al., 2000). Confirming this, in vitro expanded mouse 
NSCs have been shown to express GPC4, restricted specifically to cells that retain 
their stemness (Hagihara et al., 2000). In addition, GPC4 has been shown to be 
required for self-renewal and maintenance of both mouse ESCs and NSCs (Fico et 
al., 2012; Hagihara et al., 2000).  
 
Interestingly, a role for GPC4 in synapse function has also been implicated. In rat 
neurons GPC4 has been shown to be a ligand of the presynaptic adhesion protein 
PTPσ (Ko et al., 2015). The PTPσ/GPC4 complex is required for the activation of the 
leucine-rich repeat transmembrane protein 4 (LRRTM4) on the post-synaptic 
terminal with activation of LRRTM4 required for excitatory synaptic transmission in 
neurons (Ko et al., 2015). Also in the rat, GPC4 together with GPC6 has been shown 
to be secreted by astrocytes and required for post-synaptic glutamate receptor 
clustering, with GPC4-null mice demonstrating defects in synapse formation (Allen 
et al., 2012).  
 
GPC5 shows a specific expression pattern during nervous system development and it 
is expressed in both the mammalian adult and foetal brain with its expression in the 
early stages of development localised to post-mitotic neurons (Luxardi et al., 2007; 
Saunders et al., 1997). Several GPC5 polymorphisms have been associated in an 
Asian population with demyelinating diseases, including multiple sclerosis (MS) and 
neuromyelitis optica, implicating possible involvement for GPC5 in auto-immune 
diseases in the nervous system  (Shin et al., 2013). GPC6 is enriched in the mouse 
brain in the cerebellum and together with GPC4 it has been shown to have a role in 
synaptic function (Allen et al., 2012). In addition, GPC6 has been found to be a 
regulator of FGF-2 signalling activity during mouse cerebral cortical development 
(Salehi, 2009). 
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2.9 STEM CELL THERAPY FOR BRAIN DAMAGE TREATMENT 
 
2.9.1 Brain injury and cell therapy 
 
Acquired brain injury is a worldwide problem affecting the lives of millions of 
people and posing a significant health burden. According to Brain Injury Australia 
(www.braininjuryaustralia.org.au), brain damage acquired after birth affects 
approximately 600,000 Australians with the Brain Injury Centre Australia (Bic) 
(www.braininjurycentre.com.au/aus/) estimating that seven million people in 
Australia, European Union and North America combined have brain injury of some 
kind. Although the number of people affected by brain injury is difficult to 
accurately estimate, these statistics give an indication of the worldwide health 
problem brain damage poses.  
 
Brain damage can be caused by traumatic injury, neurodegenerative disease or stroke 
(Delcroix et al., 2010). Traumatic brain injury (TBI) results from acute trauma to the 
brain and is classified as mild if it causes no visible pathology whereas in severe 
cases it results in bleeding of the brain and in the formation of a subdural hematoma 
(Blennow et al., 2012; Zetterberg et al., 2013). In both cases, TBI can result in 
permanent disability (Blennow et al., 2012; Zetterberg et al., 2013). Common 
neurodegenerative diseases described by the loss of neurons include Parkinson’s 
disease (PD), Alzheimer’s disease (AD) and Huntington’s disease (HD) (Golas & 
Sander, 2016; Pen & Jensen, 2016). In all of these diseases no current cure is 
available and treatment consists of slowing down disease progression or managing 
the physical symptoms of patients (Golas & Sander, 2016; Pen & Jensen, 2016). In 
2011 it was estimated that in Australia 1 in 350 have PD (Parkinson’s Australia: 
Description, Incidence and Causation Information Sheet 2016) (Parkinson's, 2016) 
and current statistics estimate that over 350,000 Australians live with dementia, of 
which AD is the most common type (Fight Dementia Key Facts and Statistics 2016) 
(Alzheimer's Australia, 2016). The progressively worsening HD currently affects 
approximately 1600 Australians with 6000 estimated as being at risk of the disease 
(Huntington’s New South Wales Facts 2016) (Huntington's, 2016). Stroke is one of 
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the leading causes of death in humans and often results in disabilities that leave 
patients dependent on others (Delcroix et al., 2010). Currently, medical treatment of 
stroke is often inadequate and only effective if applied immediately with patients 
often at risk of suffering harmful side effects (Donaldson et al., 2016; Lindley, 2005).  
These causes of brain damage have a tremendous burden on society contributing to 
mortality, morbidity and disabilities worldwide and as indicated, treatment is 
insufficient and challenging with new treatment options desperately needed.  
 
Recently, more focus has been given to the use of cell therapy as a therapeutic 
approach for the treatment of brain damage (Delcroix et al., 2010; Ugoya & Tu, 
2012). Cell therapy includes the transplantation of cells into the damaged area to 
either provide more cells of a specific phenotype or to stimulate the 
growth/proliferation of existing cells in the affected area (Delcroix et al., 2010; Gage 
& Temple, 2013). Due to their multipotent neuronal differentiative properties, NSCs 
provide a promising new avenue of intervention and repair of nervous system 
injuries. However, challenges in NSC therapy remain. For the treatment to be 
efficient transplanted NSCs have to survive, proliferate, integrate and possibly 
differentiate and there needs to be control of these cellular functions to ensure safety 
and efficacy of treatment (Christie et al., 2013; Delcroix et al., 2010; Gage & 
Temple, 2013).  
 
2.9.2 Stem cell based therapy of brain injury – from rodent models to human 
 
Since the discovery of NSCs and the improved understanding of adult neurogenesis, 
new possibilities for the regenerative treatment of CNS injuries utilising stem cells 
have emerged (Eriksson et al., 1998; Ess, 2013; Kukekov et al., 1999). Rodents have 
played a major role in the development of these applications. The use of rodent 
models has enabled the establishment of in vitro derivation and expansion protocols 
of NSCs as well as the examination of adult NSCs, which from the adult human are 
challenging or impossible to harvest (reviewed in (Oikari et al., 2014)). In addition, 
rodent models have enabled the study of NSC function in vivo along with the 
development of NSC transplantation methods, which have to date shown promising 
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outcomes (reviewed in (Oikari et al., 2014)).  Rodent models of neurodegenerative 
disease and brain injury have enhanced our understanding of pathophysiology of 
brain disorders and contributed to the development of transplantation strategies for 
treatment of brain damage in humans (Giusto et al., 2014; Xiong et al., 2013). NSC 
transplantation experiments initially conducted in rodent-rodent studies successfully 
demonstrated that isolation, in vitro expansion and subsequent transplantation of 
rodent NSCs to a rodent host produced viable cells that survived and differentiated 
(Gage et al., 1995). Transplantation of rodent NSCs back to the rodent host also 
attenuated motor dysfunction following TBI or enhanced functional recovery in a PD 
model (Riess et al., 2002; Studer et al., 1998). Following these promising results, the 
transplantation of human NSCs into rodent models was tested and interestingly, 
despite the differences in brain structure, human NSCs survived, migrated and 
differentiated in the host rodent brain (Jeong et al., 2003; Svendsen et al., 1997).   
 
The primary goal of human NSC research is the development of successful strategies 
for the transplantation of human cells into a human host for the treatment of brain 
injury or neurodegenerative disease. However, the acknowledged structural 
complexity of the human brain when compared to the rodent as well as the numerous 
associated biological differences in rodent and human neurogenesis and NSC 
function pose a clear challenge when aiming to apply rodent protocols to the human. 
The differences between human and rodent models include differences in NSC 
surface marker expression and response to exogenous growth factors and cytokines 
(reviewed in (Oikari et al., 2014)) (Fig. 2-8). Rodent NSCs also express higher levels 
of telomerase and exhibit longer telomeres than human NSCs with differences in 
lineage differentiation, cell growth and culture variation between these two models 
reported (reviewed in (Oikari et al., 2014)) (Fig. 2-8).  In addition, differences in 
sensitivity to neurotoxins and chemicals affecting proliferation and apoptosis 
between rodent and human NSCs have also been reported (reviewed in (Oikari et al., 
2014)) (Fig. 2-8).  These observations suggest that rodent and human NSCs to some 
extent respond to and are regulated by different signalling environments with these 
differences important to acknowledge when extrapolating the rodent-based research 
into the human system.  
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Figure 2-8: A schematic representation of key differences between rodent and human neural 
stem cell in vitro models. A summary identified differences between these human and rodent NSC in 
vitro models. These include differences in marker expression, cell expansion, lineage differentiation, 
response to cytokine and growth factors, telomere length and telomerase expression as well as 
sensitivity to exogenous factors. Figure adapted from Oikari et al. 2014 (Oikari et al., 2014). 
 
2.9.3 Advances in human stem cell therapy 
 
To date, several human cell types, including hMSCs, hiPSCs as well as human foetal 
NSCs have been transplanted into various neuronal disease and injury rodent models 
with promising outcomes (reviewed in (Delcroix et al., 2010; Gage & Temple, 
2013)). Pre-clinical experiments have demonstrated that transplanted hMSCs 
improve nerve regeneration in a rat nerve injury model and ameliorate learning and 
memory functions in a rat ischemic stroke model (Shimizu et al., 2007; Zhou et al., 
2015). In addition, the transplantation of human iPSC-derived NSCs or NPCs into a 
rat stroke model and mouse spinal cord injury model resulted in improved functional 
recovery (Oh et al., 2015; Yuan et al., 2013). These promising results highlight the 
progress made in our understanding of human neurogenesis and the potential human 
stem cells hold in brain damage treatment.  
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Transplantation experiments of human NSCs generally involve embryo-derived cells 
due to the inaccessibility of adult human NSCs. In a study by Haus et al. it was 
shown that hESC-derived NSCs transplanted into a rat TBI model improved host 
neuronal survival and enhanced cognitive function (Haus et al., 2016). Also in the rat 
ischemic stroke model the immortalised hNSC cell line HB1.F3 was shown to 
migrate and differentiate in the damaged ischemic region and promote the 
proliferation and differentiation of host NSCs (Ryu et al., 2016). Attempts have also 
been made to transplant human cells into the brain of a human host, however, the use 
of foetal human cells raises ethical issues and also poses a risk in terms of host 
rejection and tumour formation (Delcroix et al., 2010; Harris et al., 2016). In one 
case, foetal NSCs were transplanted into a human patient resulted in the formation of 
a brain tumour with the tumour cells generated by the donor NSCs (Amariglio et al., 
2009). The use of adult human stem cells (hMSCs, hiPSCs and hNSCs) has become 
ethically more accepted and provides the opportunity for autologous transplantation 
strategies. The company “Reneuron” is currently conducting clinical trials for the 
treatment of stroke and retinal diseases, using CTX stem cells – a neural cell line 
generated using proprietary cell expansion and cell selection technologies, then taken 
through manufacturing scale-up and quality testing process, and human retinal 
progenitor cells, respectively (http://www.reneuron.com/clinical-trials/, (ReNeuron, 
2016)). With evidence of the emerging potential for the use of human stem cells in 
brain damage treatment, clear success stories of human-to-human stem cell therapy 
are yet to be reported. With by poor survival, integration and differentiation the key 
challenges of human stem cell transplantation (Delcroix et al., 2010; Harris et al., 
2016), the development of improved human stem cell therapies requires a better 
knowledge of the regulation of these aspects of human stem cell behaviour. 
 
2.9.4 Heparan sulfate proteoglycans and NSCs – a target for therapy? 
 
An improved understanding of mechanisms that mediate hNSC self-renewal and 
lineage-specific differentiation is crucial to enable the development of human-to-
human hNSC transplantation techniques. HSPGs, which are widely present in the 
nervous system and regulate multiple cellular behaviours, have the potential to 
provide novel targets to enable better NSC regulation and neural repair. The 
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important role of HS in the CNS is supported by multiple in vivo studies. HS 
expression is known to be required for normal CNS development and HS has been 
shown to mediate axonal growth and guidance, highlighting the importance of 
HSPGs within the neural niche (Coles et al., 2011; Grobe et al., 2005; Inatani et al., 
2003; Lin et al., 2000; McLaughlin et al., 2003; Pratt et al., 2006; Van Vactor et al., 
2006). Several studies in rodent models have also implicated a role for HSPGs in 
NSC and NPC function in vitro (Abaskharoun et al., 2010; Araujo et al., 2010; Fico 
et al., 2012; Hagihara et al., 2000; Pickford et al., 2011; Wang et al., 2012). As 
HSPGs are known to interact with a wide variety of extracellular signalling 
molecules, including growth factors and morphogens important in NSC function, a 
key regulatory role for HSPGs in the NSC niche is indicated (Capurro et al., 2008; 
Dreyfuss et al., 2009; Sakane et al., 2012; Wang et al., 2012). Thus, HSPGs may 
provide a novel target for developing improved therapeutic models and strategies of 
neurogenesis and neural repair. 
 
The cell membrane-associated localisation of HSPGs poses an intriguing target for 
improved NSC therapy. Optimally, by identifying key HSPGs in the hNSC niche, 
these may be able to be utilised as markers for the better identification, 
characterisation and isolation of hNSCs and lineage-specific neural cells. In addition, 
HSPGs may provide a molecular target with which to enhance cell survival and 
proliferation and control neural differentiation or migration of transplanted hNSCs. 
The overexpression of key HSPGs in hNSCs also has potential for enhancing 
extracellular signalling molecule efficiency to direct cell lineage specific 
differentiation. Identification of the HSPGs that mediate NSC self-renewal and 
differentiation would also enable the more efficient use of other human stem cells 
with neural differentiation potential, including hMSCs and hiPSCs, to be more 
readily utilised for autologous transplantation. 
 
Currently very little is known regarding the roles of HSPGs in hNSC regulation. To 
date, most of the studies examining the expression or function of HSPGs in the CNS 
or neural cells have been conducted in model organisms, such as the mouse and rat. 
It is important to highlight that while similarities between the human and rodent 
models exist, these models also exhibit differences in key cellular properties 
 58 Chapter 2: Literature Review 
(previously discussed in section 2.9.2). In addition, the majority of the literature in 
the field of HSPG function within neural cells occurred more than 10 years ago 
placing a desperate need for current, human based research. This will improve our 
understanding of nervous system biology and potentially enable the development of 
more efficient human stem cell transplantation strategies for brain damage repair.  
 
2.10 SUMMARY  
 
NSCs are multipotent stem cells of the CNS with the ability to differentiate toward 
specialised neural cell types, including neurons, astrocytes and oligodendrocytes. 
Due to their multi-lineage differentiation ability, NSCs provide a model of 
neurogenesis in vitro and pose a promising tool in the cell therapy based treatment of 
brain damage. Currently stem cell therapy of brain damage is challenged by multiple 
factors, including the poor survival, integration and differentiation of transplanted 
cells, thus a better understanding of NSC maintenance and regulation of 
differentiation is needed. The extracellular microenvironment, or the niche, is known 
to play an important role in NSC function. HSPGs are ubiquitous proteins of the 
ECM and consist of a core protein and attached HS side chains. HSPGs are mainly 
bound to the cell surface and are composed of the two major families: the syndecans 
and the glypicans. Through their HS side chains HSPGs are able to bind and mediate 
the activity of multiple extracellular signalling molecules known to be important in 
NSC regulation. Several roles for HS and for syndecan and glypican core proteins in 
the rodent neural niche have been reported, including regulation of axon growth, 
mediating NSC maintenance as well as being expressed in neurons and glial cells. 
These reports suggest that HSPGs may be key regulatory proteins of NSCs, however, 
their roles in the human system have to date been sparsely investigated. Improved 
human model based research in the field of HSPGs and neural cell regulation is 
needed to improve our understanding of human nervous system biology. This can 
potentially be applied for the development of more efficient human stem cell 
transplantation strategies.   
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2.11 HYPOTHESIS 
 
Heparan sulfate proteoglycans (HSPGs) in the human neural stem cell (hNSC) niche 
regulate hNSC self-renewal, proliferation and differentiation. Identifying key HSPGs 
that mediate hNSC fate will improve our understanding of neurogenesis and enable 
the development of efficient cell transplantation techniques for neural repair.  
 
2.12 AIMS 
 
The aim of this project was to examine HSPGs in basal hNSCs and during hNSC 
lineage differentiation to identify the key HSPGs mediating hNSC lineage 
specification. As a model of hNSCs, commercially available and adherently 
expanded hESC-derived NSCs were investigated.  The HSPG profile, including the 
expression of HS biosynthesis enzymes as well as syndecan and glypican core 
proteins was examined during basal expansion of hNSCs. hNSCs were then 
differentiated toward neurons and glial cells with lineage-specific changes in the 
neural lineage marker expression as well as the HSPG profile of the cells established. 
Differentiating hNSCs were then examined under HS and key neuroregulatory 
growth factor modulatory conditions to investigate the potential influence of HS and 
HS binding growth factors on neuronal and glial lineage specification. In addition, 
due to the high inherent neuronal differentiation potential of hESC-derived NSCs, 
the potential mechanisms behind HSPG-mediated neurogenesis were investigated 
through the examination of key HSPGs and signalling pathways in extended 
neuronal culture conditions. This study involved the optimisation of hNSC expansion 
and differentiation protocols with Q-PCR, Western blotting and immunofluorescence 
routinely used throughout the study for cell characterisation. Several techniques, 
including confocal microscopy and analysis of calcium signals were utilised to 
further examine the structure and functionality of hNSC-derived neurons.  
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2.13  RESEARCH DESIGN 
 
The research design of this study consisted of three specific Aims as outlined below: 
 
Aim 1: Characterisation of HSPGs during human neural stem cell expansion  
1.1 Expansion and characterisation of human neural stem cells (hNSCs). 
Optimised culture conditions were established for the expansion of 
commercially obtained human embryonic stem cell H9-derived NSCs (hNSC 
H9 cells). During expansion, cells were monitored for morphology and 
viability at each passage. Quantitative PCR (Q-PCR), immunofluorescence 
(IF) and Western blot (WB) analysis was performed to monitor expression of 
NSC self-renewal and neural lineage-specific markers at each passage. 
1.2 Determination of basal expression levels of heparan sulfate proteoglycan 
(HSPG) core proteins and biosynthesis enzymes in hNSC cultures. The 
expression profile of HSPG core protein genes and associated polymerisation, 
modification and sulfation enzymes of HSPG biosynthesis (approximately 30 
genes) were examined in hNSC H9 cells by Q-PCR with highly expressed 
HSPGs further examined by IF. 
1.3 Comparison of NSC and neural-lineage marker expression as well as PG 
profile between hNSCs and neural progenitor cells (hNPCs). Commercially 
available hNPCs cultured as neurospheres were expanded for use as control 
cultures for comparison to hNSCs for markers of lineage specificity. Marker 
gene expression along with the PG profile was compared and correlated 
between hNSC H9 cells and hNPCs to identify key markers and PGs of 
lineage progression from NSCs to NPCs.  
 
Aim 2: Identification of key HSPGs of human neural stem cell lineage-
specification 
2.1 Establish culture conditions for the lineage-specific differentiation of hNSCs. 
Neuronal and glial differentiation protocols of hNSC H9 cells were 
optimised. During 14 – 18 (D14-18) days of differentiation hNSC H9 cell 
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morphology was monitored and lineage specification confirmed via 
examination of the expression of lineage-specific markers via Q-PCR, IF and 
WB analysis.  
2.2 Identification of key HSPGs of hNSC lineage specification. Following 
confirmed lineage differentiation, changes in hNSC H9 cell HSPG profile 
following D14-18 of differentiation was examined via Q-PCR, IF and WB. 
Key changes in the HSPG profile of the cultures were compared to HSPG 
expression levels in hNPCs examined in Aim 1 to confirm key HSPGs of 
associated with neural lineage specificity.  
2.3 Targeted modulation of key HSPGs in hNSCs to investigate their role on 
hNSC lineage potential.  To confirm the role of the identified key HSPGs 
during hNSC H9 cell lineage specification, expression of selected HSPGs 
was downregulated in basal hNSC H9 cells using RNA-interference (RNAi) 
with the effect on lineage potential investigated through the examination of 
changes in NSC and lineage-specific marker expression by Q-PCR, IF and 
WB analysis.  
 
Aim 3: Investigation of mechanisms of HSPG-mediated neural lineage 
differentiation.  
3.1 Establishing long-term hNSC differentiation culture conditions. To enhance 
hNSC H9 cell neural and astrocyte lineage specific differentiation, day 40 
(D40) differentiation culture conditions were established. Differentiation 
efficiency was determined by examining cell morphology and marker 
expression. Marker and HSPG profile of D40 differentiated cultures was 
examined by Q-PCR, IF and WB analysis and compared to the expression of 
the cells derived in Aim 2. 
3.2 Modulation of HS and key pathways during hNSC neuronal and glial 
differentiation. Modulation of HS and selected key signalling pathways was 
performed through the addition of HS (heparin) and extracellular ligands 
(BDNF and PDGF) during D40 of lineage-specific differentiation culture. 
The effect of these in vitro modulations on lineage specificity and HSPG 
profile was determined through the examination of lineage-specific markers, 
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pathway specific markers and HSPG expression via Q-PCR, IF and WB 
analysis. 
3.3 Exploiting HS-growth factor interactions for neuronal differentiation of 
hNSCs. hNSC H9 cells were examined during extended culture in D40 and 
D60 neuronal differentiating conditions with the effect of HS and key growth 
factors (BDNF and PDGF) on neuronal lineage specification examined. To 
determine the effects of the exogenous treatments, cell survival, cell 
proliferation, marker expression and cellular structure of the cultures were 
examined. Techniques for this analysis included live/dead cell analysis 
through FDA/PI, confocal microscopy, Q-PCR and WB analysis. Neuronal 
functionality was assessed through measurement of spontaneous calcium 
signalling using Fluo-4 calcium indicator and a fluorescent microscope.  
3.4 Unravelling the mechanisms of HSPG-mediated control of neurogenesis. The 
expression and localisation of key HSPGs identified in Aims 1 – 3 along with 
BDNF and PDGF pathway receptors and ligands were examined in expanded 
D40 and D60 neuronal differentiating hNSC H9 cultures. The expression of 
key HSPGs was downregulated using RNAi in neuronal differentiating hNSC 
H9 cells and BDNF and PDGF signalling blocked by pathway specific 
inhibitors ANA-12 and Tyrphostin AG-1295. Following HSPG 
downregulation and pathway inhibition, changes in the cellular response to 
BDNF and PDGF was examined via examination of cell number, 
proliferation, pathway specific and marker expression using Q-PCR and IF in 
the cultures.  
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Chapter 3: Materials and Methods 
 
This chapter describes the research methodologies, which were used to achieve the 
specific aims of this study described in section 2.13 in Chapter 2. The first part of 
this Chapter discusses the cell models used in the study (section 3.1) followed by 
description of the basal expansion protocols used to culture the cells (section 3.2). 
The culture protocols used for lineage specific differentiation (section 3.3), in vitro 
modulations (section 3.4) and RNA-interference (section 3.5) are then presented 
followed by a description on gene and protein expression studies (section 3.6). The 
cell imaging methodologies (section 3.7) as well as the Fluo-4 calcium signal assay 
protocols (section 3.8) are then presented. At the end of this Chapter a description on 
the statistical analyses used (section 3.9) along with statement regarding ethics 
(section 3.10) and resources (section 3.11) is presented.   
 
3.1 CELL MODELS 
 
3.1.1 Human Neural Stem Cells (H9-derived)  
 
GIBCO® human neural stem cells derived from NIH approved (WA09) human 
embryonic stem cells (hNSC H9 cells) (Thermo Fisher Scientific) were utilised as 
the main model of NSC self-renewal and multi-lineage potentiality in this study.  
hNSC H9 cells were expanded as an adherent culture, during which they retain the 
capacity to self-renew and to differentiate into neurons, astrocytes and 
oligodendrocytes after multiple passages. hNSC H9 cells stain positive for the NSC-
type specific markers nestin and SOX2 and exhibit a doubling time of 40 – 50 hours. 
In this study a total of three hNSC H9 populations were obtained and expanded. The 
first population (POP0) was utilised to optimise culture conditions. The main 
experiments of this study were performed using POP1 and POP2 cells with results 
presented as the average between these two populations. 
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3.1.2 Normal Human Neural Progenitor Cells 
 
PoieticsTM Neural Progenitor Cells (nhNPCs) (Lonza) isolated from the human brain 
cortex were utilised as a model of lineage progression from NSCs to NPCs. nhNPCs 
were cultured as neurospheres and maintained in an undifferentiated state in 
suspension as a 3D aggregate. Upon adhesion to substrate nhNPCs can be induced to 
differentiate into neurons, astrocytes and oligodendrocytes, after which they stain 
positive for TUBB3 and GFAP (Lonza).  
 
3.1.3 Other cell models 
 
SHSY-5Y human neuroblastoma cells (positive control for neural cell markers, e.g. 
TUBB3, (Forster et al., 2016)) and MCF-7 human breast cancer cell line (negative 
control for neural cell markers), obtained from ATCC, were utilised for analysis of 
calcium signalling (section 3.8).  
 
3.2 BASAL CELL EXPANSION 
 
3.2.1 Culture of hNSC H9 cells 
 
hNSC H9 cells were cultured as a monolayer on GeltrexTM (Thermo Fisher 
Scientific) coated culture dishes. 
 
3.2.1.1 GeltrexTM -coating 
 
GeltrexTM (Thermo Fisher Scientific) is a lactose dehydrogenase elevating virus 
(LDEV) –free reduced growth factor basement membrane matrix extracted from 
murine Engelbreth-Holm-Swarm tumours. To make up 100X GeltrexTM working 
aliquots, the 5mL GeltrexTM stock vial was thawed slowly at 4 °C, after which it was 
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diluted 1:2 in KnockOutTM DMEM/F-12 (Thermo Fisher Scientific). Working 
aliquots of 200 – 500 μL were stored at -20 °C. Coating of culture dishes was 
achieved by diluting 100X GeltrexTM stock 1:100 with KnockOutTM DMEM/F-12 
and adding 1X GeltrexTM dilution to cover the whole of the surface area of the 
culture dish. Coated culture dishes were sealed with parafilm and maintained at room 
temperature (RT) for one hour after which they were stored at 4 °C for up to one 
month. Before plating of cells, GeltrexTM was aspirated, the culture dish rinsed with 
1X phosphate buffered saline (PBS) after which culture medium and cells were 
added.  
 
3.2.1.2 hNSC H9 expansion 
 
hNSC H9 cells were cultured in StemPro® NSC serum-free medium (NSC SFM) 
consisting of KnockoutTM DMEM/F-12, 2% StemPro® Neural Supplement and 2 
mM GlutaMAXTM-I supplemented with 20 ng/mL of FGFb and EGF all obtained 
from Thermo Fisher Scientific (Table A1, Appendix A). hNSC H9 cultures were 
established by carefully thawing the cell ampules in a water bath at 37 °C. The 
defrosted cell suspension (1 mL) was then transferred to a 15 mL Falcon tube 
containing 2 mL of pre-warmed NSC SFM. An additional 2 mL of pre-warmed NSC 
SFM was added to the tube (a total volume of 5 mL), after which the cells were 
centrifuged to a pellet at 700 X g for 5 min. Following this, the culture medium was 
aspirated, the cell pellet resuspended into fresh NSC SFM and cells plated at an 
initial density of 1 X 105 cells/cm2. For standard expansion hNSC H9 cells were 
cultured in p35 (10 cm2) dishes at a density of 5 X 104 cells/cm2 and maintained in 
5% CO2 at 37 °C in a humidified atmosphere. Cell culture medium was changed 
every two days. 
 
3.2.1.3 Passaging of hNSC H9 cells 
 
Cells were passaged at 90% confluence using TrypLE (Thermo Fisher Scientific). 
Briefly, culture medium was removed and cells rinsed gently with 1X PBS. To 
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detach cells, TrypLE (1 mL per p35 dish) was added to the cells and incubated for 2 
– 5 minutes at RT, after which NSC SFM was used to neutralise further 
trypsinisation. The cell suspension was transferred to a 15 mL tube and aliquots of 
cell suspension taken to perform cell counts. Cells were then centrifuged to a pellet at 
700 X g for 5 min, the supernatant removed and cells rinsed once more with NSC 
SFM to remove all TrypLE remnants. The cell pellet was resuspended into a desired 
volume of NSC SFM for replating.  
 
Cell numbers and cell viability were monitored using Trypan Blue and an automated 
cell counter (Bio-Rad) or a hemocytometer. For the Bio-Rad cell counter, 10 μL of 
cell suspension was combined with 10 μL of Trypan Blue with 10 μL of the mixture 
loaded on each side of the cell counter slide. For hemocytometer cell counts, 18 μL 
of cell suspension was combined with 2 μL of Trypan Blue and cell number 
calculated as follows: total cells counted X dilution factor X 104 = cells/mL. Both 
automated cell counter and hemacytometer counts were performed in duplicate and 
an average cell count calculated.  
 
3.2.1.4 Storage of hNSC H9 cells 
 
After cell passaging, hNSC H9 cells not used were stored in liquid nitrogen. Briefly, 
following trypsinisation, cells were washed once in 1X PBS and resuspended 1:1 in 
NSC SFM and 2X NSC freezing medium. The NSC SFM freezing medium 
contained NSC SFM and 20% DMSO. The cells were frozen in CryoTube vials 
(Thermo Fisher Scientific) in 1 mL aliquots containing approximately 5 X 105 cells. 
After storage of the cells overnight at – 80 °C, cells were placed under liquid 
nitrogen for long-term storage.  
 
3.2.2 Normal Human NPC expansion 
 
Normal human NPCs (nhNPCs), derived from the human foetal cortex were obtained 
from Lonza and grown as neurospheres. These cells were used as a model of more 
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lineage-restricted neural cells in comparison to the self-renewing and multipotent 
hNSC H9 cells. In this study, nhNPCs were cultured short-term to obtain samples for 
the representation of neural lineage specification of hNSCs. NhNPCs were cultured 
in Neural Progenitor Maintenance Medium (NPMM), which contained 200 mL of 
Neural Progenitor Basal Medium, 0.4 mL rhFGFb, 0.4 mL rhEGF, 4.0 mL Neural 
Survival Factor-1 and 0.4 mL Gentamicin/Amphotericin all obtained from Lonza 
(Table A2, Appendix A). To establish nhNPC neurosphere cultures, cell ampules 
were defrosted in a water bath at 37°C and divided into two T75 flasks containing 20 
mL of NPMM. Cells were maintained under 5% CO2 at 37 °C in a humidified 
atmosphere. After 72 h, the cell suspension from both T75 flasks was pooled and 
cells centrifuged to a pellet at 700 X g for 5 min. Pellets were then resuspended in 4 
mL of NPMM and a 0.5 mL of the cell suspension was added into a new T75 flask 
containing 20 mL of fresh NPMM. The remaining cells were collected for RNA, 
plated on two 8-chamber slides for microscope imaging, and additional aliquots of 
the cells were stored in liquid nitrogen (NPMM + 10% DMSO). 
 
3.3 HNSC H9 CELL LINEAGE DIFFERENTIATION 
 
3.3.1 Neuronal differentiation 
 
hNSC H9 cell neuronal differentiation was induced by culturing cells on poly-L-
ornithine and laminin coated culture dishes in neuronal differentiation medium based 
on a protocol provided by Thermo Fisher Scientific.  
 
3.3.1.1 Poly-L-Ornithine and laminin coating 
 
Lyophilised poly-L-ornithine (PO) (Sigma) was dissolved in 1 mL of dH2O to make 
up 500X stock solution of 10 mg/mL. The stock solution was aliquoted and stored at 
-20 °C until use.  PO was diluted 1:500 with dH2O to make up a 20 μg/mL working 
solution for coating. Mouse laminin 1 mg/mL (Thermo Fisher Scientific) was thawed 
slowly at 4 °C and stored in smaller aliquots at -80 °C. Before use laminin was 
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diluted 1:100 with dH2O to a 10 μg/mL working solution for coating culture dishes. 
Culture dishes were coated by adding an appropriate volume of PO to cover the 
whole surface area (e.g. 200 μL/well in a 48-well plate or 400 μL/well in a 24-well 
plate). PO was incubated on culture dishes for 1 h at 37 °C after which it was 
removed and wells rinsed 2X with dH2O. A working solution of laminin was then 
added to the culture dishes and incubated at 37 °C for 2 h. After incubation, laminin 
was removed and wells rinsed with 1X PBS. For storage, wells were filled with 1X 
PBS, sealed with parafilm and stored at 4 °C for up to two weeks. Before plating of 
cells, PBS was removed and cells added in culture medium.  
 
3.3.1.2 Neuronal induction 
 
All neuronal differentiation experiments were performed using hNSC H9 passage 5 
(P5) cells in 48- or 24-well plate format. To induce neuronal differentiation, cells 
were plated on PO and laminin coated culture plates at a density of 2.5 x 104 
cells/cm2 (48-well plate: 1.75 x 104 cells/well; 24-well plate: 4 x 104 cells/well) in 
NSC SFM. Cells were allowed to attach for 48 h, after which culture medium was 
changed to neuronal differentiation medium consisting of Neurobasal medium 
supplemented with 2% B-27 and 2mM of GlutaMAXTM-1, all obtained from Thermo 
Fisher Scientific (Table A3, Appendix A). Differentiating hNSC H9 cells under these 
conditions have been reported to result in the generation of neuronal marker βIII-
tubulin (TUBB3) and doublecortin (DCX) expressing neurons (Tennstaedt et al., 
2015; Yan et al., 2013). Neuronal differentiation medium was protected from light 
and stable for up to two weeks at 4 °C.  The culture medium volume for the 48-well 
format was 500 μL and for the 24-well plate 1 mL and during differentiation the 
culture medium was changed every 3 – 4 days. Due to the fragility of the cells, 
during media change only half of the culture medium volume was removed gently 
with a pipette after which the same volume of fresh medium was added drop wise. 
Neuronal differentiation was induced for 14 – 18 days, 40 days and 60 days during 
which cell morphology was monitored and phase-contrast images captured of live 
cells every 2 – 4 days. At the end of each differentiation experiment live/dead cell 
ratios were determined and remaining cells were harvested for RNA and protein or 
fixed for immunofluorescence imaging.  
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3.3.2 Astrocyte differentiation 
 
The astrocyte differentiation experiments were performed using hNSC H9 P5 cells 
based on a protocol provided by Thermo Fisher Scientific, shown to result in the 
generation of glial fibrillary acidic protein (GFAP)-expressing astrocytes (Yan et al., 
2013). Briefly, astrocyte differentiation was induced by plating cells on GeltrexTM 
coated culture plates at a density of 2 x 104 cells/cm2 (48-well plate: 1.75 x 104 
cells/well) in NSC SFM. Cells were allowed to attach for 48 h, after which culture 
medium was changed to astrocyte differentiation medium consisting of DMEM 
medium supplemented with 2% foetal bovine serum (FBS) (Hyclone), 2% of N-2 
supplement and 2mM of GlutaMAXTM-1 obtained from Thermo Fisher Scientific 
(Table A4, Appendix A). Astrocyte differentiation medium was protected from light 
and was stable for up to four weeks at 4 °C. During differentiation the culture 
medium was changed after every 3 – 4 days with a vacuum. Astrocyte differentiation 
was induced for 14 – 18 days and 40 days, during which cell morphology was 
monitored and phase-contrast images captured of live cells every 2 – 4 days. At the 
end of differentiation experiments live/dead cell ratios were determined and 
remaining cells were harvested for RNA and protein or fixed for 
immunofluorescence imaging.  
 
3.3.3 Oligodendrocyte differentiation 
 
Oligodendrocyte differentiation experiments were performed using hNSC H9 P5 
cells based on a protocol provided by Thermo Fisher Scientific. To induce 
oligodendrocyte differentiation, hNSC H9 cells were plated in NSC SFM on PO and 
laminin coated culture plates at a density of 2.5 x 104 cells/cm2, which equalled to 
1.75 x 104 cells/well on a 48-well plate. Cells were allowed to attach for 48 h, after 
which culture medium was changed to oligodendrocyte differentiating medium, 
composed of Neurobasal medium, 2% B-27, 2mM of GlutaMAXTM-1 (all obtained 
from Thermo Fisher Scientific) supplemented with 30 ng/mL T3 (Sigma) (Table A5, 
Appendix A).  
 
 70 Chapter 3: Materials and Methods 
3.3.4 Viability analysis of differentiated cells 
 
The viability of differentiated cells was examined by co-staining cells with 
fluorescein diacetate (FDA) and propidium iodide (PI). Live cells were detected by 
FDA, which is taken up by live cells and converted into fluorescein, a fluorescent 
metabolite (Jones & Senft, 1985). Dead cells were detected through PI, which is a 
DNA-binding dye and able to enter the nuclei of dead cells through a disrupted cell 
membrane (Jones & Senft, 1985). The FDA working solution was prepared by 
dissolving lyophilised FDA (Sigma) in acetone (5 mg/mL). The PI working solution 
was constituted by dissolving lyophilised PI (Sigma) in 1X PBS (2mg/mL). Both 
FDA and PI working solutions were stored in -20 °C. To perform FDA/PI staining, 
FDA and PI were added directly to the cells at a dilution of 1:1000 and incubated for 
10 min at RT in the dark. FDA and PI were then detected on an Olympus IX8 phase-
contrast fluorescent microscope using FITC (excitation: 490 nm, emission: 530 nm) 
and Texas Red (excitation: 590 nm, emission: 620 nm) filters, respectively. Images 
were acquired on a Hamamatsu Orca camera using Volocity® v.6.3. software (Perkin 
Elmer). The mean signal intensity for FDA and PI for a field of view was measured 
using Volocity software and the mean signal intensity for three fields of view 
averaged. The PI to FDA ratio was calculated by dividing the PI signal intensity by 
FDA signal intensity.  
 
3.4 IN VITRO MODULATIONS 
 
3.4.1 Heparin treatment 
 
Heparin (Sigma), a highly sulfated soluble analogue of heparan sulfate (HS) was 
used as a supplement in the study to examine the effect of exogenous HS on 
differentiating hNSC H9 cells. To determine the appropriate concentration of 
heparin, a dose-response experiment was performed (Fig. 3-1). Briefly, 
undifferentiated hNSC H9 P4 cells were plated at an approximate density of 17-18 x 
104 cells/well in a 48-well culture dish and treated immediately with three 
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concentrations of heparin: 0 μg/mL (control), 2.5 μg/mL (Fig. 3-1A), 5 μg/mL (Fig. 
3-1B) or 10 μg/mL (Fig. 3-1C). Cells were cultured for seven days with phase-
contrast images acquired and the number of viable cells measured and at day 1 (D1), 
D3, D5 and D7 timepoints. The experiment was performed in triplicate.  
 
The dose-response experiment demonstrated that hNSC H9 cells responded to 
heparin, with the different concentrations eliciting different effects on cell number 
when compared to control cultures. Between D1-D3, control and heparin-treated 
culture conditions exhibited linear growth (Fig. 3-1). Between D5-D7 control 
cultures continued to exhibit linear growth, while heparin-treated cultures 
demonstrated a plateau phase in growth (Fig. 3-1). When the cultures were examined 
at D7, cultures treated with 2.5 μg/mL of heparin exhibited a 10% increase in cell 
number when compared to control cultures (Fig. 3-1A). Interestingly, cultures treated 
with 5 μg/mL of heparin exhibited only a 3% increase in cell number when compared 
to control cultures at D7 (Fig. 3-1B). Treatment of cells with 10 μg/mL of heparin 
resulted in a 26% increase in cell number at D7 when compared to control cultures 
(Fig. 3-1C). With the highest increase in cell number observed following treatment 
of hNSC H9 cells with 10 μg/mL of heparin, this concentration was used as a 
supplement in neuronal and glial differentiating hNSC H9 cultures.  For heparin 
treatment of differentiating cultures, stock heparin solution (10 mg/mL) was diluted 
to a working concentration (1 mg/mL) with dH2O. The working solution of heparin 
was added to culture medium at 1:100 during every medium change. 
 
 72 Chapter 3: Materials and Methods 
 
 
 
3.4.2 BDNF and PDGF treatment 
 
Brain-derived neurotrophic factor (BDNF) and platelet-derived growth factor 
(PDGF) were added to differentiating hNSC H9 cultures at a concentration of 10 
ng/mL. The concentration of 10 ng/ml has previously been shown to be effective in 
inducing neuronal differentiation of human stem cell types by BDNF and to be 
effective in inducing glial differentiation of human mesenchymal stem cells (hMSCs) 
and rodent NPCs by PDGF (D'Aiuto et al., 2014; Hermann et al., 2004; Liu et al., 
2004; Miura et al., 2015; Palm et al., 2015). Lyophilised BDNF (Thermo Fisher 
Scientific) was dissolved in dH2O to make a stock concentration of 100 μg/mL, 
which was stored at -20 °C. A working solution of BDNF was made by diluting 
stock BDNF to a 10 μg/mL concentration dH2O, which was added to culture medium 
at 1:1000 to make up a final concentration of 10 ng/mL. Lyophilised PDGF-BB 
(Sigma) was dissolved in 4 mM HCL and 0.1% BSA for stock concentration of 50 
μg/mL, which was store at -80 °C. A working solution of PDGF was made by 
diluting stock PDGF to a 10 μg/mL concentration with dH2O, which was then added 
Figure 3-1: hNSC H9 live cell number 
following treatment of cultures with 
heparin. Cell growth curves demonstrating 
hNSC H9 live cell numbers following 
treatment of cells with A) 2.5 μg/mL B) 5 
μg/mL and C) 10 μg/mL heparin compared 
to untreated control cells. Cell numbers are 
averaged from three experiments and error 
bars represent SD. 
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to the culture medium at a concentration of 1:1000 to make up a final concentration 
of 10 ng/mL  
 
3.4.3 Trkb and PDGFRβ inhibition 
 
Specific inhibitors were used to block BDNF and PDGF pathway signalling. The 
BDNF-pathway was inhibited through the use of Trkb (BDNF receptor) inhibitor 
ANA-12 (Sigma). Lyophilised ANA-12 was dissolved in DMSO to a 20 mM stock 
solution. ANA-12 was applied to cell cultures at a final concentration of 10 μM 
(1:2000). Concentration of 10 μM of ANA-12 has previously been shown to be 
effective in the inhibition of BDNF-mediated signalling in mouse neurons without 
reduction of neuronal survival (Cazorla et al., 2011). The PDGF pathway was 
inhibited through the use of PDGFRβ-inhibitor Tyrphostin AG-1295 (AG-1295) 
(Santa Cruz Biotechnology). Lyophilised AG-1295 was dissolved in DMSO to a 10 
mM stock solution and was applied to cell cultures at a final concentration of 10 μM 
(1:1000). Concentration of 10 μM of AG-1295 has previously been shown to be 
effective in the inhibition of PDGF-mediated signalling in human adipose-derived 
stem cells and the reduction of human smooth muscle cell proliferation (Epstein et 
al., 2008; Hutton et al., 2013). A concentration of 0.001% DMSO was used as a 
control for ANA-12 and AG-1295 treatments to confirm that DMSO did not 
significantly alter cell phenotype.  
 
For BDNF and PDGF pathway inhibition, hNSC H9 P5 cells were plated on poly-L-
ornithine and laminin coated 48-well dishes at 3 x 104 cells/well. Cells were allowed 
to attach for 48 h after which cells were exposed to ANA-12 or AG-1295 for 72h. 
Following this, cell counts and viability measurements were obtained of the cultures 
and cells were harvested RNA extractions as described in section 3.6.1. 
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3.5 RNA-INTERFERENCE (RNAi) 
 
3.5.1 RNAi procedure 
 
The expression of selected syndecan (SDC) and glypican (GPC) core proteins was 
downregulated using Accell SMARTpool small interfering RNA (siRNA) 
technology (DharmaconTM). Accell siRNAs are chemically modified to enable 
uptake by cells without the use of a transfection reagent. AccellTM SMARTpool 
Human siRNAs (DharmaconTM) contain a pool of four siRNA transcripts specific to 
the human gene of interest allowing higher knockdown specificity and efficiency.  
 
Upon receipt lyophilised Accell SMARTpool Human siRNAs were resuspended in 
1X siRNA Buffer, by diluting the 5X siRNA Buffer (DharmaconTM) 1:5 with dH2O. 
A concentration of 100 μM siRNA stocks was made and stored at -20 °C until use. 
For RNAi, cells were treated with siRNA pools specific to SDC1, SDC4, GPC1 or 
GPC4 (Table 3-1). For siRNA delivery, the NSC SFM was changed to AccellTM 
siRNA Delivery Media supplemented with siRNAs at a final concentration of 1 μM.  
As a control, untreated (Delivery Media only) and non-targeting siRNA (scramble) 
treated cells were used. Cells were incubated with siRNAs for 72 h or 96 h after 
which cells were harvested for RNA and protein samples, respectively. Cell number 
and viability was measured following RNAi. 
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Table 3-1: Accell siRNA sequences 
siRNA 
#Cat 
Target Sequence 
Non-targeting 
#D-001910-10-20 
siRNA_1: UGGUUUACAUGUCGACUAA 
siRNA_2: UGGUUUACAUGUUUUCUGA 
siRNA_3: UGGUUUACAUGUUUUCCUA 
siRNA_4: UGGUUUACAUGUUGUGUGA 
Accell Human SDC1 (6382) 
#E-010621-00-0020 
siRNA A-010621-13: GGUUCAGCCAAGGUUUUAU 
siRNA A-010621-14: GUGUUGUCUCUUGAGUUUG 
siRNA A-010621-15: CUCUAGUUCUUUGUUCAUA 
siRNA A-010621-16: UGCUUAUUUGACAACGUUU 
Accell Human SDC4 (6385) 
#E-003706-00-0010 
siRNA A-003706-15: CCUUGGUGCCUCUAGAUAA 
siRNA A-003706-16: CGAACAUCUUUGAGAGAAC 
siRNA A-003706-17: CUGCUAAGUUUGUAUUUAA 
siRNA A-003706-18: CCUUUGUGCAGAUGUAUA 
Accell Human GPC1 (2817) 
#E-004303-00-0010 
siRNA A-004303-13: CUUUUAAUUUUGUAUGAGG 
siRNA A-004303-14: CCUGGAUAGUUAAGGGCUU 
siRNA A-004303-15: GCUUAGUGCUGCUUUGCUU 
siRNA A-004303-16: CUUUUGAGUCCUUGUAUGA 
Accell Human GPC4 (2239) 
#E-011271-00-0010 
siRNA A-011271-13: UCGUAGAGUUGAAACGUUA 
siRNA A-011271-14: CUGCAAAGUAAAGAUGAUU 
siRNA A-011271-15: CGAACAAUUUCAUAGAUGC 
siRNA A-011271-16: GCAAGAUGAAGAAUGCAUA 
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3.5.2 Modification of RNAi conditions 
 
RNAi was performed in hNSC maintenance or hNSC neuronal differentiation 
promoting conditions. To perform RNAi in hNSC maintenance promoting 
conditions, hNSC H9 P5 cells were plated in NSC SFM on GeltrexTM-coated 48-well 
dishes at a density of 5x104 cells/well and allowed to attach for 48 h. For the delivery 
of siRNAs, AccellTM siRNA Delivery Media was supplemented with 2% StemPro® 
Neural Supplement and 20 ng/mL of FGF-2 and EGF (Table A6, Appendix A). To 
perform RNAi in hNSC neuronal differentiation promoting conditions, hNSC H9 P5 
cells were plated in NSC SFM on PO and laminin-coated 48-well dishes at a density 
of 5x104 cells/well and allowed to attach for 48 h. For the delivery of siRNAs, 
AccellTM siRNA Delivery Media was supplemented with 2% B-27 supplement 
(Table A7, Appendix A). RNAi of target genes (SDC1, SDC4, GPC1 and GPC4) 
resulted in the significant downregulation of gene expression (example of GPC1 
downregulation is shown in Fig. 3-2A). In addition, cultures grown under neuronal 
differentiation promoting RNAi conditions (PO/laminin+B-27) expressed a 
significantly upregulated level (p<0.0001) of neuronal markers, including 
microtubule-associated protein 2 (MAP2), medium molecular weight neurofilament 
(NEFM) and doublecortin (DCX) when compared to the hNSC maintenance 
promoting RNAi conditions (Geltrex+FGF-2+EGF), supporting  that PO/laminin+B-
27 promoted neuronal differentiation (Fig. 3-2B). 
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Figure 3-2: Effect of RNAi on target gene expression and changes in gene expression following 
RNAi in hNSC maintenance and neuronal differentiation promoting conditions. A) Relative gene 
expression of glypican 1 (GPC1) in control and GPC1 RNAi (GPC1KD) conditions. A 58% decrease 
in GPC1 expression was observed following RNAi (presented graph is part of Fig. 5-9, Chapter 5). B) 
Relative gene expression of neuronal markers microtubule-associated protein 2 (MAP2), medium 
molecular weight neurofilament (NEFM) and doublecortin (DCX) following culture of hNSC H9 cells 
in hNSC maintenance promoting RNAi conditions (on GeltrexTM coating ,  media supplemented with 
FGF-2 and EGF) and neuronal differentiation promoting RNAi coditions (on Poly-L-ornithine (PO) 
and laminin coating, media supplemented with B-27).   Relative gene expression normalised to 18S, 
error bars = SEM and statistical significance calculated using paired t test and defined as: *** 
p<0.001. 
 
3.6 GENE AND PROTEIN EXPRESSION STUDIES 
 
During expansion and differentiation RNA and protein samples were harvested from 
hNSC H9 cells to characterise the expression of NSC self-renewal and neural 
lineage-specific markers as well as the expression of HS biosynthesis enzymes and 
HSPG core proteins. Expression levels were detected using quantitative PCR (Q-
PCR) and Western blotting (WB) analysis. 
 
3.6.1 Gene expression analysis by Q-PCR 
 
3.6.1.1 RNA extraction 
 
For gene expression analysis RNA was harvested from cell cultures. For this, cells 
were detached using TrypLE (Thermo Fisher Scientific) and the cell suspension 
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centrifuged to a pellet at 5000 X g for 5 min. After this the cell pellet was rinsed once 
with 1X PBS and resuspended in 200 - 300 μL of TRIzol® reagent (Invitrogen), after 
which samples were store at -80 °C overnight. RNA was then extracted using the 
Direct-zolTM RNA miniprep kit (Zymo Research) according to the manufacturer’s 
instructors (Appendix B). During extraction, samples were treated in-column with 
DNase I (Zymo Research) for 15 min to eliminate DNA contamination. RNA was 
eluted in 30 μL in RNase-free H2O and concentration and quality of RNA 
determined with a NanoDrop spectrophotometer (Thermo Scientific).  
 
3.6.1.2  cDNA synthesis 
 
RNA was reverse transcribed into cDNA utilising the Roche Transcriptor Reverse 
Transcriptase or Bio-Rad iScript reverse transcriptase enzyme.  
 
Reverse transcription using Roche Reverse Transcriptase 
For reverse transcription using the Roche enzyme, 150 – 1000 ng of RNA was 
incubated with 3 µg of Random Primer (Invitrogen) at 65 °C for 10 min made up to a 
reaction volume of 19.5 μL with nuclease-free H2O. Following this, 10U 
Transcriptor Reverse Transcriptase enzyme (Roche), 1X RT reaction buffer (Roche), 
1 mM dNTPs (New England Biolabs) and 20 U of RNaseOUT (Invitrogen) were 
added for a total reaction volume of 30 μL. For the reverse transcription reaction, 
samples were incubated for 10 min at 25 °C, followed by 30 min at 55 °C and 5 min 
at 85 °C. Concentration and quality of cDNA was measured on a NanoDrop 
spectrophotometer (Thermo Fisher Scientific) and cDNA diluted to 40 ng/mL 
working concentrations.  
 
Reverse transcription using Bio-Rad iScript 
For reverse transcription using the Bio-Rad iScript enzyme, 150 ng of RNA was 
combined with 4 μL of 5X iScript reaction mix (Bio-Rad) and 1 μL of iScript reverse 
transcriptase (Bio-Rad) to a reaction volume made of 20 μL with nuclease-free H2O. 
Samples were then incubated at for 5 min at 25 °C followed by an incubation of 20 
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min at 46 °C with the reaction terminated with a 1 min incubation at 95 °C. 
Concentration and quality of cDNA was measured on a NanoDrop 
spectrophotometer (Thermo Fisher Scientific) and cDNA diluted to 40 ng/mL 
working concentrations. 
 
3.6.1.3 Primer design 
 
Gene-specific forward and reverse primers were designed utilising NCBI Primer-
BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primers were designed 
against the human mRNA Refseq mRNA database with PCR product size ranging 
from 70 to 200 bp and optimal primer melting temperature set to 60 °C. If possible, 
one primer of the primer pair was set to span an exon-exon boundary to eliminate 
genomic DNA contamination and increase specificity. If multiple transcript variants 
existed for the gene of interest, primers were designed to capture as many of the 
variants as possible. Genes and primer sequences studied are listed in Tables C1 and 
C2 in Appendix C.  
 
3.6.1.4 Quantitative real-time PCR (Q-PCR) 
 
Q-PCR reactions were performed in quadruplicate per sample for each gene studied 
in a 384-well microtiter plate. Each reaction contained 120 ng of cDNA template, 5 
μL of SYBR®-Green PCR Master Mix (Promega), 200 ng of forward and reverse 
primer and 0.1 μL of CXR reference dye (Promega) and nuclease-free H2O in a 
reaction mix of 10 μL. Amplification was monitored using an Applied Biosystems 
ABI7900HT or Life Technologies QuantStudioTM-7 with an enzyme activation of 2 
min at 50 °C and 3 min at 95 °C followed by 50 cycles of 15 s at 95 °C and 1 min at 
60 °C. Cycle threshold (Ct) values were normalised against the endogenous control 
gene 18S Ct values (ΔCt) included in each run. Relative gene expression was 
determined by calculating the ΔΔCt value (2(-ΔCt)) and relative expression values 
presented on bar graphs are ΔΔCt x 106.  
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3.6.2 Protein expression analysis by Western blotting (WB) 
 
3.6.2.1 Sample preparation  
 
Expression of target proteins was detected using WB analysis. Briefly, cultured cells 
were detached using TrypLE (Thermo Fisher Scientific), centrifuged to a pellet at 
5000 x g for 5 min, rinsed with 1X PBS and stored at -80 °C as a pellet until protein 
extraction.  Total protein was extracted from cell pellets using protein-lysis buffer, 
comprised of 20 mM HEPES, 25% Glycerol, 1.5 mM MgCl2, 420 mM NaCl, 0.5 
mM DTT, 0.2 mM EDTA, 0.5% Igepal CA-630, 0.2 mM Na3VO4, 1 mM PMSF in 
dH2O (Table D1, Appendix D). Proteinase and phosphatase inhibitor cocktail (Cell 
Signaling) was added to the lysis buffer at a dilution of 1:100 prior to use. For 
protein extraction, protein lysis buffer was added to the cell pellet and cell pellets 
vortexed 3X for 15s. Between vortexing, samples were rested on ice. After 
vortexing, cells were further sheared by sonication. To do this, samples were 
sonicated using a Bioruptor® sonicator (Diagenode) for 30s ON/30s OFF for 5 min 
on HIGH at 4 °C. To collect the protein from lysed cells, samples were then 
centrifuged for 20 min at 4 °C at maximum speed. Following centrifugation, the 
protein containing supernatant was transferred to a new tube and the cell pellet 
discarded. Protein samples were stored at -80 °C until use.  
 
3.6.2.2 BCA assay 
 
Protein concentration for WB analysis was determined using the PierceTM BCA 
Protein Assay kit (Thermo Fisher Scientific) (Appendix D). Briefly, a BSA standard 
consisting of 8 BSA concentrations (0.025 – 2 mg/mL) was prepared from a 2 
mg/mL BSA stock vial by performing a serial dilution using 1X PBS. Of the BSA 
standard 10 μL was pipetted in duplicate into a 96-well flat-bottom plate (Corning) 
well. Samples with unknown protein concentrations were diluted 1:10 with 1X PBS 
and 10 μL of each diluted sample was pipetted in duplicate or triplicate into the 96-
well plate containing the BSA standard. A blank sample containing only 1X PBS 
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was also added to the plate. To the wells containing the BSA standard, samples and 
the blank, 200 μL of BCA working reagent containing BCA Reagent A and Reagent 
B in the ratio of 50:1, was added. The plate was then incubated at 37 °C for 30 min, 
after which it was allowed to cool to room temperature.  The protein concentration 
was determined by measuring the absorbance of the BSA standard and samples at 
562 nm using a fluorescent microplate reader (FLUOstar Omega, BMG Labtech). 
Data analysis to determine protein concentration was performed using MARS data 
analysis software (BMG Labtech). Briefly, the absorbance of each standard and 
sample was normalised to the absorbance of the blank sample and the protein 
concentration (mg/mL) calculated using 4-parameter fit calculation.  
 
3.6.2.3 SDS-PAGE, transfer and protein detection 
 
Approximately ~50 μg of total protein was separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). Prior to gel loading, samples were combined with 6X 
SDS-loading dye (Table D2, Appendix D) and boiled for 5 min at 95 °C. For 
detection of HSPG core proteins using the monoclonal antibody HS Δ3G10, protein 
samples were treated with 1.5 mU Heparitinase (Seikagaku Biobusiness) for 2.5h at 
37°C prior to the addition of loading dye and boiling. The SDS-PAGE gel tank (Bio-
Rad) was assembled and the tank filled with 1X Running Buffer (Table D3, 
Appendix D).  Samples along with 5 μL of protein size indicating PageRuler Plus 
Protein ladder (Thermo Fisher Scientific) were then loaded on a Bio-Rad 12% pre-
cast gel (Mini-PROTEAN®TGXTM, Bio-Rad) or 12% TGXTM FastCastTM 
Acrylamide gel (Bio-Rad). A constant volt of 150V was applied to the SDS-PAGE 
until the loading dye disappeared off the edge of the gel (approximately 1-1.5 hours). 
 
3.6.2.4 Protein transfer 
 
Following sample separation, protein was transferred to a PVDF membrane (0.2 μM 
pore size) utilising either a pre-packed Trans-Blot® TurboTM Mini PVDF Transfer 
Pack (Bio-Rad) or a self-assembled transfer sandwich.  The self-assembled transfer 
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sandwich was prepared as follows:  0.2 μM PVDF membrane (Millipore) was cut 
into the correct size and activated for 20 s with methanol. Following this the 
membrane was rinsed for 2 min with dH2O and equilibrated with 1X Transfer Buffer 
(Table D4, Appendix D) for 10 – 15 min. Two pieces of extra thick filter paper 
(Thermo Fisher Scientific) were also equilibrated in 1X Transfer Buffer prior to 
transfer. The transfer was performed using a Bio-Rad Trans-Blot® TurboTM system. 
For this the pre-packed transfer pack was placed into the instrument following 
instructions.  The self-assembled transfer sandwich was constructed by placing a 
piece of filter paper on the bottom of a Trans-Blot® TurboTM cassette.  The PVDF 
membrane was placed directly on top of the filter paper and air bubbles were 
removed using a roller. The gel was removed from the gel tank and placed on the 
membrane with a piece of filter paper placed on top of the gel. Air bubbles were once 
more removed before the cassette was closed and placed into the Trans-Blot Turbo 
system. For the Bio-Rad 12% pre-cast gels, mixed molecular weight transfer 
program was used, which was performed at 1.3 A for 7 min. For the 12% FasCastTM 
gels, a standard transfer program of 1.0 A for 25 min was used.  
  
3.6.2.5 Protein detection 
 
Following protein transfer, the membrane was prepared for protein detection. Non-
specific binding sites were blocked for 1 h at RT using 5% non-fat milk in Tris-
buffered saline (TBS) with 0.1% Tween (TBST) (Tables D6 and D7, Appendix D). 
The membrane was then exposed to primary antibodies which were diluted in 5% 
BSA in TBST and incubated overnight at 4 °C. A summary of the primary antibodies 
and concentrations used are presented in Table 3-2.  The following day the primary 
antibodies were removed and the membrane washed 3X for 5 min with TBST. 
Following this, the membrane was incubated with HRP-conjugated secondary 
antibodies (Table 3-2.) diluted in 5% BSA in TBST for 1 – 2 h at RT. The membrane 
was then washed 3X 5 min with TBST, followed by 1X 10 min with TBS.  Detection 
of target proteins was then performed with enhanced chemiluminescence (ECL) 
using ClarityTM ECL reagents (Bio-Rad). Equal volumes of both ClarityTM ECL 
reagents were combined, applied to the membrane and incubated for 2 – 5 min. 
Excess ECL solution was removed and the membrane placed between two pieces of 
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plastic wrap for detection. Visible protein bands on the membrane were detected 
using the Fusion FX Spectra chemiluminescence system (Vilber Lourmat, Fisher 
Biotec).  Following detection of target proteins, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was detected as a loading control. The membrane was 
incubated with the GAPDH antibody diluted in 5% BSA in TBST for 1 h at RT, after 
which the membrane was rinsed 3X 5 min with TBST. The secondary antibody was 
then applied on the membrane and incubated for 1 h at RT. The membrane was then 
washed and GAPDH detected using ECL as described above. Optical density 
quantitation of protein bands was performed using Bio-1D software (Vilber 
Lourmat).  
 
Table 3-2: Western blot antibodies 
Primary antibodies Dilution Company (Cat#) 
Anti-Sox2 (Rabbit IgG) 1:500 Millipore (2003600) 
Anti-TUBB3 (Rabbit IgG) 1:3000 Abcam (ab18207) 
Anti-MAP2 (Mouse IgG) 1:1000 Abcam (ab36447) 
Anti-CD44 (Mouse IgG) 1:500 Abcam (ab6124) 
Anti-S100B (Rabbit IgG) 1:500 Abcam (ab868) 
Anti- Δ3G10 (Mouse IgG) 1:1000 US Biological (H1890-75) 
Anti-Trkb (Mouse IgM) 1:100 Santa Cruz Biotechnology Cat# 
Loading Control Dilution Company (Cat#) 
Anti-GAPDH 1:1000 Cell Signaling (#2118) 
Secondary antibodies Dilution Company (Cat#) 
Anti-Mouse IgG-HRP  1:3000 Cell Signaling (#7076) 
Anti-Rabbit IgG-HRP  1:3000 Millipore (#7074) 
Donkey Anti-Mouse IgM-HRP 1:2000 Santa Cruz Biotechnology Cat# 
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3.7 FLUORESCENT CELL IMAGING 
 
3.7.1 Immunofluorescence (IF) 
 
IF was performed using an Olympus IX81 fluorescent microscope for the routine 
characterisation of the cells. hNSC H9 cells and nhNPCs cultured in basal growth 
conditions were plated on CC2-coated 8-chamber slides (Lab-Tek) with a density of 
approximately 5 x 104 cells/well and allowed to attach for 2 – 3 days.  hNSC H9 cells 
grown in neuronal and astrocyte differentiating conditions were cultured in 48-well 
culture dishes and stained between days 14-18 or at day 40 of differentiation. Due to 
low attachment of basal and differentiating hNSC H9 cells, PBS containing Ca2+ and 
Mg2+ was used throughout the staining protocol to enhance cell attachment. Also, 
due to the fragility of neuronal differentiating hNSC H9 cultures, all wash steps for 
these cultures were performed manually using a pipette.  
 
To stain cells for IF, cells were first rinsed with 1X PBS containing Ca2+ and Mg2+ 
and fixed with 4% paraformaldehyde (PFA) (Scharlau) for 20 – 30 min at RT. Cells 
were then blocked for 1 – 2 h at RT with blocking solution, which contained 1% 
BSA (Sigma) and 5% normal donkey serum (NDS) (Abcam) diluted in 1X PBS with 
Ca2+ and Mg2+. For intracellular proteins 0.1% of Triton-X was included in the 
blocking solution to allow permeabilisation. After blocking, primary antibodies 
diluted in blocking solution were applied to the cells and incubated overnight at 4 °C. 
Primary antibodies and isotype controls used can be found in Table 3-3. Following 
overnight incubation cells were washed three times with 1X PBS with Ca2+ and 
Mg2+, after which secondary antibodies diluted in blocking solution were applied to 
the cells and incubated at room temperature for 1 – 2 h in the dark. Cells were then 
rinsed three times with 1X PBS with Ca2+ and Mg2+ and counterstained with 
fluoroshield mounting medium with DAPI (ab104139, Abcam). A 22 x 50 mm glass 
coverslip was placed on the microscope slide, with the cells stained in 48-well dishes 
imaged directly in the culture plate. Images with 10X, 20X and 40X magnification 
were taken on an Olympus IX81 inverted phase-contrast fluorescent microscope 
using Volocity® v.6.3 software (Perkin Elmer) on a Hamamatsu C10600-10B 
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camera. To confirm antibody specificity, isotype and secondary antibody controls 
were included in each experiment  (Fig. E1 and E2 in Appendix E). The isotype 
controls and secondary antibodies used can be found in Table 3-3. 
 
3.7.2 Fluorescence intensity measurements 
 
Volocity® v.6.3 software was used to measure fluorescence intensity in acquired 
microscope fields of view. Briefly, mean signal intensity was derived through the 
software and normalised to exposure time. The mean intensities of 2 – 4 images were 
averaged and presented as a bar graph. To calculate average signal intensity per cell, 
the mean signal intensity was divided by the number of nuclei. Figure 3-3. illustrates 
an example of a fluorescence intensity measurement in hNSC H9 cells stained with 
nestin (FITC/green) and DAPI (blue). The A. panel of the figure demonstrates a 
signal intensity measurement of nestin (FITC/green), which has a mean signal 
intensity of 672.02 (circled with red) in the field of view. The B. panel of the figure 
demonstrates nuclei count based on DAPI (blue) stain. The software counted 171 
nuclei (circled with red) in the field of view. To calculate the mean nestin intensity 
per cell, nestin intensity was divided by the number of nuclei as follows: 672.02 / 
171 = 3.9.  
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Figure 3-3: An example of fluorescence intensity measurements. Screen shots taken of a 
fluorescence intensity measurement performed using Volocity® v.6.3 software (Perkin Elmer). A) 
Fluorescence intensity of the FITC channel, representing nestin, in hNSC H9 cells. Mean nestin 
intensity in the field of view has been circled with red. B) Nuclei count based on DAPI stain (blue). 
The number of nuclei detected in the field of view has been circled with red. 
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3.7.3 Confocal microscopy 
 
Confocal microscopy was used for high resolution imaging of hNSC H9-derived 
neuronal cultures. Cells were grown on 13 mm diameter plastic coverslips (Sarstedt) 
in 24-well culture plates (Corning). Prior to cell plating, cover slips were coated with 
PO and laminin as previously described (section 3.3.1.1). hNSC H9 P5 cells were 
plated at 4 x 104 cells/well and allowed to attach for 48 h after which neuronal 
differentiation was induced as previously described (section 3.3.1.2). Differentiation 
was continued for 40 or 60 days, after which cells were fixed for imaging.  
 
To ensure attachment of cells, a “pre-fix” of cells was performed prior to final fixing. 
PFA was added at a volume of 1:1 to the culture medium (e.g. 500 μL of PFA to 500 
μL of culture medium) resulting in a final PFA concentration of 2%, and incubated 
for 2 min. The PFA and culture medium was then gently removed and 400 μL of 4% 
PFA added directly on the cells. Cells were then fixed for 20 min at RT. After fixing, 
cells were rinsed for 3X 5 min with 1X PBS with Ca2+ and Mg2+ followed by 
permeabilisation for 15 min with 0.1% Triton-X in 1X PBS with Ca2+ and Mg2+. 
Following permeabilisation, cells were rinsed with 1X PBS with Ca2+ and Mg2+ and 
blocked with blocking solution (1% BSA and 5% NDS in 1X PBS with Ca2+ and 
Mg2+). Primary antibodies diluted in blocking solution were added to the cells and 
incubated over night at 4 °C. The following day, the primary antibody solution was 
removed and the cells rinsed 3X 5 min with 1X PBS with Ca2+ and Mg2+. Secondary 
antibodies diluted in blocking solution were then applied to the cells and incubated 
for 60 min at RT in the dark. Cells were then rinsed 3X 5min with 1X PBS with Ca2+ 
and Mg2+. Using tweezers, coverslips were carefully removed from the culture dish 
and placed to a glass microscope slides with cells facing upward. A drop of 
ProLong® Gold Antifade mountant with DAPI (Thermo Fisher Scientific) was 
applied to the cells and covered with a 22 x 50 mm glass coverslip. Microscope 
slides were allowed to dry for 24 h before 63X magnification images were obtained 
using the Leica TCS SP5 confocal laser-scanning microscope. Image editing, 
including contrast enhancement and brightness increase were performed using 
Volocity® v.6.3 software (Perkin Elmer).   
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Table 3-3: Antibodies used for fluorescent imaging. 
Primary antibodies Dilution Company (Cat#) 
Anti-Nestin (Mouse IgG) 1:200 Abcam (ab22035) 
Anti-Sox2 (Rabbit IgG) 1:1000 Millipore (2003600) 
Anti-TUBB3 (Rabbit IgG) 1:1000 Abcam (ab18207) 
Anti-MAP2 (Mouse IgG) 1:500 Abcam (ab36447) 
Anti-GFAP (Rabbit IgG) 1:250 Abcam (ab7260) 
Anti-S100B (Rabbit IgG) 1:200 Abcam (ab868) 
Anti-O1 (Mouse IgM) 1:500 Abcam (ab34164) 
Anti-Ki67 (Rabbit IgG) 1:1000 Abcam (ab15580) 
Anti-Trkb (Mouse IgM) 1:50 Santa Cruz Biotechnology (sc-377218) 
Anti-PDGRβ (Rabbit IgG) 1:50 Santa Cruz Biotechnology (sc-432) 
Anti-SDC4 (Rabbit IgG) 1:1000 Abcam (ab24511) 
Anti-GPC1 (Rabbit 1gG) 1:1000 Abcam (ab137604) 
Anti-GPC4 (Mouse IgG) 1:500 Abcam (ab100843) 
Anti-10E4 HS epitope 
antibody 
1:500 amsbio (370255-S) 
Isotype Controls Dilution Company (Cat#) 
Mouse IgG 1:250 Millipore (PP54-100UG) 
Rabbit IgG 1:250 Millipore (PP64-100UG) 
Mouse IgM 1:500 Millipore (2003599) 
Secondary antibodies Dilution Company (Cat#) 
Donkey Anti-Mouse IgG 
(FITC, green) 
1:250 Millipore (AP192F) 
Donkey Anti-Rabbit (H+L) 
(Cy3, yellow) 
1:250 Millipore (AP182C) 
Donkey Anti-Mouse IgM 
(AlexaFluor 594, red) 
1:500 Jackson Immunoresearch (#715-585-
020) 
 
3.8 ANALYSIS OF CALCIUM SIGNALLING IN NEURONAL CELLS 
 
The presence of spontaneous calcium oscillations was examined as a measure of 
functionality of the neuronal differentiating cultures. Synchronised calcium 
oscillations have previously been reported to occur in densely confluent rodent 
neuronal cultures (Pacico & Mingorance-Le Meur, 2014). These oscillations can 
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occur spontaneously or can be induced in a low magnesium (Mg2+) environment and 
measured using a fluorescent plate reader or a fluorescent microscope as described in 
previous studies (Hemstapat, Smith, & Monteith, 2004; Pacico & Mingorance-Le 
Meur, 2014). In this study, spontaneous calcium oscillations were measured in the 
neuronal differentiating hNSC H9 cultures in a low Mg2+ (0.1 mM) environment to 
assess neuronal functionality. The oscillations were measured in undifferentiated 
hNSC H9 cells and the MCF-7 human breast cancer cell line as a control of non-
neuronal cells. The SHSY-5Y human neuroblastoma cell line was used as a positive 
control for neuronal-type cells.  
 
hNSC H9 cell-derived neuronal cultures 
For calcium signalling measurements, hNSC H9 cells were plated in NSC SFM on 
PO and laminin coated 96-well plates at a seeding density of 7 x 103 cells/well. Cells 
were allowed to attach for 48h, after which culture medium was changed to neuronal 
differentiation medium. Cells were cultured under neuronal differentiating conditions 
for 40 to 60 days as previously described (section 3.3.1.2).  
 
hNSC H9 cell culture 
hNSC H9 P5 cells were plated on PO and laminin coated 96-well plates at a seeding 
density of 1.6 x 104 cells/well. Cells were cultured in NSC SFM until the cultures 
reached confluence (approximately 3 days) prior to measurement of calcium 
signalling.  
 
SHSY-5Y and MCF-7 cell culture 
SHSY-5Y human neuroblastoma and MCF-7 human breast cancer cell lines  
(obtained from ATCC) were plated on PO and laminin coated 96-well plates at a 
seeding density of 5 x 104 cells/well. Cells were cultured in DMEM (Thermo Fisher 
Scientific) supplemented with 10% FBS (Hyclone) and 100 U/mL 
penicillin/streptomycin (Lonza). Cells were grown until confluence (approximately 4 
days) prior to calcium signalling measurements.  
 
 90 Chapter 3: Materials and Methods 
Fluo-4 loading 
The Fluo-4 DirectTM calcium assay kit (Thermo Fisher Scientific cat#F10471) was 
used to detect calcium signals (Appendix F). Briefly, A 250 mM stock solution of 
probenecid was prepared by adding 1 mL of Fluo-4 DirectTM calcium assay buffer 
(component C) to a 77 mg vial of water-soluble probenecid (component B). 
Probenecid was vortexed until it was dissolved and stored at -20 °C. A 2X Fluo-4 
DirectTM calcium reagent was prepared by adding 10 mL of calcium assay buffer 
(Hank’s balanced salt solution containing 2 mM CaCl2, 0.1 mM MgCl2 and 20 mM 
Hepes) and 200 μl of 250 mM probenecid stock solution to one bottle Fluo-4 
DirectTM calcium reagent (component A). An equal volume of Fluo-4 DirectTM assay 
calcium reagent was added to the volume of culture medium in culture wells and 
incubated at 37 °C for 45 min. Cells were allowed to reach room temperature prior to 
imaging.  
 
Calcium imaging on a fluorescent plate reader 
The protocol for imaging of calcium signals utilising a fluorescent plate reader 
(BMG Labtech) was adapted from Pacico et al. (Pacico & Mingorance-Le Meur, 
2014). The settings were as follows: the temperature was set to 24 °C with excitation 
wavelength set to 485 nm and emission wavelength set to 525 nm. Recordings were 
taken using the bottom optic and recordings made every 0.8 s.  The total recording 
time was 200 s comprised of a total of 250 readings. Signal graphs were acquired 
utilising MARS data analysis software (BMG Labtech).  
 
Calcium imaging on a fluorescent microscope 
An Olympus IX81 fluorescent microscope with a Hamamatsu C10600-10B camera 
and Volocity® v.6.3 software was also used to detect calcium signals in the Fluo-4 
loaded cultures. Fluo-4 calcium signals were detected using FITC filter (excitation: 
490 nm, emission: 530 nm) at a 20X magnification. Images were captured for 200 s 
at 0.8 s intervals totalling to 251 timepoints captured (1.25 timepoint per second). 
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For data analysis, Volocity® v.6.3 software was used to select 20 cells (regions of 
interest = ROI) from a microscope field of view and mean fluorescence intensity (FI) 
for each selected ROI for each timepoint obtained. FI measurements were then 
exported to Microsoft Excel where data processing was performed. Briefly, FI for 
each timepoint was divided by the FI of timepoint 1 (FI0). The FI/FI0 values were 
plotted on a line graph for presentation. Figure 3-4 illustrates an example of how FI 
measurements were obtained using the Volocity® v.6.3 software. In panel A. of the 
Figure 3-4, 10 ROIs representing 10 cells have been selected. Panel B. demonstrates 
measurements obtained for each ROI. The left hand side red box indicates the ROI 
names selected from the microscope view (ROIs 1 – 10) (Fig. 3-4). The middle red 
box indicates the timepoint (=1), of which the measurements have been obtained 
(Fig. 3-4). The right hand side red box indicates mean signal intensity for each ROI 
at timepoint 1 (Fig. 3-4). 
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Figure 3-4: An example of calcium signal measurement. Screen shots taken of a calcium signal 
measurement performed using Volocity® v.6.3 software (Perkin Elmer). A) A microscope field of 
view of Fluo-4 loaded hNSC H9-derived neuronal cells. Ten regions of interest (ROIs) that represent 
single cells have been selected. B) Table illustrating a signal intensity measurement of selected ROIs. 
Left hand side red box indicates ROI name (ROIs 1-10), middle red box indicates the timepoint of the 
measurement and the right hand side red box indicates mean fluorescence intensity for each ROI at 
timepoint 1. 
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3.9 STATISTICAL ANALYSIS 
 
Results in this study are presented as an average of two biological replicates of hNSC 
H9 cells expanded in culture (populations POP1 and POP2). Each experiment 
consisted of a further 2 – 4 technical replicates, obtained by pooling culture wells for 
RNA and protein sample collection and isolation. All other hNSC H9 cell 
populations and other cell models used in this study are specified in each specific 
results Chapter where they were used as part of the experiment protocols (Chapter 4-
7). Q-PCR was performed separately for hNSC H9 populations POP1 and POP2 and 
analysed gene expression results were averaged between the two populations for 
graphical presentation. Relative gene expression is presented as bar graphs of ΔΔCt x 
106 values with error bars = SD or SEM specified in the figure legends. For WB 
analysis of protein expression, protein samples from both hNSC H9 cell populations 
were pooled prior to quantitation and performing the assay. Statistical significance 
was determined using Student’s t-test and defined as * p < 0.05, ** p < 0.01 and *** 
p < 0.001. 
 
3.10 ETHICAL REQUIREMENTS 
 
All the cell populations used in this study, including hNSC H9, nhNPC, SHSY-5Y 
and MCF-7 cells, are commercially available with no modifications other than those 
described performed. In addition to the use of these cells of human origin, no other 
human or animal samples requiring ethical approval were utilised. 
 
3.11 RESOURCES 
 
All the resources required to undertake this study were available within the 
Genomics Research Centre (GRC), Institute of Health and Biomedical Innovation 
(IHBI), Queensland University of Technology (QUT). The expertise and supervision 
required to complete this study was also available within the GRC/IHBI. Facilities 
and equipment required for this study were located within the GRC/IHBI and 
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included a tissue culture laboratory, liquid nitrogen vapour storage, microscopes and 
molecular biology (Q-PCR and WB) equipment and facilities. Access and training 
for the use of Leica TCS SP5 confocal laser scanning microscope was provided by 
the IHBI Cell Imaging Facility.  
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Chapter 4: Characterisation of HSPGs 
During Human Neural Stem 
Cell Expansion 
 
The first aim of this research project was to establish culture conditions for the long-
term expansion of commercially obtained human embryonic stem cell (ESC)-derived 
neural stem cells (hNSC H9 cells) for the characterisation of  markers of self-renewal 
and multi-lineage capacity as well as for heparan sulfate proteoglycan (HSPG) and 
HS regulatory enzyme expression. To do this, two individually obtained hNSC H9 
cell populations were expanded in culture. Cell morphology and viability was 
monitored and RNA and protein samples harvested at each passage for the analysis 
of self-renewal and multi-lineage as well as HSPG-related markers. The results 
demonstrated that during approximately 100 days in culture, hNSC H9 cells 
maintained a high level of homogeneity and expressed self-renewal and multi-
lineage markers. Undifferentiated (basal) hNSC H9 cells were shown to express HS 
biosynthesis enzymes, indicative of active HS biosynthesis with several HSPG core 
protein syndecans (SDCs) and glypicans (GPCs) expressed at a high level. To gain 
an understanding of key markers of hNSC lineage progression, the expression of all 
studied lineage and HSPG pathways markers were compared between hNSC H9 cells 
and more lineage-restricted normal human neural progenitor cells (nhNPCs).  Clear 
differences in the expression of the lineage marker and HSPG profiles between the 
two cells types were identified. The results presented here suggest that HSPGs are 
key proteins of basal hNSC H9 cells and function as markers defining hNSC 
progression to hNPCs.  
 
The introduction (section 4.1) and hNSC H9 cell expansion results (sections 4.3.1 to 
4.3.3) of this Chapter have been published in part in Stem Cell Research journal: 
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Oikari LE, Okolicsanyi RK, Qin A, Yu C, Griffiths LR, Haupt LM (2016) Cell 
surface heparan sulfate proteoglycans as novel markers of human neural stem cell 
fate determination. Stem Cell Research Jan;16(1): 92 – 104.  
 
The hNSC H9 cell and nhNPC comparison results (sections 4.3.4 to 4.3.6) of this 
Chapter have been published in part in Data in Brief journal: 
 
Oikari LE, Okolicsanyi RK, Griffiths LR, Haupt LM (2016) Data defining markers 
of human neural stem cell lineage potential. Data Brief Feb 19;7:206-215. 
 
4.1 INTRODUCTION 
 
Neural stem cells (NSCs) are self-renewing and multipotent cells of the central 
nervous system (CNS), localised in the brain in discrete locations, including the 
subventricular zone (SVZ) surrounding the lateral ventricles and the subgranular 
zone (SGZ) of the hippocampus (Alvarez-Buylla & Lim, 2004; Gage, 2000). 
Throughout life NSCs are retained in the brain where they maintain the ability to 
self-renew and differentiate into neural cell lineages, including neurons, astrocytes 
and oligodendrocytes (Alvarez-Buylla & Lim, 2004; Gage, 2000). Due to their self-
renewing and multi-lineage differentiation properties, NSCs provide a model of 
nervous system development and they have great therapeutic potential for the 
treatment of CNS injuries and disease. NSCs can be isolated from the brain and 
propagated in vitro in the presence of fibroblast growth factor 2 (FGF-2) and 
epidermal growth factor (EGF) as free-floating neurospheres (Reynolds & Weiss, 
1992). In addition, NSCs can be derived from embryonic stem cells (ESCs), which 
can be expanded as an adherent monolayer circumventing the challenges associated 
with long-term neurosphere culture (Conti et al., 2005; Zhang et al., 2001). However, 
with challenges associated with efficient NSC expansion and transplantation (Hsu, 
Chen, Wang, & Chiu, 2013), a better understanding of factors regulating the 
behaviour of these cells is required to fully exploit their capacity.  
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NSCs with self-renewal and multipotentiality express the intermediate filament 
nestin, transcription factors SRY-box 1 and 2 (SOX1 and SOX2) and the RNA-
binding protein Musashi 1 (MSI1), which have all been shown to play a role in NSC 
self-renewal and thus in the maintenance of the NSC pool (Christie et al., 2013; Ellis 
et al., 2004; Lendahl et al., 1990; Okano et al., 2005). In addition, the expression of 
telomerase (TERT) is considered a marker of true stem cell self-renewal (Thomson 
et al., 1998). NSCs give rise to neural progenitor cells (NPCs), which have a limited 
self-renewal capacity and are often unipotent giving rise to a single neural lineage 
rather than three neural cell types (neurons, astrocytes and oligodendrocytes) (Ming 
& Song, 2011; Seaberg & van der Kooy, 2003). Vimentin (VIM) has been reported 
to be a marker of stem/progenitor cells in the embryonic human brain and SOX1 is 
considered to be specifically a marker of neuronal progenitors (Cary et al., 2015; 
Tonchev et al., 2006; Vinci et al., 2016). NSCs and NPCs, however, share multiple 
functional and phenotypic characteristics with currently no definitive set of markers 
able to distinctly distinguish between the two cell types (De Filippis & Binda, 2012; 
Seaberg & van der Kooy, 2003). 
 
Once NSCs/NPCs differentiate toward the neuronal lineage the expression of 
neuron-specific markers, including βIII-tubulin (TUBB3), microtubule-associated 
protein 2 (MAP2), neurofilaments (NEFs) and doublecortin (DCX) increases (Brown 
et al., 2003; Laser-Azogui et al., 2015; Song & Filmus, 2002; von Bohlen & 
Halbach, 2011). Other markers associated with the neuronal lineage include enolase 
2 (ENO2), also known as neuron-specific enolase, and forkhead box A2 (FOXA2) 
(Grow et al., 2016; Haque et al., 2016). Markers denoting the astrocyte lineage 
include glial fibrillary acidic protein (GFAP), the surface marker CD44 and S100B 
calcium binding protein (Donato, 2001; Reeves et al., 1989; Sosunov et al., 2014), 
with oligodendrocyte lineage markers including galactosylceramidase (GalC), 
transcription factors Olig1 and Olig2 and surface markers O1 and O4 (Barateiro & 
Fernandes, 2014; Tracy et al., 2011; Wegner, 2008). 
 
The NSC microenvironment, or niche, plays a central role in regulating NSC 
stemness (self-renewal and differentiation) with local concentrations of signalling 
molecules mediating NSC maintenance and lineage differentiation (Ramasamy et al., 
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2013). The distribution and activity of extracellular signalling molecules is mediated 
by extracellular matrix (ECM) components, including proteoglycans (PGs). PGs 
consist of a core protein and attached sulfated glycosaminoglycan (GAG) side 
chains, which have central roles in influencing local concentrations of growth factors 
and ligands, thus having key roles in development, homeostasis and cell behaviour 
(Couchman & Pataki, 2012; Dreyfuss et al., 2009). Based on the GAG chain 
structure, PGs are classified into groups, with one super family formed by the 
heparan sulfate (HS) carrying heparan sulfate proteoglycans (HSPGs) (Couchman & 
Pataki, 2012). HSPGs consist of two major families: the type I transmembrane 
syndecans (SDC1-4), and the globular GPI-anchored glypicans (GPC1-6) (Choi et 
al., 2011; Filmus et al., 2008).  
 
HS chains carried by SDCs and GPCs are synthesised post-translationally via a 
complex temporal process mediated by a number of biosynthesis enzymes that 
assemble chains to the core proteins. HS chains are first polymerised by exostosin 
glycosyltransferases 1 and 2 (EXT1 and EXT2) (Busse et al., 2007), followed by 
modifications catalysed by N-deacetylase/N-sulfotransferases (NDSTs; NDST1-4) 
and epimerisation catalysed by C5-epimerase (C5-EP) (Grobe et al., 2002). O-
sulfation sites are then incorporated along the HS chains by a HS 2-O-
sulfotransferase (HS2ST1) and 6-O-sulfotransferases (HS6ST1, HS6ST2 and 
HS6ST3), respectively (Esko & Selleck, 2002). HS chain length along with the N- 
and O-sulfation pattern subsequently determine, which growth factors and signalling 
molecules HSPGs are able to bind (Esko & Selleck, 2002). 
 
HSPG SDCs and GPCs have multiple roles in regulating cellular behaviours, 
including adhesion, migration and differentiation and, importantly, they demonstrate 
specific expression and localisation patterns during CNS development (Choi et al., 
2011; Ford-Perriss et al., 2003). Importance of HSPGs within the CNS has been 
demonstrated in the mouse model through the depletion of HS synthesising EXT1, 
NDST1, HS2ST1 or HS6ST1 in the CNS, which resulted in brain malformations and 
abnormalities (Grobe et al., 2005; Inatani et al., 2003; Pratt et al., 2006). In addition, 
the depletion of SDC1, GPC1 and GPC4 in mouse NSCs or neural precursor cells in 
vitro was shown to alter cell maintenance and proliferation (Abaskharoun et al., 
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2010; Fico et al., 2012; Wang et al., 2012). These reports suggest that HS and 
HSPGs are important in CNS development and NSC function, and likely provide 
additional targets or markers for enhanced control of NSC expansion, differentiation 
or isolation. However, our knowledge of the role of HSPGs within the human CNS 
or NSC (hNSC) function is limited and reliant upon rodent models: despite the 
acknowledged differences in development, structure and regulation between the 
human and rodent nervous systems (reviewed in (Oikari et al., 2014)). With HSPGs 
likely key regulators of the hNSC niche and more research into investigating their 
roles within the human neural niche urgently needed, the aim of this Chapter was to 
examine HSPG expression in in vitro expanded hNSCs to gain insight into their 
contribution within the hNSC in vitro niche. In order to do this, hESC-derived NSC 
cultures (hNSC H9 cells) were established, expanded in culture and examined for the 
expression of NSC self-renewal and neural lineage markers along with HS 
biosynthesis enzymes and SDC and GPC core proteins. In addition, to examine the 
potential roles of HSPGs in hNSC lineage progression, the marker and HSPG profile 
of hNSC H9 cells was compared to the more lineage-restricted hNPCs.  The results 
of this Chapter demonstrate that hNSC H9 cells provide a good model for NSC self-
renewal and that these cells express HS biosynthesis enzymes indicative of an active 
HSPG machinery. Importantly, several HSPGs were expressed at a high level, 
suggesting a potential key role for these HSPGs in hNSC regulation. Interestingly, 
when expression profiles were compared between hNSC H9 cells and nhNPCs, 
analysis revealed that neural lineage markers and HSPG-related genes demonstrated 
correlated expression, with some HSPGs associated with NSC self-renewal marker 
expression (e.g. nestin and SOX2) and others with lineage marker expression (e.g. 
TUBB3 and GFAP). These results suggest that HSPGs function as novel markers of 
undifferentiated hNSCs and can be used to characterise the progression of hNSCs to 
hNPCs. This data supports the use of HSPGs as markers of hNSC characterisation 
and fate determination.   
 
 
 
 100 Chapter 4: Characterisation of HSPGs During Human Neural Stem Cell Expansion 
4.2 METHODS 
 
4.2.1 hNSC H9 cell culture 
 
Three populations (POP0, POP1 and POP2) of human neural stem cells derived from 
the NIH approved H9 (WA09) human embryonic stem cells (hNSC H9 cells) were 
purchased from Thermo Fisher Scientific. The optimisation of hNSC H9 cell basal 
expansion conditions were performed on POP0 cells with cells expanded as 
previously described (section 3.2.1.2). Cells were passaged and viability of the cells 
monitored as previously described (section 3.2.1.3). For long-term culture analysis, 
hNSC H9 POP1 and POP2 cells were expanded until cells reached passage 31 (P31) 
corresponding to approximately 100 days in culture. RNA and protein samples were 
harvested from POP1 and POP2 cells at each passage for analysis of marker and 
HSPG expression during basal expansion.  
 
4.2.2 nhNPC culture and hNSC H9 comparison  
 
Normal human neural progenitor cells (nhNPCs) obtained from Lonza were cultured 
as previously described (section 3.2.2). Cells were harvested for RNA after 72 h of 
culture and gene expression of nhNPCs was compared to hNSC H9 POP0 passage 3 
cells.  
 
4.2.3 Total RNA extraction, cDNA synthesis and Q-PCR 
 
RNA was extracted from hNSC H9 cells and nhNPCs using the Direct-zolTM RNA 
miniprep kit (Zymo Research) as previously described (section 3.6.1.1) and RNA 
was converted to cDNA using the Roche enzyme as previously described (section 
3.6.1.2). Q-PCR reactions were performed in quadruplicate per sample for each gene 
studied under amplification conditions previously described (section 3.6.1.4). Ct-
values of studied genes were normalised against Ct-values of 18S endogenous 
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control (section 3.6.1.4). Primer sequences for each gene studied can be found in 
Tables C1 and C2 (Appendix C).  
 
4.2.4 Immunofluorescence 
 
For immunofluorescent (IF) detection of target proteins, hNSC H9 cells and nhNPCs 
were stained as previously described (section 3.7.1). Primary and secondary 
antibodies as well as antibody dilutions are presented in Table 3-3 (Chapter 3). For 
signal intensity measurements, the fluorescence mean signal intensity observed under 
microscope in a field of view was obtained using Volocity® v.6.3 software (Perkin 
Elmer). The mean signal intensities of 2 to 4 fields of view were normalised to 
exposure time and averaged for graphic presentation. To calculate the mean signal 
intensity per cell, the mean signal intensity of a field of view was divided by the 
number of nuclei.  
 
4.2.5 Western blotting 
 
Western blotting (WB) was used for the analysis of protein level expression of target 
proteins. WB was performed as previously described (section 3.6.2). For WB 
analysis of protein expression, protein samples of two hNSC H9 populations (POP1 
and POP2) were pooled together. Primary and secondary antibodies used as well as 
their dilutions are presented in Table 3-2 (Chapter 3).  
 
4.2.6 Statistical analysis 
 
hNSC H9 cell expansion experiments (sections 4.3.1 to 4.3.3) consisted of two 
biological replicates (hNSC H9 POP1 and POP2) and gene expression values are 
presented as an average for two populations studied (POP1 and POP2). hNSC H9 
cell and nhNPC comparison results consisted of one cell population of each cell type. 
Relative gene expression is presented on bar graphs as ΔΔCt x 106 with error bars = 
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SD or SEM and specified in figure legends. Statistical significance was determined 
using Student’s t-test and defined as * p < 0.05, ** p < 0.01 and *** p < 0.001. 
 
4.3 RESULTS 
 
4.3.1 hNSC H9 cell expansion  
 
Commercially available hNSC H9 cells (POP1 and POP2) were independently 
established and expanded as a monolayer on Geltrex® until passage 31 (P31) 
corresponding to approximately 100 days in culture (Fig. 4-1). Cells were passaged 
at 90 – 100% confluence approximately every 3-4 days and re-plated at a seeding 
density of 5x104 cells/cm2.  Cell number and viability was assessed using Trypan 
Blue on an automated cell counter as well as via hemacytometer with morphology of 
the cells monitored under a phase-contrast microscope and images taken at each 
passage at D1. For gene expression analysis, RNA was harvested from both 
populations at passages 2, 5, 7, 11, 13, 17, 21, 23, 27/28 and 31 and gene expression 
results presented as the average for both populations at passages P2-P5, P7-P11, P13-
P17, P21-23 and P27-P31. To examine the effects of long-term culture on hNSC H9 
cell gene expression profile, any statistically significant differences in gene 
expression between early (P2-P5) and late (P27-P31) passages were examined using 
Student’s t-test. 
 
Throughout expansion cells exhibited linear growth and a high level of homogeneity 
(Fig. 4-1A-B). When the hNSC H9 populations were examined, a similar growth rate 
for both populations was observed until P6, after which POP2 grew faster with P31 
reached at D87 with POP1 reaching P31 after 105 days in culture (Fig. 4-1A). The 
average viability for both populations remained between 60 – 84% throughout 
expansion with decreased viability observed between P2 (84%) and P31 (60%) (Fig. 
4-1A). Between P2, P5, P17 and P31 (corresponding to averaged 2, 12, 52 and 96 
days in culture), cells acquired minimal morphological changes (Fig. 4-1B) and 
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maintained human TERT (hTERT) expression, with no significant change observed 
in expression between P27-P31 and P2-P5 (Fig. 4-1C). 
 
 
Figure 4-1: Expansion of hNSC H9 cells. A) Growth curve of hNSC H9 populations (POP1 and 
POP2) expanded from passage 2 (P2) to passage 31 (P31). Cells exhibit a linear growth pattern and 
maintain 60 – 80% viability. B) Phase-contrast images (20X magnification, scale bar 130 µM) of 
hNSC H9 cells at P2, P5, P17 and P31 corresponding to an average of 2 days, 12 days, 52 days and 96 
days in culture. C) Relative gene expression of human telomerase (hTERT) in hNSC H9 cells at 
passages 2-5, 7-11 13-17, 21-23 and 27-31 (error bars = SEM). Figure from Oikari et al. 2016b 
(Oikari et al., 2016b). 
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4.3.2 hNSC H9 characterisation 
 
Expanded hNSC H9 cultures were examined for expression of NSC self-renewal as 
well as neural lineage specific markers at passages P2-P5, P7-P11, P13-P17, P21-
P23 and P27-P31. NSC self-renewal markers nestin, SOX1, SOX2 and MSI1 gene 
expression was observed throughout expansion (Fig. 4-2A). Interestingly, SOX2 was 
expressed at the highest level when compared to other NSC markers and its 
expression was significantly upregulated (p=0.008) in P27-P31 cultures when 
compared to P2-P5 (Fig. 4-2A). Analysis of neuronal markers demonstrated hNSC 
H9 cells expressed a wide variety of neuronal lineage genes (Fig. 4-2B). Neuronal 
markers TUBB3, MAP2, medium molecular weight NEF (NEFM) and DCX were 
expressed during expansion with TUBB3 demonstrating the highest expression level, 
followed by MAP2, NEFM and DCX, respectively (Fig. 4-2B). Similar to SOX2, 
TUBB3 (p=0.002) and MAP2 (p=0.02) were significantly upregulated in expression 
at late passages (P27-P31) when compared to early passage (P2-P5) cells (Fig. 12B). 
 
 
Figure 4-2: hNSC H9 cells express genes denoting NSC self-renewal and the neuronal lineage 
throughout expansion. Averaged (POP1 and POP2) relative gene expression in hNSC H9 cultures of 
A) NSC markers nestin, transcription factors SOX1 and SOX2, and Musashi-1 (MSI1) and B) 
neuronal markers βIII-tubulin (TUBB3), microtubule-associated protein 2 (MAP2), medium 
molecular weight neurofilament (NEFM) and doublecortin (DCX) at passages 2-5, 7-11 13-17, 21-23 
and 27-31 (error bars = SEM, * p<0.05, ** p<0.01, *** p<0.001). Figure adapted from Oikari et al. 
2016b (Oikari et al., 2016b). 
 
hNSC H9 cells also expressed several glial markers, denoting astrocyte (S100B and 
CD44) and oligodendrocyte (GalC, Olig1 and Olig2) lineages (Fig. 4-3). The 
observed expression levels of glial markers remained markedly lower than neuronal 
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markers with the neuronal marker TUBB3 (>50x106) expressed approximately at a 
50 times higher level than the glial markers (~1x106) at P2-P5. Significant 
upregulation of the astrocyte marker S100B (p=0.0008) and oligodendrocyte markers 
Olig1 (p=0.04) and Olig2 (p=0.007) in late passage cells (P27-P31) was observed 
(Fig. 4-3A&B) with GFAP expression absent or only intermittently present in a few 
passages (data not shown).  
 
 
Figure 4-3: hNSC H9 cells express genes denoting astrocyte and oligodendrocyte lineages 
throughout expansion. Averaged (POP1 and POP2) relative gene expression in hNSC H9 cultures of 
A) astrocyte markers calcium binding protein S100B and surface marker CD44 and B) 
oligodendrocyte markers galactosylceramidase (GalC) and oligodendrocyte transcription factors Olig1 
and Olig2 at passages 2-5, 7-11 13-17, 21-23 and 27-31 (error bars = SEM, * p<0.05, ** p<0.01, *** 
p<0.001). Figure adapted from Oikari et al. 2016b (Oikari et al., 2016b). 
 
The cultures were then examined for expression of a panel of NSC and neural 
lineage markers via immunofluorescence (IF) and WB analysis. NSC markers nestin 
and SOX2 as well as neuronal (TUBB3), astrocyte (S100B) and oligodendrocyte 
(O1) markers were observed at early (P5), mid (P17) and late (P31) passages (Fig. 4-
4 and 4-5).  When detected via IF, nestin and SOX2 demonstrated a homogeneous 
expression pattern (Fig. 4-4A).  An increased SOX2 expression during expansion 
(P5-P31) was demonstrated via WB analysis indicative of maintained self-renewal 
during extended culture (Fig. 4-4B). 
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Figure 4-4: hNSC H9 cells maintain self-renewal capacity throughout extended expansion. A) 
Immunofluorescence of NSC markers nestin and SOX2 in hNSC H9 cells at passages 5, 17 and 31, 
counterstained with DAPI (40X magnification, scale bar 130 µM). B) Western blot analysis of SOX2 
at passage P3-P5, P7-P11, P13-P17, P21-P23 and P27-P31 with GAPDH loading control. Figure 
adapted from Oikari et al. 2016b (Oikari et al., 2016b). 
 
The examination of neural lineage markers via IF demonstrated a homogeneous 
expression pattern for TUBB3, with S100B demonstrating heterogeneous expression 
being highly expressed only in a few cells (Fig. 4-5A). Low expression of the 
oligodendrocyte surface marker O1 was also observed in the cells (Fig. 4-5A).  When 
the average fluorescence signal intensity per cell for all studied NSC, neuronal and 
glial markers was calculated, TUBB3 demonstrated the highest signal intensity and 
O1 demonstrated the lowest signal intensity when compared to other markers studied 
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(Fig. 4-5B). The combined expression profile of neuronal, astrocyte and 
oligodendrocyte lineage markers examined demonstrate maintained multipotent 
differentiation capacity during extended hNSC H9 in vitro expansion.  
 
 
Figure 4-5: hNSC H9 cells retain localised expression of neural lineage markers throughout 
extended expansion. A) Immunofluorescence of neuronal marker TUBB3, astrocyte marker S100B 
and oligodendrocyte marker O1 in hNSC H9 cells at passages 5, 17 and 31, counterstained with DAPI 
(40X magnification, scale bar 130 µM). B) Average signal intensity of IF NSC markers nestin and 
SOX2 and neural lineage markers TUBB3, S100B and O1 (error bars = SD). Figure adapted from 
Oikari et al. 2016b (Oikari et al., 2016b). 
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4.3.3 HSPGs during hNSC H9 expansion  
  
Following confirmation of maintenance of self-renewal and multi-lineage marker 
expression during expansion, the expression of HS biosynthesis enzyme and HSPG 
core protein genes in hNSC H9 cells was then examined. Similarly to the lineage 
markers studied, the expression of HS biosynthesis enzymes and SDCs and GPCs 
was examined from early (P2-P5) to late passages (P27-P31) and changes in the 
cells’ HSPG profile investigated. All studied HS biosynthesis enzyme genes were 
expressed in hNSC H9 cells including elongation (EXT1 and EXT2), modification 
(C5-EP and NDST1-4) and sulfation (H2ST1, HS6ST1-3) enzymes with differences 
in expression levels observed between several of the enzymes (Fig. 4-6 and 4-7). A 
higher relative gene expression for EXT1 (18x106 at P2-P5) when compared to EXT2 
(1.8x106 at P2-P5) was observed with EXT1 expression significantly downregulated 
(p=0.02) in late passage cultures (P27-P31) when compared to early passage cultures 
(P2-P5) (Fig. 4-6A). HS chain epimerising C5-epimerase (C5-EP) was expressed in 
hNSC H9 cells in all passages studied with its expression not significantly observed 
to change throughout expansion (Fig. 4-6A). 
 
 
Figure 4-6: hNSC H9 cells express HS chain elongating EXTs and HS chain epimerising C5-
epimerase indicative of active HS biosynthesis. Averaged (POP1 and POP2) relative gene 
expression in hNSC H9 cultures of A) exostosins 1 and 2 (EXT1 and EXT2) and B) C5-Epimerase 
(C5-EP) at passages 2-5, 7-11, 13-17, 21-23 and 27-31 (error bars = SEM, * p<0.05, ** p<0.01, *** 
p<0.001). Figure adapted from Oikari et al. 2016b (Oikari et al., 2016b). 
 
When the NDSTs were examined (HS chain N-deacetylation/N-sulfation catalysing), 
NDST1 demonstrated the highest expression level (22x106 at P2-P5) followed by 
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NDST2 (4.5x106 at P2-P5), NDST4 (1.1x106 at P2-P5) and NDST3 (0.2x106 at P2-
P5), respectively (Fig. 4-7A). The expression levels of the NDSTs were not 
significantly altered following expansion of the cells from P2-P5 to P27-P31. Of the 
HS sulfotransferases, HS2ST1 was the most highly expressed (60x106 at P2-P5), 
followed by HS6ST1 (15x106 at P2-P5), HS6ST2 (4x106 at P2-P5) and HS6ST3 
(0.7x106 at P2-P5), respectively (Fig. 4-7B). In addition, HS2ST1 expression was 
significantly downregulated (p=0.01) at P27-P31 when compared to P2-P5 cultures 
with a significant increase (p=0.03) in HS6ST2 gene expression observed in P27-P31 
cultures compared to early P2-P5 cultures.   
 
 
Figure 4-7: hNSC H9 cells express HS chain modifying NDSTs and HS chain sulfating 
sulfotransferases indicative of active HS chain modification. Averaged (POP1 and POP2) relative 
gene expression in hNSC H9 cultures of A) N-deacetylase/N-sulfotransferases (NDST1-4) and B) 2-
O/6-O sulfotransferases at passages 2-5, 7-11, 13-17, 21-23 and 27-31 (error bars = SEM, * p<0.05, 
** p<0.01, *** p<0.001). Figure adapted from Oikari et al. 2016b (Oikari et al., 2016b). 
 
With the expression of HS biosynthesis enzymes detected in hNSC H9 cells, the 
expression of HSPG core protein syndecans (SDCs) and glypicans (GPCs) were 
examined (Fig. 4-8). Of the syndecans, SDC2 demonstrated the highest relative gene 
expression level at P5 (63 x106) followed by SDC3 (25x106), SDC1 (17x106) and 
SDC4 (0.8x106), respectively (Fig. 4-8A). Interestingly, both SDC2 and SDC3 
showed a steady increase in gene expression during expansion with a significant 
increase in expression for SDC2 (p=0.03) and SDC3 (p=0.02) observed at late 
passage (P27-P31) cultures when compared to early passages (P2-P5) (Fig. 4-8A). 
SDC1 and SDC4 expression remained relatively stable throughout expansion. When 
the glypicans were examined, expression GPC1, GPC2, GPC3, GPC4 and GPC6 was 
detected in hNSC H9 cultures, but no GPC5 expression was detected (Fig. 4-8B). 
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The relative gene expression of GPC4 at P5 was the highest (46x106) followed by 
GPC1 (18x106), GPC2 (4x106), GPC3 (3x106) and GPC6 (2x106), respectively (Fig. 
4-8B). The expression of GPC2 (p=0.0003) and GPC4 (p<0.0001) was highly 
significantly increased in later passage (P27-P31) cultures when compared to early 
passage (P2-P5) cultures (Fig. 4-8B). The HS 10E4-epitope was also examined via 
IF demonstrating localised HS within hNSC H9 cells, providing further confirmation 
that hNSC H9 cells maintain HS expression throughout expansion (P5 to P31) (Fig. 
4-8C).  
 
 
Figure 4-8: hNSC H9 cells express HSPG core protein syndecan and glypican genes with HS 
chains localised within the cells throughout expansion. Averaged (POP1 and POP2) relative gene 
expression in hNSC H9 cultures of A) syndecans (SDC1-4) and B) glypicans (GPC1-4 and 6) at 
passages 2-5, 7-11, 13-17, 21-23 and 27-31 (error bars = SEM, * p<0.05, ** p<0.01, *** p<0.001). C) 
Immunofluorescence of pan HS 10E4 epitope in hNSC H9 cells at P5, P17 and P31 counterstained 
with DAPI (40X magnification, scale bar 130 µM). Figure adapted from Oikari et al. 2016b (Oikari 
et al., 2016b). 
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4.3.4 Comparison of markers of self-renewal and lineage specificity between 
hNSC H9 cells and nhNPCs  
 
To gain insight into key markers of hNSC lineage commitment, the marker and 
HSPG profile of hNSC H9 cells was compared to the more lineage-restricted hNPCs. 
Human cortex-derived normal human NPCs (nhNPCs, obtained from Lonza) have a 
limited self-renewal capacity and are more lineage-committed than hNSC H9 cells. 
In contrast to hNSC H9 cells, which are expanded as an adherent monolayer (Fig. 4-
9A), nhNPCs are cultured as free-floating neurospheres (Fig. 4-9B). To determine 
key markers of hNSC to hNPC progression, the expression of pluripotency, self-
renewal (NSC) and neuronal and glial (astrocyte and oligodendrocyte) lineage genes 
(21 genes) as well as extracellular proteoglycan (PG) genes and their regulatory 
enzymes (28 genes) were compared between hNSC H9 P3 (POP0) cells and nhNPCs. 
Due to lack of viability during extended expansion of nhNPCs, hNSC H9 cells and 
nhNPCs were examined following short-term culture (72h) under basal condition.  
 
 
Figure 4-9: Phenotypic examination of hNSC H9 cells and nhNPCs.  Phase-contrast images (20X 
magnification with 10X magnification insert, scale bar 130 μM) of: A) hNSC H9 cells at P3 and B) 
nhNPCs attached to surface (CC2 chamber slide). Figure adapted from Oikari et al. 2016a (Oikari et 
al. 2016a). 
 
Q-PCR analysis of pluripotency, NSC self-renewal, neuronal and glial marker genes 
demonstrated multiple significant differences in expression between hNSC H9 cells 
and nhNPCs (Fig 4-10 and 4-11). Interestingly, pluripotency genes studied, including 
hTERT and transcription factors NANOG and OCT3/4 all demonstrated higher 
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expression in nhNPCs when compared to hNSC H9 cells with NANOG (p=0.0006) 
and OCT3/4 (p=0.03) significantly upregulated (Fig. 4-10A). In contrast, multiple 
NSC self-renewal associated genes, including MSI1 (p=0.003), SOX2 (p=0.03) and 
vimentin (VIM) (p<0.0001) were significantly more highly expressed in hNSC H9 
cells when compared to nhNPCs (Fig. 4-10B). SOX1, which is considered to be an 
NPC marker (Cary et al., 2015; Tonchev et al., 2006), was more highly expressed in 
nhNPCs (p=0.007) compared to hNSC H9 cells (Fig. 4-10B).  
 
 
Figure 4-10: Q-PCR analysis of pluripotency and NSC self-renewal genes in hNSC H9 cells and 
nhNPCs. Relative gene expression in hNSC H9 cells and nhNPCs of: A) pluripotency markers human 
telomerase (hTERT) and transcription factors NANOG and OCT3/4 and B) NSC self-renewal markers 
Musashi-1 (MSI1), nestin, transcription factors SOX1 and SOX2 and vimentin (VIM). (Error bars = 
SD, statistical significance: * p<0.05, ** p<0.01, *** p<0.001). Figure adapted from Oikari et al. 
2016a (Oikari et al., 2016a). 
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Multiple neuronal lineage markers studied showed significantly higher expression in 
nhNPCs when compared to hNSC H9 cells including, DCX (p=0.0001), MAP2 
(p=0.0004), NEFM (p=0.049), neurogenin 2 (NEUROG2) (p=0.03) and TUBB3 
(p=0.03) (Fig. 4-11A). In addition, neuron-associated forkhead box 2 (FOXA2) was 
more highly expressed in nhNPCs than hNSC H9 cells, although the expression 
difference was not significant (Fig. 4-11A). Furthermore, the neuron-associated 
enolase 2 (ENO2) was interestingly significantly more highly expressed (p=0.009) in 
hNSC H9 cells than nhNPCs (Fig. 4-11A).  
 
All the glial (astrocyte and oligodendrocyte) markers studied demonstrated 
significantly higher expression in nhNPCs than hNSC H9 cells (Fig. 4-11B). These 
included the astrocyte markers CD44 (p=0.002), GFAP (p=0.002) and S100B 
(p=0.003), and the oligodendrocyte markers GalC (p=0.03), Olig1 (p=0.02) and 
Olig2 (p=0.0006) and (Fig. 4-11B). The analysis of neural lineage marker expression 
indicated higher neuron and glial lineage specificity for nhNPCs compared to hNSC 
H9 cells.  
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Figure 4-11: Q-PCR analysis of neuronal and glial lineage marker genes in hNSC H9 cells and 
nhNPCs. Relative gene expression in hNSC H9 cells and nhNPCs of: A) neuronal lineage defining 
markers doublecortin (DCX,) enolase 2 (ENO2), forkhead box protein A2 (FOXA2), microtubule-
associated protein 2 (MAP2), medium molecular weight neurofilament (NEFM), neurogenin 2 
(NEUROG2) and βIII tubulin (TUBB3); and B) glial lineage defining markers CD44, 
galactosylceramidase (GalC), glial fibrillary acidic protein (GFAP), oligodendrocyte transcription 
factors Olig1 and Olig2 and S100B calcium binding protein. (Error bars = SD, statistical significance: 
* p<0.05, ** p<0.01, *** p<0.001). Figure adapted from Oikari et al. 2016a (Oikari et al., 2016a). 
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To confirm the expression and localisation of NSC self-renewal as well as neural 
lineage marker proteins, selected markers were further examined via IF in hNSC H9 
cells and nhNPCs. Both cell types demonstrated localised expression of NSC 
markers nestin and SOX2. Nestin demonstrated similar signal intensity between the 
two cell types with the signal intensity of SOX2 significantly higher (p=0.003) in 
nhNPCs compared to hNSC H9 cells (Fig. 4-12A&B).  
 
 
Figure 4-12: Immunofluorescent examination of NSC self-renewal markers in hNSC H9 cells 
and nhNPCs. A) Immunofluorescence (IF) (20X magnification, scale bar 130 μM) of NSC markers 
nestin (FITC/green) and SOX2 (Cy3/yellow) in hNSC H9 P3 cells and nhNPCs. B) Representative 
signal intensity graphs of IF images (error bars = SD, statistical significance: ** p<0.01). Figure 
adapted from Oikari et al. 2016a (Oikari et al., 2016a). 
 
Markers denoting the neuronal, astrocyte and oligodendrocyte lineages were also 
examined in hNSC H9 cells and nhNPCs with all markers demonstrating localised 
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expression within both cell types. The neural lineage markers studied, including the 
neuronal marker MAP2, astrocyte marker GFAP and oligodendrocyte surface marker 
O1 demonstrated higher signal intensity in nhNPCs when compared to hNSC H9 
cells (Fig. 4-13A&B).  
 
 
Figure 4-13: Immunofluorescent examination of neural lineage markers in hNSC H9 cells and 
nhNPCs. A) Immunofluorescence (IF) (20X magnification, scale bar 130 μM) of neuronal marker 
microtubule-associated protein 2 (MAP2) (FITC/green), astrocyte marker glial fibrillary acidic protein 
(GFAP) (Cy3/yellow) and oligodendrocyte surface marker O1 (AF594/red) in hNSC H9 P3 cells and 
nhNPCs. B) Representative signal intensity graphs of IF images (error bars = SD). Figure adapted 
from Oikari et al. 2016a (Oikari et al., 2016a). 
 
 
 
 
 
  
Chapter 4: Characterisation of HSPGs During Human Neural Stem Cell Expansion 117 
4.3.5 Comparison of HSPG biosynthesis enzyme and syndecan and glypican 
core protein gene expression between hNSC H9 cells and nhNPCs  
 
To identify potential key HSPGs of hNSC lineage commitment, the expression of HS 
biosynthesis enzymes as well as HSPG core protein genes was examined between 
hNSC H9 cells and nhNPCs. Several distinct differences in the expression of HS 
biosynthesis enzymes, including HS chain polymerising, modifying and sulfating 
enzymes were observed between the two cell types (Fig. 4-14 and 4-15). 
Interestingly, the HS polymerising EXT2 was expressed at a significantly lower level 
(p=0.013) in nhNPCs when compared to hNSC H9 cells (Fig. 4-14A). In contrast, the 
C5-epimerising C5-EP was significantly more highly expressed (p=0.048) in 
nhNPCs when compared to hNSC H9 cells (Fig. 4-14A). The expression levels of N-
deacetylation/N-sulfation catalysing NDSTs were higher in nhNPCs when compared 
to hNSC H9 cells with NDST2 (p=0.005) and NDST4 (p=0.042) significantly 
upregulated in nhNPCs when compared to hNSC H9 cells (Fig. 4-14B).  
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Figure 4-14: Q-PCR analysis of HS polymerisation and modification enzyme gene expression in 
hNSC H9 cells and nhNPCs. Relative gene expression in hNSC H9 cells and nhNPCs of: A) HS 
chain elongating exostosins 1 and 2 (EXT1 and EXT2), HS chain modifying C5-epimerase (C5-EP) 
and HS chain digesting heparanase (HPSE) enzymes and B) HS chain N-deacetylating/N-sulfating 
enzymes (NDST1-NDST4). (Error bars = SD, statistical significance: * p<0.05, ** p<0.01, *** 
p<0.001). Figure adapted from Oikari et al. 2016a (Oikari et al., 2016a). 
 
When the expression of HS-sulfotransferases was examined and compared between 
hNSC H9 cells and nhNPCs differences in their expression levels between the two 
cell types were also detected (Fig. 4-15).  Of the HS sulfotransferases the HS 2-O-
sulfation catalysing HS2ST1 was significantly more highly expressed (p=0.048) in 
hNSC H9 cells when compared to nhNPCs (Fig. 4-15). Contrary to this, all the HS 6-
O-sulfotransferases were more highly expressed in nhNPCs when compared to hNSC 
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H9 cells. This included the significantly higher expression level of HS6ST1 
(p=0.003), HS6ST2 (p=0.0004) and HS6ST3 (p=0.02) in nhNPCs when compared to 
hNSC H9 cells (Fig. 4-15).  
 
 
Figure 4-15: Q-PCR analysis of HS sulfotransferase gene expression in hNSC H9 cells and 
nhNPCs. Relative gene expression of HS chain 2-O- (HS2ST1) and 6-O-sulfotransferases (HS6ST1, 
HS6ST2 and HS6ST3) in hNSC H9 cells and nhNPCs. (Error bars = SD, statistical significance: * 
p<0.05, ** p<0.01, *** p<0.001). Figure adapted from Oikari et al. 2016a (Oikari et al., 2016a). 
 
Following detection of HS biosynthesis enzyme expression, the expression levels of 
syndecan (SDC) and glypican (GPC) core protein genes were examined and 
compared between the hNSC H9 and nhNPC cultures (Fig 4-16). Interestingly, while 
SDC1 was significantly more highly expressed (p=0.003) in hNSC H9 cells when 
compared to nhNPCs, the other syndecans including SDC2 (p=0.009), SDC3 
(p=0.004) and SDC4 (p=0.03) were significantly more highly expressed in nhNPCs 
when compared to hNSC H9 cells (Fig. 4-16A). Similar to syndecans, majority of 
glypicans were more highly expressed in nhNPCs when compared to hNSC H9 cells, 
including GPC1 (p=0.001), GPC2 (p=0.005), GPC3 (p=0.0004) and GPC6 (p=0.001) 
(Fig. 4-16B). GPC5 was not expressed in hNSC H9 cells while its expression was 
detected in nhNPCs (Fig. 4-16B). Interestingly, contrary to other glypicans, GPC4 
was significantly more highly expressed (p=0.008) in hNSC H9 cells when compared 
to nhNPCs (Fig. 4-16B).  
 120 Chapter 4: Characterisation of HSPGs During Human Neural Stem Cell Expansion 
 
Figure 4-16: Q-PCR analysis of HSPG core protein gene expression in hNSC H9 cells and 
nhNPCs. Relative gene expression in hNSC H9 cells and nhNPCs of HSPGs A) syndecans (SDC1-
SDC4) and B) glypicans (GPC1-GPC6). (Error bars = SD, statistical significance: * p<0.05, ** 
p<0.01, *** p<0.001). Figure adapted from Oikari et al. 2016a (Oikari et al., 2016a). 
 
4.3.6 Comparison other proteoglycan-related genes between hNSC H9 cells and 
nhNPCs  
 
Gene expression levels of other PG family-related genes, including chondroitin 
sulfate proteoglycans (CSPGs), small-leucine rich PGs (SLRP)  (Bartus et al., 2012) 
and other HSPGs were also examined and compared between hNSC H9 cells and 
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nhNPCs to identify any differences in expression of other PG superfamilies between 
the two cell types (Fig. 4-17). CS-sulfotransferases CHST3 and CHST11 where more 
highly expressed in nhNPCs when compared to hNSC H9 cells although the 
expression difference was only significant (p=0.004) for CHST11 (Fig. 4-17A). 
Consistent with the observed expression levels of CS-sulfotransferases, also the 
CSPG aggrecan (AGG) was significantly (p=0.00097) more highly expressed in 
nhNPCs when compared to hNSC H9 cells (Fig. 4-17B). Conversely, the expression 
level of the CSPG versican (VCN) was significantly (p=0.005) higher in hNSC H9 
cells when compared to nhNPCS (Fig. 4-17B). Other PGs examined also showed 
significant expression differences between the two cell types studied with the 
basement membrane-specific HSPG perlecan (PER) (McCarthy, 2015) 
demonstrating significantly higher expression (p=0.002) in hNSC H9 cells when 
compared to nhNPC (Fig. 4-17C). The SLRP decorin (DCN) was not detected in 
hNSC H9 cells while it was expressed in nhNPCs (Fig. 4-17B). These results 
demonstrate that other PG superfamilies may also play a role in self-renewal and 
lineage-specification of neural cells.   
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Figure 4-17: Q-PCR analysis of the gene expression of other PG superfamilies in hNSC H9 cells 
and nhNPCs. Relative gene expression in hNSC H9 cells and nhNPCs of A) CS chain 
sulfotransferases (CHST3 and CHST11), B) extracellular CSPGs aggrecan (AGG) and versican 
(VCN) and C) basement membrane-specific HSPG perlecan (PER) and the small-leucine rich 
proteoglycan decorin (DCN). (Error bars = SD, statistical significance: * p<0.05, ** p<0.01, *** 
p<0.001). Figure adapted from Oikari et al. 2016a (Oikari et al., 2016a). 
 
4.4 DISCUSSION 
 
Self-renewing and multipotent hNSCs provide an in vitro model to study human 
neurogenesis and have potential in the regenerative treatment of CNS injuries. 
Understanding the mechanisms regulating expansion, ‘stemness’ and lineage 
commitment of hNSCs is critical for the improved understanding of the cells for their 
use in these applications. With the extracellular microenvironment contributing to the 
regulation of stem cell maintenance and fate, cell-surface HSPGs associated with 
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hNSCs and localised within the neural niche may provide novel important mediators 
of hNSCs. To investigate this, HSPGs were examined in basal hNSC H9 cells and 
more lineage-restricted nhNPCs, to identify potential key HSPGs of hNSC 
maintenance regulation.  Figure 4-18 summarises key findings of this Chapter, 
including changes observed in hNSC H9 cell marker and HSPG profile during 
extended expansion and differences identified in the gene expression profile of these 
markers between hNSC H9 cells and nhNPCs. The results of this Chapter support 
that HSPGs function as potential regulators of hNSC behaviour and that they can be 
used in combination with neural markers as novel markers of hNSC characterisation.  
 
4.4.1 hNSC H9 cells as an in vitro model of self-renewing NSCs 
 
NSCs can be isolated from foetal brain, however, several studies have demonstrated 
that the long-term culture of brain-derived neurospheres is challenged by limited 
expansive potential, high level of heterogeneity as well as loss of neurogenic 
potential following extensive expansion (Anderson et al., 2007; Ostenfeld et al., 
2000; Wright et al., 2006; Zhang et al., 2001). The results of this Chapter 
demonstrate that adherent hESC-derived NSCs (hNSC H9 cells) provide a good 
model of self-renewing NSCs as during extended culture as limited morphological 
changes were observed and the cells continued to express the pluripotency marker 
hTERT and NSC self-renewal markers nestin and SOX2. hNSC H9 cells also 
expressed a wide variety neuronal and glial lineage markers, representing the 
potential of the cells to differentiate toward different neural cell lineages and 
supporting a multipotent phenotype (Foudah et al., 2014; Zhang & Jiao, 2015). 
Interestingly, during expansion the expression of NSC self-renewal marker SOX2 as 
well as the neural and glial lineage markers TUBB3, MAP2, S100B, Olig1 and Olig2 
were upregulated in expression (Fig. 4-18). Previous studies have reported a loss of 
neuronal differentiation potential during extended culture of brain-derived hNPCs, 
indicated by reduced expression of neuronal markers, such as TUBB3, and induced 
expression of glial markers, such as S100B (Anderson et al., 2007; Wright et al., 
2006). In this study, glial markers, including S100B, Olig1 and Olig2, were also 
upregulated in expression during extended hNSC H9 expansion, however, these cells 
also retained their self-renewal and neuronal differentiative potential, indicated by 
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the upregulated expression of SOX2, TUBB3 and MAP2 (Fig. 4-18). This 
maintained expression of self-renewal and neuronal differentiation capacity 
demonstrate that hNSC H9 cells provide an ideal model for the study of NSC 
stemness, suitable for extended periods in culture.  
 
4.4.2 HSPGs in hNSC H9 cells 
 
HSPGs are ECM proteins that consist of a core protein that carries HS side chains, 
which are synthesised via the temporal coordinated action of multiple biosynthesis 
enzymes. Interestingly, key HS synthesising and modifying enzymes EXT1, NDST1 
and HS2ST1 (Busse et al., 2007; Grobe et al., 2002; Kreuger & Kjellen, 2012) were 
expressed in basal hNSC H9 cultures providing important evidence that HS chains 
are actively produced in these cells. In addition, HS biosynthesis enzyme expression 
levels fluctuated during hNSC H9 expansion, suggesting changes in HS chain 
synthesis activity and shift in incorporated HS chain modifications during culture. 
The changes observed in HS biosynthesis enzyme expression during expansion 
included a decrease in EXT1 and HS2ST1 expression, likely reflecting reduced 
synthesis of new HS chains and a decreased incorporation of 2-O-sulfation sites 
along the HS chains (Fig. 4-18).  In contrast, the 6-O-sulfation catalysing HS6ST2 
was observed to be increased in expression during extended culture, suggesting an 
increased incorporation of 6-O-sulfation sites along the HS chain length (Fig. 4-18). 
As HS chain modifications, including O-sulfation sites, determine the growth factor 
binding abilities (e.g. FGF-2 vs. FGF-1) of HS chains (Brickman et al., 1998; 
Johnson et al., 2007), these observed changes suggest a shift in the growth factor 
requirements of these cells and indicate a potential involvement for HS chains in 
hNSC maintenance regulation. 
 
The two main cell-anchored HSPG families include the SDCs and GPCs with both of 
these families known to regulate multiple cellular functions, providing potential 
targets for the control of hNSC fate. Of the SDC and GPC core protein genes, SDC1, 
SDC2, SDC3, GPC1 and GPC4 were highly expressed in basal hNSC H9 cells with 
extended culture resulting in the upregulated expression of SDC2, SDC3, GPC2 and 
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GPC4, indicating specificity for these HSPGs in the hNSC in vitro niche (Fig. 4-18). 
Previous studies have shown SDC1, GPC1 and GPC4 to be required for mouse NPC 
and ESC maintenance in vitro and SDC2 and SDC3 have been shown to localise to 
rodent neurons and NSCs in vivo (Abaskharoun et al., 2010; Allen et al., 2012; Fico 
et al., 2012; Ford-Perriss et al., 2003; Hienola et al., 2006). In addition, in vivo single 
cell RNA-sequencing (RNAseq) of human outer SVZ radial glia, which are the NSCs 
of the neocortex, revealed SDC3 and HS6ST1 to be more highly expressed in these 
cells than surrounding cells (Pollen et al., 2015). This study suggested that the ECM 
components produced by the outer SVZ radial glia provide crucial structural support 
for the niche, enhancing the signalling activity of local growth factors (Pollen et. al 
2015). Thus, the in vivo data combined with the results obtained in this study in vitro, 
support an importance for HSPGs and HS-chain modifications within the hNSC 
niche. Specifically, the results of this study suggest SDC1, SDC2, SDC3, GPC1 and 
GPC4 are key contributors to the hNSC niche, with these HSPGs and modification of 
their side chains likely having key regulatory roles in hNSCs. 
 
4.4.3 Comparison of hNSC H9 cells and nhNPCs 
 
Human brain cortex-derived neural progenitor cells (nhNPCs, Lonza) were examined 
as a model of more lineage-restricted neural precursor cells to identify potential 
markers and HSPGs of early stages of neural lineage specification. nhNPCs were 
cultured as neurospheres and contrary to hNSC H9 cells, nhNPCs lacked viability 
during extended culture, thus not being suitable for further expansion. The limited 
expansive potential of nhNPCs was likely due to technical difficulties associated 
with passaging of neurospheres as well as to a limited self-renewal potential within 
the cultures.  Neurosphere cultures are known to be highly heterogeneous, consisting 
of pools of self-renewing cells as well as neuron- and glial progenitor cells (Pollard 
et al.,  2006). In addition, human neurospheres are known to reach senescence during 
extended culture, consistent with observations in the nhNPC model used in this study 
(Anderson et al., 2007; Wright et al., 2006). Thus for the study of continued self-
renewal, hNSC H9 cells provide a more appropriate model than nhNPCs.  
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Interestingly, multiple significant differences in marker gene expression between 
hNSC H9 cells and nhNPCs were identified, reflecting the differential lineage 
differentiation status of these cultures. As expected, the gene expression levels of 
NSC self-renewal markers, including SOX2, MSI and VIM were higher in hNSC H9 
cells than nhNPCs while the majority of the neuronal and all of the glial markers 
studied were more highly expressed in nhNPCs when compared to hNSC H9 cells 
(Fig. 4-18). These results indicate that hNSC H9 cultures possess a higher self-
renewal capacity than nhNPCs while the nhNPC cultures contain a higher number of 
more lineage-committed neuronal and glial progenitors than hNSC H9 cultures. 
Interestingly, pluripotency markers, including Nanog and OCT4 were shown to be 
significantly more highly expressed in nhNPCs than hNSC H9 cells. While these 
results are surprising, they are consistent with several previous reports. For example, 
human neurospheres have been shown to retain OCT4 expressing cells in the centre 
of the neurosphere, suggestive of a maintained pool of stem cells within the 
neurosphere core (Ilieva & Dufva, 2013). In addition, similarly to this study, 
Sundberg et al. (2011) compared the gene expression of hESC-derived NSCs and 
human foetal NPCs and reported higher gene expression levels of OCT4 and Nanog 
in human foetal NPCs than hESC-derived NSCs (Sundberg et al., 2011). 
Interestingly, however, protein level expression of OCT4 was not detectable in foetal 
hNPCs, while it was detected in hESC-derived NSCs, thus Sundberg et al. 
hypothesised that OCT4 may not being translated to protein in foetal hNPCs, with 
the biological significance of this, as yet not known (Sundberg et al., 2011). It is 
important to acknowledge that gene expression of pluripotency markers does not 
confirm functional pluripotency with expression potentially due to other factors 
including the microenvironment and 3D clustering of neurospheres (Ilieva & Dufva, 
2013). Further investigation into the role of pluripotency genes within neurospheres 
is required to fully elucidate their function with this research likely revealing novel 
characteristics of human neural cell biology. 
 
Interestingly, HSPG-related genes demonstrated significant differences in expression 
between hNSC H9 cells and nhNPCs, indicating a possible association with HSPGs 
and differentiation status. Intriguingly, the majority of HS side chain modification 
enzymes studied (C5-EP, HPSE and NDST2 and -4) and HS 6-O-sulfotransferases 
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(HS6ST1-3) were more highly expressed in nhNPCs than hNSC H9 cells (Fig. 4-18). 
In contrast, HS polymerising EXT2 and HS 2-O-sulfation catalysing HS2ST1 were 
expressed at a significantly lower level in nhNPCs when compared to hNSC H9 cells 
(Fig. 4-18). These observed differences in the HS biosynthesis enzyme expression 
strongly suggests that reduced HS synthesis, increased modification 
(NDST2/NDST4) and a shift from 2-O-sulfation to 6-O-sulfation on existing HS 
chains occurs during hNSC to hNPC lineage progression. As discussed earlier, the 
shift in HS O-sulfation site modifications indicates in shift in the growth factor 
requirements of the cells, suggesting that nhNPCs respond to a different signalling 
environment from hNSC H9 cells. The changes in HS chain structure and 
composition is potentially highly important in driving neural cell differentiation.  
 
Correlating with differences in HS biosynthesis enzyme expression, the majority of 
the HSPGs studied, including SDC2-4 and GPC1-3 and GPC6, were more highly 
expressed in nhNPCs when compared to hNSC H9 cells (Fig. 4-18). Interestingly, 
the expression of several of the studied HSPGs correlated specifically with NSC self-
renewal or neural lineage markers. For example, SDC1 and GPC4, associated with 
NSC maintenance in the mouse model (Fico et al., 2012; Wang et al., 2012), were 
more highly expressed in hNSC H9 cells along with NSC markers SOX2, MSI1 and 
VIM. In contrast multiple HSPGs, reported to demonstrate neuron-specific 
expression, including SDC2, SDC3, GPC1 and GPC2 (Abaskharoun et al., 2010; 
Ford-Perriss et al., 2003; Hienola et al., 2006; Inatani et al., 2003), were more highly 
expressed in nhNPCs than hNSC H9 cells along with the majority of neuronal and 
glial markers studied. Interestingly, the basement membrane-associated HSPG 
perlecan was shown to be more highly expressed in hNSC H9 cells than in the 
nhNPCs (Fig. 4-18). Previous work by Fietz et al. using RNAseq of human and 
mouse SVZ and cortex revealed expression of perlecan to be associated with NSC 
self-renewal markers, supporting a similar role for this HSPG in hNSC maintenance 
(Fietz et al., 2012). The correlated expression of key HSPGs with key NSC and 
neural lineage markers indicate potential regulatory roles for HSPGs during hNSC to 
hNPC lineage progression and support the use of HSPGs as additional markers for 
distinguishing between these cell lineages. In addition, it is important to note that as 
observed with pluripotency markers, the increased expression of HSPG genes in 
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nhNPCs when compared to hNSC H9 cells may reflect the 3D versus 2D structure of 
these cultures. The brain is a 3D structure, where neural cells are able to form 
multiple connections and extend neuronal protrusions in a complex manner (Hodberg 
et al., 2013). PGs likely having key roles in providing the structural support needed 
and elucidating their specific regulatory effects on neural cell types will have key 
implications in the translational use of PGs as targets.   
 
4.5 SUMMARY AND CONCLUSIONS 
 
 
Figure 4-18: A schematic summary of changes in NSC and lineage markers (neuronal and glial), 
HS and CS biosynthesis enzymes and PG core proteins during hNSC H9 cell expansion and in 
comparison to nhNPCs. Key differences were identified between early (P2–P5) and late (P27–P31) 
passage hNSC H9 cell cultures and in comparison between P2-P5 hNSC H9 cells and nhNPCs 
indicative of lineage progression of hNSCs to hNPCs. 
 
 
The results of this Chapter demonstrate that hNSC H9 cells provide a good in vitro 
model for the study of hNSC self-renewal and importantly, hNSC H9 cells express 
HS biosynthesis enzyme and SDC and GPC core protein genes indicative of active 
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biosynthesis machinery in these cells. The fluctuations in the expression of key HS 
biosynthesis enzymes during extended culture suggest changes in HS synthesis 
activity and continued HS chain modification, indicating changes in growth factor 
binding abilities of the cells during long-term culture. High levels of SDC2, SDC3, 
GPC2 and GPC4 expressed by hNSC H9 cells suggest specificity for these HSPGs in 
the hNSC niche and the potential to use them as novel markers of self-renewing 
hNSCs, further supported by several mouse and human in vitro and in vivo studies. 
The more lineage-restricted nhNPCs investigated in this study expressed lower levels 
of NSC markers and higher levels of neural lineage markers when compared to 
hNSC H9 cells, providing a model of neural lineage commitment.  Comparison of 
HS biosynthesis enzyme and HSPG gene expression between hNSC H9 cells and 
nhNPCs demonstrated significant differences between the cell types, with several of 
the neural makers and HSPG pathway genes demonstrating correlated expression. 
This suggests a potential involvement for HSPGs during hNSC progression to 
hNPCs, providing additional markers for distinguishing hNSC and hNPC lineages 
from each other. Interestingly, several HS chain modification enzymes, particularly 
6-O-sulfotransferases, were more highly expressed in nhNPCs than hNSC H9 cells, 
indicating differential HS chain modification between these two lineages. This likely 
allows hNPCs respond to a different signalling environment than required for hNSC 
maintenance, further supporting a regulatory role for HSPGs in the hNSC niche.  
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Chapter 5: HSPGs During Human Neural 
Stem Cell Lineage Commitment 
 
As previously demonstrated (Chapter 4), hNSC H9 cells maintain their self-renewal 
and multipotent capacity during extended expansion and express HS biosynthesis 
enzymes as well as HSPG core protein genes.  Next hNSC H9 cells were examined 
under neuronal and astrocyte lineage specific culture conditions to confirm hNSC H9 
multipotency as well as to identify associated changes in neural cell marker 
expression and HSPG profile during lineage commitment.  The results demonstrated 
that hNSC H9 cells exhibit high neuronal and a restricted glial differentiative 
potential, indicated by a high level of neuronal marker expression. In addition, 
neuronal lineage differentiation significantly increased the expression of multiple HS 
biosynthesis enzymes and resulted in the upregulated expression of HSPGs SDC4, 
GPC1, GPC2, G3 and GPC6. Astrocyte differentiation of hNSC H9 cells resulted in 
fewer changes in cellular HSPG profile, however, the expression of GPC4 was 
highly upregulated under astrocyte differentiative culture conditions. Finally, to 
assess the potential role of HSPGs in hNSC lineage regulation, the expression of 
selected HSPG core protein genes was downregulated in basal hNSC H9 cells using 
RNA-interference. Following HSPG knockdown altered hNSC H9 cell lineage 
potential was observed.  The results of this Chapter demonstrate that HSPGs function 
as novel markers of hNSC fate determination and are likely important in mediating 
hNSC differentiation.  
 
The results of this Chapter have been published in part in the journal Stem Cell 
Research: 
 
Oikari LE, Okolicsanyi RK, Qin A, Yu C, Griffiths LR, Haupt LM (2016) Cell 
surface heparan sulfate proteoglycans as novel markers of human neural stem cell 
fate determination. Stem Cell Research Dec 17;16 (1): 92 – 104.  
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5.1 INTRODUCTION 
 
NSCs provide an excellent model to study processes of neurogenesis and gliogenesis 
in vitro due to their ability to differentiate to neurons and glial cells (astrocytes and 
oligodendrocytes). The multi-lineage differentiation capacity of NSCs also makes 
them a promising therapeutic option in the treatment of CNS injuries. In the brain 
NSCs respond to exogenous signalling molecules, which either promote the 
maintenance of NSCs in an undifferentiated state or induce lineage-specific 
differentiation (reviewed in (Ramasamy et al., 2013)). In the in vitro environment 
human NSCs (hNSCs) are maintained in an undifferentiated state in the presence of 
FGF-2 and EGF with withdrawal of these growth factors inducing lineage-specific 
differentiation (Denham & Dottori, 2009; Elkabetz & Studer, 2008). Specific culture 
conditions optimised for neuron or glial cell culture further support the growth of 
lineage-specific neural cells for extended expansion. 
 
In this study, to induce lineage-specific differentiation of hNSC H9 cells, protocols 
provided by Thermo Fisher Scientific were used 
(https://www.thermofisher.com/au/en/home/references/protocols/neurobiology/neuro
biology-protocols/differentiating-neural-stem-cells-into-neurons-and-glial-
cells.html). Several studies have successfully applied these protocols, specifically the 
neuron and astrocyte differentiation conditions, for the successful differentiation of 
human embryonic stem cell (ESC)-derived NSCs (O’Brien et al., 2015; Tennstaedt et 
al., 2015; Yan et al., 2013). Briefly, neuronal differentiation of hNSC H9 cells was 
induced by culturing the cells on poly-L-ornithine and laminin coated culture dishes 
in Neurobasal® medium supplemented with B-27® Serum-Free Supplement. 
Astrocyte differentiation of hNSC H9 cells was induced by culturing the cells on 
GeltrexTM in DMEM supplemented with N-2 Supplement and foetal bovine serum 
(FBS). Oligodendrocyte differentiation of hNSC H9 cells was induced by culturing 
the cells on poly-L-ornithine and laminin coated culture dishes in Neurobasal® 
medium supplemented with B-27® Serum-Free Supplement and thyroid hormone 
triiodothyronine (T3). Laminin has previously been shown to effectively promote the 
proliferation, migration and process formation of human neural stem and progenitor 
cells, likely due these cells expressing a wide variety of laminin binding integrins on 
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their cell surface (Flanagan et al., 2006). The commercial B-27 supplement was 
developed in the early 1990s and it consists of 20 defined components that eliminate 
the use of serum and support neuronal survival (Brewer et al., 1993). Along with B-
27 supplement, Neurobasal medium was developed. It contains no glutamate or 
aspartate and has lower osmolarity than standard DMEM with these conditions 
shown to increase neuronal survival (Brewer et al., 1993). The commercially 
available N-2 supplement consists of several defined components, including human 
transferrin, recombinant human insulin, selenite, putrescine and progesterone 
(http://www.thermofisher.com/au/en/home/technical-resources/media-
formulation.166.html). Similar to B-27 supplement, N-2 supplement supports the 
growth of neural cells. T3 is known to induce the expression of myelin genes and 
myelination in the CNS, thus it is commonly used in vitro in oligodendrocyte 
differentiation (Dugas et al., 2012; Misumi et al., 2013) 
 
As previously described (Chapter 4), differentiation of NSCs toward lineage-specific 
neural cells is associated with increased expression of lineage-specific markers. The 
commonly used and well characterised neuronal lineage markers include βIII-tubulin 
(TUBB3), microtubule-associated protein 2 (MAP2), neurofilaments (NEFs) and 
doublecortin (DCX) (Brown et al., 2003; Laser-Azogui et al., 2015; Song & Filmus, 
2002; von Bohlen & Halbach, 2011). Commonly used markers for astrocyte lineage 
characterisation include glial fibrillary acidic protein (GFAP), the surface marker 
CD44 and S100B calcium binding protein (Donato, 2001; Reeves et al., 1989; 
Sosunov et al., 2014). The oligodendrocyte lineage is generally characterised through 
the expression of galactosylceramidase (GalC), transcription factors Olig1 and Olig2 
and surface markers O1 and O4 (Barateiro & Fernandes, 2014; Tracy et al., 2011; 
Wegner, 2008). 
 
An important consideration in the use of these lineage-specific markers is, however, 
the overlap in expression between the markers, with several of these markers not 
being specific for a single lineage. For example nestin, MSI1 and MAP2, expressed 
by immature NSCs and neuronal cells, respectively, are also expressed by reactive 
astrocytes (Duggal et al., 1997; Geisert et al., 1990; Oki et al., 2010). In addition, the 
oligodendrocyte markers Olig1 and Olig2 are also expressed by motor neurons with 
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Olig2 also shown to be required for NSC proliferation and maintenance (Anderson et 
al., 2007; Ligon et al., 2007; Zhou & Anderson, 2002). Thus, the identification of 
new lineage specification markers and/or defining novel combinations of markers of 
lineage specification is necessary to enable the more efficient isolation and 
downstream utilisation of lineage-specific neural cells.  
 
As previously demonstrated (Chapter 4), HSPGs provide novel markers for the 
characterisation of undifferentiated hNSCs and mark the early stages of lineage 
progression from hNSCs to hNPCs. It is possible therefore that HSPGs also likely 
provide novel markers for the characterisation of lineage-specific neural cells, 
supported by numerous examples in the literature. For example, the four 
transmembrane HSPG syndecans (SDC1-SDC4) demonstrate specific localisation in 
the mammalian brain (Ford-Perriss et al., 2003; Hsueh & Sheng, 1999). SDC1 
expression in the brain is mainly associated with areas of increased proliferation with 
a role in NPC maintenance implicated and SDC2 and SDC3 expression is largely 
associated with neurons with a role for SDC3 also in neuronal migration 
demonstrated (Ethell & Yamaguchi, 1999; Ford-Perriss et al., 2003; Hienola et al., 
2006; Hsueh & Sheng, 1999; Wang et al., 2012). SDC4 expression, in contrast, is 
associated with glial cells as it is largely localised to the white matter (Avalos et al., 
2009; Hsueh & Sheng, 1999). The GPI-anchored HSPGs glypicans (GPCs) exhibit a 
specific expression pattern and also have regulatory roles in the CNS. GPC1 has 
been reported to exhibit neuron-specific expression, localising specifically to the 
axons, and it is also a ligand of Slit axon guidance proteins (Litwack et al., 1998; 
Ronca et al., 2001). GPC2 has been identified to localise predominantly to neurons 
and it has been shown to have neurite outgrowth stimulating properties (Ford-Perriss 
et al., 2003; Kurosawa et al., 2001; Stipp et al., 1994).  While GPC4 is largely 
associated with undifferentiated NSCs, it has also been suggested to have multiple 
roles in regulating synapse function (Allen et al., 2012; Fico et al., 2012; Hagihara et 
al., 2000; Ko et al., 2015). GPC6 and GPC4 have both been reported to be astrocyte-
specific and have a role in astrocyte-mediated synaptic regulation (Allen et al., 
2012).  In addition, GPC6 has also been reported to be a regulator of FGF-2 
signalling activity during mouse cerebral cortical development (Allen et al., 2012; 
Salehi, 2009).  
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Along with the reports of HSPGs associated with neural cells, HSPGs also interact 
and mediate the activity of key neuroregulatory signalling pathways, including, 
FGFs, EGF, PDGF, BMP, Shh and Wnts (Capurro et al., 2008; Capurro et al., 2014; 
Dreyfuss et al., 2009; Harmer, 2006; Sakane et al., 2012; Wilson & Stoeckli, 2013). 
Together these reports suggest that HSPGs may be key mediators of hNSC lineage 
differentiation and by identifying key HSPGs of lineage-specific neural cells, this 
may provide additional markers of neural cell characterisation or targets for 
enhanced control of these cells. To date, our understanding of the expression and 
roles of HSPGs in human neural cells is limited as the majority of the reported 
studies have been conducted in model organisms, such as the mouse or rat. The aim 
of this Chapter was to examine HSPGs during lineage commitment of hNSC H9 cells 
to identify potential key HSPGs of human neural cell lineage specification. The 
findings of this Chapter demonstrate that several HSPGs function as novel markers 
of hNSC neuronal and astrocyte fate determination and HSPGs have potential roles 
in mediating hNSC lineage differentiation potential. 
 
5.2 METHODS 
 
5.2.1 Lineage differentiation of hNSC H9 cells 
 
hNSC H9 POP1 and POP2 cells were differentiated as previously described toward 
the neuronal  (section 3.3.1), astrocyte (section 3.3.2) and oligodendrocyte linages 
(section 3.3.3). Differentiation was induced in 48-well plates for 14 – 18 days (D14-
18) using passage 5 (P5) cells and during differentiation cells were monitored for 
morphological changes as well as expression changes in lineage markers and HSPGs. 
Due to low differentiation efficiency and poor viability of the cells following 
initiation of oligodendrocyte differentiation, this lineage was not further examined.  
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5.2.2 RNA-interference 
 
The gene expression of selected HSPG core protein genes was downregulated in 
hNSC H9 P5 cells using Accell siRNA SMARTpool technology (DharmaconTM) as 
previously described (section 3.5). The sequences for siRNA pools used to 
downregulate target gene expression are presented in Table 3-1 (Chapter 3). Cells 
were treated with siRNA pools for 72h, after which cell numbers and viability were 
assessed as previously described (section 3.2.1.3) and cells harvested for RNA 
extraction. 
 
5.2.3 Gene and protein expression 
 
RNA and protein samples were harvested from differentiating cells at D14-18 of 
culture with samples consisting of two to four pooled wells of cells. RNA was 
harvested from siRNA knockdown cultures at 72h with samples consisting of two 
pooled wells of cells. RNA was extracted and expression of selected genes was 
studied by Q-PCR as previously described (section 3.6.1). Primer sequences for 
examined genes can be found in Tables C1 and C2 in Appendix C. Analysis of 
protein expression via Western blot (WB) analysis was performed as previously 
described (section 3.6.2). Prior to WB analysis, protein samples harvested from both 
differentiating populations (hNSC H9 POP1 and POP2) were pooled into a single 
protein sample. For the detection of HSPG core proteins using the monoclonal 
antibody HS Δ3G10, protein samples were treated with 1.5 mU Heparitinase 
(Seikagaku Biobusiness) for 2.5 h at 37 °C prior to SDS-PAGE as previously 
described (section 3.6.2.3). A list of antibodies used for WB is presented in Table 3-2 
(Chapter 3). Optical density of protein bands was quantified using Bio-1D software 
(Vilber Lourmat) as previously described (section 3.6.2.5). 
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5.2.4 Immunofluorescence 
 
Immunofluorescence (IF) was used to detect the expression and localisation of 
proteins of interest in differentiating hNSC H9 cultures using specific antibodies 
presented in Table 3-3 (Chapter 3). Differentiating cultures were stained for IF in 48-
well culture plates between D14 and D18 of differentiation as previously described 
(section 3.7.1). Average signal intensity for studied markers per cell was calculated 
using Volocity® v6.3 software (Perkin Elmer). This was done by normalising the 
mean signal intensity to exposure time and dividing it by the number of nuclei. The 
signal intensity values presented are an average of mean signal intensities between 
two to four images. 
 
5.2.5 Statistical analysis 
 
Differentiation and siRNA knockdown experiments consisted of two biological 
replicates (hNSC H9 POP1 and POP2). RNA and protein samples were obtained by 
pooling two to four culture wells per population and for WB analysis protein lysates 
of both populations were pooled together. Gene expression results presented are an 
average of the two (POP1 and POP2) cell populations studied and relative gene 
expression is presented on bar graphs as ΔΔCt x 106 with error bars = SEM unless 
otherwise stated. Statistical significance was determined using Student’s t-test and 
defined as * p < 0.05, ** p < 0.01 and *** p < 0.001. 
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5.3 RESULTS 
 
5.3.1 Markers of hNSC H9 cell neuronal and astrocyte differentiation 
 
In order to confirm hNSC multipotency and to identify any associated changes in the 
HSPG profile following lineage commitment, hNSC H9 cells were examined under 
lineage differentiating culture conditions for 14-18 days. To confirm differentiation, 
changes in cell morphology as well as NSC and lineage marker expression were 
examined. However, hNSC H9 cultures differentiated toward the oligodendrocyte 
lineage lacked viability and were not suitable for further examination, thus analysis 
of lineage specification was focussed on neuronal and astrocyte lineage cultures.  
 
 
Figure 5-1: Neuronal and astrocyte differentiation of hNSC H9 cells alters cell morphology. 
Phase contrast images of basal hNSC H9 P5 cells and following neuronal (D15) and astrocyte (D17) 
lineage differentiation (20X and 40X magnification, scale bar 130 µM). Figure adapted from Oikari 
et al. 2016b (Oikari et al., 2016b). 
 
Following D14-18 of differentiation, cells cultured under neuronal differentiating 
conditions acquired thin, elongated protrusions characteristic of neuronal cells, while 
astrocyte lineage cultures exhibited a large cell body when compared to basal and 
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neuronal cultures (Fig. 5-1). When the gene expression levels of the NSC markers 
nestin, SOX1 and SOX2 were studied, these were not significantly altered following 
neuronal or astrocyte differentiation (Fig. 5-2).  Interestingly, MSI1, which is also a 
marker of reactive astrocytes, was highly significantly upregulated in astrocyte 
cultures when compared to basal (p<0.0001) and neuronal (p=0.0001) cultures (Fig. 
5-2).  
 
 
Figure 5-2: NSC marker gene expression following neuronal and astrocyte differentiation of 
hNSC H9 cells. Averaged (POP1 and POP2) relative gene expression of NSC markers nestin, 
transcription factors SOX1, SOX2 and Musashi-1 (MSI1) in basal hNSC H9 cells and following 
neuronal and astrocyte differentiation (error bars = SEM, statistical significance: * p<0.05, ** p<0.01, 
*** p<0.001). Figure adapted from Oikari et al. 2016b (Oikari et al., 2016b). 
 
Interestingly, all neuronal markers examined were significantly upregulated in 
neuronal cultures when compared to the basal hNSC H9 cultures including: TUBB3 
(p=0.03), MAP2 (p=0.02), NEFM (p=0.0006) and DCX (p=0.02) (Fig. 5-3), 
indicating neuronal lineage commitment. In addition, NEFM (p=0.002) and DCX 
(p=0.03) were significantly upregulated in neuronal cultures when compared to 
astrocyte cultures (Fig. 5-3). Interestingly, the gene expression levels of all neuronal 
markers studied, including TUBB3 (p=0.009), MAP2 (p<0.0001), NEFM (p=0.01) 
and DCX (p=0.03) were also upregulated in the astrocyte cultures when compared to 
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basal cultures (Fig. 5-3).  However, as the expression level of NEFM and DCX in 
astrocyte cultures remained lower than in the neuronal cultures, this suggested high 
neuronal lineage specificity for these markers (Fig. 5-3).  
 
 
Figure 5-3: Neuronal marker gene expression following neuronal and astrocyte differentiation 
of hNSC H9 cells. Averaged (POP1 and POP2) relative gene expression of neuronal markers βIII-
tubulin (TUBB3), microtubule-associated protein 2 (MAP2), medium molecular weight neurofilament 
(NEFM) and doublecortin (DCX) in basal hNSC H9 cells and following neuronal and astrocyte 
differentiation (error bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** p<0.001). Figure 
adapted from Oikari et al. 2016b (Oikari et al., 2016b). 
 
The expression of the astrocyte markers S100B and CD44 were also examined 
following differentiation.  The gene expression of S100B was undetectable by Q-
PCR in neuronal cultures, while it was highly significantly upregulated (p<0.0001) in 
astrocyte cultures when compared to the basal hNSC H9 cultures (Fig. 5-4A). In 
addition, the glial marker CD44 was significantly upregulated in both neuronal 
(p=0.008) and astrocyte (p=0.0003) cultures when compared to basal hNSC H9 cells 
(Fig. 5-4A). Interestingly, a higher relative gene expression of CD44 was observed in 
neuronal cultured cells when compared to the astrocyte differentiating cultures (Fig. 
5-4A).  
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To confirm protein expression of selected markers, WB analysis was performed for 
TUBB3, SOX2, S100B and CD44. WB analysis confirmed the upregulation of 
TUBB3, SOX2 and CD44 in neuronal differentiating cultures when compared to 
both basal hNSC H9 and astrocyte differentiating cultures (Fig. 5-4B). However, no 
protein expression of the astrocyte marker S100B was observed under any culture 
conditions. This was likely due to the low expression level of this marker in the 
cultures.  
 
 
Figure 5-4: Astrocyte marker gene expression and Western blot analysis of protein level 
expression of lineage markers following neuronal and astrocyte differentiation of hNSC H9 
cells. A) Averaged (POP1 and POP2) relative gene expression of astrocyte markers calcium binding 
protein S100B and surface marker CD44 in basal hNSC H9 cells and following neuronal and astrocyte 
differentiation (error bar = SD for CD44, other error bars = SEM, statistical significance: * p<0.05, ** 
p<0.01, *** p<0.001). B) Western blot analysis of neuronal marker βIII-tubulin (TUBB3), NSC 
transcription factor SOX2 and CD44 (GAPDH loading control) in basal hNSC H9 cells and following 
neuronal and astrocyte differentiation. Figure adapted from Oikari et al. 2016b (Oikari et al., 2016b). 
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Selected NSC and neural lineage markers were then examined via IF to compare 
expression and localisation of markers between basal and lineage differentiating 
hNSC H9 cells (Fig. 5-5A). Fluorescence signal intensities were measured to 
estimate differences in protein level expression of studied markers (Fig. 5-5B). 
Neuronal and astrocyte differentiating cells continued to express NSC markers nestin 
and SOX2 (Fig. 5-5A), however, when the signal intensities were closely examined, 
neuronal cultures exhibited significantly decreased average signal intensity of nestin 
(vs. hNSC H9 p=0.04, vs. astrocyte p=0.005) and SOX2 (vs. hNSC H9 p=0.048, vs. 
astrocyte p=0.029) when compared to the basal hNSC H9 and astrocyte 
differentiating cultures (Fig. 5-5B). In contrast, astrocyte cultures demonstrated 
increased nestin intensity when compared to the basal hNSC H9 cultures (p=0.02) 
(Fig. 5-5B). Although not significant, neuronal cultures demonstrated the highest 
TUBB3 signal intensity when compared to the other conditions with a significantly 
decreased signal intensity of S100B observed when compared to basal (p=0.008) and 
astrocyte (p=0.03) cultures (Fig. 5-5B). The average signal intensity of S100B in the 
astrocyte differentiating cultures remained lower than in basal hNSC H9 cultures 
(p=0.008) (Fig. 5-5B). However, a higher number of cells demonstrated strong 
S100B staining in the astrocyte culture conditions when compared to the other 
culture conditions indicative of astrocyte lineage commitment (Fig. 5-5A).  
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Figure 5-5: Immunofluorescent detection of NSC, neuronal and astrocyte markers following 
hNSC H9 cell lineage differentiation. A) Immunofluorescence (20X magnification, scale bar 130 
µM) and B) an average fluorescence signal intensity graph (error bars = SD, statistical significance: * 
p<0.05, ** p<0.01, *** p<0.001) of NSC markers nestin (FITC/green)/SOX2 (Cy3/yellow), neuronal 
marker βIII-tubulin (TUBB3) (Cy3/yellow) and astrocyte marker calcium binding protein S100B 
(Cy3/yellow) in basal hNSC H9 cells and following neuronal and astrocyte differentiation. Figure 
adapted from Oikari et al. 2016b (Oikari et al., 2016b). 
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5.3.2 Lineage specific changes in HS biosynthesis enzyme expression following 
neuronal and astrocyte differentiation of hNSC H9 cells 
 
Following confirmation of lineage specification as indicated by changes observed in 
cell morphology and lineage-specific marker expression, the neuronal and astrocyte 
differentiating cultures were then examined for changes in the HSPG profile.   
 
To identify changes in HS synthesis activity following lineage differentiation, the 
gene expression of HS biosynthesis enzymes, including polymerisation, modification 
and sulfation enzymes was examined. HS biosynthesis enzymes are expressed in 
basal hNSC H9 cells, as previously demonstrated (Chapter 4). Interestingly, 
following culture of hNSC H9 cells in neuronal and astrocyte differentiating culture 
conditions, the expression of multiple HS biosynthesis enzymes was significantly 
upregulated when compared to basal hNSC H9 cultures. The HS chain 
polymerisation enzyme exostosin 2 (EXT2) was highly significantly upregulated in 
neuronal cultures when compared to both basal hNSC H9 (p<0.0001) and astrocyte 
(p=0.0001) cultures with the HS modifying enzyme C5-epimerase (C5-EP) also 
demonstrating a significantly higher expression level in the neuronal cultures when 
compared to the astrocyte cultures (p=0.02) (Fig. 5-6A). Following neuronal and 
astrocyte lineage commitment, the N-deacetylation/N-sulfation catalysing NDSTs 
exhibited multiple significant changes in expression. NDST2 was significantly 
upregulated (p=0.04) in the neuronal cultures when compared to basal hNSC H9 and 
astrocyte cultures; NDST3 was significantly upregulated in both neuronal and 
astrocyte (p=0.003) cultures when compared to basal hNSC H9 cultures, with a 
significant difference also observed between neuronal and astrocyte cultures 
(p=0.04); and NDST4 was highly significantly upregulated in neuronal cultures when 
compared to basal hNSC H9 (p<0.0001) and astrocyte (p=0.0006) cultures (Fig. 5-
6B). The gene expression level of the HS 2-O-sulfotransferase HS2ST1 was not 
altered following hNSC H9 cell differentiation, however, HS 6-O-sulfotransferases 
HS6ST2 (p=0.006) and HS6ST3 (p=0.02) gene expression was significantly 
upregulated in neuronal cultures when compared to basal hNSC H9 cultures with 
HS6ST2 expression also demonstrating a significant increase in expression (p=0.03) 
in neuronal cultures when compared to the astrocyte cultures (Fig. 5-6C). Finally, 
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HS6ST1 (p=0.049) and HS6ST2 (p=0.013) were significantly upregulated in 
expression following astrocyte lineage differentiation when compared to basal hNSC 
H9 cultures (Fig. 5-6C).  
 
 
Figure 5-6: HS biosynthesis enzyme expression in hNSC H9 cells following neuronal and 
astrocyte differentiation. Averaged (POP1 and POP2) relative gene expression of A) exostosins 
EXT1 and EXT2 and C5-Epimerase (C5-EP), B) N-deacetylase/N-sulfotransferases (NDST1-4) and 
C) HS 2-O/6-O-sulfotransferases (HS2ST1 and HS6ST1-3) in basal hNSC H9 cells and following 
neuronal and astrocyte differentiation (error bar for NDST3 basal hNSC H9 condition = SD, other 
error bars = SEM, statistical significant: * p<0.05, ** p<0.01, *** p<0.001). Figure adapted from 
Oikari et al. 2016b (Oikari et al., 2016b). 
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5.3.3 Lineage specific changes in syndecan and glypican expression following 
neuronal and astrocyte differentiation of hNSC H9 cells 
 
Changes in HSPG core protein gene expression following lineage differentiation of 
hNSC H9 cells were also examined. Gene expression of SDC1, SDC2 and SDC3 was 
not altered following neuronal differentiation when compared to basal hNSC H9 
cultures (Fig. 5-7A). Interestingly, however, SDC4 expression was significantly 
upregulated (P=0.03) in neuronal cultures when compared to basal hNSC H9 and 
astrocyte differentiating cultures (Fig. 5-7A). In addition, SDC2 was significantly 
upregulated (p=0.011) in astrocyte cultures when compared to neuronal 
differentiating cultures (Fig. 5-7A). Significant increases in expression were 
observed for several GPCs in the neuronal cultures when compared to basal hNSC 
H9 and astrocyte cultures as follows: GPC1 neuronal vs. basal (p=0.049), neuronal 
vs. astrocyte (p=0.048); GPC2 neuronal vs. basal (p=0.009) and neuronal vs. 
astrocyte (p=0.011); GPC3 neuronal vs. basal (p=0.014) and neuronal vs. astrocyte 
(p=0.013); and GPC6 neuronal vs. basal (p=0.009) and neuronal vs. astrocyte 
(p=0.02) (Fig. 5-7B). GPC4 was highly significantly upregulated in the astrocyte 
differentiating cultures when compared to basal hNSC H9 (p=0.0001) and neuronal 
(p=1.8e-5) cultures with GPC6 also showing significant upregulation (p=0.02) in the 
astrocyte cultures when compared to basal cultures (Fig. 5-7B). Finally, to examine 
the protein level expression of HSPGs, the HS Δ3G10 epitope was detected in basal 
and lineage differentiating hNSC H9 cultures via WB analysis (Fig. 5-7C).  
Following heparitinase digest of protein lysates of the three culture condition, three 
major bands representing multiple HSPGs associated with the cell membrane of 
approximately 70 kDa (glypicans), 35 kDa and 15 kDa (syndecans) (Haupt et al., 
2009) were observed (Fig. 5-7C). Optical quantitation normalised to a GAPDH 
loading control demonstrated higher intensity for the 70 kDa band in neuronal and 
astrocyte cultures with the 35 kDa and 15 kDa bands demonstrating higher intensity 
in the basal cultures suggesting HSPG modifications during lineage commitment 
(Fig. 5-7D). 
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Figure 5-7: HSPG core protein syndecan and glypican expression in hNSC H9 cells following 
neuronal and astrocyte lineage differentiation. Relative gene expression of A) syndecans (SDC1-4) 
and B) glypicans (GPC1-4, 6) in basal hNSC H9 cells and following neuronal and astrocyte 
differentiation (error bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** p<0.001). C-D) 
Western blot analysis and optical quantitation of the heparan sulfate Δ3G10 epitope in basal and 
lineage differentiated cells. Figure adapted from Oikari et al. 2016b (Oikari et al., 2016b). 
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SDC4, GPC1 and GPC4 were further examined via IF under basal and lineage 
differentiating hNSC H9 culture conditions and average signal intensities for the 
studied markers measured (Fig. 5-8A-D). All HSPGs examined demonstrated 
cellular localisation within all the culture conditions. Neuronal differentiating 
cultures exhibited a higher SDC4 signal intensity when compared to basal hNSC H9 
and astrocyte cultures, however this was not significant (Fig. 5-8D). In contrast, 
GPC1 demonstrated significantly stronger staining in neuronal differentiating 
cultures cells when compared to astrocyte cultures (p=0.03) (Fig. 5-8D). While IF of 
GPC4 did not demonstrate significantly higher signal intensity in the astrocyte 
cultures, high levels of expression were localised to areas of dense cell-cell contact 
reflective of the observed phenotypic changes when compared to the basal and 
neuronal cells (Fig. 5-8C&D).  
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Figure 5-8: Immunofluorescent detection of syndecan-4 (SDC4), glypican-1 (GPC1) and 
glypican-4 (GPC4) core proteins in hNSC H9 cells following neuronal and astrocyte 
differentiation. Immunofluorescence (20X magnification, scale bar 130 µM) of A) SDC4 
(Cy3/yellow), B) GPC1 (Cy3/yellow) and C) GPC4 (FITC/green) along with a D) representative 
average signal intensity graphs (error bars = SD, statistical significance: * p<0.05) in basal hNSC H9 
cells and following neuronal and astrocyte differentiation with Figure adapted from Oikari et al. 
2016b (Oikari et al., 2016b). 
 
5.3.4 HSPGs in mediating hNSC H9 cell lineage potential 
 
To examine the influence of potential key HSPGs on hNSC H9 lineage 
differentiation potential, the expression of SDC1, SDC4, GPC1 and GPC4 was 
downregulated in basal hNSC H9 cells at the mRNA level using gene specific siRNA 
pools. Following siRNA knockdown (KD) changes in cell number and viability as 
well as marker gene expression was compared to control conditions (=averaged 
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untreated+scramble). No change in cell number or viability was observed following 
siRNA KD (Fig. 5-9A). SDC1KD, GPC1KD and GPC4KD cultures expressed 
significantly reduced levels of SDC1 (p<0.0001, 71% reduction to control), GPC1 
(p<0.0001, 58% reduction to control) and GPC4 (p<0.0001, 73% reduction to 
control) (Fig. 5-9B). However, the downregulation of SDC4 via siRNAs did not 
result in the significant decrease of SDC4 expression (39% reduction to control) (Fig. 
5-9B). 
 
 
Figure 5-9: Downregulation of syndecan-1 (SDC1), syndecan-4 (SDC4), glypican-1 (GPC1) and 
glypican-4 (GPC4) in hNSC H9 cells using siRNA pools. A) Cell number and viability in control 
(untreated+scramble) hNSC H9 P5 cells and in SDC1, SDC4, GPC1 and GPC4 knockdown (KD) 
cultures. B) Relative gene expression and percentage of reduction in expression of SDC1, SDC4, 
GPC1 and GPC4 in control hNSC H9 cells and following SDC1, SDC4, GPC1 and GPC4 KD, 
respectively (error bars = SEM, statistical significant: * p<0.05, ** p<0.01, *** p<0.001). Figure 
partially adapted from Oikari et al. 2016b (Oikari et al., 2016b). 
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Following confirmation of successful downregulation of SDC1, GPC1 and GPC4, 
the effect of HSPG downregulation on hNSC H9 lineage potential was examined by 
investigating the expression of NSC and neural cell lineage specific marker genes 
following KD. The KD of SDC1 did not significantly alter the expression of any 
studied marker genes (data not shown). In contrast, KD of GPC1 significantly 
reduced the gene expression levels of nestin (p=0.005), MSI1 (p=0.004), TUBB3 
(p=0.004) and NEFM (p=0.003) when compared to control cultures (Fig. 5-10).  In 
addition, the KD of GPC4 significantly reduced the expression of NEFM (p=0.03) 
and S100B (p=0.004) gene expression compared to control cultures (Fig. 5-10). 
These results demonstrated a potential role for GPC1 and GPC4 in mediating hNSC 
H9 lineage potential.  
 
 
Figure 5-10: Effect of glypican-1 (GPC1) and glypican-4 (GPC4) downregulation on hNSC H9 
cell lineage marker expression. Relative gene expression of NSC (nestin, SOX1, SOX2, MSI1), 
neuronal (TUBB3, MAP2, NEFM and DCX) and astrocyte (S100B) lineage marker genes in control 
hNSC H9 cultures and following GPC1 and GPC4 knockdown (KD) (error bars = SEM, statistical 
significant: * p<0.05, ** p<0.01, *** p<0.001). Figure adapted from Oikari et al. 2016b (Oikari et 
al., 2016b). 
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5.4 DISCUSSION 
 
Multipotent hNSCs provide an in vitro model to study human neurogenesis and 
gliogenesis and have potential in the regenerative treatment of CNS injuries. 
Understanding markers of neuronal or glial lineage commitment is crucial for the 
better isolation and characterisation of lineage-specific neural cells and for the more 
efficient derivation of these cells from NSCs. As cell-surface HSPGs SDCs and 
GPCs are highly expressed in basal hNSCs (Chapter 4) they may be key mediators of 
hNSC lineage commitment. In order to unravel the potential roles of HSPGs in 
hNSC lineage commitment, hNSC H9 cells were cultured under neuronal and 
astrocyte differentiating culture conditions and examined for changes in the lineage-
specific marker expression along with the HSPG profile. The key findings of this 
Chapter are presented in Figure 5-11, which summarises changes in lineage marker 
and HSPG pathway expression following neuronal and astrocyte differentiation of 
hNSC H9 cells, proposing markers for the characterisation of hNSC-derived lineage-
specific neural cells.  
 
5.4.1 Markers of hNSC H9 neuronal and astrocyte differentiation  
 
Understanding markers of neurogenesis and astrogliosis is crucial for the better 
isolation and characterisation of these cells and for the more efficient control of 
hNSC lineage differentiation. The high level of neuronal marker expression and the 
low level of glial marker expression in basal hNSC H9 cells as previously 
demonstrated (Chapter 4), indicated high inherent neuronal versus glial 
differentiation potential of these cells, a characteristic of NSCs previously reported in 
vitro and in vivo (Gao et al., 2014; Götz & Gallo, 2015). Surprisingly, during 
neuronal differentiation expression levels of the self-renewal marker SOX2 did not 
decrease, indicating a maintained pool of self-renewing cells within the cultures. This 
observation may be due to the short differentiation time, with a longer time in culture 
(e.g. 4 – 8 weeks) likely required for a higher yield of mature neurons and 
subsequent decrease in SOX2 expression (Hu et al., 2010; Hu et al., 2016; 
Swistowski et al., 2010; Zhang & Zhang, 2010). Additionally, SOX2 is a key 
transcription factor of neural initiation with low levels of SOX2 expression reported 
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in some neuron types (Puligilla et al., 2010; Thomson et al., 2011). Thus, it is 
possible that SOX2 expression is maintained to some level in hNSC H9-derived 
neuron cultures, with this not necessarily indicating a presence self-renewing cells. 
 
The neuronal potential of hNSC H9 cells was confirmed following neuronal lineage 
differentiation, which resulted in the upregulation of all neuronal markers studied 
when compared to basal hNSC H9 cultures. Of the neuronal markers, TUBB3 
(protein level), NEFM (transcript) and DCX (transcript) were upregulated in the 
neuronal cultures when compared to both basal and astrocyte lineage cultures (Fig. 5-
11). Specifically, the mRNA levels of NEFM and DCX demonstrated highly specific 
expression in neuronal cultures when compared to the other culture conditions, 
supporting their specific expression in the neuronal lineage and suitability for use in 
neuronal characterisation. Consistent with observed marker expression in basal 
hNSC H9 cultures, glial differentiation of these cells was achieved at a lower 
efficiency. The oligodendrocyte cultures produced from hNSC H9 cells were not 
viable and not suitable for further examination. In addition, the astrocyte marker 
GFAP was undetectable following 14-18 days of culture, however, the upregulated 
expression of the astrocyte marker S100B in astrocyte cultures when compared to 
basal hNSC H9 and neuronal cultures provided evidence of astrocyte lineage 
commitment (Fig. 5-11). 
 
Interestingly, several lineage markers examined in this study demonstrated an 
unexpected expression pattern. The surface marker CD44, which has been found 
expressed in fibrous astrocytes both in the human and mouse brain (Naruse et al., 
2013; Sosunov et al., 2014), demonstrated higher expression levels in the neuronal 
cultures than in the astrocyte differentiating cultures (Fig. 5-11). CD44 is widely 
used as a marker of cells of the mesenchyme lineage and has been shown to be 
expressed in all CNS cell types and non-neural cells (Naruse et al., 2013; 
Okolicsanyi et al., 2015). This suggests that CD44 lacks specificity to characterise a 
single lineage. Interestingly, however, CD44 expression has been reported in some 
neuron subtypes (Dzwonek & Wilczynski, 2015; Naruse et al., 2013), suggesting that 
neuron cultures generated in the conditions used in this study resemble subtypes of 
CD44 expressing neurons. Unexpected expression patterns at the transcript level 
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were also detected for the NSC marker MSI1 and neuronal lineage markers TUBB3 
and MAP2, which demonstrated significantly higher expression in the astrocyte 
cultures than basal hNSC H9 cells. This may reflect the high neuronal potential of 
hNSC H9 cells and a presence of a higher proportion of neuronal progenitors in the 
astrocyte cultures following 14-18 days of differentiation, with extended culture 
likely reducing this. There are also reports of MSI1, TUBB3 and MAP2 expression 
in reactive astrocytes, which are generated in response to CNS injury (Geisert et al., 
1990; Noristani et al., 2016; Oki et al., 2010).  It is, thus, possible that  the astrocytes 
generated under the culture conditions possess a reactive astrocyte phenotype, with 
the cause of this phenotype important to investigate and the suitability of the 
astrocyte protocol to consider. Of note, due to their high expression in astrocyte 
differentiating cultures, TUBB3 and MAP2 may not be specific markers for the 
characterisation of the neuronal lineage, particularly when used independently. These 
results reinforce the overlap in expression of many neural lineage markers and the 
need to define combinations rather than single markers for accurate characterisation. 
 
5.4.2 Changes in HS biosynthesis enzyme expression following hNSC H9 
neuronal and astrocyte differentiation  
 
Following neuronal and astrocyte differentiation, multiple significant changes in the 
HSPG profile of hNSC H9 cells were observed. Interestingly, in the neuronal 
cultures the expression of multiple HS biosynthesis enzymes, including EXT2, 
NDST2, NDST4, HS6ST2 and HS6ST3 was induced indicating altered HS 
biosynthesis activity and differential incorporation of HS chain modifications during 
neuronal commitment (Fig. 5-11). Fewer changes in HS biosynthesis enzyme 
expression were detected during astrocyte differentiation, however, upregulation of 
NDST3 and HS6ST1 following astrocyte commitment suggests shifts in N- and 6-O-
sulfation sites during astrocyte differentiation (Fig. 5-11). As previously discussed 
(Chapter 4), HS chain modifications are associated with a shift in growth factor 
binding abilities (e.g. FGF-2 vs. FGF-1) (Brickman et al., 1998; Johnson et al., 
2007), thus HS chain modification are likely crucial in allowing lineage 
differentiating neural cells to respond to a different signalling environment. In 
support of this hypothesis similar observations have been demonstrated in other 
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models, including in mouse ESCs, which during embryoid body (EB) formation, the 
process used as an intermediate step to derive NSCs from ESCs, demonstrate a 
significant upregulation in the expression of multiple HS enzymes (Nairn et al., 
2007; Zhang et al., 2001). Similarly, the upregulation of NDST4 and 6-O-
sulfotransferase gene expression has been demonstrated following neural 
differentiation of mouse ESCs (Grobe et al., 2002; Johnson et al., 2007). Finally, 
NDST3 is highly expressed in mouse hippocampus and cerebellum (Lein et al., 
2007), with its upregulated expression during neuronal and astrocyte differentiation 
suggesting NDST3 activity plays a role within the neural niche, specifically during 
lineage specification. Supporting the importance of HS modifications in neural cell 
development comes from in vivo studies where with depletion of NDST1, HS2ST1 
and HS6ST1 in the mouse brain resulted in abnormal brain development, neural cell 
function and axon guidance defects (Grobe et al., 2005; McLaughlin et al., 2003; 
Pratt et al., 2006). Overall, these results provide strong evidence for the importance 
of HS chain expression and modification during hNSC fate commitment, with their 
specific roles in the human CNS important to investigate. 
 
5.4.3 Changes in HSPG expression following hNSC H9 neuronal and astrocyte 
differentiation  
 
Consistent with increased HS biosynthesis enzyme transcription, was the upregulated 
expression of multiple cell surface HSPG core proteins, including SDC4, GPC1, 
GPC2, GPC3 and GPC6 following culture of hNSC H9 cells in neuronal 
differentiating conditions (Fig. 5-11). Interestingly, SDC4 has previously been 
identified as glial-specific (Avalos et al., 2009; Hsueh et al., 1998), however, its 
upregulation in neuronal cultures suggests it has a role in neuronal lineage 
specification. The importance of, in particular, GPC proteins in the neuronal lineage 
is supported by their correlated expression with neuronal lineage markers as 
previously shown (Chapter 4: hNSC H9 vs. nhNPC comparison; (Oikari et al., 
2016a)). In addition, previous studies have reported the localised expression of GPC1 
and GPC2 to rodent neurons in vivo (Ford-Perriss et al., 2003; Ivins et al., 1997; Jen 
et al., 2009; Luxardi et al., 2007) as well as an upregulation in the expression of 
GPC2, -3 and -6 following mouse EB differentiation in vitro (Nairn et al., 2007). 
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These studies together with the findings of this Chapter suggest an association with 
increased GPC expression during neuronal commitment. This is further supported by 
KD of GPC1 and GPC4, which resulted in reduced neuronal marker expression 
TUBB3 and NEFM, suggesting these GPCs mediate neuronal lineage potential. 
Interestingly, the results of this Chapter propose GPC4 as an astrocyte lineage 
marker (Fig. 5-11). This is supported by highly upregulated GPC4 gene expression in 
astrocyte cultures with its IF localisation demonstrating a distinct “clustering” pattern 
that differed from basal hNSC H9 and neuronal cultures. Additionally, KD of GPC4 
in basal hNSC H9 cultures resulted in the downregulation of the astrocyte marker 
S100B, indicating potential regulatory roles for GPC4 in astrocyte lineage 
commitment. The combination of GPC4 and GPC6 may be of importance in the 
astrocyte niche, as increased transcription of GPC6 was also observed in astrocyte 
cultures when compared to basal hNSC H9 cultures, with previous studies in rodents 
further supporting this hypothesis (Allen et al., 2012). Identification of regulators of 
the astrocyte lineage would greatly enhance the more efficient derivation of 
astrocytes from hNSCs. While these results are preliminary and further confirmation 
of the lineage specificity of the studied HSPGs needed, these data provides a 
promising insight into the role of HSPGs as novel markers and mediators of human 
neural lineages.  
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5.5 SUMMARY AND CONCLUSIONS 
 
 
 
Figure 5-11: A schematic summary of changes in NSC and lineage markers (neuronal and glial) 
as well as HS biosynthesis enzymes and HSPG core proteins following neuronal and astrocyte 
differentiation of hNSC H9 cells. Key differences were identified between early (P2–P5) passage 
hNSC H9 cell cultures and neuronal and astrocyte differentiating cultures.   
 
The data presented here demonstrates that during neuronal and astrocyte 
differentiation, hNSC H9 cells not only acquire changes in their lineage specific 
marker expression, but also significantly alter their HSPG profile, suggesting HSPGs 
may be involved in neural lineage specification. Neuronal differentiation was 
indicated by the upregulated expression of all neuronal lineage markers studied and 
astrocyte differentiation was indicated by upregulated S100B expression. 
Interestingly, several lineage markers with unexpected expression patterns were 
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identified, including high SOX2 and CD44 expression in neuronal cultures and high 
MSI1, TUBB3 and MAP2 expression in astrocyte cultures. These results may be 
caused by high culture heterogeneity, which can be reduced by extending culture 
time, or an overlap in expression of these markers between different neural cell 
lineages. For the latter case, it is important to use caution when utilising these 
markers for cell identification and characterisation purposes. The results also 
demonstrated that lineage differentiation of hNSC H9 cells was accompanied by 
altered HS biosynthesis enzyme expression, reflecting altered HS chain synthesis and 
modification activity and an altered ability of the cells to interact with the 
surrounding microenvironment. Lineage differentiation of hNSC H9 cells was also 
associated with altered HSPG core protein gene expression, with neuronal cultures 
demonstrating specifically an increase in GPC gene expression and GPC4 identified 
as a potential marker and mediator of the astrocyte lineage. These results suggest a 
role for HS in hNSC neural lineage specification and HS biosynthesis enzymes and 
HSPGs as additional markers of neural lineage characterisation, particularly when 
used in combination with other lineage markers. Finally, due to their cell surface 
localisation, HSPGs may provide easy targets for translational purposes, including 
cell isolation, enrichment and differentiation of neural cells. To confirm the roles of 
HSPGs in neural regulation it is important to further examine them in vitro under 
extended lineage specific culture conditions and also to examine the protein level 
expression of the specific HSPG core proteins in specific lineages. Overall, the 
results presented in this Chapter provide new knowledge regarding HSPGs in neural 
cells enhancing our understanding of human neurogenesis biology. 
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Chapter 6: Heparan Sulfate-Mediated 
Lineage Specification of Human 
Neural Stem Cells 
 
As previously demonstrated (Chapter 5), culture of hNSC H9 cells under neuronal- 
and astrocyte-specific culture conditions for up to 18 days induced the expression of 
lineage-specific markers and significantly altered the HSPG profile of the cells. To 
examine the ability to enhance lineage specification, the duration of the time hNSC 
H9 cells were cultured under differentiation conditions was extended to 40 days 
(D40) and lineage marker and HSPG profile of the cells then examined. Following 
D40 of differentiation, lineage-specific marker expression in both neuronal and 
astrocyte cultures was highly increased indicating enhanced lineage commitment. In 
addition, the HSPG profile of differentiating cells was shown to be vastly different to 
basal hNSC H9 cells with more changes acquired by D40 neuronal differentiating 
cells for HS biosynthesis enzyme and HSPG core protein expression than observed 
in the D14-18 differentiation cultures (Chapter 5). With the confirmation that the 
D40 differentiation timepoint enhanced lineage-specificity, cultures were examined 
in the presence of exogenous HS (heparin) as well as key neuroregulatory signalling 
molecules BDNF (neuronal) and PDGF (astrocyte) to gain insight into possible roles 
of HS and key pathways during lineage specification of hNSCs. HS and growth 
factor treatments were examined in differentiating cultures for effects on 
morphology, lineage-specific marker expression, culture heterogeneity and HSPG 
profile to determine if in vitro modulations altered features of lineage-specificity and 
its regulation. The observed changes induced by the in vitro modulations suggest a 
potential role for HS and key growth factors in mediating hNSC lineage 
specification.  
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6.1 INTRODUCTION 
 
The differentiation of neural stem cells (NSCs) to lineage-specific neural cells 
(neurons and glial cells; Chapter 5) can be induced by culturing the cells in lineage-
specific culture conditions. The length of time required to generate mature neural 
cells, including neurons and astrocytes varies in the literature. Several studies have 
reported that between 28 to 56 days (4 to 8 weeks) is required to generate action 
potential evoking neurons from human pluripotent or multipotent stem cell types, 
including human embryonic stem cells (hESCs), human induced pluripotent stem 
cells (hiPSCs) or human NSCs (hNSCs) (Hu et al., 2010; Hu et al., 2016; Schulz et 
al., 2004; Swistowski et al., 2010; Zhang & Zhang, 2010). For the generation of 
astrocytes from these same human stem cell types (hESCs, hiPSCs and hNSCs) 
reported differentiation times range from 30 to 60 days (Haidet-Phillips et al., 2014; 
Palm et al., 2015; P. W. Zhang et al., 2016). Interestingly, several studies have 
reported that approximately 60 days is required to generate a population of astrocytes 
that demonstrate a high and homogenous expression level of astrocyte markers, 
including S100B and CD44 (Haidet-Phillips et al., 2014; Palm et al., 2015).  
 
In addition to extending differentiation time, hNSC differentiation toward neural 
lineages can also be enhanced through the addition of various cell growth or 
differentiation stimulating supplements. Heparin is a highly sulfated agonist of 
heparan sulfate (HS) and is commonly used in cell culture to promote survival or 
proliferation of various cell types. Heparin is known to be required for FGF-
dependent signalling and has been shown to induce proliferation of several cell types, 
including human breast cancer cells and hESCs (Furue et al., 2008; Lundin et al., 
2000; Okolicsanyi et al., 2014b; Ornitz et al., 1992). Through an FGF-dependent 
mechanism heparin has also been identified to promote maintenance of hESCs in an 
undifferentiated state (Furue et al., 2008). In human mesenchymal stem cells 
(hMSCs) heparin treatment has been shown to promote osteogenic differentiation 
(Mathews et al., 2014; Simann et al., 2015) and within neural cell types, heparin 
promotes human neuroblast differentiation leading to suppressed growth of 
neuroblastomas (Knelson et al., 2014). Together with FGF-2, heparin 
supplementation has been shown to promote the differentiation of mouse iPSCs 
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toward neuronal cells and the use of heparin in neuronal induction of hESCs has also 
been reported (Yamasaki et al., 2013; Zhang & Zhang, 2010). Several studies have 
also shown the beneficial effects of heparin-binding growth factor (FGF, EGF, 
midkine) treatments on neuronal differentiation and survival (Hienola et al., 2004; 
Ishikawa et al., 2009; Jin et al., 2004). Heparin-immobilised FGF-2 or EGF also 
stimulates axon growth of hESC-derived neuronal cells more efficiently than soluble 
FGF-2 and EGF (Lam et al., 2010).  
 
Brain-derived neurotrophic factor (BDNF) belongs to the group of growth factors, 
known as neurotrophins (Islam et al., 2009; Wei et al., 2015). The functions of 
neurotrophins include their ability to promote survival, differentiation and migration 
of CNS neurons (Islam et al., 2009; Wei et al., 2015). BDNF is one of the most well 
characterised neurotrophin and is known to promote neuronal differentiation, 
survival and proliferation with its administration to in vitro neuronal cultures 
resulting in larger neurosphere diameter (Li et al., 2009; Wei et al., 2015). The 
positive effects of BDNF on neuronal differentiation have been widely reported in 
the literature with BDNF supplementation together with nerve growth factor 
resulting in the generation of a high number of TUBB3 positive cells from rat NSCs 
(Liu et al., 2014). In addition, human neural progenitor cells (hNPCs) transplanted 
into a rat auditory nerve degeneration model treated with BDNF demonstrated higher 
cell differentiation and migration than transplants not receiving BDNF treatment 
(Jiao et al., 2014). BDNF supplementation has also been shown to promote the 
neural differentiation of non-neuronal stem cells, including rat adipose-derived stem 
cells and guinea pig bone marrow-derived MSCs (Ji et al., 2015; Liu et al., 2015). In 
addition, BDNF (10 ng/mL) together with B-27 supplementation has been shown to 
efficiently promote the differentiation of hiPSCs to neurons (D'Aiuto et al., 2014).  
 
The platelet-derived growth factor (PDGF) family consists of PDGF-A, -B, -C and –
D isoforms that bind to the PDGF receptors (PDGFRs) (Shim et al., 2010).  PDGF 
signalling is considered important in driving oligodendrocyte production with PDGF 
a central mitogen to oligodendrocyte precursors (Baron et al., 2002; Jackson et al., 
2006; Rakic & Zecevic, 2003). There is also a subset of cells in the CNS, known as 
the PDGF-responsive neural precursors (PRPs) with PDGFAA supplementation in 
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vitro shown to induce their differentiation toward oligodendrocytes, astrocytes and 
neurons (Chojnacki et al., 2011; Moore et al., 2014). Further support of the 
importance of PDGF signalling in glial differentiation is provided from in vitro 
studies, where PDGFBB administration has been shown to stimulate the proliferation 
of rat astrocytes and overexpression of PDGFB in mouse GFAP-positive astrocytes 
resulting in significantly increased cell proliferation (Dai et al., 2001; Luo & Miller, 
1999). 
 
As stated, heparin mediates proliferation and differentiation of several human stem 
cell types and BDNF and PDGF have known roles in the neural niche regulating 
neuron and glial cell function. In addition, BDNF and PDGF are known to bind 
glycosaminoglycans (GAGs), including HS chains, which are carried by 
proteoglycans (PGs), such as HSPGs (Maeda et al., 2011). A study by Kanato et al. 
showed direct interaction of BDNF with HS and chondroitin sulfate (CS) (Kanato et 
al., 2009). In addition, PDGF has been reported to interact with HS (Abramsson et 
al., 2007; Sasisekharan et al., 2002) with HSPGs shown to be required to facilitate 
PDGF-fibronectin interaction, critical during Xenopus development (Smith et al, 
2009). The complexes formed by GAGs and GAG-binding growth factors are 
important in enhancing the binding of growth factors to their receptors and forming 
growth factor reservoirs in the brain (Kanato et al., 2009; Maeda et al., 2011). As 
such, supplementation of hNSC cultures with heparin together with key 
neuroregulatory HS-binding growth factors likely enhances neural differentiation of 
hNSCs.  
 
The first aim of this Chapter was to establish day 40 (D40) neuronal and astrocyte 
differentiation cultures to assess the effect of an extended differentiation time on 
lineage specific marker expression and the cell HSPG profile when compared to 
basal hNSC H9 cultures. The second aim of this Chapter was to establish D40 
neuronal and astrocyte cultures treated with heparin and BDNF (neuronal cultures) or 
PDGF (astrocyte cultures) during differentiation. To examine potential HS and 
growth factor interactions, BDNF and PDGF treated cultures were also supplemented 
with heparin. The final aim of this Chapter was to examine any changes in cell 
morphology and marker and HSPG expression between untreated and 
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heparin/growth factor treated neural differentiation cultures to assess the influence of 
HS/growth factor interactions on hNSC neural lineage differentiation efficiency. 
 
6.2 METHODS 
 
6.2.1 Neuronal and astrocyte differentiation of hNSC H9 cells 
 
hNSC H9 POP1 and POP2 cells were differentiated under neuronal and astrocyte 
specific culture conditions as previously described (section 3.3). Differentiation was 
performed as previously described (Chapter 5) for 40 days. During differentiation, 
phase-contrast images were acquired of cells every 2 – 3 days to monitor 
morphological changes. Measurements, including sphere diameter and protrusion 
length, were obtained using Volocity® v.6.3. software (Perkin Elmer). 
 
6.2.2 In vitro modulation of culture condition 
 
The hNSC H9 cell differentiation cultures were modulated as previously described 
through the addition of heparin (10 μg/mL) (section 3.4.1), BDNF (10 ng/mL) 
(section 3.4.2) or PDGF-BB (10 ng/mL) (section 3.4.2). The added heparin and 
growth factors were mixed into the culture medium and applied to cells along with 
media changes every 3 – 4 days.  
 
6.2.3 Examination of gene and protein expression 
 
RNA and protein samples were harvested from differentiating cells at D40 with each 
sample consisting of minimum of 3 – 4 pooled culture wells. RNA was extracted and 
gene expression analyses performed as previously described (section 3.6.1) utilising 
gene specific primers (Tables C1 and C2, Appendix C). Western blot (WB) for 
protein expression analysis was performed as previously described (section 3.6.2) 
utilising specific antibodies (Table 3-2, Chapter 3). Gene expression results 
presented are an average between hNSC H9 POP1 and POP2 results. For WB 
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analysis, protein samples from both cell populations were pooled prior to SDS-
PAGE. Optical density of protein bands was measured using Bio1D software (Vilber 
Lourmat) and normalised to the optical density of a GAPDH loading control.  
 
6.2.4 Immunofluorescence 
 
Immunofluorescent (IF) staining of cells grown under differentiating culture 
conditions was performed in 48-well culture plates at D40. The IF staining was 
performed as previously described (section 3.7.1). Antibodies used are presented in 
Table 3-3 (Chapter 3). For signal intensity measurements, the fluorescence mean 
intensity for a microscope field of view was obtained using Volocity software 
(Perkin Elmer). The mean signal intensities of 2 to 4 fields of view were normalised 
to exposure time and averaged for graphic presentation as previously described 
(3.7.2).  
 
6.2.5 Statistical analysis 
 
Differentiation experiments consisted of two biological replicates (hNSC H9 POP1 
and POP2). RNA and protein samples from each population (POP1 and POP2) were 
obtained by pooling multiple culture wells. Gene and protein expression results 
presented are an average of the two cell populations studied. Relative gene 
expression was normalised to the endogenous control 18S and results are presented 
on bar graphs as ΔΔCt x 106 with error bars = SEM unless otherwise stated. Statistical 
significance was determined using Student’s t-test and defined as * p < 0.05, ** p < 
0.01 and *** p < 0.001. 
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6.3 RESULTS 
 
6.3.1 Cell morphology during D40 neuronal and astrocyte differentiation of 
hNSC H9 cells 
 
hNSC H9 cells were differentiated until D40 under neuronal and astrocyte lineage-
specific culture conditions. During differentiation cell morphology was monitored by 
acquiring phase-contrast images of the cells every 2 – 3 days at 4X, 10X and 20X 
magnification.  During early stages of differentiation (D8-D18) neuronal cultures 
acquired relatively limited morphological changes (Fig. 6-1). Interestingly, at around 
D29 of differentiation, long elongated protrusions became apparent in the cells (Fig. 
6-1). Thin, finely structured protrusions accompanied by thick protrusion (indicated 
by white solid line) were apparent in the cultures at D29 (Fig. 6-1). These thick 
structures were likely a bundle of numerous protrusions, or “neurites” arising from 
multiple cells. At D40 of differentiation large sphere-like aggregates of cells became 
apparent in the cultures and interestingly, these spheres were connected by thick 
neuronal protrusions (Fig. 6-1). When the sphere diameters were measured in the 
presented D40 microscope field of view (indicated by a red dashed line), a sphere 
diameter of approximately 200 μM was obtained (Fig. 6-1). The thick sphere-
connecting protrusion (indicated by a solid white line) in the presented D40 
microscope field of view was 849 μM in length indicating the ability of the neuronal 
differentiating cells to build long connections (Fig. 6-1). 
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Figure 6-1: Morphological changes observed in hNSC H9 cells during D40 neuronal 
differentiation.  Phase-contrast images (10X magnification, scale bar 130 μM) of hNSC H9 cells 
cultured in neuronal differentiating culture conditions for 8, 18, 29 and 40 days. In the D29 
representative image white arrows point thick neurites observed in the cultures. In the D40 
representative image red dashed lines indicated sphere diameter (μM) and white solid line indicates 
length (μM) of sphere-connecting protrusion. 
 
hNSC H9 cells cultured under astrocyte differentiating conditions appeared to 
acquire morphological changes more rapidly than the neuronal differentiating 
cultures. At D8 of differentiation, differentiating astrocytes looked morphologically 
different to D8 differentiating neurons with the astrocyte differentiating cells having 
larger and more angular cell bodies (Fig. 6-2). Although, based on the neuronal 
differentiation protocol hNSC H9 cells were seeded at a lower density prior to 
astrocyte differentiation in comparison to neuronal differentiation (2 x 104 cells/cm2 
vs. 2.5 x 104 cells/cm2, respectively), astrocyte differentiating hNSC H9 cells 
proliferated rapidly with near 100% confluence reached at D21 of differentiation 
(Fig. 6-2).  At D29 of differentiation large dense sphere-like structures were 
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observed in the astrocyte differentiating cultures with cells in more sparsely 
populated areas demonstrating the thin, elongated, “neuron-like” protrusions (Fig. 6-
2). These dense sphere-like clusters visible within the cultures ranged from 277 to 
521 μM in diameter (indicated by a red dashed line) (Fig. 6-2). At D40 of 
differentiation, similar to D29 cultures, the cells cultured in astrocyte conditions 
appeared very dense with cells in less confluent areas demonstrating thin neuron-like 
morphologies (Fig. 6-2). However, in contrast to the cells grown in the neuronal 
culture conditions, thick “sphere-connecting” protrusions were not apparent in the 
astrocyte differentiating cultures.  
 
 
Figure 6-2: Morphological changes during observed in hNSC H9 cells during D40 astrocyte 
differentiation. Phase-contrast images (10X magnification, scale bar 130 μM) of hNSC H9 cells 
cultured in astrocyte differentiating culture conditions for 8, 21, 29 and 40 days. In the D29 
representative image red dashed lines indicate sphere diameter.  
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6.3.2 Changes in lineage specific marker expression following D40 neuronal and 
astrocyte differentiation of hNSC H9 cells 
 
Following D40 neuronal and astrocyte differentiation, differences in NSC, neuronal 
and astrocyte lineage marker expression was compared to basal hNSC H9 cultures to 
assess lineage specificity. When the gene expression of NSC self-renewal markers in 
D40 neuronal cultures were examined, a significant downregulation (p<0.0001) of 
nestin in neuronal differentiated cells when compared to basal hNSC H9 cells was 
observed (Fig. 6-3A). In contrast, a significant upregulation of SOX1 (p=0.007) and 
Musashi-1 (MSI1) (p=0.01) was detected in D40 neuronal cultures when compared 
to basal hNSC H9 cells (Fig. 6-3A). Cells cultured under astrocyte differentiating 
conditions demonstrated a significantly lower gene expression of SOX1 (p=0.04) and 
SOX2 (p=0.03) than basal hNSC H9 cells (Fig. 6-3A). In contrast, MSI1 expression 
was highly significantly (p<0.0001) upregulated in astrocyte differentiating cells at 
D40 when compared to basal hNSC H9 cells (Fig. 6-3A). When D40 neuronal and 
astrocyte cultures were compared to each other, SOX1 (p=0.005) and SOX2 (p=0.01) 
were significantly upregulated in D40 neuronal cultures when compared to D40 
astrocyte cultures (Fig. 6-3A).  
 
Indicative of neuronal lineage commitment, D40 differentiating neurons 
demonstrated significantly higher expression levels of all neuronal markers studied, 
including βIII-tubulin (TUBB3) (p=0.046), microtubule-associated protein 2 (MAP2) 
(p=0.001), medium molecular weight neurofilament (NEFM) (p=0.0001) and 
doublecortin (DCX) (p=0.0002) when compared to basal hNSC H9 cells (Fig. 6-3B). 
Interestingly, a significant upregulation in neuronal markers TUBB3 (p=0.02), 
NEFM (p<0.0001) and DCX (p=0.01) was also observed in D40 astrocyte 
differentiating cells when compared to basal hNSC H9 cells (Fig. 6-3B). However, 
MAP2 (p=0.003), NEFM (p=0.0001) and DCX (p=0.0004) demonstrated 
significantly higher expression in D40 neuronal cells when compared to D40 
astrocyte differentiating cells (Fig. 6-3B).   
 
The astrocyte lineage marker S100B demonstrated significant upregulation in both 
D40 neuronal (p=0.02) and astrocyte (p=0.02) differentiating cells when compared to 
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basal hNSC H9 cells (Fig. 6-3C). Interestingly, the astrocyte marker glial fibrillary 
acidic protein (GFAP), which was barely detectable in basal hNSC H9 cells, showed 
highly significant upregulation in D40 astrocyte differentiated cells when compared 
with basal (p<0.0001) and D40 neuronal cells (p<0.0001) - indicative of astrocyte 
lineage commitment (Fig. 6-3C). 
 
 
Figure 6-3: NSC and neural lineage marker gene expression following D40 neuronal and 
astrocyte differentiation of hNSC H9 cells. Relative gene expression of A) NSC markers nestin, 
SOX1, SOX2 and Musashi-1 (MSI1) B) neuronal markers βIII-tubulin (TUBB3), microtubule-
associated protein 2 (MAP2), medium molecular weight neurofilament (NEFM) and doublecortin 
(DCX) and C) astrocyte markers S100B and glial fibrillary acidic protein (GFAP) in basal hNSC H9 
cells and following D40 neuronal and astrocyte differentiation (Error bars for hNSC H9 and Neuronal 
D40 GFAP =SD, other error bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** p<0.001).  
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Selected NSC, neuronal and astrocyte markers were imaged via IF in D40 neuronal 
and astrocyte cultures. Consistent with the gene expression results, NSC markers 
nestin and SOX2 were expressed in neuronal and astrocyte cultures following D40 of 
differentiation (Fig. 6-4). Both nestin and SOX2 demonstrated homogenous 
expression within the differentiating cultures indicating that a high level of self-
renewal potential was maintained in neuronal (Fig. 6-4A) and astrocyte cultures (Fig. 
6-4B) following D40 of differentiation.  
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Figure 6-4: Immunofluorescent detection of NSC markers following D40 neuronal and astrocyte 
differentiation of hNSC H9 cells. Immunofluorescence of NSC markers nestin (FITC/green) and 
SOX2 (Cy3/yellow) without and with DAPI counterstain (blue) in hNSC H9-derived D40 (A) 
neuronal and (B) astrocyte differentiating cells (10X and 20X magnification, scale bar 130 µM). 
 
The neuronal marker TUBB3 was also examined by IF and shown to be highly 
expressed in both D40 neuronal and astrocyte differentiating cultures, consistent with 
the observed gene expression results (Fig. 6-5A). TUBB3 staining clearly 
demonstrated thin elongated structures within the D40 neuronal cultures, which 
differed from the shorter and structurally more homogeneous cell bodies observed in 
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the D40 astrocyte cultures (Fig. 6-5A). WB analysis of TUBB3 demonstrated 
upregulated expression of this protein in the D40 neuronal differentiating cells when 
compared to the basal hNSC H9 and D40 astrocyte differentiating cultures 
confirming the gene expression results (Fig. 6-5B). 
 
 
Figure 6-5: Immunofluorescent and protein level detection of neuronal markers following D40 
neuronal and astrocyte differentiation of hNSC H9 cells. A) Immunofluorescence of the neuronal 
marker βIII-tubulin (TUBB3) (Cy3/yellow) along with DAPI counterstain (blue) in hNSC H9-derived 
D40 neuronal and astrocyte differentiating cells (10X and 20X magnification, scale bar 130 µM). B) 
Western blot analysis of TUBB3 with GAPDH loading control in basal hNSC H9 and in D40 
neuronal and astrocyte differentiating cultures. 
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Markers denoting the astrocyte lineage, S100B and GFAP, were also examined in the 
D40 neuronal and differentiating cultures via IF.  Astrocyte markers S100B (Fig. 6-
6A) and GFAP (Fig. 6-6B) demonstrated strong staining in the D40 astrocyte 
differentiating cultures confirming the presence of astrocyte lineage committing 
cells.  S100B exhibited uniform expression in the D40 astrocyte cultures while it was 
present only in a low number of cells in D40 neuronal cultures (Fig. 6-6A). When 
GFAP was examined via IF, filamentous structures exhibiting strong GFAP staining 
were observed in the D40 astrocyte differentiating cultures (Fig. 6-6B). While low 
GFAP staining was also detected in D40 neuronal cultures, the filamentous GFAP 
structures observed within the astrocyte cultures were absent (Fig. 6-6B).  
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Figure 6-6: Immunofluorescent detection of astrocyte markers following D40 neuronal and 
astrocyte differentiation of hNSC H9 cells. Immunofluorescence of the astrocyte markers A) 
calcium binding protein S100B (Cy3/yellow) and B) glial fibrillary acidic protein (GFAP) 
(Cy3/yellow) along with DAPI counterstain (blue) in hNSC H9-derived D40 neuronal and astrocyte 
differentiating hNSC cells (10X and 20X magnification, scale bar 130 µM).  
 
 
  
Chapter 6: Heparan Sulfate-Mediated Lineage Specification of Human Neural Stem Cells 175 
6.3.3 Changes in HSPG profile following D40 neuronal and astrocyte 
differentiation of hNSC H9 cells 
 
Following the identification of lineage specific changes associated with the 
differentiation culture conditions, the HSPG profile of D40 neuronal and astrocyte 
differentiating cultures was examined and compared to basal hNSC H9 cells. In order 
to gain insight into HS biosynthesis activity following D40 neuronal and astrocyte 
differentiation of hNSC H9 cells, the gene expression of multiple HS biosynthesis 
enzymes was examined. Similar to observed changes during D14-18 differentiation 
(Chapter 5), the expression of multiple HS biosynthesis enzymes was significantly 
altered following D40 neuronal differentiation. Interestingly, the expression of HS 
elongating exostosin 1 (EXT1) (p=0.0002) and HS-2-O-sulfotransferase (HS2ST1) 
(p=0.001) enzymes was significantly downregulated following D40 neuronal 
differentiation of hNSC H9 cells when compared to basal hNSC H9 cells (Fig. 6-
7A&C). In contrast, the majority of the HS modifying and sulfation enzymes studied 
were expressed at a significantly higher level following D40 neuronal differentiation 
when compared to basal hNSC H9 cells, including the C5-epimerase (C5-EP) 
(p=0.009) (Fig. 6-7A), N-deacetylation/N-sulfotransferases NDST1 (p=0.01), 
NDST3 (p<0.0001) and NDST4 (p=0.03) (Fig. 6-7B) and HS-6-O-sulfotransferases 
HS6ST2 (p=0.02) and HS6ST3 (p=0.02) (Fig. 6-7C).  
 
D40 astrocyte differentiation also induced multiple changes in the gene expression of 
HS biosynthesis enzymes. Similar to neuronal cultures, EXT1 (p=0.0002) and 
HS2ST1 (p=0.003) were significantly downregulated in the D40 astrocyte cultures 
when compared to basal hNSC H9 cells (Fig. 6-7A&C). In contrast to neuronal 
cultures, the majority of HS biosynthesis enzymes were significantly downregulated 
in expression following D40 astrocyte differentiation when compared to basal hNSC 
H9 cell, including C5-EP (p=0.04), NDST1 (p=0.02), NDST2 (p=0.003), NDST4 
(p=0.01), HS6ST1 (p=0.02), HS6ST2 (p=0.03) and HS6ST3 (p=0.04) (Fig. 6-7A-C). 
Interestingly, the only HS biosynthesis enzyme significantly upregulated (p=0.01) 
following D40 astrocyte differentiation when compared to basal hNSC H9 cells was 
NDST3 (Fig. 6-7B). The upregulation of NDST3 was also observed following D14-
18 astrocyte differentiation as previously reported (Chapter 5). 
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When D40 neuronal and astrocyte cultures were compared, neuronal cultures 
exhibited a significantly higher expression level of C5-EP (p=0.006), NDST1 
(p=0.006), NDST2 (p=0.007), NDST3 (p=0.01), NDST4 (p=0.005), HS6ST1 
(p=0.01), HS6ST2 (p=0.01) and HS6ST3 (p=0.01) when compared to D40 astrocyte 
cultures (Fig. 6-7A-C). In contrast, the expression of HS2ST1 remained at a 
significantly higher level (p=0.02) in D40 astrocyte differentiating cultures when 
compared to D40 neuronal differentiating cultures (Fig. 6-7C). 
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Figure 6-7: HS biosynthesis gene expression following D40 neuronal and astrocyte 
differentiation of hNSC H9 cells. Relative gene expression of HS chain synthesising and modifying 
A) exostosins 1 and 2 (EXT1 and EXT2) and C5-epimerase (C5-EP), B) N-deacetylase/N-
sulfotransferases NDST1-4 and C) HS-2-O- and 6-O-sulfotransferases (HS2ST1 and HS6ST1-3) in 
basal hNSC H9 cells and following D40 neuronal and astrocyte differentiation (Error bars for hNSC 
H9 NDST3 =SD, other error bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** p<0.001). 
 
Following examination of HS biosynthesis enzyme gene expression in D40 
differentiating cultures, the gene expression of the HSPG core protein syndecan 
(SDC) and glypican (GPC) genes was examined (Fig. 6-8). Consistent with the 
observed increase in HS biosynthesis enzyme gene expression, expression levels of 
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the majority of SDC and GPC core protein genes were shown to be upregulated 
following D40 neuronal differentiation when compared to basal hNSC H9 and D40 
astrocyte differentiating cultures (Fig. 6-8). SDC1 was significantly more highly 
expressed in D40 neuronal cultures compared to basal hNSC H9 (p=0.02) and D40 
astrocyte differentiating cultures (p=0.01) (Fig. 6-8A). SDC3 demonstrated 
significantly higher expression (p=0.003) in D40 neuronal cultures when compared 
to D40 astrocyte differentiating cultures and also SDC4 was more highly expressed 
in D40 neuronal cultures when compared to both basal hNSC H9 (p=0.01) and D40 
astrocyte differentiating cultures (p=0.01) (Fig. 6-8A). No significant difference in 
SDC2 expression between the three culture conditions was observed. All the GPCs 
studied were significantly more highly expressed in D40 neuronal cultures when 
compared to both basal hNSC H9 and D40 astrocyte differentiating cultures. GPC1 
(p=0.009), GPC2 (p=0.008), GPC3 (p=0.03), GPC4 (p=0.01) and GPC6 (p=0.01) all 
demonstrated significantly higher expression in D40 neuronal cultures when 
compared to basal hNSC H9 cultures (Fig. 6-8B). A similar pattern was seen when 
D40 neuronal cultures were compared to D40 astrocyte cultures, with a significantly 
higher expression of GPC1 (p=0.007), GPC2 (p=0.006), GPC3 (p=0.02), GPC4 
(p=0.02) and GPC6 (p=0.0097) in neuronal cultures observed (Fig. 6-8B).  
 
In contrast to D40 neuronal differentiating cultures, the D40 astrocyte differentiating 
cultures acquired only a few changes in SDC and GPC gene expression when 
compared to basal hNSC H9 cells. SDC1 (p=0.009) and SDC3 (p=0.01) were 
significantly downregulated in D40 astrocyte cultures when compared to basal hNSC 
H9 cultures (Fig. 6-8A).  No difference in SDC2 or SDC4 expression was observed 
between D40 astrocyte differentiating and basal hNSC H9 cultures. Of the glypicans 
only the expression of GPC4 and GPC6 was significantly altered following astrocyte 
differentiation (Fig. 6-8B). Similar to SDCs, the expression of GPC6 was 
significantly downregulated (p=0.046) in D40 astrocyte differentiating cultures when 
compared to basal hNSC H9 cultures (Fig. 6-8B).  Interestingly, GPC4 demonstrated 
a significantly higher expression level (p=0.002) in D40 astrocyte differentiating 
cultures when compared to basal hNSC H9 cells (Fig. 6-8B), a result also previously 
reported following D14-18 astrocyte differentiation of hNSC H9 cells (Chapter 5.).  
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Figure 6-8: HSPG core protein gene expression following D40 neuronal and astrocyte 
differentiation of hNSC H9 cells. Relative gene expression of A) syndecans (SDC1-4) and B) 
glypicans (GPC1-4, -6) in basal hNSC H9 cells and following D40 neuronal and astrocyte 
differentiation (Error bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** p<0.001).  
 
The D40 neuronal and astrocyte differentiating cultures were then examined via IF 
for expression and localisation of GPC1 and GPC4, previously identified as potential 
key HSPGs mediating hNSC H9 lineage potential (Chapter 5) (Fig. 6-9). When 
examined via IF, both GPC1 and GPC4 demonstrated localised expression within 
D40 neuronal and astrocyte cultures (Fig. 6-9). Co-localisation examination of GPC1 
and GPC4 through a GPC1/GPC4 co-stain and image merge identified that these two 
HSPGs were discretely localised (Fig. 6-9). GPC1 and GPC4 appeared to be 
predominantly localised to cell bodies and cell-cell interaction points with GPC4 also 
localised to the observed neurite-like structures commonly arising from nests of cells 
(Fig. 6-9). Calculation of the fluorescence signal intensities of GPC1 and GPC4 
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demonstrated slightly higher signal intensity for GPC1 and GPC4 in neuronal 
differentiating cultures when compared to astrocyte differentiating cultures, 
supporting Q-PCR results of high GPC expression in hNSC H9 neuronal cultures 
(Fig. 6-9).  
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Figure 6-9: Immunofluorescence of glypican 1 and 4 following 40 days of neuronal and astrocyte 
differentiation of hNSC H9 cells. A) Immunofluorescent detection (20X magnification, scale bar 130 
µM) of glypican 1 (GPC1) (Cy3/yellow) and glypican 4 (GPC4) (FITC/green) along with DAPI 
counterstain (blue) in hNSC H9 cells cultured under neuronal and astrocyte differentiating culture 
conditions for 40 days. B) Fluorescence signal intensity of GPC1 and GPC4 in D40 neuronal and 
astrocyte differentiating cultures. 
 182 Chapter 6: Heparan Sulfate-Mediated Lineage Specification of Human Neural Stem Cells 
6.3.4 In vitro modulation of D40 hNSC H9 differentiation cultures 
 
With the confirmation that extended differentiation time (D40) enhanced neuronal 
and astrocyte lineage specification of hNSC H9 cells, it was then examined if 
exogenous HS and key HS-binding neural regulatory signalling molecules could be 
used to modulate hNSC lineage specification. In order to do this, hNSC H9 cells 
were differentiated toward neuronal and astrocyte lineages for 40 days in the 
presence of heparin (Hep), a highly sulfated soluble analogue of HS, as well as the 
growth factors BDNF or PDGF, known HS ligands. Cultures were treated with 
heparin at a concentration of 10 μg/mL, which elicited the highest proliferative 
response in basal hNSC H9 cells as previously demonstrated (section 3.4.1 Chapter 
3).  BDNF was added to neuronal differentiating cultures at 10 ng/mL and PDGF 
was added to astrocyte differentiating cultures at 10 ng/mL based on previous reports 
in the literature (D'Aiuto et al., 2014; Hermann et al., 2004; Miura et al., 2015). In 
addition, to identify the effect of HS-growth factor interactions, culture conditions 
co-treated with heparin and BDNF or PDGF were also established. To examine the 
effects of these in vitro modulations on hNSC H9 lineage specification, cell 
morphology and lineage-specific marker expression was examined following D40 of 
culture and compared to untreated cultures. In addition, to identify any changes 
elicited by the heparin/growth factor-modulated culture conditions, HS enzyme and 
HSPG core protein gene expression was also examined and compared between the 
heparin/growth factor-modulated and untreated cultures.  
 
6.3.5 Heparin and BDNF induced changes on D40 neuronal differentiating 
hNSC H9 cells 
 
hNSC H9 cells were cultured under neuronal differentiating conditions in the 
presence of +Hep, +BDNF and +BDNF+Hep. During neuronal differentiation, cell 
morphology was monitored every 2 – 3 days by acquiring 4X and 10X magnification 
phase-contrast images of the cells. For the first 9 days of differentiation, cells 
cultured under all conditions appeared morphologically similar, largely resembling 
undifferentiated hNSC H9 cells (Fig. 6-10). When the cultures reached D28-29 of 
differentiation, morphological differences were observed in the cultures. All culture 
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conditions (+Hep, +BDNF and +BDNF+Hep) appeared to result in a denser number 
of cells at D28-29, suggestive of a higher number of cells than observed in the D7-9 
differentiation cultures (Fig. 6-10). In addition, sphere formations were observed in 
all neuronal differentiation cultures with a range of differences in the size and shape 
of these formations between the cultures identified (Fig. 6-10). In addition, thin 
elongated “neuron-like” cell bodies were apparent in all neuronal differentiation 
culture conditions (+Hep, +BDNF and +BDNF+Hep) (Fig. 6-10). 
 
 
Figure 6-10: Morphological changes during neuronal differentiation of hNSC H9 cells in the 
presence of heparin, BDNF and BDNF+heparin.  Phase-contrast images (10X magnification, scale 
bar 140 μM) of hNSC H9 cells cultured in neuronal differentiating conditions in the presence of 
heparin (Hep), BDNF or BDNF+Hep for 7 to 29 days.  
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When the D40 timepoint of differentiation was reached, all cultures exhibited a high 
number of cells, however, cell number appeared to be higher in the +BDNF and 
+BDNF+Hep treated cultures than in +Hep treated cultures (Fig. 6-11). Although 
this was not quantitated, this observation was made based on apparent cell density of 
the cultures. Sphere structures and thick sphere-connecting protrusions had 
developed in all the culture conditions (Fig. 6-11). When sphere diameters were 
measured in the displayed representative microscope field of view (indicated by a red 
dashed line), similar sized spheres were identified in the +Hep and +BDNF+Hep 
treated culture conditions ranging from 137 μM to 157 μM in diameter (Fig. 6-11). 
The +BDNF treated neuronal differentiating cultures exhibited varying sized spheres 
with both larger (Ø = 214 μM) and smaller (Ø = 116 μM) spheres detected in these 
cultures when compared to the +Hep and +BDNF+Hep treated cultures (Fig. 6-11). 
The thick sphere-connecting protrusions (indicated by a solid white line) identified 
within the cultures varied in length between the different conditions.  In the 
presented representative field of view, protrusion length varied from 243 μM 
(+BDNF+Hep) to 478 μM (+Hep) with the longest protrusion (644 μM) observed in 
+BDNF treated cultures (Fig. 6-11). The large sphere diameter along with the long 
protrusions observed in the +BDNF treated cultures likely reflect the high cell 
number observed in the cultures.  
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Figure 6-11: Culture morphology at D40 of neuronal differentiation of hNSC H9 cells in the 
presence of heparin, BDNF and BDNF+heparin. Phase-contrast images (4X and 10x magnification, 
scale bar 140 μM) of hNSC H9 cells cultured in neuronal differentiating conditions in the presence of 
heparin (Hep), BDNF or BDNF+Hep for 40 days. Red dashed lines indicated sphere diameter and 
white solid lines indicate length of sphere-connecting protrusions. 
 
The effect of the addition of +Hep, +BDNF and +BDNF+Hep treatments to the 
cultures on neuronal lineage marker gene expression, including TUBB3, MAP2, 
NEFM and DCX, was then examined by comparing treated neuronal cultures to 
untreated neuronal cultures. Treatments of the cultures with +Hep or +BDNF did not 
significantly alter TUBB3 expression when compared to untreated D40 neuronal 
cultures (Fig. 6-12A). In contrast, the +BDNF+Hep treated cultures expressed a 
significantly higher level of TUBB3 when compared to untreated (p<0.0001) and 
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+BDNF alone treated (p=0.001) neuronal cultures (Fig. 6-12A). NEFM (p=0.03) and 
DCX (p=0.0001) expression was significantly lower in +BDNF treated neuronal 
cultures when compared to untreated neuronal cultures (Fig. 6-12A). The +Hep 
treated cultures also expressed a significantly reduced level of DCX (p=0.012) when 
compared to untreated neuronal cultures (Fig. 6-12A). In addition, DCX expression 
was highly significantly downregulated (p=0.0009) following +BDNF+Hep 
treatment, however, DCX expression in the +BDNF+Hep treated neuronal cultures 
remained at a significantly higher level (p=0.0005) than in +BDNF only treated 
neuronal cultures (Fig. 6-12A). TUBB3 was further examined at the protein level in 
all conditions via WB analysis. Quantitation of protein bands by normalising TUBB3 
optical density to loading control GAPDH optical density demonstrated decreased 
expression of TUBB3 in the +Hep, +BDNF and +BDNF+Hep culture conditions 
when compared to untreated neuronal cultures (Fig. 6-12B). Consistent with the 
observed gene expression levels, the protein level expression of TUBB3 was higher 
in the +BDNF+Hep treated cultures when compared to +BDNF only treated cultures 
(Fig. 6-12B). 
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Figure 6-12: Neuronal marker expression in untreated, heparin, BDNF and BDNF+heparin 
treated D40 neuronal cultures. A) Relative gene expression of neuronal markers βIII-tubulin 
(TUBB3), microtubule-associated protein 2 (MAP2), medium molecular weight neurofilament 
(NEFM) and doublecortin (DCX) following D40 neuronal differentiation of hNSC H9 cells in 
untreated, heparin (Hep), BDNF or BDNF+Hep treated conditions (Error bars = SEM, statistical 
significance: * p<0.05, ** p<0.01, *** p<0.001) B) Western blot analysis and optical quantitation of 
the neuronal marker TUBB3 along with GAPDH loading control in untreated and +Hep, +BDNF and 
+BDNF+Hep treated D40 neuronal cultures. 
 
To examine the structure of the neuronal differentiating cultures, TUBB3 was 
examined via IF in the +Hep, +BDNF and +BDNF+Hep treated neuronal cultures 
(Fig. 6-13). Homogenous TUBB3 expression was observed in all culture conditions 
(Fig. 6-13). In addition, TUBB3 staining demonstrated that all cultures exhibited a 
clear neuronal phenotype with TUBB3 expression localising to elongated neuronal 
protrusions in the cultures (Fig. 6-13).  
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Figure 6-13: Immunofluorescence of the neuronal marker TUBB3 in heparin, BDNF and 
BDNF+heparin treated D40 neuronal cultures. Immunofluorescence images (10X and 20X 
magnification, scale bar 130 µM) of the neuronal marker βIII-tubulin (TUBB3) (Cy3/yellow) along 
with DAPI counterstain (blue) following D40 neuronal differentiation of hNSC H9 cells in the 
presence of heparin (+Hep), +BDNF and +BDNF+Hep treatments.  
 
6.3.6 Heterogeneity in heparin and BDNF treated D40 neuronal differentiating 
hNSC H9 cells 
 
To assess the effect of heparin and BDNF treatments on D40 neuronal differentiating 
culture heterogeneity, the expression of NSC self-renewal markers and markers 
denoting the astrocyte lineages was examined (Fig. 6-14). As representative NSC 
self-renewal markers, the gene expression of nestin and SOX2 was examined. 
Neuronal cultures treated with +BDNF (p<0.0001) and the combination of 
+BDNF+Hep (p=0.02) expressed a significantly higher level of nestin when 
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compared to untreated neuronal cultures, suggesting an increased pool of nestin 
expressing cells (Fig. 6-14A). In contrast, no difference in SOX2 expression was 
identified between the different neuronal cultures.  
 
To assess the presence of other glial differentiating cells, neuronal cultures were then 
examined for the expression of astrocyte lineage markers. The expression of 
astrocyte markers S100B and GFAP was examined in neuronal differentiating 
cultures with all cultures expressing both markers (Fig. 6-14B). A similar level of 
S100B expression was observed between untreated, +Hep and +BDNF treated 
neuronal cultures, with +BDNF+Hep treated cultures expressing a significantly 
higher level of S100B (p=0.02) expression when compared to untreated neuronal 
cultures (Fig. 6-14B). In addition, all the neuronal cultures expressed low levels 
GFAP with the +Hep, +BDNF and +BDNF+Hep treated cultures shown to express 
lower levels of GFAP when compared to untreated neuronal cells, although this was 
not significant (Fig. 6-14B). 
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Figure 6-14: Self-renewal and astrocyte lineage marker expression in untreated, heparin, BDNF 
and BDNF+heparin treated D40 neuronal cultures. Relative gene expression of A) NSC self-
renewal markers nestin and SOX2 and B) astrocyte markers S100B and glial fibrillary acidic protein 
(GFAP) in untreated, heparin (Hep), BDNF or BDNF+Hep treated D40 neuronal cultures (Error bars 
for GFAP = SD, other error bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** p<0.001)  
 
Examination of nestin and SOX2 via IF in heparin and +BDNF treated neuronal 
cultures demonstrated the maintained expression of these markers within the cultures 
(Fig. 6-15). Similar to untreated D40 neuronal differentiating cultures (Fig. 6-4) 
SOX2 expression was localised within the cell nuclei of +Hep and +BDNF treated 
D40 neuronal cultures with nestin localised within the elongated cell bodies (Fig. 6-
15). The observed homogenous SOX2 and nestin expression indicated maintained 
self-renewal within these in vitro modulated neuronal cultures.  
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Figure 6-15: Immunofluorescence of NSC self-renewal markers in heparin and BDNF and 
treated D40 neuronal cultures. Phase-contrast and immunofluorescence images (10X magnification, 
scale bar 130 µM) of the NSC self-renewal markers nestin (FITC/green) and SOX2 (Cy3/yellow) 
along with DAPI counterstain (blue) in heparin (LHS panel) and BDNF (RHS panel) treated D40 
neuronal differentiating hNSC H9 cells.  
 
6.3.7 Heparin and BDNF induced changes on the HSPG profile of D40 neuronal 
differentiating hNSC H9 cells 
 
Following examination of neuronal lineage marker expression and heterogeneity in 
the +Hep, +BDNF and +BDNF+Hep treated neuronal cultures, the HSPG profile of 
the cultures was next examined to identify any changes following in vitro treatments 
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when compared to untreated cultures. Interestingly, +BDNF treatment of neuronal 
cultures significantly upregulated (p=0.009) the expression of the HS synthesising 
enzyme EXT1 when compared to the untreated neuronal cells (Fig. 6-16A). In 
contrast, both the +BDNF (p=0.01) and +BDNF+Hep (p=0.005) treated neuronal 
cultures expressed a significantly lower level of EXT2 when compared to untreated 
neuronal cultures (Fig. 6-16A). The expression of C5-EP was shown not to be altered 
following +Hep, +BDNF or +BDNF+Hep treatments (Fig. 6-16A).  
 
Interestingly, when the effect of the +Hep, +BDNF and +BDNF+Hep treatments on 
NDST enzyme gene expression was examined, a similar response following all 
treatments was observed (Fig. 6-16B).  The expression of NDST1 was highly 
significantly downregulated (p<0.0001) following treatment of the neuronal 
differentiating cultures with +Hep, +BDNF and +BDNF+Hep when compared to 
untreated neuronal cultures (Fig. 6-16B).  Similarly, addition of +Hep (p=0.0004), 
+BDNF (p=0.003) and +BDNF+Hep (p=0.007) to the cultures resulted in a 
significantly lower level of NDST2 gene expression when compared to the untreated 
neuronal cultures (Fig. 55B).   NDST3 gene expression was significantly lower in the 
+Hep (p=0.004), +BDNF (p=0.02) and +BDNF+Hep (p=0.003) treated cultures 
when compared to untreated neuronal cultures (Fig. 6-16B). NDST4 expression was 
not altered following the +BDNF and +BDNF+Hep treatments, however, neuronal 
cultures treated with +Hep expressed a significantly lower level (p=0.01) of NDST4 
when compared to untreated neuronal cultures (Fig. 6-16B).   
 
When the HS-sulfotransferase genes were examined, all neuronal culture conditions 
expressed a similar level of HS2ST1 (Fig. 6-16C). In contrast, the gene expression of 
the HS-6-O-sulfotransferases HS6ST1 and HS6ST2 was significantly downregulated 
following treatment of the neuronal cultures with +BDNF and +BDNF+Hep when 
compared to untreated neuronal cells (Fig. 6-16C). In the +BDNF (p=0.04) and 
+BDNF+Hep (p=0.03) treated cultures, significantly lower levels of HS6ST1 gene 
expression was observed when compared to untreated neuronal cells, however, the 
expression of HS6ST1 was significantly higher (p<0.0001) in the +BDNF only 
treated cultures when compared to the +BDNF+Hep treated cultures (Fig. 6-16C).  
HS6ST2 expression was significantly downregulated in the neuronal cultures treated 
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with +BDNF (p=0.04) and +BDNF+Hep (p=0.045) when compared to untreated 
neuronal cultures (Fig. 6-16C).  The expression HS6ST3 was not altered following 
treatment of neuronal cultures with +Hep, +BDNF or +BDNF+Hep. 
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Figure 6-16: HS biosynthesis enzyme gene expression in untreated, heparin, BDNF and 
BDNF+heparin treated D40 neuronal cultures. Relative gene expression of HS chain synthesising 
and modifying A) exostosins 1 and 2 (EXT1 and EXT2) and C5-epimerase (C5-EP), B) N-
deacetylase/N-sulfotransferases NDST1-4 and C) HS-2-O- and 6-O-sulfotransferases (HS2ST1 and 
HS6ST1-3) following D40 neuronal differentiation of hNSC H9 cells in untreated, heparin (Hep), 
BDNF or BDNF+Hep treated conditions (Error bars = SEM, statistical significance: * p<0.05, ** 
p<0.01, *** p<0.001). 
  
Chapter 6: Heparan Sulfate-Mediated Lineage Specification of Human Neural Stem Cells 195 
Following examination of HS biosynthesis enzymes in the untreated, +Hep, +BDNF 
and +BDNF+Hep treated D40 neuronal cultures, the gene expression of SDC and 
GPC core protein genes was then examined. SDC1 expression was not altered 
following the +Hep or +BDNF treatments when compared to the untreated neuronal 
cultures, however, its expression was significantly upregulated (p=0.048) in the 
+BDNF+Hep condition when compared to +BDNF only treated cultures (Fig. 6-
17A).   In contrast, SDC2 gene expression was clearly altered in response to +Hep, 
+BDNF and +BDNF+Hep treatments. While the +Hep treated cultures expressed a 
significantly lower level (p=0.03) of SDC2, the +BDNF (p<0.0001) and 
+BDNF+Hep (p=0.001) treated cultures expressed a highly significantly increased 
level of SDC2 when compared to untreated neuronal cultures (Fig. 6-17A).  The 
combined treatment of +BDNF+Hep further potentiated the effect of +BDNF with 
these cultures expressing a significantly higher level (p=0.01) of SDC2 when 
compared to +BDNF only treated cultures (Fig. 6-17A). SDC3 gene expression 
demonstrated an opposing change in expression to the one observed for SDC2 with 
both the +BDNF and +BDNF+Hep treated cultures expressing a significantly lower 
level (p<0.0001) of SDC3 when compared to untreated cultures (Fig. 6-17A). SDC4 
was shown to be expressed at a significantly lower level in the +BDNF (p=0.02) and 
+BDNF+Hep (p=0.007) treated cultures when compared to untreated conditions 
(Fig. 6-17A). Further downregulation of SDC4 expression (p<0.0001) was observed 
in the +BDNF+Hep cultures when compared to the +BDNF only cultures.  
 
The expression of the majority of GPCs was shown to be downregulated following 
treatment of the neuronal cultures with +Hep, +BDNF and +BDNF+Hep when 
compared to untreated cultures (Fig. 6-17B). Cells grown in culture conditions with 
the addition of +Hep (p=0.02), +BDNF (p=0.0003) and +BDNF+Hep (p=3.34e-5) 
expressed a significantly lower level of GPC1 when compared to the untreated 
neuronal cultures (Fig. 6-17B). While the +Hep treatment had no effect on GPC2 
expression, both +BDNF (p=0.03) and +BDNF+Hep (p=0.02) treated cultures 
expressed a significantly lower level of GPC2 when compared to untreated neuronal 
cells (Fig. 6-17B). GPC3 and GPC4 expression in the cultures was observed to be 
similar in the +BDNF+Hep treated cultures, with a significantly lower level of GPC3 
(p=0.04) and GPC4 (p=0.047) observed when compared to untreated neuronal 
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cultures (Fig. 6-17B). The +BDNF+Hep culture condition also demonstrated 
decreased GPC3 (p<0.0001) and GPC4 (p=0.01) expression when compared to the 
+BDNF only treated cultures (Fig. 6-17B). Similarly, GPC6 was observed to be 
downregulated following the +BDNF (p=0.04) and +BDNF+Hep (p=0.03) 
treatments when compared with the untreated neuronal cultures (Fig. 6-17B). 
 
 
Figure 6-17: HSPG core protein syndecan and glypican gene expression in untreated, heparin, 
BDNF and BDNF+heparin treated D40 neuronal cultures. Relative gene expression of A) 
syndecans (SDC1-4) and B) glypicans (GPC1-4, -6) following D40 neuronal differentiation of hNSC 
H9 cells in untreated, heparin (Hep), BDNF or BDNF+Hep treated conditions (Error bars = SEM, 
statistical significance: * p<0.05, ** p<0.01, *** p<0.001). 
 
  
Chapter 6: Heparan Sulfate-Mediated Lineage Specification of Human Neural Stem Cells 197 
6.3.8 Heparin and PDGF induced changes on D40 astrocyte differentiating 
hNSC H9 cells 
 
The hNSC H9 cells were also differentiated astrocyte lineage culture conditions in 
the presence of +Hep, +PDGF and +PDGF+Hep. During astrocyte differentiation, 
cell morphology was monitored every 2 – 3 days by acquiring 4X and 10X 
magnification phase-contrast images of the cells. Between D9 and D11 of astrocyte 
differentiation, a higher cell density was observed in the +Hep and +PDGF+Hep 
treated cultures than in the +PDGF treated cultures (Fig. 6-18). When D28 of 
differentiation was reached, astrocyte differentiating cultures had become very dense 
with large sphere formations along with thick elongated “sphere-connecting” 
protrusion apparent in the +Hep and +PDGF treated cultures (Fig. 6-18). The 
+PDGF+Hep treated cultures exhibited sphere-like aggregates, however, these 
appeared smaller in size when compared +Hep and +PDGF+Hep treated cultures  
(Fig. 6-18). 
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Figure 6-18: Morphological changes during astrocyte differentiation of hNSC H9 cells in the 
presence of heparin, +PDGF and +PDGF+heparin treatments.  Phase-contrast images (10X 
magnification, scale bar 140 μM) of hNSC H9 cells cultured in astrocyte differentiating conditions in 
the presence of heparin (Hep), PDGF or PDGF+Hep for 9 to 28 days. 
 
When the astrocyte differentiation cultures were monitored at D40 of differentiation, 
large cell aggregates or “sphere formations” were observed in these cultures, likely 
due to the high cell density (Fig. 6-19). Thick sphere-connecting protrusions were 
also apparent in the cultures, however these protrusions were less clearly-defined 
than in the neuronal differentiating cultures (Fig. 6-1 and 6-11). The observed sphere 
formations varied in diameter length (indicated by a red dashed line) in the displayed 
representative microscope fields of view ranging from Ø = 80 μM to Ø = 438 μM 
between the different astrocyte culture conditions (Fig. 6-19). Astrocyte cultures 
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treated with +Hep and +PDGF exhibited the largest spheres with Ø = 406 μM and Ø 
= 438 μM sized spheres, respectively, observed in these cultures (Fig. 6-19). The 
largest sphere identified in the +PDGF+Hep treated culture condition was Ø = 153 
μM (Fig. 6-19). In addition, protrusions observed to arise from the spheres varied 
from 188 μM to 404 μM in length between the astrocyte differentiating culture 
conditions with the longest protrusions (404 μM) identified in +PDGF+Hep treated 
cultures (Fig. 6-19).  
 
 
Figure 6-19: Culture morphology at D40 of astrocyte differentiation of hNSC H9 cells in the 
presence of heparin, +PDGF and +PDGF+heparin treatments. Phase-contrast images (4X and 10x 
magnification, scale bar 140 μM) of hNSC H9 cells cultured in neuronal differentiating culture 
conditions in the presence of heparin (Hep), PDGF or PDGF+Hep for 40 days. Diameter of sphere 
aggregates indicated by a red dashed and length of sphere-connecting protrusion indicated by a white 
solid line. 
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Astrocyte marker expression in D40 astrocyte cultures was then examined. Astrocyte 
differentiating cultures treated with +Hep alone did not express significantly altered 
levels of the astrocyte markers S100B or GFAP at the gene expression level when 
compared to untreated astrocytes cultures (Fig. 6-20A). In contrast, astrocyte cultures 
treated with the +PDGF+Hep combination expressed a significantly higher level of 
S100B when compared to untreated astrocyte (p=0.02) and +PDGF alone treated 
(p=0.04) cultures (Fig. 6-20A). In addition, astrocyte cultures treated with +PDGF 
expressed a significantly higher level (p=0.03) of GFAP when compared to untreated 
astrocyte cultures (Fig. 6-20A). At the protein level, expression of S100B was also 
examined via WB analysis with all the astrocyte differentiating cultures shown to 
express a similar level of S100B (Fig. 6-20B). When the S100B bands were 
normalised to the GAPDH loading control, no distinct differences were observed in 
the calculated S100B optical density between the culture conditions (Fig. 6-20B). 
The protein level expression of S100B was observed to be slightly lower in the 
+PDGF+Hep treated astrocyte cultures when compared to untreated astrocyte 
cultures in contrast to the gene expression results in these cultures (Fig. 6-20B). 
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Figure 6-20: Astrocyte marker expression in untreated, heparin, PDGF and PDGF+heparin 
treated D40 astrocyte cultures. A) Relative gene expression of astrocyte markers S100B and glial 
fibrillary acidic protein (GFAP) following D40 astrocyte differentiation of hNSC H9 cells in 
untreated, heparin (Hep), PDGF or PDGF+Hep treated conditions (Error bars = SEM, statistical 
significance: * p<0.05, ** p<0.01, *** p<0.001). B) Western blot analysis and optical quantitation of 
the astrocyte marker S100B along with GAPDH loading control in untreated and +Hep, +PDGF and 
+PDGF+Hep treated D40 astrocyte cultures. 
 
The astrocyte markers S100B and GFAP were next examined via IF in the +Hep, 
+PDGF and +PDGF+Hep treated astrocyte cultures (Fig. 6-21 and 6-22). All culture 
conditions expressed S100B (Fig. 6-21), localised to similar “filamentous” structures 
observed in the untreated D40 differentiating astrocyte cultures (Fig. 6-6). When 
compared to the +Hep and +PDGF+Hep treated astrocyte cultures, cultures treated 
with +PDGF+Hep appeared to demonstrate a more heterogeneous S100B expression 
pattern, with fewer cells expressing S100B when compared to the +Hep and +PDGF 
treated cultures (Fig. 6-21).  
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Figure 6-21: Immunofluorescence of the astrocyte marker S100B in heparin, PDGF and 
PDGF+heparin treated D40 astrocyte cultures. Immunofluorescence images (10X and 20X 
magnification, scale bar 130 µM) of the astrocyte marker S100B (Cy3/yellow) along with DAPI 
counterstain (blue) following D40 astrocyte differentiation of hNSC H9 cells in the presence of 
heparin (+Hep), +PDGF or +PDGF+Hep treatments. 
 
Similar to signal observed in the untreated D40 astrocyte differentiating cultures 
(Fig. 6-6), GFAP demonstrated strong filamentous expression, in particular in the 
+Hep and +PDGF treated astrocyte cultures (Fig. 6-22). Interestingly, the 
localisation of GFAP in the +PDGF+Hep treated astrocyte cultures differed to the 
localisation observed in the other culture conditions, with reduced filamentous GFAP 
expression observed (Fig. 6-22). GFAP expression in the +PDGF+Hep treated 
cultures demonstrated a diffuse localisation and predominantly nuclear localisation, 
much different to the localisation pattern observed in the other astrocyte culture 
conditions (Fig. 6-22). 
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Figure 6-22: Immunofluorescence of the astrocyte marker glial fibrillary acidic protein (GFAP) 
in heparin, PDGF and PDGF+heparin treated D40 astrocyte cultures. Immunofluorescence 
images (10X and 20X magnification, scale bar 130 µM) of the astrocyte marker GFAP (Cy3/yellow) 
along with DAPI counterstain (blue) following D40 astrocyte differentiation of hNSC H9 cells in the 
presence of heparin (+Hep), +PDGF or +PDGF+Hep treatments. 
 
6.3.9 Heterogeneity in heparin and PDGF treated D40 astrocyte differentiating 
hNSC H9 cells 
 
The expression of NSC self-renewal markers and markers denoting the neuronal 
lineage were next examined in the heparin and PDGF treated astrocyte cultures to 
begin to assess culture heterogeneity. When the astrocyte differentiating cultures 
were examined for the expression of NSC self-renewal markers, the gene expression 
of nestin was observed to be at a similar level in the untreated, heparin and PDGF 
treated cultures (Fig. 6-23A). In contrast, the NSC self-renewal marker SOX2 was 
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shown to be expressed at a highly significantly increased level in astrocyte cultures 
treated with +PDGF (p=0.0003) and +PDGF+Hep (p<0.0001) when compared to 
untreated astrocyte cultures, suggesting an increased proportion of SOX2 expressing 
cells (Fig. 6-23A). 
 
When the astrocyte differentiating cultures were examined for the gene expression of 
neuronal lineage markers, including TUBB3, MAP2, NEFM and DCX, significant 
differences in expression were identified between the culture conditions (Fig. 6-
23B). While the level of TUBB3 expression was observed to be similar in all culture 
conditions, treatment of the cultures with +PDGF (p<0.0001) and +PDGF+Hep 
(p=0.0005) resulted in a significantly higher level of MAP2 expression when 
compared to untreated astrocyte cultures (Fig. 6-23B). Cultures treated with 
+PDGF+Hep (p=0.0001) and the +PDGF only treated cultures (p=0.0008) expressed 
a significantly higher level of NEFM, when compared to untreated astrocyte cultures 
(Fig. 6-23B). A significantly higher level of DCX expression (p=0.007) was also 
observed in the +PDGF+Hep treated astrocyte cultures when compared to +PDGF 
only treated cultures (Fig. 6-23B). This data suggests an increased number of 
neuronal marker expressing cells following the +PDGF and +PDGF+Hep treatments 
of cells cultured in astrocyte differentiating conditions.  
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Figure 6-23: Self-renewal and neuronal marker expression in untreated, heparin, PDGF and 
PDGF+heparin treated D40 astrocyte cultures. Relative gene expression of A) NSC self-renewal 
markers nestin and SOX2 and B) neuronal markers βIII-tubulin (TUBB3), microtubule-associated 
protein 2 (MAP2), medium molecular weight neurofilament (NEFM) and doublecortin (DCX) in 
untreated, heparin (Hep), PDGF or PDGF+Hep treated D40 astrocyte cultures (Error bars for GFAP = 
SD, other error bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** p<0.001).  
 
Similar to the neuronal cultures, nestin and SOX2 were also examined via IF in the 
+Hep and +PDGF treated astrocyte cultures. Interestingly, SOX2 demonstrated high 
localised signal and expression within the observed sphere structures in both the 
+Hep and +PDGF treated astrocyte cultures (Fig. 6-24). In addition, nestin was 
shown to be highly expressed and localised to cell bodies protruding from the 
spheres (Fig. 6-24). The SOX2/nestin co-stain clearly demonstrated that the +Hep 
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and +PDGF treated cultures contained dense sphere structures (6-24), with these 
structures less evident in the untreated astrocyte cultures as shown in Figure 6-4. 
 
 
Figure 6-24: Immunofluorescence of NSC self-renewal markers in heparin and PDGF treated 
D40 astrocyte cultures. Phase-contrast and immunofluorescence images (10X magnification, scale 
bar 130 µM) of the NSC self-renewal markers nestin (FITC/green) and SOX2 (Cy3/yellow) along 
with DAPI counterstain (blue) in heparin (LHS panel) and PDGF (RHS panel) treated D40 astrocyte 
differentiating hNSC H9 cells. 
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6.3.10 Heparin and PDGF induced changes on the HSPG profile of D40 
astrocyte differentiating hNSC H9 cells 
 
Following examination of marker expression in the D40 astrocyte differentiating 
cultures, the effects of the +Hep, +PDGF and +PDGF+Hep treatments on the HSPG 
profile of the astrocyte cultures was next examined by examining the level of HS 
biosynthesis enzyme expression in all the culture conditions. Interestingly, the +Hep 
alone treatment did not induce many changes in the expression of the HS 
biosynthesis enzymes examined. The expression of NDST4 was significantly 
induced (p=0.005) in the +Hep treated cultures when compared to untreated astrocyte 
cultures (Fig. 6-25B).  In contrast, the addition of +PDGF along with the 
combination of +PDGF+Hep induced the expression of multiple biosynthesis 
enzymes when compared to untreated astrocyte cultures. HS elongating enzymes 
EXT1 (p=0.001) and EXT2 (p=0.01) were expressed at a significantly increased 
level in the +PDGF treated cultures when compared to untreated astrocyte cultures 
(Fig. 6-25A). Cultures treated with +PDGF also demonstrated highly significantly 
increased gene expression of EXT1 (p=0.0006) when compared to cultures treated 
with a combination of +PDGF+Hep (Fig. 6-25A). Cultures treated with +PDGF+Hep 
also expressed EXT2 at a significantly higher level (p=0.03) when compared to 
untreated cultures (Fig. 6-25A).  The cells grown in the presence of both +PDGF 
(p=0.02) and +PDGF+Hep (p=0.03) culture conditions demonstrated a significantly 
higher expression level of the HS chain epimerising C5-EP when compared to 
untreated astrocyte cultures (Fig. 6-25A). 
 
Consistent with the observed increase in the expression of HS chain synthesising 
enzymes following the +PDGF and +PDGF+Hep treatments of astrocyte cultures, 
the expression of HS chain modifying NDSTs and HS sulfotransferases was also 
shown to be induced following these treatments (Fig. 6-25B-C).  NDST1 (p=0.03) 
and NDST4 (p=0.03) expression was significantly higher in cultures treated with 
+PDGF when compared to the untreated astrocyte cultures (Fig. 6-25B-C).  
Treatment of cultures with +PDGF+Hep resulted in the significant increase in gene 
expression of all the NDSTs studied when compared to untreated astrocyte cultures, 
including; NDST1 (p=0.03); NDST2 (p=0.02); NDST3 (p=0.02) and NDST4 
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(p=0.02) (Fig. 6-25B).   Cultures treated with the combination of +PDGF+Hep also 
expressed a significantly higher level (p=0.02) of NDST2 when compared to the 
+PDGF only treated cultures (Fig. 6-25B).   
 
The astrocyte differentiating cultures treated with +PDGF and +PDGF+Hep also 
demonstrated a highly significantly increased level of HS-sulfotransferase gene 
expression when compared to the untreated astrocytes cultures (Fig. 6-25C).  The 
expression of HS2ST1 (p=0.004), HS6ST1 (p=0.004), HS6ST2 (p=0.01) and 
HS6ST3 (p=0.02) was significantly upregulated in astrocytes cultures treated with 
+PDGF when compared to untreated astrocyte cultures (Fig. 6-25C). A similar 
response was observed in the presence of +PDGF+Hep, with these cultures 
expressing a significantly higher level of HS2ST1 (p<0.0001), HS6ST1 (p=0.002), 
HS6ST2 (p=0.006) and HS6ST3 (p=0.02) when compared to untreated astrocyte 
cultures (Fig. 6-25C). The combination of +PDGF+Hep further upregulated the 
expression of HS2ST1 (p=0.005), HS6ST1 (p=0.01) and HS6ST2 (p=0.04) when 
compared to the +PDGF only treated cultures, perhaps an indication of the co-
stimulatory effect of +PDGF and +Hep on HS sulfotransferase gene expression (Fig. 
6-25C).  
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Figure 6-25: HS biosynthesis enzyme gene expression in untreated, heparin, PDGF and 
PDGF+heparin treated D40 astrocyte cultures. Relative gene expression of HS chain synthesising 
and modifying A) exostosins 1 and 2 (EXT1 and EXT2) and C5-epimerase (C5-EP), B) N-
deacetylase/N-sulfotransferases NDST1-4 and C) HS-2-O- and 6-O-sulfotransferases (HS2ST1 and 
HS6ST1-3) following D40 astrocyte differentiation of hNSC H9 cells in untreated, heparin (Hep), 
PDGF or PDGF+Hep treated conditions (Error bars = SEM, statistical significance: * p<0.05, ** 
p<0.01, *** p<0.001). 
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Following analysis of HS biosynthesis enzyme gene expression, the expression of the 
HSPG SDC and GPC core protein genes in the astrocyte cultures was examined. 
Cultures treated with +Hep maintained a similar level of SDC1-3 expression to 
untreated cultures, while in contrast, SDC4 (p<0.0001) was highly significantly 
upregulated in the +Hep treated cultures when compared to untreated astrocyte 
cultures (Fig. 6-26A).   Consistent with induced expression of multiple HS 
biosynthesis enzymes following +PDGF and +PDGF+Hep treatment of astrocytes 
cultures, the expression of all SDC genes was shown to be increased following these 
treatments (Fig. 6-26A).  The +PDGF treated cultures expressed a significantly 
higher level of SDC1 (p=0.006), SDC2 (p=0.0004), SDC3 (p<0.0001) and SDC4 
(p=0.0001) when compared to untreated astrocyte cultures (Fig. 6-26A).  A similar 
response was observed in the +PDGF+Hep treated cultures, with these cultures also 
expressing a significantly increased level of SDC1 (p=0.02), SDC2 (p=0.008), SDC3 
(p<0.0001) and SDC4 (p=0.03) when compared to untreated astrocyte cultures (Fig. 
6-26A). Cultures treated with the combination of +PDGF+Hep demonstrated a 
significantly higher expression of SDC3 (p<0.0001) than cultures treated with 
+PDGF alone (Fig. 6-26A).  
 
When the expression of GPC genes was examined, the +Hep treated astrocyte 
cultures expressed a significantly higher level of GPC4 (p=0.0009) and GPC6 
(p=0.04) when compared to untreated astrocyte cultures (Fig. 6-26B). Similar to 
SDC expression, astrocyte cultures treated with +PDGF and +PDGF+Hep expressed 
an upregulated level of all GPCs studied when compared to untreated astrocyte 
cultures (Fig. 6-26B). The +PDGF treated cultures exhibited a significantly 
upregulated expression of GPC1 (p=0.009), GPC2 (p=3.4e-5), GPC3 (p=0.001), 
GPC4 (p<0.0001) and GPC6 (p<0.0001) when compared to untreated astrocyte 
cultures (Fig. 6-26B).  Cultures treated with +PDGF+Hep similarly expressed an 
increased level of GPC1 (p=0.04), GPC2 (p=0.0097), GPC3 (p=0.03), GPC4 
(p=0.02) and GPC6 (p=0.03) when compared to the untreated astrocyte cultures (Fig. 
6-26B). The +PDGF+Hep treated cultures also demonstrated a significantly higher 
expression level (p=0.03) of GPC2 than the +PDGF alone treated cultures (Fig. 6-
26B).  
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Figure 6-26: HSPG core protein syndecan and glypican gene expression in untreated, heparin, 
PDGF and PDGF+heparin treated D40 astrocyte cultures.  Relative gene expression of A) 
syndecans (SDC1-4) and B) glypicans (GPC1-4, -6) following D40 astrocyte differentiation of hNSC 
H9 cells in untreated, heparin (Hep), PDGF or PDGF+Hep treated conditions (Error bars = SEM, 
statistical significance: * p<0.05, ** p<0.01, *** p<0.001). 
 
6.4 DISCUSSION 
 
In this Chapter, hNSC H9 cells were cultured under neuronal and astrocyte lineage 
differentiation conditions as previously described (Chapter 5, (Oikari et al., 2016b)). 
The results of Chapter 5 suggested that following 14-18 days of differentiation, a 
high level of heterogeneity was maintained, indicated by NSC and astrocyte marker 
expression in neuronal cultures and neuronal marker expression in astrocyte cultures. 
In addition, the expression level of astrocyte markers remained low in astrocyte 
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cultures indicating that astrocyte differentiation was achieved at lower efficiency 
when compared to neuronal differentiation. Thus, to examine the ability to enhance 
lineage specification of hNSC H9 cells, an extended differentiation time of 40 days 
was introduced in this Chapter. This chosen culture length is supported by previous 
reports of approximately 28 to 60 days required for the generation of active and 
functioning neurons or astroglia from hNSCs or other human stem cell types (Haidet-
Phillips et al., 2014; Hu et al., 2010; Hu et al., 2016; Palm et al., 2015; Schulz et al., 
2004; Swistowski et al., 2010; Zhang et al., 2016).  
 
When examined at D40 of differentiation the neuronal and astrocyte cultures clearly 
differed morphologically from basal hNSC H9 cultures, suggestive of lineage-
specific differentiation. In particular, the neuronal differentiating cultures were 
distinctly neuron-like, indicated by an elongated cell body and a high number of 
protrusions or “neurites” visible within the cultures. An interesting observation was 
the formation of “sphere-like” structures in both the neuronal and astrocyte cultures 
following D40 of differentiation. Contributing to the formation of these structures 
may have been the fact that the cultures were not passaged during differentiation and 
spheres structures resulted from high cell density in some areas. More interestingly, 
the purpose for the sphere structures may be the maintenance of pools of specific 
cells, such as self-renewing cells, as has been reported in floating human 
neurospheres (Ilieva & Dufva, 2013). This hypothesis was supported by high SOX2 
expression, localised within sphere structures in the +Hep and +PDGF treated 
astrocyte differentiating cultures (Fig. 6-24), although further investigation into the 
function of these SOX2 expressing cells is needed to confirm their role.  
 
Following D40 of neuronal and astrocyte differentiation, the lineage marker and 
HSPG profiles of the differentiating cells were compared to basal hNSC H9 cultures 
and the identified differences summarised in Figure 6-27. Briefly, increased lineage 
specificity following D40 of differentiation was indicated by the observed decrease 
in NSC self-renewal marker gene expression, including nestin in neuronal 
differentiating cultures and SOX1 and SOX2 in astrocyte differentiating cultures 
(Fig. 6-27). Interestingly, MSI1, identified as an astrocyte specific marker following 
D14-18 of differentiation (Oikari et al., 2016b), was upregulated in both D40 
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neuronal and astrocyte differentiating cultures (Fig. 6-27). In addition, nestin 
demonstrated high localised expression in both differentiating neurons and astrocytes 
when examined via IF. MSI and nestin generally considered as markers of self-
renewing NSCs, were shown to maintain their expression during hNSC H9 lineage 
specification. In vivo MSI1 has been shown to be expressed in developing neurons 
and astrocytes and, interestingly, there is increasing evidence of nestin expression in 
mature neurons where it has been identified in the adult mouse, rat and human brain 
(Clingman et al., 2014; Farzanehfar et al., 2017; Hendrickson et al., 2011; Kuwako et 
al., 2010).  These reports strongly indicate that makers descripted as NSC proteins 
have a wider expression profile than previously thought, likely also exhibiting key 
functional roles in mature neural cells. 
 
SOX1, a marker of proliferating NPCs in vivo (Cary et al., 2015; Kuipers et al., 
2015) was highly upregulated in D40 neuronal differentiating cultures, suggesting 
increased neurogenesis (Fig. 6-27). Increased culture length positively influenced 
neuronal lineage commitment with neuronal markers MAP2, NEFM and DCX highly 
upregulated in the D40 neuronal differentiating cultures when compared to both 
basal hNSC H9 and astrocyte cultures (Fig. 6-27). Similarly to observations 
following D14-18 of differentiation (Chapter 5), both neuronal and astrocyte cultures 
exhibited a significant increase in TUBB3 expression when compared to basal hNSC 
H9 cultures (Fig. 6-27). Interestingly, transcript levels of TUBB3 did not differ 
between neuronal and astrocyte cultures, however, evidently higher TUBB3 protein 
level expression was observed in neuronal cultures. These results indicate that 
upregulated TUBB3 transcription is a characteristic of hNSC neuronal and astrocyte 
in vitro differentiation with TUBB3 protein translation predominantly occurring in 
neuronal cultures. This supports the fact that TUBB3 is required as a structural 
protein in neurons, such as for axon growth and guidance (Qu et al., 2013).   
 
Astrocyte lineage specificity was clearly enhanced following D40 in culture when 
compared to D14-18 in culture (Chapter 5, Oikari et al., 2016b), indicated by high 
GFAP expression detectable by Q-PCR and IF (Fig. 6-27). Interestingly, when 
examined via IF, S100B and GFAP demonstrated a distinct filamentous expression 
pattern in the astrocyte differentiating cultures resembling astrocyte processes as 
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demonstrated in vitro and in vivo (Kirwan et al., 2015; Srinivasan et al., 2016). 
Interestingly, a level of culture heterogeneity was observed in both D40 neuron and 
astrocyte cultures, as neuronal cultures expressed an upregulated level of S100B and 
astrocyte cultures expressed an upregulated level of NEFM and DCX, when 
compared to basal hNSC H9 cells, observed (Fig. 6-27). This indicates that hNSC H9 
cell populations likely compose of cells with a differentiation potential (neuron 
versus glia), reflecting the heterogeneous ability of populations of radial glia in the 
CNS to generate different neural cell subtypes (Greig et al., 2013). In addition, with 
gliogenesis known to occur post neurogenesis in the developing brain in vivo, it is 
likely that a longer differentiation time is required to yield a pure astrocyte culture 
and reduce heterogeneity (Gao et al., 2013).  
  
Consistent with observations following D14-18 of differentiation (Chapter 5, Oikari 
et al., 2016b), HS biosynthesis enzyme expression was distinctly altered following 
specifically neuronal differentiation of hNSC H9 cells when examined at D40.  
Several interesting observations were made including the reduced expression of the 
HS elongating EXT1 and 2-O-sulfation catalysing HS2ST1 genes following both 
neuronal and astrocyte differentiation of hNSC H9 cells (Fig. 6-27). Consistent with 
previous findings (Chapters 4 & 5), these results suggested reduced HS chain 
synthesis and 2-O-sulfation during hNSC lineage commitment.  In contrast, a 
significant upregulation in the expression of the majority of the N-deacetylation/N-
sulfation and 6-O-sulfation catalysing NDSTs (NDST1, -3 and -4) and 6-O-
sulfotransferases (HS6ST2 and 3), respectively, was observed following neuronal 
differentiation (Fig. 6-27). With these findings consistent with results observed 
following D14-18 of culture (Oikari et al., 2016b), they strongly suggest hNSC 
neurogenesis is associated with increased HS side chain N-deacetylation/N-sulfation 
and 6-O-sulfation modifications. This hypothesis is supported by previous studies 
where changes in N-deacetylation/N-sulfation as well as 6-O-sulfation activity were 
associated with ESC neural differentiation in vitro (Lanner et al., 2010; Nairn et al., 
2007).  It appears that neuronal differentiating cells develop a preference to interact 
with growth factors and signalling molecules that bind to the sites produced by 
NDSTs and HS6STs. As an example, specific FGF family members are known to 
bind specific O-sulfation sites along HS chains, thus the changed sulfation pattern 
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may indicate altered FGF response (Ashikari-Hada et al., 2004). Interestingly, the 
upregulation of HS modification enzyme expression was not observed during 
astrocyte differentiation of hNSC H9 cells, suggesting the same HS-associated 
mechanisms do not occur during astrogliosis (Fig. 6-27). However, consistent with 
previous findings (Chapter 5, Oikari et al., 2016b), NDST3 expression was 
significantly upregulated in the astrocyte differentiating cultures (Fig. 6-27), 
supporting the findings of Chapter 5 that the activity of this enzyme has potential 
importance during hNSC lineage commitment. Overall, these results indicate that the 
different combinations of N-deacetylation/N-sulfation and 6-O-sulfation sites along 
HS chains are important in driving human neural cell development. A key avenue for 
further investigation would be to identify the specific HS-chain and signalling 
molecule interactions that occur during hNSC lineage commitment and exploit these 
for enhanced control of hNSC fate. 
 
Consistent with extensively altered HS biosynthesis enzyme expression following 
D40 neuronal differentiation, the HSPG profile of the neuronal cultures was 
distinctly different to the profile observed in basal hNSC H9 cultures. This indicates 
that hNSC neuronal specification is associated with an increase in expression in cell 
surface HSPGs. Similarly to following D14-18 of neuronal differentiation (Chapter 
5, Oikari et al., 2016b), SDC4, GPC1, GPC2, GPC3 and GPC6 were shown to be 
significantly upregulated in the D40 neuronal cultures when compared to basal hNSC 
H9 cells, supporting their specificity to the neuronal lineage (Fig. 6-27). 
Interestingly, SDC1 and GPC4, previously identified to be associated with self-
renewing NSCs (Fico et al., 2012; Wang et al., 2012), were also highly upregulated 
in D40 neuronal cultures when compared to both basal hNSC H9 and astrocyte 
cultures (Fig. 6-27). This indicates that also these two HSPGs are associated with the 
neuronal lineage. Overall, these observations indicate that high expression of the two 
main HSPG families SDCs and GPCs is associated with human neurogenesis, 
possibly required for neurite outgrowth, synaptic formation or axon guidance as has 
been demonstrated in other model organisms (Allen et al., 2013; de Wit et al., 2013; 
Ko et al., 2015; Murakami et al., 2015; Ronca et al., 2001). Due to the high 
expression level of these SDCs and GPCs observed in the neuronal cultures, these 
HSPGs have potential to be used as novel markers of human neuron characterisation, 
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specifically in combination with other neuronal markers, including MAP2, NEFM 
and DCX. Interestingly, the astrocyte cultures demonstrated an opposing change in 
their HSPG profile when compared to neuronal cultures, with the majority of the 
SDCs and GPCs examined shown to be downregulated in expression. However, 
consistent with previous data (Chapter 5, Oikari et al., 2016b), GPC4 was shown to 
be upregulated in the astrocyte cultures following D40 of differentiation (Fig. 6-27). 
These results suggest that HS and HSPG core proteins are not required for driving 
astrocyte lineage differentiation and these differences may be due to structural 
differences of the two cell types. Astrocytes do not possess neurites or axons, 
potential key locations for HSPG expression and localisation. GPC4, however, 
appears to be important in the astrocyte lineage and its function in astrocytes may be 
to modulate neuron synaptic function, as reported previously in the mouse (Allen et 
al., 2012). The results presented here support the use of GPC4 as an additional 
astrocyte marker when used in combination with S100B and GFAP.  
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Figure 6-27: A schematic summary of changes in NSC and lineage markers (neuronal and glial) 
and well as HS biosynthesis enzymes and HSPG core proteins following D40 neuronal and 
astrocyte differentiation of hNSC H9 cells. Key differences were identified between early (P2–P5) 
passage hNSC H9 cultures and D40 neuronal and astrocyte differentiating cultures.   
 
With distinct but differential changes observed in hNSC H9 HSPG profile during 
neuronal and astrocyte differentiation, the ability to mediate hNSC lineage specificity 
through exogenous HS together with HS binding neuroregulatory growth factors was 
examined. This was done by exposing neuronal differentiating hNSC H9 cultures to 
heparin, BDNF and BDNF+heparin and astrocyte differentiating hNSC H9 cultures 
to heparin, PDGF and PDGF+heparin. Heparin is known to promote proliferation 
and differentiation of various human cell types and BDNF and PDGF are key 
mediators of differentiation and survival of neurons and glial cells, respectively, 
suggesting these factors alone or in combination can be used to mediate hNSC 
lineage specification (Baron et al., 2002; D'Aiuto et al., 2014; Dai et al., 2001; Furue 
et al., 2008; Okolicsanyi et al., 2014b; Wei et al., 2015).  Heparin treatment alone did 
not induce a distinct phenotypical changes in the neuronal or astrocyte differentiating 
cultures, however, BDNF and PDGF treatments with and without heparin had 
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significant effects of cell phenotype. Although cell numbers were not quantitated, 
neuronal differentiating cultures exposed to BDNF and BDNF+Hep demonstrated 
increased cell density when compared to untreated cultures supporting the known 
neuronal survival and differentiation stimulating effects of BDNF (D'Aiuto et al., 
2014; Wei et al., 2015). Interestingly, several changes in the cells’ gene expression 
profile in response to BDNF were observed, including significantly reduced 
expression of neuronal markers NEFM and DCX, significantly induced expression of 
the NSC marker nestin and a significant downregulation in the expression of the 
majority of the HS biosynthesis enzymes and HSPG core protein genes studied.  It 
appears, thus, that BDNF exposure regulates the expression of both lineage specific 
and HSPG pathway genes in a correlative manner, with the biological function of 
this unknown. Interestingly, the combination of BDNF+heparin elicited significant 
differences to BDNF alone, including induced expression of TUBB3 and DCX, 
reduced expression of HS6ST1, SDC4, GPC3 and GPC4, and induced expression of 
SDC2.  This indicates interaction between HS and BDNF, consistent with previous 
reports (Kanato et al., 2009) and supporting the use of heparin to induce the effects 
of BDNF.  
 
The PDGF and PDGF+heparin treatments also modulated astrocyte culture 
phenotype, including astrocyte marker expression. Interestingly, both GFAP and 
S100B expression was induced following PDGF and PDGF+heparin, when 
compared to untreated cultures, suggesting a stimulatory effect for PDGF on 
astrocyte marker expression. However, the results also demonstrated that PDGF and 
PDGF+heparin treatments vastly increased culture heterogeneity, as both NSC self-
renewal (SOX2) and neuronal markers (MAP2 and NEFM) were highly upregulated 
in these cultures when compared to untreated astrocyte cultures. Consistent with this 
induced gene expression, an activated level of HS biosynthesis pathway expression 
was observed with HS biosynthesis enzyme and HSPG genes highly upregulated in 
PDGF and PDGF+heparin cultures when compared to untreated astrocyte cultures. 
Interestingly, the combination of heparin with PDGF further potentiated the effects 
observed for PDGF alone suggesting a synergistic interaction for heparin and PDGF 
in these cultures.  
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These results demonstrate that differentiating hNSC-derived neural cells respond to 
HS-binding neuroregulatory growth factors BDNF and PDGF with co-
supplementation with the HS-analogue heparin modulating this response. 
Interestingly, although BDNF supplementation did not stimulate neuronal marker 
expression, it promoted neuronal survival. Heparin further potentiated the effects of 
BDNF, suggesting BDNF+heparin together may be beneficial in situations where a 
large number of neuronal progenitors are needed for downstream applications. 
Interestingly, PDGF had distinct stimulatory effects on the neuronal marker 
expression and HSPG profile of astrocyte differentiating cells, suggesting it may 
stimulate the neuronal rather than the glial differentiation potential of hNSCs. 
Importantly, PDGF supplementation stimulated HSPG biosynthesis and core protein 
gene expression, suggesting PDGF has potential to be used as mediator to enhance 
HSPG-associated signalling in neural cells. Thus, these results suggest that the 
combined use of BDNF and PDGF may beneficially stimulate hNSC neurogenesis.   
 
6.5 SUMMARY AND CONCLUSIONS 
 
Extending differentiation to 40 days enhanced lineage specificity, which was 
indicated by distinctly altered cell morphology and lineage marker expression in both 
neuronal and astrocyte differentiating cultures derived from hNSC H9 cells. 
Interestingly, several NSC markers, including MSI1 and nestin were maintained at a 
high level in differentiating cultures, suggesting a wider expression profile for these 
markers than expected. Similarly to observations made following D14-18 of 
differentiation (Chapter 5) the HSPG prolife of neuronal and astrocyte cultures were 
significantly altered when compared to basal hNSC H9 cells. The majority of the HS 
modifying NDSTs and HS6STs as well as SDC and GPCs genes were upregulated in 
expression following neuronal differentiation, suggesting a key importance for HS 
modifications and HSPG expression during human neurogenesis. In contrast, 
astrocyte differentiation was associated with a reduced expression of HS biosynthesis 
enzymes and HSPG core protein genes, suggesting a reduced requirement for HSPG-
associated regulation during human astrocyte commitment. SDC1, SDC4, GPC1-4 
and GPC6 were identified as novel markers of the neuronal lineage when used in 
combination with neuronal markers MAP2, NEFM and DCX. Consistent with 
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previous findings in Chapter 5, GPC4 was identified as a marker of the astrocyte 
lineage when used in combination with S100B and GFAP. Finally, the results of this 
Chapter demonstrate that hNSC H9 lineage specification can be modulated through 
HS-binding neuroregulatory growth factors (BDNF and PDGF) and the effect of 
these growth factors can be further modulated through exogenous HS in the form of 
heparin. Overall BDNF stimulated survival of neuronal cultures, while, interestingly, 
PDGF in astrocyte cultures stimulated a neuron marker expressing phenotype. These 
results support the benefit of using BDNF, PDGF and potentially BDNF+PDGF in 
combination with heparin to modulate human neurogenesis with this hypothesis 
further explored in the following Chapter 7.  
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Chapter 7: Unravelling mechanisms of 
HSPG-mediated control of 
human neurogenesis 
 
The final aim of this research was to gain an insight into the mechanisms behind 
HSPG-mediated control of human neurogenesis by building on the research 
previously presented in this Thesis. With hNSC H9 cells exhibiting a high neuronal 
lineage differentiation potential (identified previously in Chapters 5 and 6), this 
Chapter aimed to gain a more in-depth understanding of HS- or HSPG-mediated 
control of hNSC neurogenesis.  The first part of this Chapter (Part A) expanded on 
research conducted in Chapter 6 where the effect of heparin and key growth factor 
treatments on lineage specification of differentiating hNSC H9 cells was examined. 
In this Chapter, hNSC H9 cultures were differentiated toward the neuronal lineage in 
the presence of BDNF, PDGF and the combination of BDNF and PDGF in the 
absence or presence of heparin for up to 60 days.  To assess the influence of the 
treatments on neuronal lineage specificity, multiple characteristics, including cell 
morphology, viability, proliferation, marker expression and heterogeneity of the 
cultures were examined. To assess the presence of functional neurons within the 
differentiating cultures, spontaneous calcium oscillations were also monitored. The 
second part (Part B) of this Chapter aimed to gain insight into the possible 
involvement of previously identified key HSPGs GPC1 and GPC4 (Chapters 5 and 
6) in the regulation of BDNF or PDGF-mediated neuronal differentiation of hNSCs. 
The expression of GPC1 and GPC4 along with BDNF and PDGF pathway ligands 
and receptors were first examined in differentiating hNSC-derived neuronal cultures.  
With the confirmation that differentiating neuronal cultures maintain expression of 
GPC1 and GPC4 as well as BDNF and PDGF pathway components, the expression 
of GPC1 and GPC4 as well as BDNF/PDGF signalling was modulated through 
RNA-interference and specific pathway inhibitors. The results of this Chapter 
demonstrate that hNSC neuronal lineage specificity can be influenced through key in 
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vitro modulations and that GPC1 and GPC4 are neuronal proteins with potential as 
key mediators of BDNF and PDGF pathway regulation in human neurogenesis.  
 
7.1 INTRODUCTION 
 
Our ability to efficiently generate a large number of functioning neurons from stem 
cells within a reduced amount of time is critical for the use of these cells in 
downstream application, including therapy. Neuronal differentiation protocols 
described in the current literature vary in time ranging from as little as 20 to over 70 
days in culture (Hu et al., 2010; Li et al., 2016a; Sances et al., 2016; Swistowski et 
al., 2010). In addition, as described previously (Chapter 6) human stem cell survival, 
proliferation and differentiation can be modulated through the addition of exogenous 
factors, of which in the neuronal differentiation context, the use of the heparan 
sulfate (HS) analogue heparin along with HS-binding neuroregulatory growth factors 
brain-derived neurotrophic factor (BDNF) and platelet-derived growth factor 
(PDGF) has been described (Baron et al., 2002; D'Aiuto et al., 2014; Dai et al., 2001; 
Furue et al., 2008; Wei et al., 2015; Zhang & Zhang, 2010). The addition of these 
exogenous factors to the in vitro culture environment has the potential to beneficially 
impact neuronal differentiation efficiency. The results of Chapter 6 demonstrated that 
by extending hNSC H9 neuronal differentiation time to 40 days (D40) from D14-18 
(Chapter 5), the differentiation efficiency of the cells was enhanced. The results of 
Chapter 6 also demonstrated that heparin, BDNF and PDGF supplementation in 
hNSC H9-derived neuronal and astrocyte differentiating cultures resulted in altered 
cell number, morphology and lineage marker expression. The important observations 
of Chapter 6 were that BDNF promoted neuronal cell survival with PDGF increasing 
neuronal marker expression within astrocyte differentiating cultures. In addition, 
when BDNF and PDGF were combined with heparin, a potentiated effect of these 
growth factors was observed. These results suggest that BDNF and PDGF 
supplementation has potential to be used for improved control of hNSC neurogenesis 
with heparin further modulating this response 
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The results of Chapter 6 demonstrated that modulation of differentiating hNSC H9 
cultures with BDNF and PDGF altered the heparan sulfate proteoglycan (HSPG) 
profile of the cultures. Specifically, the gene expression of HS biosynthesis enzymes 
and syndecan (SDC) and glypican (GPC) core proteins was significantly altered 
following treatment of the differentiating hNSC H9 cultures with BDNF or PDGF. 
With HSPGs known to interact with and mediate the activity of multiple signalling 
pathways (reviewed in (Dreyfuss et al., 2009)), the altered HSPG prolife of the cells 
following in vitro modulation of culture conditions, likely allows the cells to adapt to 
the changing signalling environment. Throughout this study (Chapters 4-6) the 
importance of HSPGs as markers or potential regulators of hNSCs and lineage-
specific neural cells has been demonstrated. Specifically two glypicans (GPCs), 
GPC1 and GPC4, pose as key markers of hNSC lineage fate specification and 
lineage potential. The evidence supporting the importance of GPC1 and GPC4 within 
the hNSC niche is their high expression level in basal hNSC H9 cells in comparison 
to other GPC family members (Chapter 4 (Oikari et al., 2016b)). In addition, lineage 
differentiation of hNSC H9 cells significantly upregulated the expression of these 
GPCs (Chapters 5 and 6, (Oikari et al., 2016b)). The results suggest that GPC1 is a 
specific marker to the neuronal lineage (Chapters 5 and 6, (Oikari et al., 2016b)), 
with GPC4 appearing to be a marker of both neuronal and astrocyte lineages 
(Chapters 5 and 6, (Oikari et al., 2016b)). Supporting the findings of this study, 
several roles for GPC1 and GPC4 in neural cell function have also been reported in 
the rodent model (Abaskharoun et al., 2010; Allen et al., 2012; Fico et al., 2012; 
Litwack et al., 1998; Ronca et al., 2001). The results of this study combined with 
previous reports in the rodent model strongly suggest that GPC1 and GPC4 are key 
regulators of human neural lineage commitment. 
 
The aim of this Chapter was to investigate the potential mechanisms of HSPG-
mediated control of human neurogenesis by examining the effect of HS and HS-
binding growth factors during human neurogenesis and examining the potential role 
of GPC1 and GPC4 in mediating these responses.  In order to approach this, the first 
aim of this Chapter (Part A) was to establish hNSC neurogenesis cultures modulated 
by exogenous heparin and key growth factors (BDNF and PDGF) and to examine 
effect of the treatments on neuronal lineage specification. Specifically, hNSC H9 
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cells were cultured under neuronal differentiating culture conditions in the presence 
of exogenous heparin, BDNF and PDGF. In addition, as BDNF was shown to 
promote the survival of hNSC H9-derived neuronal cultures and PDGF induced the 
expression of neuron-specific markers in astrocyte cultures (Chapter 6), the 
combination of BDNF+PDGF was also examined on hNSC H9 neurogenesis for 
enhanced cell survival and lineage specificity. Finally, to examine any potential HS-
growth factor interactions, all growth factor conditions were presented in the 
presence or absence of heparin. Cultures were examined at D40 and D60 of 
differentiation for differences in cell morphology, viability, proliferation, lineage 
marker expression and heterogeneity with functionality of the cultures examined 
through spontaneous calcium signals within the cultures. The second aim of this 
Chapter (Part B) was to examine the potential roles of GPC1 and GPC4 in mediating 
BDNF and PDGF response during human neuronal differentiation. First, the 
expression and localisation of GPC1 and GPC4 in D40 and D60 neuronal 
differentiating hNSC H9 cultures was examined along with the expression of BDNF 
and PDGF pathway components. Finally, it was examined if altered GPC1 and GPC4 
expression resulted in altered BDNF or PDGF response to identify any interactions 
between these HSPGs and pathways of interest.  The methods for both sections (Part 
A and Part B) are first described followed by Part: A Results and Discussion and 
Part: B Results and Discussion, respectively. 
 
7.2 METHODS 
 
7.2.1 Neuronal differentiation of hNSC H9 cells 
 
hNSC H9 POP1 and POP2 cells were differentiated as previously described toward 
the neuronal lineage as previously described (section 3.3.1). Differentiation was 
induced as previously described (Chapter 5) and continued until D40 and D60. 
Differentiation was performed in 96-, 48- and 24- well plates. During differentiation 
phase-contrast images of cells were acquired every 2 – 3 days to monitor 
morphological changes. Measurements, including sphere diameter and protrusion 
length, were obtained using Volocity® v.6.3. software (Perkin Elmer).  
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7.2.2 In vitro modulation of neuronal cultures 
 
Neuronal differentiating hNSC H9 cultures were modulated as previously described 
(section 3.4). Heparin (10 μg/mL) (section 3.4.1), BDNF (10 ng/mL) (section 3.4.2), 
PDGF-BB (section 3.4.2) or the combination of BDNF+PDGF was added to the 
cultures. All combinations of growth factors (BDNF, PDGF and BDNF+PDGF) 
were added in the presence or absence of heparin. Heparin and growth factors were 
mixed into the culture medium and applied to cells at media changes every 3 – 4 
days.  
 
7.2.3 FDA/PI analysis neuronal cultures 
 
At D40 and D60 of differentiation, the viability of neuronal cultures was examined 
by co-staining the cells with fluorescein diacetate (FDA) and propidium iodide (PI) 
as previously described (section 3.3.4). Briefly, live cells stain positive for FDA, 
which is taken up by the cells and converted into a fluorescent metabolite. PI enters 
the nuclei of dead cells through a permeabilised cell membrane staining the cells red. 
Neuronal cultures loaded with FDA and PI were visualised on an Olympus IX81 
phase-contrast fluorescent microscope using FITC and Texas Red filters, 
respectively, and images acquired on a Hamamatsu Orca camera using Volocity® 
v.6.3. software (Perkin Elmer). The mean signal intensity for FDA and PI per field of 
view was measured using Volocity software and the mean signal intensity of 3 – 4 
fields of view averaged. This was presented as the PI to FDA ratio, calculated by 
dividing the PI averaged signal intensity by FDA averaged signal intensity.  
 
7.2.4 Gene and protein expression analysis 
 
Neuronal differentiating cultures for RNA and protein sample collection were 
cultured in 48-well plates. RNA and protein samples were harvested at D40 or D60 
of differentiation with samples consisting of minimum of 3 – 4 pooled wells. RNA 
was extracted and gene expression analyses performed as previously described 
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(section 3.6.1) utilising gene specific primers (Tables C1 and C2, Appendix C). Gene 
expression results are presented as an average of the hNSC H9 POP1 and POP2 data. 
Western blot (WB) analysis for protein expression analysis was performed as 
previously described (section 3.6.2) utilising specific antibodies (Table 3-2, Chapter 
3). For WB analysis, protein samples from both cell populations were pooled. The 
optical density of protein bands was measured using Bio1D software (Vilber 
Lourmat) and the optical density for three acquired blot images averaged for graphic 
presentation (error bars = SD). Protein of interest optical density was normalised to 
the loading control GAPDH optical density.  
 
7.2.5 Confocal microscopy 
 
Confocal microscopy was used to gain higher magnification (63x) images of D40 
and D60 neuronal differentiating hNSC H9 cultures as previously described (section 
3.7.2) utilising specific antibodies (Table 3-3. Chapter 3). Images were obtained 
using a Leica TCS SP5 confocal laser scanning microscope. Image editing, including 
contrast enhancement and brightness increase was performed using Volocity® v.6.3 
software (Perkin Elmer). S100B and Ki67 quantitation was performed by calculating 
the number of Ki67- or S100B-positive nuclei per field of view divided by the total 
number of nuclei. Data is presented as an average of three fields of view unless 
otherwise stated. 
 
7.2.6 Fluo-4 calcium signalling assay 
 
The Fluo-4 DirectTM calcium assay (Thermo Fisher Scientific cat#F10471) was used 
to determine calcium signalling in hNSC H9-derived neuronal cultures as previously 
described (section 3.8). In comparison, calcium signalling was also determined in 
undifferentiated hNSC H9 cells as well as in SHSY-5Y human neuroblastoma cells 
(positive control for neuronal cells) and non-neuronal MCF-7 human breast cancer 
cells (negative control) as previously described (section 3.8). Briefly, the detection of 
calcium signals was done utilising a fluorescent plate reader (BMG Labtech), using a 
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protocol adapted from Pacico et al. (Pacico & Mingorance-Le Meur, 2014), or on an 
Olympus IX81 fluorescent microscope. Fluo-4 dye added to the cells and excited at 
488 nm. Cells were monitored for 200s and readings or images captured every 0.8s. 
For analysis of results, 20 neurons (regions of interest = ROIs) were selected using 
the Volocity® v.6.3 software (Perkin Elmer). Fluorescence intensity (FI) for each 
ROI for each time point (251 timepoints) was measured. FI was normalised to 
timepoint 1 FI (FI0) with FI/FI0 values plotted on a graph using Microsoft Excel.  
 
7.2.7 RNA-interference 
 
Gene and protein level expression of the GPC1 and GPC4 core proteins was 
downregulated using Accell siRNA technology (DharmaconTM) as previously 
described (section 3.5). The siRNA sequences of the four pooled siRNAs used to 
downregulate target gene expression are summarised in Table 3-1 (Chapter 3). hNSC 
H9 POP1 and POP2 passage 5 (P5) cells plated on poly-L-ornithine (PO) and 
laminin were exposed to Accell siRNA pools diluted in AccellTM siRNA Delivery 
Media supplemented with 2% B-27 and BDNF (10 ng/mL) or PDGF (10 ng/mL). 
siRNAs were incubated in the cultures for 72 h or 96 h for downregulation of GPC1 
and GPC4 at the RNA or protein level, respectively. After siRNA knockdown, cell 
number and viability was assessed utilising an automated cell counter as previously 
described (section 3.2.1.3). Expression of GPC1 and GPC4 was then assessed post 
siRNA knockdown via Q-PCR and IF.  
 
7.2.8 BDNF and PDGF pathway inhibition  
 
The BDNF-pathway was inhibited through the addition of the Trkb (BDNF receptor) 
inhibitor ANA-12 and the PDGF pathway inhibited through addition of the PDGFRβ 
(PDGF receptor) inhibitor Tyrphostin AG-1295 (AG-1295) to cultures as previously 
described (section 3.4.3). hNSC H9 POP1 and POP2 P5 cultures plated on PO and 
laminin were exposed to ANA-12, AG-1295 or a DMSO control with and without 
exogenous BDNF or PDGF for 72 h. Following this, cell number and viability was 
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assessed utilising an automated cell counter as previously described (section 3.2.1.3). 
RNA was harvested as previously described (section 3.6.1) and cells stained for 
immunofluorescent (IF) imaging as previously described (section 3.7.1).  
 
7.2.9 Immunofluorescence 
 
IF was used to examine the expression and localisation of target proteins in cultures 
treated with siRNAs or pathway-specific inhibitors. Cultures were grown in 96-well 
plates followed by staining of the cultures with specific antibodies at 96 h for 
siRNA-treated cultures and at 72 h for inhibitor-treated cultures.  The antibodies used 
are presented in Table 3-2 in Chapter 3. Mean signal intensity as well as nuclei and 
Ki67 counts per field of view was determined using the Volocity® v.6.3 software 
(Perkin Elmer) as previously described (section 3.7.2).  
 
7.2.10 Statistical analysis 
 
Neuronal differentiation, RNA-interference and inhibitor experiments consisted of 
two biological replicates (hNSC H9 POP1 and POP2). RNA and protein samples 
were obtained by pooling culture 3 – 4 wells. Gene and protein expression results 
presented are an average of the two cell populations studied. Relative gene 
expression was normalised to the endogenous control 18S and results presented in 
bar graphs as ΔΔCt x 106 with error bars = SEM unless otherwise stated. Statistical 
significance was determined using Student’s t-test and defined as * p < 0.05, ** p < 
0.01 and *** p < 0.001.  
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7.3 RESULTS PART A: CONTROL OF HUMAN NEUROGENESIS 
THROUGH HEPARAN SULFATE (HS) AND HS-BINDING GROWTH 
FACTORS 
 
7.3.1 Morphology of hNSC H9-derived neuronal cultures following heparin and 
growth factor treatments 
 
hNSC H9 cells were differentiated toward the neuronal lineage for 40 (D40) and 60 
(D60) days. Throughout differentiation cultures were modulated through the addition 
of heparin (Hep), a highly sulfated analogue of heparan sulfate, or key growth factors 
BDNF, PDGF or the combination of BDNF and PDGF. All growth factor treatments 
were also performed in the presence or absence of Hep. During differentiation, cell 
morphology was monitored by acquiring phase-contrast images of the cells every 2 – 
3 days.   
 
As previously demonstrated (Chapter 6), following D40 of neuronal differentiation in 
untreated and +Hep, +BDNF and +BDNF+Hep treated neuronal conditions, cultures 
acquired a “neuron-like” morphology with cells exhibiting an elongated neuronal cell 
body (Fig. 7-1). Also, as previously demonstrated (Chapter 6), at D40 of 
differentiation untreated (Fig. 7-1A) and +Hep (Fig. 7-1B), +BDNF (Fig. 7-1C) and 
+BDNF+Hep (Fig. 7-1D) treated neuronal cultures acquired large sphere-like 
clusters with thick protrusions arising from the spheres building connections between 
the spheres. When the morphology of the neuronal cultures treated with +PDGF (Fig. 
7-1E), +PDGF+Hep (Fig. 7-1F), +BDNF+PDGF (Fig. 7-1G) and 
+BDNF+PDGF+Hep (Fig. 7-1H) at D40 was examined, high cell density was 
observed in all the culture conditions. Several irregular small sphere-like clusters 
were observed in the +PDGF, +PDGF+Hep, +BDNF+PDGF and 
+BDNF+PDGF+Hep (Fig. 7-1E-H) treated cultures, however, the shape of these 
spheres was less clearly defined than in the untreated, or +Hep, +BDNF and 
+BDNF+Hep treated cultures (Fig. 7-1A-D).  In addition, cultures treated with 
+PDGF, +PDGF+Hep, +BDNF+PDGF and +BDNF+PDGF+Hep (Fig. 7-1E-H) 
produced less clearly defined thick protrusions as those observed in the untreated or 
+Hep, +BDNF and +BDNF+Hep treated cultures (Fig. 7-1A-D).  
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Figure 7-1: Morphology at day 40 of neuronal differentiation of hNSC H9 cells cultured under 
untreated or heparin and growth factor treated conditions. Phase-contrast images (4X 
magnification, scale bar 140 μM) of hNSC H9 cells cultured under A) untreated neuronal 
differentiating culture conditions or in the presence of B) heparin (Hep), C) BDNF, D) BDNF+Hep, 
E) PDGF, F) PDGF+Hep, G) BDNF+PDGF or H) BDNF+PDGF+Hep for 40 days.   
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When the neuronal differentiating hNSC H9 cells were examined at D60, extended 
time in culture resulted in distinct morphological changes in all the neuronal 
differentiating cultures (Fig. 7-2). All conditions obtained large defined sphere 
formations as well as thick neuronal protrusions (Fig. 7-2). When the sphere 
diameter in the representative field of view was measured, varying sized spheres 
were identified in the different neuronal conditions. The smallest detected sphere 
diameter was 60 μM (+Hep treated cultures, Fig. 7-2B) with the largest measured 
sphere diameter 410 μM (+BDNF+PDGF+Hep treated cultures, Fig. 7-2H). The 
largest spheres were observed in untreated (Fig. 7-2A), +PDGF (Fig. 7-2E), 
+BDNF+PDGF (Fig. 7-2G) and +BDNF+PDGF+Hep (Fig. 7-2H) treated cultures 
with all of these culture conditions containing spheres of 300 μM or greater in 
diameter. In all culture conditions thick protrusions arising from the sphere structures 
were observed with these protrusions building extensive connections between the 
spheres (Fig. 7-2). Sphere structures and sphere-connecting protrusions were 
particularly evident in the +BDNF (Fig. 7-2C), +BDNF+Hep (Fig. 7-2D) and 
+PDGF (Fig. 7-2E) treated cultures, suggesting that growth factor treatments 
contributed to the formation of these networks. The protrusions arising from the 
spheres varied in length ranging from 320 μM (+PDGF treated cultures, Fig. 7-2E) to 
1060 μM (+BDNF+PDGF treated cultures, Fig. 7-2G). The protrusions also appeared 
to vary in thickness with these thicker protrusions appearing to be shorter in length. 
The +BDNF (Fig. 7-2C), +BDNF+Hep (Fig. 7-2D) and +PDGF (Fig. 7-2E) treated 
cultures generally exhibited thicker and shorter protrusions ranging from 320 μM to 
710 μM in length. The untreated (Fig. 7-2A), +Hep (Fig. 7-2B), +PDGF+Hep (Fig. 
7-2F), +BDNF+PDGF (Fig. 7-2G) and +BDNF+PDGF+Hep (Fig. 7-2H) treated 
cultures generally exhibited thinner protrusions ranging from 860 μM – 1060 μM in 
length. When compared to the untreated neuronal cultures, the addition of heparin 
and growth factors to the cultures was observed to have a positive effect on the 
number of sphere structures formed. In addition, the presence of heparin in the 
cultures appeared to promote the formation of long sphere-connecting neuronal 
protrusions.   
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Figure 7-2: Morphology at day 60 of neuronal differentiation of hNSC H9 cells cultured under 
untreated or heparin and growth factor treated conditions. Phase-contrast images (4X 
magnification, scale bar 140 μM) of hNSC H9 cells cultured under A) untreated neuronal 
differentiating culture conditions or in the presence of B) heparin (Hep), C) BDNF, D) BDNF+Hep, 
E) PDGF, F) PDGF+Hep, G) BDNF+PDGF or H) BDNF+PDGF+Hep.  Red dashed lines indicate 
sphere diameter and white solid lines indicate length of neuronal protrusions. 
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7.3.2 Viability of hNSC H9-derived neuronal cultures following heparin and 
growth factor treatments 
 
The presence of viable cells within sphere structures was next examined in all the 
neuronal culture conditions. To determine the ratio of live and dead cells, FDA/PI 
co-stain was performed as previously described (section 3.4.4) with live cells 
identified through FDA (green) and dead cells identified through PI (red). Neuronal 
cultures were exposed to FDA and PI at D40 and D60 of differentiation. After a brief 
incubation, cultures were imaged under an Olympus IX81 phase-contrast fluorescent 
microscope. Fluorescence intensities for FDA and PI were measured from 3 – 4 
fields of view using Volocity® software (Perkin Elmer) and the PI to FDA signal 
ratio plotted on a bar graph. 
 
The FDA/PI stain of the D40 and D60 neuronal differentiating cultures revealed both 
live (green) and dead (red) cells in the sphere structures in all culture conditions (Fig. 
7-3 to 7-8). When the fluorescence intensities of FDA and PI were quantified in the 
D40 neuronal differentiating cultures, the live cell percentage (FDA intensity) was 
approximately 73% in the untreated D40 neuronal cultures (Fig. 7-5). Interestingly, 
following treatment of the cultures with +Hep, +BDNF, +BDNF+Hep, +PDGF, 
+PDGF+Hep, +BDNF+PDGF and +BDNF+PDGF+Hep, the viability of the cultures 
at D40 increased with an FDA percentage of 78% or higher (Fig. 7-5). Significantly 
increased viability was observed at D40 in +BDNF (p=0.02), +PDGF (p=0.049) and 
+BDNF+PDGF (p=0.04), when compared to untreated neuronal cultures, increasing 
the FDA ratio to 90%, 86% and 87%, respectively, (Fig. 7-5). 
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Figure 7-3: Live/dead cell analysis at day 40 of neuronal differentiation of hNSC H9 cells 
cultured under untreated or BDNF-treated conditions without and with heparin. 
Immunofluorescence of live (FDA/green) and dead (PI/red) cells (10x magnification, scale bar 140 
μM) of hNSC H9 cells cultured under A) untreated or B) BDNF-treated neuronal differentiating 
conditions without and with heparin (Hep) for 40 days. 
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Figure 7-4: Live/dead cell analysis at day 40 of neuronal differentiation of hNSC H9 cells 
cultured under PDGF- or BDNF+PDGF-treated conditions without and with heparin. 
Immunofluorescence of live (FDA/green) and dead (PI/red) cells (10x magnification, scale bar 140 
μM) of hNSC H9 cells cultured under neuronal differentiating culture conditions treated with A) 
PDGF or B) BDNF+PDGF without and with heparin (Hep) for 40 days. 
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Figure 7-5: Live/dead cell ratio at day 40 of neuronal differentiation of hNSC H9 cells cultured 
under untreated or heparin and growth factor treated conditions. A bar graph indicating dead 
(PI/red) to live (FDA/green) cell ratio based on fluorescence intensity with the percentage of live cells 
shown. PI/FDA ratio was calculated for a minimum of three microscope fields of view for hNSC H9-
derived neuronal cultures at day 40 cultured under untreated, heparin (Hep), BDNF, BDNF+Hep, 
PDGF, PDGF+Hep, BDNF+PDGF or BDNF+PDGF+Hep-treated culture conditions. (Error bars = 
SD, statistical significance: * p<0.05). 
 
The FDA/PI stain on D60 neuronal differentiating cultures revealed that although 
live cells (FDA/green) were detectable in all culture conditions, an increase in the 
number of dead (PI/red) cells was observed (Fig. 7-6 to 7-8). Fluorescence intensity 
quantitation of FDA and PI revealed that the live cell percentage (FDA intensity) was 
approximately 83% in untreated D60 neuronal cultures (Fig. 7-8), higher than the 
percentage observed at D40 (Fig. 7-5). Interestingly, neuronal cultures treated with 
+Hep, +BDNF, +BDNF+Hep, +PDGF, +PDGF+Hep, +BDNF+PDGF and 
+BDNF+PDGF+Hep exhibited lower cell viability than observed in the untreated 
neuronal cultures at D60 with an FDA percentage of 82% or lower (Fig. 7-8). The 
FDA percentage observed was below 80% in the +Hep (71%), +PDGF (77%), 
+PDGF+Hep (59%) and +BDNF+PDGF (77%) treated cultures (Fig. 7-8). However, 
no significant difference in the FDA ratio between the culture conditions was 
observed, likely due to high variation between the quantitated fields of view. 
Neuronal differentiating cultures treated with +BDNF maintained a similar level of 
viability when compared to untreated neuronal cultures with both +BDNF and 
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+BDNF+Hep treated cultures exhibiting an FDA ratio of 82% at D60 (Fig. 7-8). 
With +BDNF treated cultures maintaining a similar or a higher level of viability 
when compared to untreated neuronal cultures at both D40 and D60, this supports a 
role for BDNF in promoting neuronal survival.  
 
 
Figure 7-6: Live/dead cell analysis at day 60 of neuronal differentiation of hNSC H9 cells 
cultured under untreated or BDNF-treated conditions without and with heparin. 
Immunofluorescence of live (FDA/green) and dead (PI/red) cells (10x magnification, scale bar 130 
μM) of hNSC H9 cells cultured under A) untreated or B) BDNF-treated neuronal differentiating 
conditions without and with heparin (Hep) for 60 days. 
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Figure 7-7: Live/dead cell analysis at day 60 of neuronal differentiation of hNSC H9 cells 
cultured under PDGF- or BDNF+PDGF-treated conditions without and with heparin. 
Immunofluorescence of live (FDA/green) and dead (PI/red) cells (10x magnification, scale bar 130 
μM) of hNSC H9 cells cultured under neuronal differentiating culture conditions treated with A) 
PDGF or B) BDNF+PDGF without and with heparin (Hep) for 60 days. 
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Figure 7-8: Live/dead cell ratio at day 60 of neuronal differentiation of hNSC H9 cells cultured 
under untreated or heparin and growth factor treated conditions. A bar graph indicating dead 
(PI/red) to live (FDA/green) cell ratio based on fluorescence intensity with the percentage of live cells 
shown. PI/FDA ratio was calculated for a minimum of three microscopic fields of view for hNSC H9-
derived neuronal cultures at day 60 cultured under untreated, heparin (Hep), BDNF, BDNF+Hep, 
PDGF, PDGF+Hep, BDNF+PDGF or BDNF+PDGF+Hep-treated culture conditions. (Error bars = 
SD, statistical significance: * p<0.05). 
 
7.3.3 Proliferating cells within hNSC H9-derived neuronal cultures following 
heparin and growth factor treatments 
 
To assess the level of active neurogenesis within D40 and D60 neuronal 
differentiating hNSC H9 cultures, the cultures were examined for the co-expression 
of a proliferation marker (Ki67) and a neuronal marker (MAP2). Ki67 and MAP2 
were identified using confocal microscopy with the ratio of highly Ki67-positive 
(Ki67+) nuclei within representative fields of view (2 – 4 fields) averaged for 
graphical presentation. 
 
When the neuronal differentiating cultures were examined at D40, homogenous 
MAP2 expression was identified in all the culture conditions (Fig. 7-9 and 7-10). In 
addition, proliferating, i.e. highly Ki67 positive cells were present in all cultures at 
D40 (Fig. 7-9 and 7-10). When the number of Ki67+ nuclei was quantitated, 
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approximately 11% of the nuclei in the untreated D40 neuronal differentiating 
cultures were Ki67+ (Fig. 7-11).  Interestingly, treatment of the cultures with heparin 
and growth factors increased the proportion of Ki67+ nuclei within the cultures with 
the treated cultures containing between 15% to 36% Ki67+ nuclei at D40 (Fig. 7-11).  
The proportion of Ki67+ nuclei when compared to untreated neuronal cultures was 
significantly increased following treatment of the cultures with +BDNF (21%; 
p=0.03) and +BDNF+Hep (26%; p=0.03) (Fig. 7-11).  Neuronal cultures treated with 
+Hep (31%) and +PDGF+Hep (22%) also exhibited a higher percentage of Ki67+ 
nuclei when compared to the untreated neuronal cultures at D40, however, due to 
high the variation observed between measurements, this difference was not 
significant (Fig. 7-11). The treatment of the cultures with +BDNF+PDGF (15%) and 
+BDNF+PDGF+Hep (13%) maintained a similar level of Ki67+ nuclei when 
compared to the untreated neuronal cultures (Fig. 7-11).      
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Figure 7-9: Ki67/MAP2 co-expression at day 40 of neuronal differentiation of hNSC H9 cells 
cultured under untreated or BDNF-treated conditions without and with heparin. Confocal 
microscopy of the proliferation marker Ki67 (yellow) and neuronal marker microtubule-associated 
protein 2 (MAP2, green) along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). 
Images are representative of hNSC H9 cells cultured under A) untreated or B) BDNF-treated neuronal 
differentiating conditions without and with heparin (Hep) for 40 days. 
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Figure 7-10: Ki67/MAP2 co-expression at day 40 of neuronal differentiation of hNSC H9 cells 
cultured under PDGF- or BDNF+PDGF-treated conditions without and with heparin. Confocal 
microscopy of the proliferation marker Ki67 (yellow) and neuronal marker microtubule-associated 
protein 2 (MAP2, green) along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). 
Images are representative of hNSC H9 cells cultured under neuronal differentiating conditions treated 
with A) PDGF or B) BDNF+PDGF without and with heparin (Hep) treatment for 40 days. 
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Figure 7-11: Percentage of Ki67-positive nuclei at day 40 of neuronal differentiation of hNSC 
H9 cells cultured under untreated or heparin and  growth factor treated conditions. A bar graph 
indicating the percentage of Ki67 positive (Ki67+) nuclei within hNSC H9-derived neuronal cultures 
at day 40. The number of Ki67+ nuclei out of the total number of nuclei was calculated for 2 – 4 
microscopic fields of view for untreated, heparin (Hep), BDNF, BDNF+Hep, PDGF, PDGF+Hep, 
BDNF+PDGF or BDNF+PDGF+Hep-treated neuronal differentiating cultures (Error bars = SD, 
statistical significance: * p<0.05). 
 
When Ki67 and MAP2 expression was examined in the D60 differentiating neurons, 
both markers were observed in all culture conditions (Fig. 7-12 and 7-13). Similar to 
D40 neuronal differentiating cultures, MAP2 demonstrated homogenous expression 
in the neuronal culture conditions at D60 (Fig. 7-12 and 7-13). In addition, the 
presence of proliferating (Ki67+) cells was observed in all culture conditions (Fig. 7-
12 and 7-13). When the number of Ki67+ cells was quantitated, approximately 30% 
of nuclei in the untreated D60 neuronal differentiating cells were positive for Ki67 
(Fig. 7-14).  Interestingly, this was higher than the proportion of Ki67+ nuclei 
observed in the untreated neuronal cultures at the D40 timepoint (Fig. 7-8). Similar 
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to D40 neuronal cultures, treatment of the cultures with +Hep, +BDNF and 
+BDNF+Hep significantly increased the proportion of Ki67+ nuclei at D60 of 
neuronal differentiation when compared to untreated neuronal cells (Fig. 7-14).  
Neuronal differentiating cultures treated with +Hep exhibited 41% Ki67+ nuclei at 
D60, significantly higher (p=0.03) than untreated neuronal cultures (Fig. 7-14).  
Treatment of the cultures with +BDNF increased the proportion of Ki67+ nuclei to 
55%, highly significantly higher (p=0.0002) than in untreated D60 neuronal cells 
(Fig. 7-14).  The treatment of the cultures with +BDNF+Hep further increased the 
proportion of Ki67+ nuclei to 56% with this also being significantly higher 
(p=0.005) when compared to the number of Ki67+ cells within untreated D60 
neuronal cultures (Fig. 7-14).  Similar to D40 neuronal cultures, at D60 neuronal 
cultures treated with +PDGF and +PDGF+Hep (29%) exhibited a similar level of 
proliferating (Ki67+) cells than observed in the untreated D60 neuronal cultures (Fig. 
7-14).  The average Ki67+ percentage in +BDNF+PDGF  (47%) treated neuronal 
cultures at D60 was higher when compared to untreated neuronal cultures, however, 
due to variation in measurement there was no significant difference demonstrated 
(Fig. 7-14).  Interestingly, the combined treatment of +BDNF+PDGF+Hep of the 
neuronal cultures resulted in a decreased number of proliferating cells when 
compared to untreated neuronal cultures, exhibiting a Ki67+ proportion of 24% in 
the cultures at D60 (Fig. 7-14).   
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Figure 7-12: Ki67/MAP2 co-expression at day 60 of neuronal differentiation of hNSC H9 cells 
cultured under untreated or BDNF-treated conditions without and with heparin. Confocal 
microscopy of the proliferation marker Ki67 (yellow) and neuronal marker microtubule-associated 
protein 2 (MAP2, green) along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). 
Images are representative of hNSC H9 cells cultured under A) untreated or B) BDNF-treated neuronal 
differentiating conditions without and with heparin (Hep) for 60 days. 
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Figure 7-13: Ki67/MAP2 co-expression at day 60 of neuronal differentiation of hNSC H9 cells 
cultured under PDGF- or BDNF+PDGF-treated conditions without and with heparin. Confocal 
microscopy of the proliferation marker Ki67 (yellow) and neuronal marker microtubule-associated 
protein 2 (MAP2, green) along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). 
Images are representative of hNSC H9 cells cultured under neuronal differentiating conditions treated 
with A) PDGF or B) BDNF+PDGF without and with heparin (Hep) treatment for 60 days. 
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Figure 7-14: Percentage of Ki67-positive nuclei at day 60 of neuronal differentiation of hNSC 
H9 cells cultured under untreated or heparin and growth factor treated conditions. A bar graph 
indicating the percentage of Ki67 positive (Ki67+) nuclei within hNSC H9-derived neuronal cultures 
at day 60. The number of Ki67+ nuclei out of the total number of nuclei was calculated for 2 – 4 
microscopic fields of view for untreated, heparin (Hep), BDNF, BDNF+Hep, PDGF, PDGF+Hep, 
BDNF+PDGF or BDNF+PDGF+Hep-treated neuronal differentiating cultures (Error bars = SD, 
statistical significance: * p<0.05, ** p<0.01).  
 
7.3.4 Neuronal marker expression and structural examination of hNSC H9-
derived neuronal cultures following heparin and growth factor treatments 
 
To assess the level of neuronal lineage commitment, neuronal marker expression in 
the D40 and D60 neuronal differentiating hNSC H9 cultures was examined. The 
effect of heparin, BDNF, PDGF and BDNF+PDGF treatments on neuronal marker 
expression was examined by comparing treated cultures to untreated neuronal 
cultures.  In addition, to examine the effect of heparin supplementation on neuronal 
marker expression, +Hep-treated cultures were compared to cultures not treated with 
+Hep. Any statistically significant differences were identified using Student’s t-test.  
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As previously demonstrated (Chapter 6), at D40 the +Hep and +BDNF-treatments 
did not induce the gene expression of any neuronal markers studied, including βIII-
tubulin (TUBB3), microtubule-associated protein 2 (MAP2), medium molecular 
weight neurofilament (NEFM) or doublecortin (DCX) when compared to cells 
cultured under untreated neuronal differentiation conditions (Fig. 7-15A). In contrast, 
a significant upregulation (p<0.0001) was observed in TUBB3 expression when a 
combination of +BDNF+Hep was added to the culture medium when compared to 
the untreated D40 neuronal cell cultures (Fig. 7-15A). A significant downregulation 
(p=0.03) in NEFM expression was observed following treatment of the cultures with 
+BDNF when compared with untreated neuronal cells (Fig. 7-15A). In addition, 
DCX expression was significantly downregulated following treatment of the cultures 
with +Hep (p=0.01), +BDNF (p=0.0001) and +BDNF+Hep (p=0.0009) (Fig. 7-15A). 
Interestingly, cultures treated with +BDNF+Hep retained a significantly higher 
expression level of TUBB3 (p=0.001) and DCX (p=0.0005) when compared to 
+BDNF-treated cultures (Fig. 7-15A).  
 
When the gene expression of neuronal differentiating hNSC H9 cells treated with 
+PDGF and +BDNF+PDGF at D40 was examined, multiple significant changes in 
the neuronal marker gene expression profile was observed when compared to 
untreated neuronal cultures (Fig. 7-15A). Treatment of neuronal differentiating cells 
with +PDGF resulted in the significant upregulation of TUBB3 (p=0.001) and MAP2 
(p<0.0001) when compared to untreated D40 neuronal cells (Fig. 7-15A). Similar to 
this, an upregulation in TUBB3 (p<0.0001) and MAP2 (p=0.02) expression was also 
observed in +PDGF+Hep treated cultures (Fig. 7-15A). In contrast, +PDGF 
(p=0.045) and +PDGF+Hep (p<0.0001) treatments resulted in the significant 
downregulation of DCX expression when compared to untreated neuronal cultures 
(Fig. 7-15A).  The addition of heparin to the +PDGF-treated cultures appeared to 
have an inhibitory effect on neuronal marker expression with all the studied neuronal 
markers, including TUBB3 (p=0.04), MAP2 (p=9.9e-6), NEFM (p=0.002) and DCX 
(p=0.0002) expressed at a significantly lower level when compared to the +PDGF 
only treated cultures (Fig. 7-15A).  
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Similar to the observed effects of +BDNF and +PDGF treatments on neuronal 
differentiating cells, the treatment of cultures with the combination of 
+BDNF+PDGF and +BDNF+PDGF+Hep resulted in the highly significant 
upregulation (p=0.0003) of TUBB3 expression when compared to the untreated 
neuronal cultures at D40 (Fig. 7-15A). In contrast, the expression of NEFM was 
significantly downregulated following treatment of the cultures with +BDNF+PDGF 
(p=0.04) and +BDNF+PDGF+Hep (p=0.04) when compared to untreated D40 
neuronal cultures (Fig. 7-15A). However, the addition +BDNF+PDGF+Hep to the 
cultures resulted in the maintenance of a significantly higher level (p=0.04) of NEFM 
expression when compared to the +BDNF+PDGF only culture condition (Fig. 7-
15A). Expression of DCX was also shown to be highly significantly downregulated 
following treatment of neuronal differentiating cultures with +BDNF+PDGF 
(p<0.0001) and +BDNF+PDGF+Hep (p<0.0001) when compared to untreated D40 
neuronal cells (Fig. 7-15A).  
 
When the gene expression of neuronal markers was examined following culture of 
hNSC H9 cells under neuronal differentiating culture conditions at D60, some of the 
gene expression differences observed at the D40 timepoint were not apparent at D60. 
In contrast to the D40 timepoint, no significant differences in TUBB3 gene 
expression was observed between the neuronal cultures at D60 (Fig. 7-15B). In 
addition, MAP2 expression was significantly downregulated in the neuronal cultures 
differentiated in the presence of +BDNF (p=0.02), +BDNF+Hep (p=0.006), +PDGF 
(p=0.01), +PDGF+Hep (p=0.006), +BDNF+PDGF (p=0.003) and 
+BDNF+PDGF+Hep (p=0.007) when compared to the untreated D60 neuronal 
cultures (Fig. 7-15B). Interestingly, MAP2 was expressed at a highly significantly 
higher level in +BDNF+PDGF+Hep (p=0.0004) cultures when compared to 
+BDNF+PDGF only cultures (Fig. 7-15B). Consistent with the D40 timepoint, 
+BDNF (p=0.01), +BDNF+Hep (p=0.02), +PDGF (p=0.047), +PDGF+Hep 
(p=0.04), +BDNF+PDGF (p=0.01) and +BDNF+PDGF+Hep (p=0.01) treatments 
resulted in the significant downregulation of NEFM expression when compared to 
the untreated D60 neuronal cultures (Fig. 7-15B). In contrast, DCX expression was 
significantly upregulated (p=0.0003) following treatment of the cultures with +Hep 
when compared to the untreated D60 neuronal cultures while no significant 
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differences in DCX expression was observed between the other culture conditions 
and the untreated D60 neuronal cultures (Fig. 7-15B). Interestingly, the 
+BDNF+PDGF+Hep treated cultures expressed a significantly higher level of DCX 
(p=0.04) when compared to the +BDNF+PDGF only culture conditions, a response 
not observed following D40 of neuronal differentiation (Fig. 7-15B). 
 
Figure 7-15: Lineage marker expression in neuronal differentiating hNSC H9 cells cultured 
under untreated or heparin and growth factor treated conditions for 40 and 60 days. Relative 
gene expression of neuronal markers βIII-tubulin (TUBB3), microtubule-associated protein 2 
(MAP2), medium molecular weight neurofilament (NEFM) and doublecortin (DCX) following culture 
of hNSC H9 cells under untreated, heparin (Hep), BDNF, BDNF+Hep, PDGF, PDGF+Hep, 
BDNF+PDGF or BDNF+PDGF+Hep-treated neuronal differentiating culture conditions for A) 40 and 
B) 60 days. (Error bars: Neuronal D60 and +BDNF+PDGF D60 = SD, other error bars = SEM, 
statistical significance: * p<0.05, ** p<0.01, *** p<0.001). Black lines indicate statistically significant 
difference between treated and the untreated neuronal conditions. Red lines indicate statistically 
significant difference between Hep-treated and non-Hep-treated growth factor-modulated conditions.  
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The protein level expression of neuronal markers was also examined by WB analysis 
along with optical density quantitation of identified protein bands. As previously 
demonstrated (Chapter 6) at the D40 timepoint the protein level expression of 
TUBB3 remained lower in the +Hep, +BDNF and +BDNF+Hep treated culture 
conditions when compared to untreated D40 neuronal cultures (Fig. 7-16A). This 
was also observed following treatment of the cultures with +PDGF, +PDGF+Hep, 
+BDNF+PDGF and +BDNF+PDGF+Hep with these cultures expressing a lower 
level of TUBB3 at the protein level when compared to untreated D40 neuronal 
cultures (Fig. 7-16A). Interestingly, the level of TUBB3 protein expression was 
higher in the +BDNF+Hep treated cultures when compared to +BDNF only cultures, 
an effect also seen when the gene expression of TUBB3 was examined, suggesting a 
stimulatory effect for heparin in combination with BDNF on this neuronal marker 
(Fig. 7-15A and 7-16A).  
 
At the D60 timepoint, the protein level expression of TUBB3 was similar between all 
the neuronal culture conditions (Fig. 7-16B(i)). When the optical density of TUBB3 
bands was quantitated, similar to the D40 timepoint, the untreated neuronal cultures 
demonstrated the highest level of TUBB3 expression when compared to the other 
culture conditions at D60 (Fig. 7-16(i)). Consistent with gene expression results, 
cultures treated with +BDNF+Hep expressed a decreased level of TUBB3 while 
cultures treated with +PDGF expressed a similar level of TUBB3 when compared to 
the untreated D60 neuronal cultures (Fig. 7-16B(i)). The expression of MAP2 was 
also examined via WB analysis in the D60 neuronal cultures (Fig. 7-16(ii)). An 
approximate 80 kDa-size band was predominantly visible for the MAP2 protein, 
corresponding to the low molecular weight MAPc/d isoforms (70-75 kDa) (Guo et 
al., 2012) (Fig. 7-16B(ii)). MAP2 was observed to be increased in the +Hep treated 
neuronal cultures when compared to untreated with optical quantitation confirming 
this (Fig. 7-16B(ii)). When the other neuronal cultures were examined, a similar level 
of MAP2 expression was observed between the majority of the culture conditions 
with +BDNF+PDGF and +BDNF+PDGF+Hep treated cultures exhibiting reduced 
MAP2 expression when compared to the untreated D60 neuronal cultures confirming 
gene expression results (Fig. 7-16B(ii)). 
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Figure 7-16: Protein level expression of neuronal markers in neuronal differentiating hNSC H9 
cells cultured under untreated or heparin and growth factor treated conditions for 40 and 60 
days. A) Western blot analysis and optical quantitation of the neuronal marker βIII-tubulin (TUBB3) 
along with GAPDH loading control following culture of hNSC H9 cells under untreated, heparin 
(Hep), BDNF, BDNF+Hep, PDGF, PDGF+Hep, BDNF+PDGF or BDNF+PDGF+Hep-treated culture 
conditions for 40 days. B) Western blot analysis and optical quantitation of the neuronal markers (i) 
TUBB3 and (ii) microtubule-associated protein 2 (MAP2) along with GAPDH loading control 
following culture of hNSC H9 cells under untreated, Hep, BDNF, BDNF+Hep, PDGF, PDGF+Hep, 
BDNF+PDGF or BDNF+PDGF+Hep-treated culture conditions for 60 days. 
 
In order to examine the cellular structure of hNSC H9 neuronal differentiating 
cultures at the D40 and D60 timepoints, the expression and localisation of the NSC 
intermediate filament nestin and the neuronal marker TUBB3 was examined using 
confocal microscopy.  The fragile nature of long-term differentiated neuronal 
cultures posed a challenge for the microscopic imaging of these cultures, thus good 
representative images were not always obtained from all culture conditions.  
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When nestin (green) and TUBB3 (red) were examined in the D40 differentiating 
neuronal cultures, both markers demonstrated homogenous expression and 
localisation within the cultures, indicating the cultures maintained high level of NSC 
and neuronal marker expression throughout extended differentiation (Fig. 7-17 and 
7-18). Interestingly, the nestin/TUBB3 merge images also demonstrate that these two 
proteins are not ubiquitously present in the cells and do not always co-localise with 
the orange colour representing the co-localisation signal (Fig. 7-17 and 7-18).  The 
untreated D40 neuronal cultures exhibited thin elongated cell bodies while the 
neuronal cultures treated with +Hep were observed to exhibit larger cell bodies (Fig. 
7-17). Similar to +Hep treated neuronal cultures, the cell bodies of neurons 
differentiated in the presence of +BDNF and +BDNF+PDGF had larger cell bodies 
when compared to untreated neuronal cells (Fig. 7-17 and 7-18).   In contrast, 
neuronal cultures treated with +PDGF exhibited similar finely structured cell bodies 
to the untreated D40 neuronal cultures (Fig. 7-18). Higher cell density was also 
observed in cultures treated with +BDNF, +BDNF+Hep, +PDGF+Hep, 
+BDNF+PDGF and +BDNF+PDGF+Hep when compared to the untreated D40 
neuronal cultures (Fig. 7-17 and 7-18).  Interestingly, nestin and TUBB3 staining 
revealed the presence of high density cell “bundles” in the +BDNF+Hep, 
+PDGF+Hep and +BDNF+PDGF+Hep cultures when compared with +BDNF, 
+PDGF and +BDNF+PDGF cultures, respectively (Fig. 7-17 and 7-18).  This 
suggests that heparin in the presence of key growth factors may promote the 
formation of these structures.  
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Figure 7-17: Nestin/TUBB3 co-expression at day 40 of neuronal differentiation of hNSC H9 cells 
cultured under untreated or BDNF-treated conditions without and with heparin. Confocal 
microscopy of the NSC marker nestin (green) and the neuronal marker βIII-tubulin (TUBB3, red) 
along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). Images are representative 
of hNSC H9 cells cultured under A) untreated or B) BDNF-treated neuronal differentiating conditions 
without and with heparin (Hep) for 40 days. 
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Figure 7-18: Nestin/TUBB3 co-expression at day 40 of neuronal differentiation of hNSC H9 cells 
cultured under PDGF- or BDNF+PDGF-treated conditions without and with heparin. Confocal 
microscopy of the NSC marker nestin (green) and the neuronal marker βIII-tubulin (TUBB3, red) 
along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). Images are representative 
of hNSC H9 cells cultured under A) PDGF- or B) BDNF+PDGF-treated neuronal differentiating 
conditions without and with heparin (Hep) for 40 days. 
 
When the neuronal differentiating cultures were examined at the D60 timepoint, 
homogenous nestin and TUBB3 expression was observed suggesting that along with 
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neuronal lineage markers, the NSC marker nestin persists in neuronal differentiating 
cells even after long-term differentiation (Fig. 7-19 and 7-20). The nestin/TUBB3 co-
stain also revealed that following D60 of differentiation, the cell morphologies in the 
neuronal differentiating cultures had become more “neuron-like” when compared to 
D40 neuronal cultures, indicated by the presence of long elongated cell bodies in all 
the culture conditions (Fig. 7-19 and 7-20). Some of the structural differences 
observed for nestin and TUBB3 localisation became more apparent at D60 of 
differentiation. Specifically, when the +BDNF, and +BDNF+Hep treated neuronal 
cultures were examined, TUBB3 was localised to the finely structured neuronal 
protrusions within the neuronal cultures while nestin appeared to localise to cell 
bodies or thick neuronal protrusions (Fig. 7-19B).  The nestin/TUBB3 co-stain also 
revealed morphological differences between the different neuronal culture conditions 
at D60. Consistent with observations made in the D40 neuronal differentiating 
cultures, cell density was higher in cultures treated with +BDNF, +BDNF+Hep, 
+PDGF and +PDGF+Hep when compared to untreated D60 neuronal cultures (Fig. 
7-19B and 7-20A). Interestingly, in contrast to the D40 timepoint, the dense cell 
bundles observed in the +BDNF+Hep and +PDGF+Hep treated cultures were less 
apparent following D60 of differentiation, although similar structures were observed 
in the +PDGF only treated D60 neuronal cultures (Fig. 7-19B and 7-20A). In 
addition, in contrast to observations made at the D40 timepoint, cultures treated with 
+BDNF+PDGF and +BDNF+PDGF+Hep did not exhibit a higher cell density than 
observed in the untreated neuronal cultures at D60 with the cell density similar 
between these culture conditions (Fig. 7-19A and 7-20B). 
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Figure 7-19: Nestin/TUBB3 co-expression at day 60 of neuronal differentiation of hNSC H9 cells 
cultured under untreated or BDNF-treated conditions without and with heparin. Confocal 
microscopy of the NSC marker nestin (green) and the neuronal marker βIII-tubulin (TUBB3, red) 
along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). Images are representative 
of hNSC H9 cells cultured under A) untreated or B) BDNF-treated neuronal differentiating conditions 
without and with heparin (Hep) for 60 days. 
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Figure 7-20: Nestin/TUBB3 co-expression at day 60 of neuronal differentiation of hNSC H9 cells 
cultured under PDGF- or BDNF+PDGF-treated conditions without and with heparin. Confocal 
microscopy of the NSC marker nestin (green) and the neuronal marker βIII-tubulin (TUBB3, red) 
along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). Images are representative 
of hNSC H9 cells cultured under A) PDGF- or B) BDNF+PDGF-treated neuronal differentiating 
conditions without and with heparin (Hep) for 60 days. 
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7.3.5 Heterogeneity in hNSC H9-derived neuronal cultures following heparin 
and growth factor treatments 
 
To assess the level of heterogeneity in the D40 and D60 neuronal differentiating 
hNSC H9 cultures, NSC self-renewal and glial marker expression was examined in 
these cultures. As already observed through structural examination of the D40 and 
D60 neuronal differentiating cultures, the expression of the NSC marker nestin was 
maintained throughout differentiation until D60 (Fig. 7-17 to 7-20). To more 
specifically examine the level of NSC and glial marker expression, the gene 
expression levels of NSC self-renewal markers nestin and SOX2 as well as the 
astrocyte marker S100 calcium binding protein B (S100B) was examined in the D40 
and D60 neuronal differentiating cultures.  
 
Nestin and SOX2 gene expression was shown to be maintained in D40 and D60 
differentiating neuronal cultures with growth factor treatments altering their 
expression levels (Fig. 7-21).  As previously demonstrated at the D40 timepoint 
(Chapter 6), BDNF supplementation induced nestin gene expression with +BDNF 
(p<0.0001) and +BDNF+Hep (p=0.02) treated cultures expressing a significantly 
higher level of nestin when compared to the untreated D40 neuronal cultures (Fig. 7-
21A). In the other culture conditions, a similar response was observed, with nestin 
also shown to be highly significantly more highly expressed in the +PDGF 
(p=0.006), +PDGF+Hep (p<0.0001), +BDNF+PDGF (p<0.0001) and 
+BDNF+PDGF+Hep (p<0.0001) treated cultures when compared to untreated D40 
neuronal cultures (Fig. 7-21A). When the +BDNF+PDGF+Hep treated cultures were 
examined, these cultures also exhibited a significantly higher expression (p=0.0001) 
of nestin when compared to the +BDNF+PDGF alone treated cultures (Fig. 7-21A). 
As previously demonstrated (Chapter 6), SOX2 gene expression was not induced 
following +BDNF or +BDNF+Hep treatments of the neuronal cultures. In contrast, 
neuronal cultures treated with +PDGF (p<0.0001) and +PDGF+Hep (p=0.0002) 
expressed a highly significantly induced level of SOX2 when compared to untreated 
D40 neuronal cultures (Fig. 7-21A). A similar effect was observed in cultures treated 
with +BDNF+PDGF (p=0.002) and +BDNF+PDGF+Hep (p=0.0008) with these 
cultures exhibiting significantly higher levels of SOX2 expression when compared to 
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untreated D40 neuronal cultures (Fig. 7-21A). Interestingly, at D40 heparin treatment 
alone did not induce any significant changes in NSC self-renewal marker expression 
when compared to untreated neuronal cultures (Fig. 7-21A). 
 
When the gene expression level of nestin was examined in the D60 neuronal 
differentiating cultures, a similar level of nestin expression was observed between 
the majority of the culture conditions (Fig. 7-21B). Neuronal differentiating cultures 
treated with +BDNF+PDGF (p=0.008) and +BDNF+PDGF+Hep (p<0.0001) 
expressed a significantly higher level of nestin when compared to untreated D60 
neuronal cultures (Fig. 7-21B). Interestingly, cultures treated with 
+BDNF+PDGF+Hep expressed a significantly induced level (p=0.003) of nestin 
when compared to the +BDNF+PDGF only treated cultures (Fig. 7-21B). 
Interestingly, SOX2 gene expression was reduced in the majority of the heparin and 
growth factor treated neuronal cultures when compared to untreated D60 neuronal 
cultures (Fig. 7-21B). A significant downregulation in SOX2 expression when 
compared to the untreated D60 neuronal cultures was observed in cultures treated 
with +Hep (p=0.04), +PDGF (p=0.03), +PDGF+Hep (p=0.045) and +BDNF+PDGF 
(p=0.04) (Fig. 7-21B). A similar trend was also seen in +BDNF and 
+BDNF+PDGF+Hep treated cultures, although this was not significant.  
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Figure 7-21: NSC self-renewal marker expression in neuronal differentiating hNSC H9 cells 
cultured under untreated or heparin and growth factor treated conditions for 40 and 60 days. 
Relative gene expression of NSC markers nestin and SOX2 following neuronal differentiation of 
hNSC H9 cells under untreated, heparin (Hep), BDNF, BDNF+Hep, PDGF, PDGF+Hep, 
BDNF+PDGF or BDNF+PDGF+Hep-treated culture conditions for A) 40 and B) 60 days. (Error bars: 
Neuronal D60 and +BDNF+PDGF D60 = SD, other error bars = SEM, statistical significance: * 
p<0.05, ** p<0.01, *** p<0.001). Black lines indicate statistically significant differences between 
untreated and treated neuronal conditions. Red lines indicate statistically significant differences 
between Hep-treated and non-Hep-treated growth factor-modulated conditions. 
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The gene expression of the astrocyte marker S100B was also examined in the 
neuronal differentiating cultures at D40 and D60 to assess the presence of glial 
marker expressing cells. Gene expression analysis of S100B demonstrated that the 
expression of this marker was maintained until D60 in the neuronal differentiation 
culture conditions examined (Fig. 7-22).  As previously demonstrated (Chapter 6), at 
D40 of neuronal differentiation cultures treated with +Hep or +BDNF did not 
express significantly altered gene expression levels of S100B, while +BDNF+Hep 
(p=0.02) treated cultures expressed a significantly increased level of S100B when 
compared to untreated D40 neuronal cultures (Fig. 7-22). When the other culture 
conditions were examined, the addition of +PDGF (p<0.0001) and +PDGF+Hep 
(p=0.006) resulted in the highly significant increase of S100B expression while 
+BDNF+PDGF and +BDNF+PDGF+Hep treated cultures expressed a similar level 
of S100B to untreated D40 neuronal cultures (Fig. 7-22). Interestingly, the combined 
treatment of +BDNF+PDGF+Hep significantly reduced (p=0.007) S100B expression 
when compared to the +BDNF+PDGF treated condition (Fig. 7-22). Interestingly, 
when S100B gene expression was examined following D60 of culture, opposite 
results to the D40 timepoint was detected (Fig. 7-22). In contrast to the D40 
timepoint, neuronal cultures treated with +PDGF (p=0.03), +PDGF+Hep (p=0.03), 
+BDNF+PDGF (p=0.02) and +BDNF+PDGF+Hep (p=0.02) expressed a 
significantly reduced level of S100B when compared to the untreated D60 neuronal 
cultures, suggesting a decreased presence of S100B expressing cells (Fig. 7-22). 
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Figure 7-22: S100B expression in neuronal differentiating hNSC H9 cells cultured under 
untreated or heparin and growth factor treated conditions for 40 and 60 days. Relative gene 
expression of the astrocyte marker S100 calcium binding protein B (S100B) following neuronal 
differentiation of hNSC H9 cells under untreated, heparin (Hep), BDNF, BDNF+Hep, PDGF, 
PDGF+Hep, BDNF+PDGF or BDNF+PDGF+Hep-treated culture conditions for 40 and 60 days. 
(Error bars: Neuronal D60 and +BDNF+PDGF D60 = SD, other error bars = SEM, statistical 
significance: * p<0.05, ** p<0.01, *** p<0.001). Black lines indicate statistically significant 
differences between treated and untreated neuronal conditions. Red lines indicate statistically 
significant differences between Hep-treated and non-Hep-treated growth factor-modulated conditions. 
 
The ratio of S100B gene expression to TUBB3 gene expression revealed that at the 
D40 timepoint in untreated neuronal cultures, S100B relative gene expression was 
approximately 13% of the observed TUBB3 relative expression (Fig. 7-23A). 
Interestingly, despite the increase in S100B gene expression at D40 following, 
+BDNF+Hep, +PDGF and +PDGF+Hep treatments when compared to untreated 
neuronal cultures (Fig. 7-22), the S100B/TUBB3 ratio in the treated neuronal 
cultures remained lower than in the untreated neuronal cultures at D40. Calculation 
of the S100B/TUBB3 ratio in cultures treated with +Hep (8%), +BDNF (10%), 
+BDNF+Hep (7%), +PDGF (9%), +PDGF+Hep (11%), +BDNF+PDGF (4%) and 
+BDNF+PDGF+Hep (3%) demonstrated lower relative ratio of S100B than in the 
untreated D40 neuronal cultures (13%) (Fig. 7-23A).  
 
When the S100B/TUBB3 ratio was examined in the untreated neuronal 
differentiating cultures at D60, the level of S100B expression was shown to be 
clearly higher than at D40 with a 30% S100B to TUBB3 ratio observed (Fig. 7-23B). 
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Similarly, an increase in the S100B/TUBB3 ratio when compared to the D40 
timepoint was observed in the D60 neuronal cultures treated with +Hep (11%), 
+BDNF (23%) and +BDNF+Hep (15%) (Fig. 7-23B). The S100B/TUBB3 ratio was 
decreased when compared to the D40 timepoint in +PDGF (5%) and +PDGF+Hep 
(5%) treated cultures at D60 (Fig. 7-23B). A similar S100B/TUBB3 ratio was 
maintained in the +BDNF+PDGF (5%) and +BDNF+PDGF+Hep (4%) treated 
cultures at the D60 timepoint when compared to the D40 timepoint (Fig. 7-23B). 
Overall, neuronal cultures treated with heparin or growth factors exhibited a lower 
S100B/TUBB3 ratio than untreated D60 neuronal cultures (Fig. 7-23).  
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Figure 7-23: S100B/TUBB3 ratio in neuronal differentiating hNSC H9 cells cultured under 
untreated or heparin and growth factor treated conditions for 40 and 60 days. Relative gene 
expression of the astrocyte marker S100 calcium binding protein B (S100B) and the neuronal marker 
βIII-tubulin (TUBB3) indicating the S100B/TUBB3 ratio (%) following neuronal differentiation of 
hNSC H9 cells under untreated, heparin (Hep), BDNF, BDNF+Hep, PDGF, PDGF+Hep, 
BDNF+PDGF or BDNF+PDGF+Hep-treated conditions for A) 40 and B) 60 days. (Error bars: 
Neuronal D60 and +BDNF+PDGF D60 = SD, other error bars = SEM) 
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Confocal microscopy was used to visually determine the localisation of S100B-
positive (S100B+) cells within the D60 neuronal differentiating cultures. To provide 
a structural marker, cultures were a co-stained for the ubiquitously expressed marker 
nestin. The nestin/S100B co-stain revealed several highly positive S100B cells in all 
the D60 neuronal differentiating cultures (indicated by white arrows in Fig. 7-24 and 
7-25). Further observations of the neuronal cultures demonstrated that less than 50% 
of the cells demonstrated high S100B expression in all culture conditions (Fig. 7-24 
and 7-25). To gain insight into the proportion of S100B expressing cells within the 
D60 neuronal cultures, the percentage of S100B+ cells was quantified in relation to 
the total number nuclei observed in a microscopic field of view. The quantitation 
revealed that the untreated D60 neuronal cultures exhibited 29% S100B+ cells (Fig. 
7-26). The percentage of S100B+ cells remained similar following treatment of the 
cultures with +Hep (33%), +BDNF (24%), +BDNF+Hep (23%), +PDGF+Hep (26%) 
and +BDNF+PDGF+Hep (26%) (Fig. 7-26). Cultures treated with +PDGF exhibited 
a lower percentage of S100B+ (11%) cells with cultures treated with +BDNF+PDGF 
(45%) exhibiting a clearly higher percentage (45%) of S100B+ cells than observed in 
the untreated D60 neuronal cultures (Fig. 7-26). Of note, the +BDNF+PDGF treated 
cultures exhibited a high level of variability between measured fields of view and 
only one field of view was obtained for the +BDNF+Hep treated cultures, thus the 
S100B quantitation from the microscope images provides only a crude estimation of 
the level of S100B+ expression within these cultures.  
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Figure 7-24: S100B expression at day 60 of neuronal differentiation of hNSC H9 cells cultured 
under untreated and BDNF-treated conditions without and with heparin. Confocal microscopy 
of the NSC marker nestin (green) and the astrocyte marker S100 calcium binding protein B (S100B, 
yellow) along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). Images are 
representative of hNSC H9 cells cultured under A) untreated or B) BDNF-treated neuronal 
differentiating conditions without and with heparin for 60 days. White arrows indicate highly S100B-
positive cells.  
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Figure 7-25: S100B expression at day of neuronal differentiation of hNSC H9 cells cultured 
under PDGF- and BDNF+PDGF-treated conditions without and with heparin. Confocal 
microscopy of the NSC marker nestin (green) and the astrocyte marker S100 calcium binding protein 
B (S100B, yellow) along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). 
Images are representative of hNSC H9 cells cultured under A) PDGF- or B) BDNF+PDGF-treated 
neuronal differentiating conditions without and with heparin for 60 days. White arrows indicate highly 
S100B-positive cells.  
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Figure 7-26: Quantitation of S100B-positive cells in neuronal differentiating hNSC H9 cells 
cultured under untreated or heparin and growth factor treated conditions for 60 days. A bar 
graph indicating the percentage of S100B expressing cells of the total number of nuclei present in a 
microscopic field of view. Calculations have been performed for neuronal differentiating hNSC H9 
cells cultured under untreated, heparin (Hep), BDNF, BDNF+Hep, PDGF, PDGF+Hep, 
BDNF+PDGF or BDNF+PDGF+Hep-treated culture conditions for 60 days.  (Error bars = SD).  
 
7.3.6 Spontaneous calcium oscillations in hNSC H9-derived neuronal cultures 
 
As a measure of neuronal functionality, the occurrence of spontaneous calcium 
(Ca2+) oscillations was measured in the neuronal differentiating cultures. 
Spontaneously occurring Ca2+ oscillations are a characteristic of densely cultured 
mouse neuronal cultures and can be induced to occur more readily in a low 
magnesium (Mg2+) environment (Pacico & Mingorance-Le Meur, 2014). Ca2+ 
oscillations can be identified using a Ca2+ indicator, such as Fluo-4 and measured 
using a fluorescence-based method, including a fluorescent plate-reader or a 
fluorescent microscope (Hemstapat et al., 2004; Pacico & Mingorance-Le Meur, 
2014).  To assess if neuronal differentiating hNSC H9 cultures spontaneously 
generate Ca2+ oscillations, cultures were examined using the Fluo-4 dye for the 
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presence of Ca2+ signals in a low Mg2+ environment (0.1 mM) as previously 
described (section 3.8). A fluorescent plate-reader based assay was tested (previously 
described by Pacico et al.(Pacico & Mingorance-Le Meur, 2014)) to examine Ca2+ 
signals in the hNSC cultures, however, the Ca2+signals generated by the cells were 
too low to be reliably recorded (data not shown). A more sensitive and reliable 
detection of Ca2+ signals was then performed by monitoring the neuronal cultures 
using time-lapse imaging and a fluorescent microscope. Neuronal cultures loaded 
with Fluo-4 were imaged for 200s with images acquired every 0.8 seconds. An 
example of Ca2+ signal detection in D60 neuronal cultures over a measurement 
period of 200s is presented in Figure 7-27. As indicated by the white arrows in 
representative image panels at 33s, 74s, 100s and 121s timepoints, progressive 
changes in fluorescence intensity (FI) indicative of Ca2+ signalling was observed at 
these timepoints in the cultures (Fig. 7-27). The Ca2+ signal was observed to travel 
through the cell bodies as well as neurites of the cells (Fig. 7-27). 
 
 
Figure 7-27: Occurrence of calcium signals in hNSC H9-derived neuronal cultures at day 60. 
Representative images of calcium (Ca2+) signals detected by Fluo-4 (green) at 0.8s, 33s, 74, 100s, 
121s and 200s timepoints in hNSC H9-derived neuronal cultures at day 60. White arrows indicate 
areas where Ca2+ signals can be detected. 
 
For graphic analysis of Ca2+ signalling, FI of the Fluo-4 signal was plotted as a line 
graph. To do this, 20 regions of interest (ROIs), each representing a single cell, were 
selected from the field of view using Volocity® software (Perkin Elmer). For each 
ROI the mean FI for each timepoint was obtained using Volocity® software. Mean 
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FI values were exported to Microsoft Excel where FI for each timepoint was 
normalised to timepoint 1 fluorescence intensity (FI0) for each ROI studied. The 
FI/FI0 values were plotted on a graph to determine any Ca2+ signal peaks or 
oscillatory behaviour of Ca2+ signalling in the selected neuronal cells within the 
cultures.  
 
To ensure the reliability of the Ca2+ signals observed within hNSC H9-derived 
neuronal cultures, spontaneous Ca2+ signalling was examined in non-neuronal 
(negative control) and neuronal (positive control) cells to determined baseline 
signalling levels and oscillations. Non-neuronal MCF-7 human breast cancer cells 
were used as a representative negative control with the SHSY-5Y human 
neuroblastoma cell line used as a representative positive control. In addition, the 
generation of spontaneous Ca2+ signals was measured in basal hNSC H9 passage 5 
(P5) cells to compare differences between undifferentiated and neuronal 
differentiated hNSC H9 cultures. When Ca2+ signals in MCF-7, SHSY-5Y and basal 
hNSC H9 cells were examined, all cell types produced a signal curve, which differed 
in shape between the cell types (Fig. 7-28). The Ca2+ signal curve observed in MCF-7 
cells demonstrated a steady linear increase in signal with no apparent peak in signal 
observed during the 200s measurement (Fig. 7-28A). In contrast the SHSY-5Y 
cultures generated an early and synchronised Ca2+ signal peak during measurement 
(between timepoint 1 and 100), however, no oscillatory Ca2+ signal was observed 
(Fig. 7-28B). Similar to the MCF-7 cells, basal hNSC H9 cells demonstrated 
increased fluorescence toward the end stage of the measurement (Fig. 7-28C). 
However, in contrast to the MCF-7 cells, a number of cells in the basal hNSC H9 
cultures generated a peak-like Ca2+ signal during the measurement (Fig. 7-28C). For 
the comparison of Ca2+ signals between basal and neuronal differentiating hNSC H9 
cultures, a control Ca2+ signal curve was calculated (Fig. 7-28C insert).  This was 
done by averaging the FI/FI0 values of all ROIs in a single hNSC H9 measurement, 
then averaging three separate hNSC H9 measurements together and plotting the 
obtained averaged values on a graph. The height of the control curve was measured 
with height plus standard deviation of the curve (=1.62) used as a baseline for 
neuronal differentiating cultures, with any peaks exceeding this value considered to 
be a differential Ca2+ signal. 
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Figure 7-28: Detection of calcium signals in MCF-7, SHSY-5Y and hNSC H9 cells. Fluorescence 
intensity (FI) graph of the calcium indicator Fluo-4 signal in A) MCF-7 human breast cancer cells, B) 
SHSY-5Y human neuroblastoma cells and C) hNSC H9 passage 5 (P5) cells. Insert within panel C 
demonstrates an averaged FI graph of three separate hNSC H9 P5 measurements with a peak height of 
1.62. FI of Fluo-4 was measured for 200s at 0.8s intervals (251 timepoints) and FI of each timepoint 
was normalised to FI of timepoint 1 (FI0) and presented as FI/FI0. 
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Ca2+ signals were then examined in the D40 and D60 neuronal differentiating 
cultures. Similar to the MCF-7, SHSY-5Y and basal hNSC H9 cells, the FI/FI0 
values of 20 cells (ROIs) were examined. The percentage of ROIs generating a peak 
exceeding 1.62 in height was also calculated in each culture condition. When the 
untreated D40 neuronal cultures were examined, several high Ca2+ peaks generated 
by a number of ROIs were observed around mid-stage of the measurement (Fig. 7-
29A). Of the 20 ROIs examined, 5 ROIs (25%) were found to generate a peak that 
exceeded 1.62 in height (Fig. 7-29A), suggesting a signal different to basal hNSC H9 
cultures (Fig. 7-28C). When the D40 neuronal cultures treated with +Hep were 
examined, no clear peak-like Ca2+ signals were observed for the FI/FI0 values (Fig. 7-
29B). Confirming this, none of the examined ROIs generated a Ca2+ signal peak that 
exceeded 1.62 in height (Fig. 7-29B).  
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Figure 7-29: Detection of calcium signals at day 40 in hNSC H9-derived neuronal cultures 
without or with heparin treatment. A representative fluorescence image along with fluorescence 
intensity (FI) graph of the calcium (Ca2+) indicator Fluo-4 (green) in A) untreated or B) heparin-
treated hNSC H9-derived neuronal cultures at day 40. Fluorescence image demonstrates selected 
regions of interest (ROIs) with ROIs, along with percentage that generated a Ca2+ peak over 1.62 
marked in yellow. Line graph indicates fluorescence intensity (FI) for each ROI at each timepoint. FI 
of Fluo-4 was measured for 200s at 0.8s intervals (251 timepoints) and FI of each timepoint was 
normalised to FI of timepoint 1 (FI0) and presented as FI/FI0. Black arrows indicate FI peaks. 
 
When D40 neuronal cultures treated with +BDNF and +BDNF+Hep were examined, 
no clear oscillatory Ca2+ signalling was observed (Fig. 7-30). In the +BDNF treated 
D40 neuronal cultures, several of the examined ROIs simultaneously generated a 
Ca2+ signal peak toward the end stage of the measurement (indicated by a black 
arrow) (Fig. 7-30A). One of the examined ROIs (5%) was found to generate a peak 
that exceeded 1.62 in height (Fig. 7-30A), however, no clear Ca2+ signal peaks were 
observed in the +BDNF+Hep D40 neuronal cultures (Fig. 7-30B). 
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Figure 7-30: Detection of calcium oscillations at day 40 in hNSC H9-derived neuronal cultures 
treated with BDNF or BDNF+heparin. A representative fluorescence image along with 
fluorescence intensity (FI) graph of the calcium indicator Fluo-4 (green) in hNSC H9-derived day 40 
neuronal cultures treated with A) +BDNF or B) +PDGF+heparin. Fluorescence image demonstrates 
selected regions of interest (ROIs) with ROIs, along with percentage that generated a Ca2+ peak over 
1.62 marked in yellow. Line graph indicates fluorescence intensity (FI) for each ROI at each 
timepoint. FI of Fluo-4 was measured for 200s at 0.8s intervals (251 timepoints) and FI of each 
timepoint was normalised to FI of timepoint 1 (FI0) and presented as FI/FI0. Black arrow indicates a FI 
peak. 
 
In the D40 neuronal cultures treated with +PDGF and +PDGF+Hep, several ROIs 
exhibited peak-like Ca2+ signals (indicated by black arrows) (Fig. 7-31). Of the 20 
examined ROIs, one ROI (5%) in the +PDGF treated D40 neuronal cultures 
generated a Ca2+ peak that exceeded 1.62 in height (Fig. 7-31A). In contrast, although 
several distinct Ca2+ peaks were observed in +PDGF+Hep treated D40 cultures, none 
of these peaks exceeded 1.62 in height (Fig. 7-31B). 
 
 276 Chapter 7: Unravelling mechanisms of HSPG-mediated control of human neurogenesis 
 
Figure 7-31: Detection of calcium oscillations at day 40 in hNSC H9-derived neuronal cultures 
treated with PDGF or PDGF+heparin. A representative fluorescence image along with 
fluorescence intensity (FI) graph of the calcium indicator Fluo-4 (green) in hNSC H9-derived day 40 
neuronal cultures treated with A) +PDGF or B) +PDGF+heparin. Fluorescence image demonstrates 
selected regions of interest (ROIs) with ROIs, along with percentage that generated a Ca2+ peak over 
1.62 marked in yellow. Line graph indicates fluorescence intensity (FI) for each ROI at each 
timepoint. FI of Fluo-4 was measured for 200s at 0.8s intervals (251 timepoints) and FI of each 
timepoint was normalised to FI of timepoint 1 (FI0) and presented as FI/FI0. Black arrows indicate FI 
peaks. 
 
Similar to the +PDGF treated D40 neuronal culture condition, of the ROIs examined 
+BDNF+PDGF treated cultures, one ROI (5%) exhibited a clear Ca2+ peak (indicated 
by a black arrow) exceeding the height of 1.62 (Fig. 7-32A). In contrast, none of the 
other cells examined generated any Ca2+ waves (Fig. 7-32A). In addition, in the 
+BDNF+PDGF+Hep treated cultures a single ROI generated a Ca2+ peak exceeding 
1.62 in height was observed (indicated by a black arrow) (Fig. 7-32B). 
 
  
Chapter 7: Unravelling mechanisms of HSPG-mediated control of human neurogenesis 277 
 
Figure 7-32: Detection of calcium oscillations at day 40 in hNSC H9-derived neuronal cultures 
treated with BDNF+PDGF or BDNF+PDGF+heparin. A representative fluorescence image along 
with fluorescence intensity (FI) graph of the calcium indicator Fluo-4 (green) in hNSC H9-derived 
day 40 neuronal cultures treated with A) +BDNF+PDGF or B) +BDNF+PDGF+heparin. Fluorescence 
image demonstrates selected regions of interest (ROIs) with ROIs, along with percentage that 
generated a Ca2+ peak over 1.62 marked in yellow. Line graph indicates fluorescence intensity (FI) for 
each ROI at each timepoint. FI of Fluo-4 was measured for 200s at 0.8s intervals (251 timepoints) and 
FI of each timepoint was normalised to FI of timepoint 1 (FI0) and presented as FI/FI0. Black arrows 
indicate FI peaks. 
 
Interestingly, when the D60 neuronal differentiating cultures were examined for Ca2+ 
signals, all cultures generated clear Ca2+ peaks with many of the examined ROIs 
demonstrating synchronicity (Fig. 7-33 to 7-36).  Examination of the untreated D60 
neuronal cultures identified several Ca2+ peaks during the 200s measurement 
(indicated by black arrows) (Fig. 7-33A). Fluorescence peaks appeared at regular 
intervals throughout the measurement, suggesting an oscillatory behaviour for the 
Ca2+ signals, with several ROIs demonstrating synchronicity by peaking at 
simultaneous times (Fig. 7-33A). Of the observed ROIs in the untreated D60 
cultures, 50% of the ROIs generated a Ca2+ peak that exceeded 1.62 in height 
 278 Chapter 7: Unravelling mechanisms of HSPG-mediated control of human neurogenesis 
demonstrating a clear increase when compared with the D40 timepoint (Fig. 7-33A).  
D60 neuronal cultures treated with +Hep also exhibited oscillatory Ca2+ signals with 
multiple Ca2+ peaks detected throughout the measurement (indicated by black 
arrows) (Fig. 7-33B). Reduced synchronicity between selected ROIs was observed at 
the beginning of the measurement with single ROIs generating Ca2+ peaks, followed 
by the observation of several synchronised peaks as time progressed (Fig. 7-33B). Of 
the studied ROIs, 40% generated a Ca2+ peak that exceeded 1.62 in height (Fig. 7-
33B). 
 
 
Figure 7-33: Detection of calcium oscillations at day 60 in hNSC H9-derived neuronal cultures 
without or with heparin treatment. A representative fluorescence image along with fluorescence 
intensity (FI) graph of the calcium indicator Fluo-4 (green) in A) untreated or B) heparin-treated 
hNSC H9-derived neuronal cultures at day 60. Fluorescence image demonstrates selected regions of 
interest (ROIs) with ROIs, along with percentage that generated a Ca2+ peak over 1.62 marked in 
yellow. Line graph indicates fluorescence intensity (FI) for each ROI at each timepoint. FI of Fluo-4 
was measured for 200s at 0.8s intervals (251 timepoints) and FI of each timepoint was normalised to 
FI of timepoint 1 (FI0) and presented as FI/FI0. Black arrows indicate FI peaks. 
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Similar to untreated and +Hep treated D60 neuronal cultures, oscillatory Ca2+ waves 
were observed in +BDNF and +BDNF+Hep treated D60 neuronal cultures (Fig. 7-
34). The +BDNF and +BDNF+Hep cultures exhibited multiple Ca2+ signalling peaks 
(indicated by black arrows) during the 200s measurement (Fig. 7-34). The onset of 
Ca2+ signalling peaks between +BDNF and +BDNF+Hep treated cultures was 
slightly different with +BDNF+Hep treated neuronal cultures demonstrating a later 
onset of Ca2+ signalling peaks when compared to the +BDNF treated cultures (Fig. 7-
34). After approximately 125s of measurement, multiple synchronised Ca2+ 
signalling was observed in the +BDNF treated cultures, however, surprisingly none 
of the ROIs examined generated a  Ca2+ signal exceeding 1.62 in height (Fig. 7-34A). 
Similarly, in the +BDNF+Hep treated cultures synchronised Ca2+ signalling was 
observed toward the end of the measurement period with 40% of the examined ROIs 
exceeding 1.62 in height (Fig. 7-34B). 
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Figure 7-34: Detection of calcium oscillations at day 60 in hNSC H9-derived neuronal cultures 
treated with BDNF or BDNF+heparin. A representative fluorescence image along with 
fluorescence intensity (FI) graph of the calcium indicator Fluo-4 (green) in hNSC H9-derived day 60 
neuronal cultures treated with A) +BDNF or B) +PDGF+heparin. Fluorescence image demonstrates 
selected regions of interest (ROIs) with ROIs, along with percentage that generated a Ca2+ peak over 
1.62 marked in yellow. Line graph indicates fluorescence intensity (FI) for each ROI at each 
timepoint. FI of Fluo-4 was measured for 200s at 0.8s intervals (251 timepoints) and FI of each 
timepoint was normalised to FI of timepoint 1 (FI0) and presented as FI/FI0. Black arrows indicate FI 
peaks. 
 
D60 neuronal cultures treated with +PDGF and +PDGF+Hep exhibited multiple 
synchronised peaks (indicated by black arrows) throughout the 200s measurement 
time indicating synchronicity of the oscillatory Ca2+ signal (Fig. 7-35). Neuronal 
cultures treated with +PDGF demonstrated highly synchronous Ca2+ peaks during the 
first half of the measurement period with several single cells observed to generate 
signalling peaks toward the end of the measurement (Fig. 7-35A). Interestingly, 85% 
of the examined ROIs generated a Ca2+ signalling peak higher than 1.62 (Fig. 7-
35A). Similar to this, cultures treated with +PDGF+Hep exhibited several regularly 
occurring synchronised signal peaks during the first half of the measurement (Fig. 7-
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35B). Several lower signal peaks generated by one or two ROIs were observed at the 
later stage of the measurements in neuronal cultures treated in the +PDGF+Hep 
cultures (Fig. 7-35B). A lower percentage (65%) of ROIs generating a peak 
exceeding 1.62 in height was observed in the +PDGF+Hep treated cultures when 
compared to the +PDGF alone cultures (Fig. 7-35B). 
 
 
Figure 7-35: Detection of calcium oscillations at day 60 in hNSC H9-derived neuronal cultures 
treated with PDGF or PDGF+heparin. A representative fluorescence image along with 
fluorescence intensity (FI) graph of the calcium indicator Fluo-4 (green) in hNSC H9-derived day 60 
neuronal cultures treated with A) +PDGF or B) +PDGF+heparin. Fluorescence image demonstrates 
selected regions of interest (ROIs) with ROIs, along with percentage that generated a Ca2+ peak over 
1.62 marked in yellow. Line graph indicates fluorescence intensity (FI) for each ROI at each 
timepoint. FI of Fluo-4 was measured for 200s at 0.8s intervals (251 timepoints) and FI of each 
timepoint was normalised to FI of timepoint 1 (FI0) and presented as FI/FI0. Black arrows indicate FI 
peaks. 
 
Interestingly, when D60 neuronal cultures treated with +BDNF+PDGF were 
examined, only a few clear Ca2+  signalling peaks (indicated by black arrows) were 
observed in the representative measurement (Fig. 7-36A). Several of the ROIs 
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demonstrated synchronised peak formation, however, a large number of the 
examined ROIs did not generate any Ca2+ signal peaks during the measurement (Fig. 
7-36A) with none of the examined ROIs observed to generate a peak higher than 
1.62 (Fig. 7-36A). Neuronal cultures treated with +BDNF+PDGF+Hep demonstrated 
several Ca2+ signalling peaks (indicated by black arrows) during the 200s 
measurement suggesting similar oscillatory Ca2+ signalling behaviour to that 
observed in the other D60 neuronal cultures (Fig. 7-36B). A high level of signal 
synchronicity was observed within the peaks during the midpoint of the signal 
measurement (Fig. 7-36B). In contrast to the +BDNF+PDGF treated neuronal 
cultures, 50% of the examined ROIs in the +BDNF+PDGF+Hep treated cultures 
generated Ca2+ signalling peaks observed to be higher than 1.62 (Fig. 7-36B). 
 
Figure 7-36: Detection of calcium oscillations at day 60 in hNSC H9-derived neuronal cultures 
treated with BDNF+PDGF or BDNF+PDGF+heparin. A representative fluorescence image along 
with fluorescence intensity (FI) graph of the calcium indicator Fluo-4 (green) in hNSC H9-derived 
day 60 neuronal cultures treated with A) +BDNF+PDGF or B) +BDNF+PDGF+heparin. Fluorescence 
image demonstrates selected regions of interest (ROIs) with ROIs, along with percentage that 
generated a Ca2+ peak over 1.62 marked in yellow. Line graph indicates fluorescence intensity (FI) for 
each ROI at each timepoint. FI of Fluo-4 was measured for 200s at 0.8s intervals (251 timepoints) and 
FI of each timepoint was normalised to FI of timepoint 1 (FI0) and presented as FI/FI0. Black arrows 
indicate FI peaks. 
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7.4 SUMMARY AND DISCUSSION OF PART A 
 
The results of the first part of this Chapter demonstrate that in vitro neuronal 
differentiation of hNSC H9 cells can be modulated through the addition of 
exogenous HS (heparin) and key HS-binding growth factors (BDNF and PDGF). 
These results support previous studies, which have demonstrated that in vitro heparin 
supplementation stimulates the growth and differentiation of numerous human cell 
types (Furue et al., 2008; Okolicsanyi et al., 2014b; Simann et al., 2015; Zhang & 
Zhang, 2010) and that BDNF and PDGF modulate neuronal survival and 
differentiation, respectively (D'Aiuto et al., 2014; Liu et al., 2014; Wei et al., 2015; 
Yang et al., 2013; Yao et al., 2012). The results presented here are the first to 
comprehensively examine and characterise the effects of heparin, BDNF, PDGF and 
BDNF+PDGF supplementation during hNSC in vitro neuronal differentiation in 
terms of culture morphology, viability, proliferation and lineage-specificity from 
D40 to D60 of culture. The results here show that neuronal cultures produced in the 
presence of BDNF and PDGF in vitro are phenotypically different and that 
combining heparin with BDNF and PDGF further modulates growth factor 
responses. These results have potential key implications for the optimisation of 
human neuron differentiation protocols.  
 
When culture morphology was examined, hNSC H9 neuronal cultures differentiated 
in the presence of BDNF and PDGF were morphologically different to untreated 
neuronal cultures, indicated by differences in cell number, the number and size of 
sphere structures as well as the length and thickness of sphere-connecting protrusions 
present in the cultures. During extended culture, hNSC H9 cultures treated with 
BDNF demonstrated increased cell number supporting neuronal survival promoting 
effects of BDNF. In contrast, PDGF did not seem to have similar neuronal growth 
promoting effects to BDNF, as during differentiation PDGF supplemented cultures 
generally contained fewer cells than the BDNF treated cultures (Fig. 3 Appendix G). 
Interestingly, cultures exposed to BDNF or PDGF with and without the addition of 
heparin exhibited more extensive networks of spheres and sphere-connecting 
protrusions when compared to the other culture conditions at D60. These networks 
resembled the in vivo formation of neuronal circuits as demonstrated in vitro with 
 284 Chapter 7: Unravelling mechanisms of HSPG-mediated control of human neurogenesis 
human embryonic stem cell-derived NSCs and rat hippocampal neural progenitor 
cells grown on neural extracellular matrix substrate (Garcia-Parra et al., 2013; Koch 
et al., 2009), indicating a positive effect for BDNF and PDGF on the formation of 
these networks. BDNF has been shown to have a modulatory effect on rodent neuron 
morphology, including dendritic spine maturation and axonal branching (Chapleau et 
al., 2008; Danzer et al., 2002; Kellner et al., 2014) and the ablation of PDGF receptor 
β (PDGFRβ) in the mouse CNS has been shown to result in decreased dendritic spine 
and hippocampal density (Shioda et al., 2012), potentially explaining the network 
formation promoting effects of BDNF and PDGF. Staining of single neurons with an 
intracellular marker, including biocytin, along with axonal, dendritic or synaptic 
markers would allow the examination of the effects of BDNF and PDGF on cell 
morphology at a single cell level, potentially revealing key effects of these growth 
factors on neuronal morphology (Marx et al., 2012; Mohan et al., 2015; Schmitz et 
al., 2011). The structural differences between the culture conditions likely reflect key 
differences in cellular composition of the cultures, having potential implications on 
downstream use of the cells. Interestingly, cultures treated with the combination of 
BDNF and PDGF did not exhibit similar extensive networks of spheres and sphere-
connecting protrusions to those observed in the BDNF- or PDGF-only treated 
culture. This suggests the combination of BDNF or PDGF may compete for 
influence over cell behaviour rather than provide a co-ordinated signalling 
environment for neuron maturation, not supporting their combined use. 
 
Interestingly, heparin, BDNF and PDGF (without or with heparin) supplementation 
was shown to promote viability of hNSC H9 neuronal differentiating cultures 
following 40 days of differentiation, indicated by a reduced level of PI+ cells when 
compared to the untreated cultures, further supporting the cell survival promoting 
effects of these supplements outlined above. Interestingly, prolonged exposure of 
heparin and the growth factors did not beneficially affect neuronal viability, with 
D60 cultures demonstrating no clear difference in PI+ cells between the untreated 
and heparin/growth factor treated neuronal cultures. This may be due to the high 
number of sphere structures observed in the BDNF and PDGF treated cultures, which 
are known contain a higher number of non-viable cells when compared to areas of 
monolayer cells, resulting from a decreased accessibility to nutrients (Li et al., 2012). 
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Thus to ensure maintained viability, it is likely important to control the size of the 
spheres generated, which may be achieved by altering the concentrations of  BDNF 
and PDGF or withdrawing them from the culture medium at an appropriate time. 
Passaging of the neuronal cultures is also an option to reduce sphere size, however, 
this is likely not feasible due to the fragile nature of neuronal cells.   
 
Interestingly, actively proliferating (Ki67+) and neuronal marker (MAP2) expressing 
cells were maintained in all neuronal differentiating cultures when examined at the 
D60 timepoint suggesting continued active neurogenesis (Ansorg et al., 2012; Ernst 
et al., 2014).  Specifically, heparin, BDNF and BDNF+heparin supplementation was 
shown to significantly increase the number of proliferative cells within the neuronal 
cultures when compared to the untreated neuronal cultures at D40 and D60. 
Interestingly, combining heparin with BDNF further enhanced the proliferation 
stimulating effects of BDNF alone, suggesting an interaction between heparin and 
BDNF. Neuronal cultures supplemented with PDGF exhibited a similar level of 
Ki67+ cells as untreated neuronal cultures, suggesting PDGF did not mediate 
neuronal proliferation similarly to BDNF. While a level of proliferation is important 
to maintain for continued expansive potential, it may also affect differentiation 
efficiency. Thus, both BDNF and PDGF supplementation may have beneficial 
effects on neuronal differentiation with this depending whether an increased cell 
number or enhanced lineage commitment is required. 
 
Differentiation efficiency of the hNSC H9-derived neuronal cultures was assessed by 
examining neuronal marker expression. Multiple significant differences were 
observed between untreated and heparin/growth factor treated cultures, suggesting a 
modulatory effect of the used treatments on neuronal lineage specification. 
Interestingly, prolonged heparin exposure exhibited a stimulatory effect on neuronal 
marker expression, as following 60 days heparin treated cultures expressed an 
induced level of TUBB3 and DCX when compared to untreated cultures. These 
results suggest a stimulatory effect for heparin on neuronal lineage commitment, 
supporting its use as a supplement in human stem cell neuronal differentiation 
protocols (Forsberg et al., 2012; Zhang & Zhang, 2010). The beneficial effects of 
heparin are likely achieved through its ability to bind HS-binding molecules, 
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including growth factors, in the extracellular space resulting in enhanced downstream 
signalling (Forsten et al., 2000). Importantly, the results here show that heparin 
supplementation alters gene expression, which is rarely investigated and an important 
consideration in protocols where heparin is used. 
 
Interestingly, treatment of the neuronal cultures with BDNF and PDGF had 
differential effects on neuronal marker gene expression. Surprisingly, when 
examined at D60, BDNF and BDNF+heparin supplementation downregulated the 
expression of neuronal marker genes when compared to the untreated cultures. A 
similar effect was already observed in Chapter 6, following D40 of differentiation. 
Interestingly, however, BDNF and BDNF+heparin did not increase SOX2 or S100B 
expression, indicating that the reduced neuronal marker expression was not 
associated with a higher maintenance of self-renewing cells or a higher presence of 
astrocyte differentiating cells. Thus, explaining lower level of expression of the 
studied neuronal markers may be differences in neuronal progenitor, immature 
neuron or neuron subtype composition within BDNF and untreated cultures. This 
hypothesis is supported by previous research where a link between BDNF and the 
generation of γ-aminobutyric acid (GABA)ergic neurons has been reported (Silva et 
al., Rego, 2009) and the examination of neuron subtype-specific markers would be 
important in further investigating this. With BDNF a common stimulatory 
supplement of neuronal differentiation protocols, it is important to understand its 
effects on neuronal lineage specificity.   
 
In contrast to BDNF, supplementation of PDGF and PDGF+heparin induced the 
expression of TUBB3 and MAP2 genes at D40 and at D60 these cultures expressed a 
similar level of TUBB3 and DCX when compared to the untreated neuronal cultures. 
These results suggest that in contrast to BDNF, PDGF stimulates the expression of 
some of the neuronal markers, likely regulating differentiating neurons via a different 
pathway to BDNF. Importantly, when examined at D60, SOX2 and S100B 
expression was not induced in cultures treated with PDGF and PDGF+heparin, 
indicating that similarly to BDNF, PDGF did not promote the maintenance of self-
renewing NSCs or stimulate astrocyte differentiation.  It is thus likely that PDGF 
promotes the generation of a different neuron subtype to BDNF, with this an 
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interesting area of research to further elucidate the effects of this growth factor.  
Finally, cultures differentiated in the presence of BDNF+PDGF exhibited neuronal 
marker expression similar to BDNF-only cultures, suggesting a dominant effect for 
BDNF over PDGF. No differential effect of BDNF+PDGF to BDNF alone was 
observed, indicating that the combined use of these growth factors is not supported.   
 
To examine the functionality of the neuronal cultures generated in this study, the 
occurrence of spontaneous Ca2+ signals within these cultures was investigated. The 
generation of spontaneous and synchronised Ca2+ oscillations is a characteristic of 
rodent neuronal cultures in vitro and is associated with action potential generation 
(Hemstapat et al., 2004; Pacico & Mingorance-Le Meur, 2014). Interestingly, 
spontaneous Ca2+ signals were detected in all the neuronal culture conditions, 
specifically at D60, indicating spontaneous activity and functionality of the cultures. 
Importantly, some of the signals observed in the neuronal cultures demonstrated 
synchronicity and exhibited a higher change in fluorescence intensity than those 
observed in basal hNSC H9 cultures, suggesting differential cellular behaviour of 
neuronal differentiating cultures than undifferentiated hNSC H9 cells. Interestingly, 
differences in the generation of Ca2+ signalling spikes between the different culture 
conditions were observed, suggesting effects of the in vitro modulations on neuronal 
functionality.  The most prominent effect was observed in the PDGF and 
PDGF+heparin treated cultures, which contained the highest proportion (65-85%) of 
cells that generated Ca2+ spikes differing from basal hNSC H9 cells. These results 
suggest that the presence of PDGF and PDGF+heparin in the culture medium 
promotes neuronal functionality. However, in order to prove that these oscillations 
are indeed action potential-mediated, further investigation is required, such as 
exposing the cells to a voltage-gated sodium channel blocker (Dravid & Murray, 
2004). Another important focus would be to examine spontaneous Ca2+ signalling in 
hNSC H9-derived astrocyte cultures.  Astrocytes are known to demonstrate a high 
level of Ca2+ signalling, with this largely occurring in response to sensory stimuli, 
including neuron activity (Navarrete et al., 2013; Volterra et al., 2014). Comparison 
of Ca2+ signalling between hNSC H9-derived neuron and astrocyte cultures would 
allow the distinction between glia versus neuronal Ca2+ signals and confirm that the 
Ca2+ signals generated in this study were indeed associated with neuronal 
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functionality and not astrocyte functionality. While a link between action potentials 
and Ca2+ signals was not established in this study, support for neuronal functionality 
arises from the obtained time-lapse videos which demonstrate a spike-like pattern for 
Ca2+ signals in the hNSC H9-derived neuronal cultures, clearly differing from Ca2+ 
signals observed in undifferentiated hNSC H9 and non-neuronal MCF-7 cells 
(Digital attachment - USB-drive, Appendix H). Importantly, the observations of this 
study highlight the importance of studying spontaneous activity of human neuronal 
cultures, with this a complex area of research. Napoli and Obeid recently reported 
that human neurons exhibit differential electrical activity in comparison to rodent 
neurons, contributing to challenges in spontaneous activity measurements in human 
cells (Napoli & Obeid, 2016). In this study rodent and human neuronal cultures 
behaved highly differently, with human neuron cultures requiring almost 40 days to 
achieve any level of electrical function that remained at a markedly lower level to 
that generated by rat neurons after 10 days (Napoli & Obeid, 2016). In addition, 
human neurons were shown to lack co-ordinated network activity, with rat neurons 
shown to be highly synchronised (Napoli & Obeid, 2016). This highlights the 
challenge of examining human neuronal network activity as well as applying rodent-
based models to the human system.  
 
In conclusion, the addition of heparin, BDNF and PDGF to neuronal differentiating 
hNSC H9 cultures modulated cell viability, proliferation, lineage-specific marker 
expression and spontaneous activity of the cultures. BDNF clearly promoted survival 
and proliferation of differentiating human neurons with heparin further stimulating 
the effects of BDNF. In contrast, PDGF did not promote viability or proliferation 
when compared to untreated neuronal cultures, however, PDGF treated cultures 
maintained the expression of neuronal markers that were downregulated in the 
presence of BDNF. Interestingly, PDGF and PDGF+heparin promoted neuronal 
functionality with these cultures containing the highest proportion cells that 
generated Ca2+ spikes that differed from undifferentiated hNSC H9 cells.  The 
combined treatment of cultures with BDNF and PDGF did not have any benefit 
above the addition of BDNF and PDGF alone, not supporting their use in 
combination to promote human neurogenesis. These results suggest that optimal 
human neurogenesis may be achieved by modulating the concentration and timing of 
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BDNF and PDGF administration, such as first culturing hNSC-derived 
differentiating neurons under BDNF+heparin to promote cell number and survival, 
followed by a switch to PDGF to promote the generation of action potential evoking 
neurons. Finally, the investigation of specific neuron subtypes generated under 
BDNF and PDGF would allow for better understanding of the cell composition 
within these cultures and enable the development of neuron subtype-specific 
differentiation protocols.    
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7.5 RESULTS PART B: EXAMINATION OF GLYPICANS 1 AND 4 AS 
REGULATORY PROTEINS OF NEURONAL COMMITMENT  
 
Glypican 1 (GPC1) and glypican 4 (GPC4) were previously identified in this study 
(Chapters 4-6) as potential key HSPGs of hNSC regulation. GPC1 and GPC4 genes 
demonstrated high expression level in undifferentiated hNSC H9 cells in comparison 
to other GPCs (Chapter 4) with neural lineage commitment significantly 
upregulating the expression of these HSPGs (Chapters 5 and 6). Due to these 
findings, the final aim of this research was to more closely examine the expression of 
GPC1 and GPC4 in hNSC-derived neuronal cultures and specifically their potential 
role in mediating BDNF- or PDGF signalling efficiency. Expression of GPC1 and 
GPC4 along with BDNF and PDGF pathway ligands and receptors was examined in 
D40 and D60 hNSC H9-derived neuronal differentiating cultures. Following this, 
GPC1 and GPC4 were downregulated by siRNAs under neuronal differentiating 
conditions to determine if there was an altered response to exogenous BDNF and 
PDGF. To establish a link between GPC1 and GPC4 with the BDNF and PDGF 
pathways, neuronal differentiating hNSC H9 cells were also examined under BDNF 
and PDGF pathways inhibitory conditions to identify any correlations with GPC1 
and GPC4 downregulated conditions.  
 
7.5.1.1 Expression of GPC1 and GPC4 in neuronal differentiating hNSC H9 
cells 
 
To gain insight into the expression of GPC1 and GPC4 during human neuronal 
differentiation, these HSPGs were detected in the D40 and D60 neuronal 
differentiating hNSC H9 cultures examined in Part A of this Chapter. Gene 
expression levels of GPC1 and GPC4 in hNSC H9 neuronal cultures were examined 
and any statistically significant differences in GPC1 and GPC4 expression between 
untreated and heparin/growth factor treated culture conditions determined using 
Student’s t-test.  
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Both GPC1 and GPC4 were shown to be expressed at the gene expression level in 
D40 and D60 neuronal differentiating cultures, indicating the maintained expression 
of these HSPGs during neuronal differentiation (Fig. 7-37). As previously 
demonstrated (Chapter 6), GPC1 expression was significantly downregulated in the 
D40 neuronal differentiating cultures treated with +Hep (p=0.02), +BDNF 
(p=0.0003) and +BDNF+Hep (p<0.0001) when compared to untreated neuronal 
cultures (Fig. 7-37A). When neuronal cultures treated with +PDGF and +PDGF+Hep 
were examined, a similar level of GPC1 expression was detected to the untreated 
D40 neuronal cultures (Fig. 7-37A). Interestingly, neuronal cultures treated with  
+BDNF+PDGF (p=0.0003) and +BDNF+PDGF+Hep (p=0.0002) expressed a 
significantly lower level of GPC1 when compared to the untreated D40 neuronal 
cultures, suggesting +BDNF supplementation may contribute to decreased GPC1 
expression (Fig. 7-37A). When the expression of GPC4 in D40 neuronal 
differentiating cultures was examined, fewer differences in its expression were 
observed between the different culture conditions (Fig. 7-37A). As previously 
demonstrated (Chapter 6), +BDNF+Hep treated neuronal cultures demonstrated 
significantly (p=0.047) reduced expression of GPC4 when compared to untreated 
D40 neuronal cultures with +BDNF+Hep treated cultures expressing a significantly 
(p=0.01) lower level of GPC4 when compared to +BDNF only treated cultures (Fig. 
7-37A). This trend was consistent with lower GPC4 expression in the +Hep, 
+BDNF, +PDGF, +PDGF+Hep, +BDNF+PDGF and +BDNF+PDGF treated cultures 
when compared to untreated D40 neuronal cultures, however, the difference in 
expression was not shown to be significant (Fig. 7-37A). 
 
Examination of the D60 neuronal differentiation cultures demonstrated similarities in 
gene expression for GPC1 and GPC4 when compared to the D40 neuronal cultures 
(Fig. 7-37B). Similar to the D40 timepoint, at D60 the addition of +Hep (p=0.045) 
and +BDNF (p=0.04) to the neuronal cultures resulted in a significantly decreased 
level of GPC1 when compared to the untreated neuronal cultures (Fig. 7-37B). 
Cultures treated with +PDGF (p=0.04), +PDGF+Hep (p=0.03), +BDNF+PDGF 
(p=0.03) and +BDNF+PDGF+Hep (p=0.03) were also shown to express a 
significantly downregulated level of GPC1 when compared to the untreated D60 
neuronal cultures (Fig. 7-37B). Interestingly, conversely to the D40 timepoint, at 
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D60 neuronal cultures treated with the combination of +BDNF+Hep maintained a 
similar level of GPC1 expression when compared to the untreated neuronal cultures 
and expressed a significantly increased (p=0.04) level of GPC1 when compared to 
the +BDNF only treated cultures (Fig. 7-37B). A similar response was observed in 
the cultures treated with +BDNF+PDGF+Hep, which were shown to express a 
significantly upregulated (p=0.01) level of GPC1 when compared to the 
+BDNF+PDGF treated cultures (Fig. 7-37B). In contrast, cultures treated with 
+PDGF+Hep expressed a significantly reduced (p=0.003) level of GPC1 when 
compared to the +PDGF only cultures (Fig. 7-37B). When GPC4 gene expression 
was examined in the D60 neuronal differentiating cultures, expression was not 
significantly altered following addition of +Hep, +BDNF, or +BDNF+Hep to the 
cultures (Fig. 7-37B).  In contrast, GPC4 expression was significantly downregulated 
in cultures treated with +PDGF (p=0.02), +PDGF+Hep (p=0.02) and +BDNF+PDGF 
(p=0.03) when compared to the untreated D60 neuronal cultures (Fig. 7-37B).  These 
results suggested that GPC1 and GPC4 expression is altered following BDNF and 
PDGF treatments.  
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Figure 7-37: Glypican 1 and 4 expression in neuronal differentiating hNSC H9 cells cultured 
under untreated or heparin and growth factor treated conditions for 40 and 60 days. Relative 
gene expression of glypican 1 (GPC1) and glypican 4 (GPC4) following neuronal differentiation of 
hNSC H9 cells under untreated, heparin (Hep), BDNF, BDNF+Hep, PDGF, PDGF+Hep, 
BDNF+PDGF or BDNF+PDGF+Hep-treated conditions for A) 40 and B) 60 days. (Error bars = SD 
for +BDNF+PDGF D60, other error bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** 
p<0.001). Black lines indicate statistically significant differences between treated and untreated 
neuronal conditions. Red lines indicate statistically significant differences between Hep-treated and 
non-Hep-treated growth factor-modulated conditions. 
 
Following confirmation that D40 and D60 neuronal differentiating hNSC H9 cultures 
express GPC1 and GPC4 genes with the addition of Hep, BDNF and PDGF to the 
cultures altering the expression of these HSPGs, confocal microscopy was used to 
further investigate their expression and localisation in D40 and D60 neuronal 
differentiating hNSC H9 cultures (Fig. 7-38 to 7-41). GPC1/GPC4 co-staining was 
performed to examine and compare similarities and differences in expression and 
localisation of these two HSPGs. At D40 of neuronal differentiation the expression 
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pattern differed for the two GPCs with GPC1 demonstrating a punctate expression 
pattern while GPC4 was more uniformly expressed within the cells (Fig. 7-38 and 7-
39).  The punctate expression pattern of GPC1 was particularly evident in the 
+BDNF+Hep, +PDGF and +PDGF+Hep treated D40 neuronal cultures (Fig. 7-38B 
and 7-39A). When the localisation of GPC1 and GPC4 was examined, cell 
membrane-associated localisation for GPC1 and GPC4 was evident in all the D40 
neuronal culture conditions with GPC1 and GPC4 predominantly localising to 
neurites of differentiating neurons (Fig. 7-38 and 7-39). However the localisation of 
GPC1 and GPC4 differed in specific areas within the cultures, with the differential 
localisation of GPC1 and GPC4 particularly evident in GPC1/GPC4 merge images 
where GPC1 (yellow) and GPC4 (green) could be clearly distinguished from each 
other. The different localisation patterns of GPC1 and GPC4 were most evident in 
the +Hep and +BDNF treated D40 neuronal cultures, where large areas were 
observed to be only GPC1-positive or GPC4-positive (Fig. 7-38). In the +Hep treated 
D40 neuronal cultures GPC1 appeared to be localised ubiquitously within cell bodies 
while GPC4 appeared to cluster in areas of cell-cell contacts (Fig. 7-38A). GPC1 also 
localised to cell bodies in the +BDNF treated D40 cultures while GPC4 appeared to 
localise to the thin neuronal protrusions, or neurites visible within these cultures (Fig. 
7-38B). Strong GPC1 expression in the +BDNF+PDGF and +BDNF+PDGF+Hep 
treated D40 neuronal cultures was also evident, however, due to high cell density in 
areas of high GPC1 or GPC4 expression, the signal was difficult to distinguish 
between the two HSPGs (Fig. 7-39B). 
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Figure 7-38: Glypican 1 and 4 expression at day 40 of neuronal differentiation of hNSC H9 cells 
cultured under untreated and BDNF-treated conditions without and with heparin. Confocal 
microscopy of glypican 1 (GPC1, yellow) and glypican 4 (GPC4, green) along with DAPI (blue) 
counterstain (63X magnification, scale bar 37 μM). Images are representative of hNSC H9 cells 
cultured under A) untreated or B) BDNF-treated neuronal differentiating conditions without and with 
heparin for 40 days. 
 
 
 
 296 Chapter 7: Unravelling mechanisms of HSPG-mediated control of human neurogenesis 
 
Figure 7-39: Glypican 1 and 4 expression at day 40 of neuronal differentiation of hNSC H9 cells 
cultured under PDGF- and BDNF+PDGF-treated conditions without and with heparin. 
Confocal microscopy of glypican 1 (GPC1, yellow) and glypican 4 (GPC4, green) along with DAPI 
(blue) counterstain (63X magnification, scale bar 37 μM). Images are representative of hNSC H9 cells 
cultured under A) PDGF- or B) BDNF+PDGF-treated neuronal differentiating conditions without and 
with heparin for 40 days. 
 
Confocal imaging of GPC1 and GPC4 in the D60 neuronal differentiating hNSC H9 
cultures revealed the cells maintained expression of these HSPGs (Fig. 7-40 and 7-
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41). Similar to the D40 neuronal cultures, differential expression and localisation was 
observed for GPC1 and GPC4 at D60 of differentiation (Fig. 7-40 and 7-41). As 
observed in the D40 neuronal cultures, GPC1 demonstrated a punctate expression 
pattern in all the D60 neuronal cultures while the GPC4 expression pattern was more 
uniform (Fig. 7-40 and 7-41). Areas of differential localisation of GPC1 and GPC4 
were more evident in the D60 cultures than in the D40 cultures and easily identified. 
All D60 neuronal culture conditions demonstrated areas of strong GPC1 expression 
that contained low or absent GPC4 expression or areas of strong GPC4 expression 
that contained low or absent GPC1 expression (Fig. 7-40 and 7-41). The areas where 
GPC1 expression was low or absent with GPC4 expression detected, or areas where 
GPC4 expression was low or absent with GPC1 expression detected, are indicated by 
white arrows in the representative images in all D60 neuronal culture conditions (Fig. 
7-40 and 7-41). Interestingly, GPC1 and GPC4 localised along thin elongated 
neurites in the D60 neuronal cultures, clearly evident in the untreated and +Hep 
treated cultures (Fig. 7-40A). In the untreated and +BDNF treated D60 neuronal 
cultures GPC1 appeared to localise within the larger cell bodies with GPC4 absent 
from these areas (indicated by a white arrow in the GPC1/DAPI image) (Fig. 7-40B). 
In the +BDNF+Hep cultures GPC1 and GPC4 were both localised within the larger 
cell bodies, however, GPC4 was clearly more extensively expressed in finely 
structured neurite networks than GPC1 (indicated by a white arrow the in the 
GPC4/DAPI image) (Fig. 7-40B). In the +PDGF and +PDGF+Hep treated cultures 
these finely structured networks appeared to be GPC4 positive and GPC1 negative 
(indicated by a white arrow in the GPC4/DAPI image) (Fig. 7-41A). In the 
+BDNF+PDGF and +BDNF+PDGF+Hep cultures GPC1 and GPC4 both localised to 
larger-sized cell bodies within the cultures, however, several thin neuronal 
protrusions appeared to be more highly GPC4 positive (indicated by a white arrow in 
the GPC4/DAPI image) (Fig. 7-41B).  
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Figure 7-40: Glypican 1 and 4 expression at day 60 of neuronal differentiation of hNSC H9 cells 
cultured under untreated and BDNF-treated conditions without and with heparin. Confocal 
microscopy of glypican 1 (GPC1, yellow) and glypican 4 (GPC4, green) along with DAPI (blue) 
counterstain (63X magnification, scale bar 37 μM). Images are representative of hNSC H9 cells 
cultured under A) untreated or B) BDNF-treated neuronal differentiating conditions without and with 
heparin for 60 days. In GPC1/DAPI images white arrows indicate areas of strong GPC1 expression 
where GPC4 expression is low or absent and in GPC4/DAPI images white arrows indicate areas of 
strong GPC4 expression where GPC1 expression is low or absent. 
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Figure 7-41: Glypican 1 and 4 expression at day 60 of neuronal differentiation of hNSC H9 cells 
cultured under PDGF- and BDNF+PDGF-treated conditions without and with heparin. 
Confocal microscopy of glypican 1 (GPC1, yellow) and glypican 4 (GPC4, green) along with DAPI 
(blue) counterstain (63X magnification, scale bar 37 μM). Images are representative of hNSC H9 cells 
cultured under A) PDGF- or B) BDNF+PDGF-treated neuronal differentiating conditions without and 
with heparin for 60 days. In GPC1/DAPI images white arrows indicate areas of strong GPC1 
expression where GPC4 expression is low or absent and in GPC4/DAPI images white arrows indicate 
areas of strong GPC4 expression where GPC1 expression is low or absent 
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7.5.2 BDNF and PDGF pathway expression in neuronal differentiating hNSC 
H9 cultures 
 
Following examination of GPC1 and GPC4 expression in neuronal differentiating 
hNSC H9 cultures, the expression of the BDNF and PDGF pathway ligands and 
receptors was examined in these cultures. Similar to GPC1 and GPC4, the gene 
expression of BDNF and PDGF and their receptors Trkb and PDGFRβ, respectively, 
was first examined in the D40 and D60 neuronal cultures. To gain insight into the 
expression and localisation pattern of Trkb and PDGFRβ proteins, these were further 
examined via confocal microscopy in D40 and D60 neuronal differentiating hNSC 
H9 cultures.  
 
7.5.2.1 Expression of the BDNF pathway in hNSC H9 neuronal differentiating 
cultures  
 
The gene expression of the BDNF ligand as well as the BDNF receptor Trkb was 
examined in D40 and D60 hNSC H9 neuronal differentiating cultures. All neuronal 
culture conditions at D40 and D60 expressed BDNF and Trkb (Fig. 7-42). The D40 
neuronal cultures treated with +Hep or +BDNF did not demonstrate altered 
expression of BDNF when compared to the untreated D40 neuronal cultures (Fig. 7-
42A). In contrast, neuronal cultures treated with +BDNF+Hep expressed a 
significantly decreased level of BDNF when compared to the untreated (p=0.04) and 
+BDNF only treated (p=0.04) D40 cultures (Fig. 7-42A). Neuronal cultures treated 
with +PDGF (p=0.02) and +PDGF+Hep (p=0.01) expressed a significantly increased 
level of BDNF with the +BDNF+PDGF (p=0.006) and +BDNF+PDGF+Hep 
(p=0.006) treated cultures both expressing a significantly reduced level of BDNF 
when compared to the untreated D40 neuronal cultures (Fig. 7-42A). When the 
expression of Trkb was examined, cultures treated with +Hep did not exhibit altered 
Trkb gene expression when compared to the untreated D40 neuronal cultures (Fig. 7-
42A). Interestingly, the +BDNF (p=0.02) and +BDNF+Hep (p=0.03) cultures where 
shown to express a significantly higher level of Trkb when compared to the untreated 
D40 neuronal cultures (Fig. 7-42A). Similarly, the addition of +PDGF (p<0.0001) 
and +PDGF+Hep (p=1.5e-8) to the neuronal cultures resulted in a highly 
significantly induced level of Trkb expression when compared to the untreated D40 
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neuronal cultures (Fig. 7-42A). A similar response was observed in cultures treated 
with the combinations of +BDNF+PDGF (p<0.001) and +BDNF+PDGF+Hep 
(p<0.001) with highly upregulated Trkb expression observed when compared to the 
untreated D40 neuronal cultures (Fig. 7-42A). Interestingly, the addition of heparin 
with BDNF appeared to have inhibitory effect on BDNF pathway expression with 
the +BDNF+Hep treated cultures expressing a significantly (p=0.04) lower level of 
BDNF when compared to the +BDNF only treated cultures (Fig. 7-42A). A similar 
effect was observed in the +PDGF treated cultures with the +PDGF+Hep cultures 
expressing a significantly lower (p=0.0007) level of Trkb when compared to the 
+PDGF only treated cultures (Fig. 7-42A).   
 
When the D60 neuronal cultures were examined for BDNF expression, cultures 
treated with +Hep (p=0.047), +BDNF (p=0.04), +PDGF+Hep (p=0.03), 
+BDNF+PDGF (p=0.03) and +BDNF+PDGF+Hep (p=0.03) all expressed a 
significantly reduced level of BDNF when compared to the untreated D60 neuronal 
cultures (Fig. 7-42B). Interestingly, in contrast to observations made at the D40 
timepoint, cells cultured for 60 days in the presence of +BDNF+Hep maintained a 
similar level of BDNF expression to the untreated D60 neuronal cultures and 
expressed a significantly increased (p=0.049) level of BDNF when compared to the 
+BDNF only treated cultures  (Fig. 7-42B). In addition, cultures treated with 
+PDGF+Hep also exhibited a significantly reduced (p=0.003) BDNF gene 
expression when compared to the untreated D60 neuronal cultures and +PDGF only 
treated cultures (p=0.048) (Fig. 7-42B). Interestingly, when heparin was added to the 
+BDNF+PDGF cultures, a stimulatory effect was observed with the 
+BDNF+PDGF+Hep treated cultures expressing a significantly increased (p=0.001) 
level of BDNF when compared to the +BDNF+PDGF only treated cultures (Fig. 7-
42B). When the gene expression of Trkb was examined in the D60 cultures, the 
stimulatory effects of the growth factor treatments on Trkb expression observed in 
the D40 cultures were not replicated. In contrast, at D60 the +PDGF (p=0.02), 
+PDGF+Hep (p=0.02), +BDNF+PDGF (p=0.02) and +BDNF+PDGF+Hep (p=0.02) 
treatments resulted in the significant downregulation of Trkb expression when 
compared to the untreated D60 neuronal cultures (Fig. 7-42B). Trkb expression was 
further examined at the protein level in the D60 neuronal cultures via WB analysis. 
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Three bands of approximately 100 kDa, 55 kDa and 40 kDa in size were identified in 
all the culture conditions (Fig. 7-42C), with all of these Trkb bands shown to be 
present across mammalian species and the 55 kDa band corresponding to a truncated 
Trk isoform (Wessels et al., 2014). With the 100 kDa and 55 kDa protein bands most 
prominent, these were quantitated against a GAPDH loading control. Optical 
quantitation of the 100 kDa band revealed its expression was the highest in +PDGF 
treated neuronal cultures followed by +BDNF+Hep and +BDNF+PDGF+Hep treated 
neuronal cultures respectively (Fig. 7-42C). A slightly reduced expression of the 100 
kDa band when compared to the untreated D60 neuronal cultures was observed in the 
cultures treated with +Hep and BDNF (Fig. 7-42C). A similar expression level of the 
100 kDa band to the untreated D60 neuronal cultures was observed in cultures 
treated with +PDGF+Hep and +BDNF+PDGF (Fig. 7-42C). When the expression of 
the 55 kDa band was examined, it was expressed at similar level between the 
majority of the culture conditions (Fig. 7-42C). Similar to the 100 kDa band, 
neuronal cultures treated with +BDNF+PDGF demonstrated the highest level of 
expression of the 55 kDa band.  
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Figure 7-42: BDNF-pathway expression in neuronal differentiating hNSC H9 cells cultured 
under untreated or heparin and growth factor treated conditions for 40 and 60 days. Relative 
gene expression of brain-derived neurotrophic factor (BDNF) and the BDNF receptor Trkb following 
neuronal differentiation of hNSC H9 cells under untreated, heparin (Hep), BDNF, BDNF+Hep, 
PDGF, PDGF+Hep, BDNF+PDGF or BDNF+PDGF+Hep-treated conditions for A) 40 and B) 60 
days. (Error bar = SD for +BDNF+PDGF D60, other error bars = SEM, statistical significance: * 
p<0.05, ** p<0.01, *** p<0.001). Black lines indicate statistically significant differences between 
treated and untreated neuronal conditions. Red lines indicate statistically significant differences 
between Hep-treated and non-Hep-treated growth factor-modulated conditions. C) Western blot 
analysis of Trkb along with GAPDH loading control following culture of hNSC H9 cells under 
untreated, Hep, BDNF, BDNF+Hep, PDGF, PDGF+Hep, BDNF+PDGF or BDNF+PDGF+Hep-
treated culture conditions for 60 days. Optical quantitation was performed for 100 kDa and 55 kDa 
Trkb bands relative to GAPDH and is presented as bar graphs. 
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Expression and localisation of the Trkb receptor in D40 and D60 neuronal 
differentiating cultures was then examined using confocal microscopy. The NSC 
marker nestin was used as a structural marker due to its ubiquitous expression in 
neuronal differentiating hNSC H9 cells. Examination of Trkb via confocal 
microscopy revealed that Trkb was expressed in all neuronal differentiating culture 
conditions at both the D40 and D60 timepoints (Fig. 7-43 to 7-46). In the D40 
neuronal differentiating cultures Trkb demonstrated a degree of co-localisation with 
nestin (orange colour) indicating cytoplasmic and cell membrane-associated 
localisation of the two proteins (Fig. 7-43 and 7-44). This nestin/Trkb co-localisation 
was clearly evident in the +BDNF and +BDNF+Hep treated D40 neuronal cultures 
(Fig. 7-43B). Interestingly, Trkb also demonstrated areas of expression not 
associated with nestin (red colour) in all the D40 neuronal culture conditions (Fig. 7-
43 and 7-44). In the D40 differentiating neuronal cultures Trkb was largely expressed 
along cell neurites as was clearly evident in +BDNF and +PDGF treated cultures 
(Fig. 7-43 and 7-44). In addition, Trkb clustering was observed in areas of cell-cell 
contacts in the +BDNF+Hep, +PDGF+Hep and +BDNF+PDGF treated cultures (Fig. 
7-43B and 7-44). 
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Figure 7-43: Trkb expression at day 40 of neuronal differentiation of hNSC H9 cells cultured 
under untreated and BDNF-treated conditions without and with heparin. Confocal microscopy 
of the NSC marker nestin (green) and Trkb (red) along with DAPI (blue) counterstain (63X 
magnification, scale bar 37 μM). Images are representative of hNSC H9 cells cultured under A) 
untreated or B) BDNF-treated neuronal differentiating conditions without and with heparin for 40 
days.  
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Figure 7-44: Trkb expression at day 40 of neuronal differentiation of hNSC H9 cells cultured 
under PDGF- and BDNF+PDGF-treated conditions without and with heparin. Confocal 
microscopy of the NSC marker nestin (green) and Trkb (red) along with DAPI (blue) counterstain 
(63X magnification, scale bar 37 μM). Images are representative of hNSC H9 cells cultured under A) 
PDGF- or B) BDNF+PDGF-treated neuronal differentiating conditions without and with heparin for 
40 days.  
 
When Trkb was examined in neuronal differentiating hNSC H9 cells at D60, a high 
level of expression in all the neuronal culture conditions was observed (Fig. 7-45 and 
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7-46). Similar to observations in the D40 neuronal cultures, at D60 Trkb 
demonstrated a degree of co-localisation with nestin (orange colour), evident 
particularly in the +BDNF+PDGF and +BDNF+PDGF+Hep treated neuronal 
cultures (Fig. 7-46B). In addition, similar to D40 neuronal cultures, in all of the D60 
neuronal cultures, there were areas of Trkb only expression, indicated by the red 
colour in the nestin/Trkb merge image (Fig. 7-45 and 7-46). Ubiquitous cytoplasmic 
or cell surface localisation of Trkb was also observed in the D60 neuronal cultures 
conditions (Fig. 7-45 and 7-46). In these cultures Trkb clustering was observed in 
areas of dense cell-cell contacts, particularly apparent in the +BDNF+Hep, +PDGF, 
and +BDNF+PDGF treated cultures (Fig. 7-45B and 7-46). Strong Trkb expression 
along cell neurites was particularly evident in the +BDNF+PDGF+Hep treated 
cultures (Fig. 7-46B).  
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Figure 7-45: Trkb expression at day 60 of neuronal differentiation of hNSC H9 cells cultured 
under untreated and BDNF-treated conditions without and with heparin. Confocal microscopy 
of the NSC marker nestin (green) and Trkb (red) along with DAPI (blue) counterstain (63X 
magnification, scale bar 37 μM). Images are representative of hNSC H9 cells cultured under A) 
untreated or B) BDNF-treated neuronal differentiating conditions without and with heparin for 60 
days. 
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Figure 7-46: Trkb expression at day 60 of neuronal differentiation of hNSC H9 cells cultured 
under PDGF- and BDNF+PDGF-treated conditions without and with heparin. Confocal 
microscopy of the NSC marker nestin (green) and Trkb (red) along with DAPI (blue) counterstain 
(63X magnification, scale bar 37 μM). Images are representative of hNSC H9 cells cultured under A) 
PDGF- or B) BDNF+PDGF-treated neuronal differentiating conditions without and with heparin for 
60 days. 
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7.5.2.2 The PDGF pathway in neuronal differentiating hNSC H9 cultures  
 
Following examination of the BDNF pathway in D40 and D60 neuronal 
differentiating hNSC H9 cultures, the expression levels of the PDGFB ligand and the 
PDGFRβ was then examined in the neuronal cultures.  The PDGFB ligand can bind 
to both PDGFRα and PDGFRβ receptors, however, studies from the mouse model 
indicate that PDGFRβ is predominantly expressed in neurons localising to both to 
pre- and post-synaptic areas (Ishii et al., 2006; Shioda et al., 2012), thus the 
expression of PDGFRβ in hNSC H9 neuronal differentiating cultures was 
specifically examined.  
 
The relative gene expression levels of PDGFB (ΔΔCtx106=1.3) and PDGFRβ 
(ΔΔCtx106=0.04) were lower than those observed for BDNF (ΔΔCtx106=37) and Trkb 
(ΔΔCtx106=61) in the untreated D40 neuronal cultures (Fig. 7-47).  Interestingly, D40 
neuronal cultures treated with +BDNF (p=0.009), +BDNF+Hep (p<0.0001), +PDGF 
(p=0.0001), +PDGF+Hep (p=0.001), +BDNF+PDGF (p<0.0001) and 
+BDNF+PDGF+Hep (p<0.0001) all expressed a highly significantly induced level of 
PDGFB when compared to untreated D40 neuronal cultures (Fig. 7-47A). This was 
also observed for PDGFRβ expression, which demonstrated highly significantly 
upregulated (p<0.0001) expression following treatment of the cultures with +PDGF, 
+PDGF+Hep, +BDNF+PDGF and +BDNF+PDGF+Hep suggesting a stimulatory 
effect for PDGF supplementation on PDGF pathway gene expression (Fig. 7-47A). 
In addition, the addition of +BDNF+Hep to the cultures resulted in a significantly 
higher level (p=0.0098) of PDGFRβ expression when compared to the +BDNF only 
treated cultures (Fig. 7-47A). However, the effect of heparin on the +BDNF+PDGF 
treated cultures was different, with the +BDNF+PDGF+Hep condition shown to 
express a significantly lower level (p=0.045) of PDGFRβ than the level observed in 
the +BDNF+PDGF treated cultures (Fig. 7-47A). 
 
In contrast to the D40 neuronal differentiation cultures no significant differences in 
PDGFB expression was demonstrated between the D60 neuronal culture conditions 
(Fig. 7-47B). A slight increase in PDGFB expression was observed in cultures 
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treated with +Hep, +BDNF, +BDNF+PDGF and +BDNF+PDGF+Hep when 
compared to the untreated D60 neuronal cultures (Fig. 7-47B). Similarly, PDGFRβ 
expression was not shown to be significantly altered between the untreated and 
heparin or growth factor treated cultures (Fig. 7-47B). Interestingly however, the 
addition of the combination of +PDGF+Hep to the cultures resulted in a significantly 
lower level (p=0.02) of PDGFRβ gene expression when compared to the +PDGF 
only treated cultures, with the +BDNF+PDGF+Hep treated cultures shown to 
express a significantly higher level (p=0.002) of PDGFRβ when compared to the 
+BDNF+PDGF treated cultures (Fig. 7-47B). WB analysis was used to examine the 
protein level expression of PDGFRβ in the D60 neuronal cultures, however, no 
visible bands were observed, likely due to the low expression level of this receptor 
within the cultures.  
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Figure 7-47: PDGF-pathway gene expression in neuronal differentiating hNSC H9 cells cultured 
under untreated or heparin and growth factor treated conditions for 40 and 60 days. Relative 
gene expression of platelet-derived growth factor B (PDGFB) and the PDGF receptor β (PDGFRβ) 
following neuronal differentiation of hNSC H9 cells under untreated, heparin (Hep), BDNF, 
BDNF+Hep, PDGF, PDGF+Hep, BDNF+PDGF or BDNF+PDGF+Hep-treated conditions for A) 40 
and B) 60 days. (Error bars = SD for PDGFB: +BDNF+PDGF D60; PDGFRβ: Neuronal D60, +Hep 
D60, +BDNF D60, +BDNF+Hep D60 and +BDNF+PDGF D60. Other error bars = SEM, statistical 
significance: * p<0.05, ** p<0.01, *** p<0.001). Black lines indicate statistically significant 
differences between treated and untreated neuronal conditions. Red lines indicate statistically 
significant differences between Hep-treated and non-Hep-treated growth factor-modulated conditions. 
 
The expression and localisation of the PDGF receptor PDGFRβ was then examined 
in D40 and D60 neuronal differentiating cultures using confocal microscopy with 
nestin used as a structural marker. Confocal microscopy revealed that PDGFRβ was 
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expressed in all the neuronal differentiating culture conditions at D40 and D60, 
however, its localisation was vastly different to the pattern observed for Trkb (Fig. 7-
48 to 7-51). In addition, PDGFRβ demonstrated a differential localisation pattern 
between the different neuronal culture conditions (Fig. 7-48 to 7-51). Largely, 
PDGFRβ demonstrated heterogeneous expression, was not identified to be present in 
all cells, and exhibited nuclear localisation, indicated by co-localisation with DAPI 
(Fig. 7-48 to 7-51).  
 
When the D40 neuronal differentiating cultures were examined, interesting 
observations for PDGFRβ localisation in the untreated and +Hep treated neuronal 
cultures was demonstrated (Fig. 7-48A). PDGFRβ expression was shown to be 
localised to the nucleus in cells, however, a number of cells also demonstrated 
diffuse cytoplasmic/cell surface localised PDGFRβ (Fig. 7-48A). This was 
particularly evident in the untreated D40 neuronal cultures, where large non-neuronal 
looking cells were identified with these cells ubiquitously expressing PDGFRβ (Fig. 
7-48A).  In addition, the D40 neuronal cultures treated with +BDNF demonstrated 
PDGFRβ expression that localised to the elongated neurites within the cultures (Fig. 
7-48B).  When the D40 neuronal cultures treated with +BDNF+Hep, +PDGF, 
+PDGF+Hep, +BDNF+PDGF and +BDNF+PDGF+Hep were examined, a highly 
heterogeneous, nuclear localised expression for PDGFRβ was observed, with 
expression not observed in all cells within the culture (Fig. 7-48B and 7-49).  
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Figure 7-48: PDGFRβ expression at day 40 of neuronal differentiation of hNSC H9 cells 
cultured under untreated and BDNF-treated conditions without and with heparin. Confocal 
microscopy of the NSC marker nestin (green) and platelet-derived growth factor receptor β (PDGFRβ, 
yellow) along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). Images are 
representative of hNSC H9 cells cultured under A) untreated or B) BDNF-treated neuronal 
differentiating conditions without and with heparin for 40 days. 
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Figure 7-49: PDGFRβ expression at day 40 of neuronal differentiation of hNSC H9 cells 
cultured under PDGF- and BDNF+PDGF-treated conditions without and with heparin. 
Confocal microscopy of the NSC marker nestin (green) and platelet-derived growth factor receptor β 
(PDGFRβ, yellow) along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). 
Images are representative of hNSC H9 cells cultured under A) PDGF- or B) BDNF+PDGF-treated 
neuronal differentiating conditions without and with heparin for 40 days. 
 
When the D60 neuronal differentiating cultures were examined for PDGFRβ 
expression, a similar localisation pattern as observed in the D40 cultures was 
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identified with PDGFRβ predominantly demonstrating nuclear localisation (Fig. 7-50 
to 7-51). Cytoplasmic/cell membrane localised PDGFRβ expression was also 
observed, most evident in the untreated and +BDNF+PDGF treated D60 neuronal 
cultures (Fig. 7-50A and 7-51B). Cultures treated with +Hep, +BDNF, +PDGF+Hep, 
+BDNF+PDGF and +BDNF+PDGF+Hep appeared to contain more PDGFRβ 
expressing cells than observed in the untreated D60 neuronal cultures, however, this 
was not quantitated (Fig. 7-50 and 7-51). A higher level of PDGFRβ expressing cells 
were observed in the +BDNF+PDGF+Hep treated cultures when compared to the 
+BDNF+PDGF treated D60 neuronal cultures, supporting gene expression results 
(Fig. 7-51B). 
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Figure 7-50: PDGFRβ expression at day 60 of neuronal differentiation of hNSC H9 cells 
cultured under untreated and BDNF-treated conditions without and with heparin. Confocal 
microscopy of the NSC marker nestin (green) and platelet-derived growth factor receptor β (PDGFRβ, 
yellow) along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). Images are 
representative of hNSC H9 cells cultured under A) untreated or B) BDNF-treated neuronal 
differentiating conditions without and with heparin for 60 days. 
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Figure 7-51: PDGFRβ expression at day 60 of neuronal differentiation of hNSC H9 cells 
cultured under PDGF- and BDNF+PDGF-treated conditions without and with heparin. 
Confocal microscopy of the NSC marker nestin (green) and platelet-derived growth factor receptor β 
(PDGFRβ, yellow) along with DAPI (blue) counterstain (63X magnification, scale bar 37 μM). 
Images are representative of hNSC H9 cells cultured under A) PDGF- or B) BDNF+PDGF-treated 
neuronal differentiating conditions without and with heparin for 60 days. 
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7.5.3 The effect of GPC1 and GPC4 downregulation on BDNF and PDGF 
response in hNSC H9 cells 
 
With GPC1 and GPC4 along with Trkb and PDGFRβ shown to be expressed in 
hNSC H9-derived neuronal differentiating cultures, the potential roles of GPC1 and 
GPC4 in mediating BDNF or PDGF response in hNSC H9 cells was then 
investigated. GPC1 and GPC4 were downregulated at the RNA level utilising gene-
specific Accell siRNA pools as previously described (section 3.5) in the presence of 
BDNF and PDGF. To mimic neuronal differentiation conditions, hNSC H9 cells 
were plated on PO and laminin coated culture dishes and Accell siRNA Delivery 
Media was supplemented with B-27 supplement, used in neuronal differentiation 
medium of hNSC H9 cells (previously described in section 3.5.2). Downregulation 
of GPC1 and GPC4 gene expression was performed in untreated, BDNF and PDGF 
treatment conditions. Following knockdown (KD), cell number, proliferation and 
gene expression was compared to control (CTRL = untreated + scramble) and any 
statistically significant differences identified using Student’s t-test. 
 
Examination of cell numbers following GPC1 and GPC4 KD demonstrated that 
downregulation of GPC1 or GPC4 did not markedly alter cell number (cells x 
105/mL) (Fig. 7-52A). In addition, in CTRL cultures, +BDNF and +PDGF 
supplementation to the cultures did not significantly alter cell number (Fig. 7-52A). 
In contrast, in the GPC1KD and GPC4KD cultures, supplementation of the cultures 
with +BDNF and +PDGF resulted in increased cell numbers when compared to 
untreated KD cultures (Fig. 7-52A). In GPC1KD cultures, +BDNF and +PDGF 
supplementation resulted in 1.4 and 1.3 fold increases in cell number, respectively, 
with the most evident increase in cell number observed in the GPC4KD cultures 
where +BDNF and +PDGF treatments resulted in 1.9 and 1.5 fold increases in cell 
number, respectively (Fig. 7-52A) The percentage of viable cells was similar 
between CTRL (71%), GPC1KD (71%) and GPC4KD (75%) cultures with a slightly 
increased viability observed in cultures treated with +BDNF and +PDGF when 
compared to untreated cultures in both CTRL and KD culture conditions (Fig. 7-
52A). To determine the presence of proliferative cells within the different culture 
conditions, CTRL, GPC1KD and GPC4KD cultures were stained for the 
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proliferation marker Ki67 (Fig. 7-52B). The presence of Ki67+ cells within the 
cultures was quantitated by calculating the number of Ki67+ nuclei within the total 
number of nuclei in three fields of view. CTRL cultures exhibited approximately 
53% Ki67+ cells with BDNF and PDGF supplementation increasing the proportion 
of Ki67+ cells to 68% (Fig. 7-52C). The proportion of Ki67+ cells within the 
GPC1KD cultures (58%) was similar to the number observed in CTRL cultures, with 
+BDNF and +PDGF treatments of GPC1KD cultures increasing the proportion of 
Ki67+ nuclei to 64% and 62%, respectively (Fig. 7-52C). Interestingly, the presence 
of Ki67+ cells was observed to be highest in the GPC4KD cultures when compared 
to CTRL or GPC1KD cultures, with these cultures exhibiting 74% Ki67+ cells (Fig. 
7-52C). In contrast to CTRL and GPC1KD cultures, +BDNF treatment of GPC4KD 
cultures decreased the proportion of Ki67+ cells (66%) with treatment of GPC4KD 
cultures with +PDGF maintaining the proportion of Ki67+ nuclei (75%) similar to 
the level observed in the GPC4KD cultures (Fig. 7-52C). 
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Figure 7-52: Cell number, viability and Ki67 expression following glypican 1 and glypican 4 
downregulation in hNSC H9 cells. A) Cell number/mL (x105) and viability (%) in control 
(CTRL=untreated+scramble), glypican 1 knockdown (GPC1KD) and glypican 4 knockdown 
(GPC4KD) hNSC H9 cultures without or with BDNF or PDGF treatment. Red line indicates cell 
number in untreated CTRL cultures. B) Immunofluorescence of Ki67 (Cy3/yellow) along with DAPI 
counterstain (blue) (20X magnification, scale bar 130 μM) in CTRL, GPC1KD and GPC4KD 
cultures. C) Quantitation of Ki67-positive (ki67+) nuclei in CTRL, GPC1KD and GPC4KD cultures 
without or with BDNF or PDGF treatments.   
 
To confirm downregulation of GPC1 and GPC4 following siRNA KD, GPC1 and 
GPC4 expression was examined in the GPC1 and GPC4 KD cultures, respectively. 
GPC1 expression was shown to be significantly downregulated when compared to 
CTRL in GPC1KD (p<0.0001), GPC1KD+BDNF (p=0.004) and GPC1KD+PDGF 
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(p=0.003) cultures (Fig. 7-53A). In addition, examination of GPC1 via IF 
demonstrated lower GPC1 expression in the GPC1KD cultures when compared to 
CTRL cultures, indicated by significantly lower (p=0.006) GPC1 signal intensity 
(Fig. 7-53B).  
 
 
Figure 7-53: Glypican 1 (GPC1) expression following GPC1 knockdown in hNSC H9 cells.  A) 
Relative gene expression of GPC1 in GPC1 knockdown (GPC1KD) hNSC H9 cultures compared to 
control (CTRL=untreated+scramble) cultures without or with BDNF or PDGF treatment. (Error bars = 
SEM, statistical significance: ** p<0.01, *** p<0.001). B) Immunofluorescence of GPC1 
(Cy3/yellow) along with DAPI counterstain (blue) (20X magnification, scale bar 130 μM) in CTRL 
and GPC1KD hNSC H9 cultures along with representative GPC1 signal intensity graph (Error bar = 
SD, statistical significance: ** p<0.01). 
 
GPC4 expression was shown to be significantly downregulated when compared to 
CTRL cultures in the GPC4KD (p=0.0009), GPC4KD+BDNF (p=0.005) and 
GPC4KD+PDGF (p<0.0001) treated cultures (Fig. 7-54). Examination of GPC4 via 
IF demonstrated slightly reduced GPC4 signal intensity in the GPC4KD cultures 
when compared to CTRL, however, the difference in GPC4 signal intensity between 
CTRL and GPC4KD cultures was not shown to be significant.  
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Figure 7-54: Glypican 4 (GPC4) expression following GPC4 knockdown in hNSC H9 cells.  A) 
Relative gene expression of GPC4 in GPC4 knockdown (GPC4KD) hNSC H9 cultures compared to 
control (CTRL=untreated+scramble) cultures without or with BDNF or PDGF treatment. (Error bars= 
SD GPC4KD+BDNF and GPC4KD+PDGF samples, other error bars = SEM, statistical significance: 
** p<0.01, *** p<0.001). B) Immunofluorescence of GPC4 (FITC/green) along with DAPI 
counterstain (blue) (20X magnification, scale bar 130 μM) in CTRL and GPC4KD hNSC H9 cultures 
along with representative GPC4 signal intensity graph (Error bar = SD). 
 
With confirmation that GPC1 and GPC4 expression was downregulated following 
KD of the genes in all the examined culture conditions, the gene expression levels of 
BDNF (BDNF and Trkb) and PDGF (PDGFB and PDGFRβ) pathway genes were 
then examined. Gene expression between CTRL and KD cultures was compared, 
then the effect of +BDNF and +PDGF treatments on gene expression in all of the 
culture conditions was examined. Interestingly, when the gene expression of BDNF 
was examined, it was significantly (p=0.009) upregulated following GPC1KD when 
compared to CTRL cultures (Fig. 7-55A). A similar level of BDNF expression was 
observed in GPC4KD cultures when compared to CTRL cultures (Fig. 7-55A). The 
expression of Trkb was observed to be higher in both the GPC1KD and GPC4KD 
cultures with GPC4KD cultures demonstrating significantly (p=0.006) increased 
Trkb expression when compared to CTRL cultures (Fig. 7-55B). Changes in BDNF 
and Trkb expression were then examined in all the culture conditions following 
 324 Chapter 7: Unravelling mechanisms of HSPG-mediated control of human neurogenesis 
+BDNF and +PDGF treatments. When the CTRL cultures were examined, a 
significantly induced level of BDNF expression was observed following treatment of 
the cultures with +BDNF (p=0.01) and +PDGF (p=0.04) (Fig. 7-55C). In contrast, in 
the GPC1KD cultures the addition of +BDNF to the cultures did not elicit any 
change in BDNF expression with the +PDGF treatment resulting in significantly 
(p=0.001) reduced BDNF expression when compared to the untreated GPC1KD 
cultures (Fig. 7-55C). A similar effect was observed in the GPC4KD cultures with 
both +BDNF (p=0.003) and +PDGF (p=0.002) treatments resulting in significantly 
reduced BDNF gene expression when compared to the untreated GPC4KD cultures 
(Fig. 7-55C). When the gene expression of Trkb was examined in CTRL cultures, the 
addition of +PDGF to the cultures resulted in the significant upregulation (p=0.003) 
of Trkb when compared to the untreated CTRL cultures (Fig. 7-55D). Conversely, no 
significantly altered Trkb expression was observed in the GPC1KD and GPC4KD 
cultures following the addition of +BDNF or +PDGF to the cultures (Fig. 7-55D). 
However, decreased Trkb expression was observed in GPC1KD and GPC4KD 
cultures treated with +BDNF and +PDGF when compared to the untreated GPC1KD 
and GPC4KD cultures, respectively (Fig. 7-55D). 
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Figure 7-55: BDNF pathway expression following glypican 1 and glypican 4 knockdown in 
hNSC H9 cells. Relative gene expression of A) BDNF and B) Trkb in control (CTRL) hNSC H9 
cultures and following glypican 1 (GPC1) and glypican 4 (GPC4) knockdown (KD). Changes in 
relative expression of C) BDNF and D) Trkb in CTRL, GPC1KD and GPC4KD cultures following 
treatment of the cultures with BDNF or PDGF. (Error bars= SD GPC4KD+BDNF and 
GPC4KD+PDGF samples, other error bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** 
p<0.001). 
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Interestingly, gene expression of PDGFB was shown to be significantly 
downregulated in the GPC1KD (p=0.02) and GPC4KD (p=0.002) when compared to 
CTRL cultures (Fig. 7-56A). In contrast, the opposite effect was observed for 
PDGFRβ expression, with a significant increase (p=0.04) in PDGFRβ expression 
observed in GCP4KD cultures when compared to the CTRL cultures (Fig. 7-56B). 
When the effect of the addition of +BDNF and +PDGF on PDGFB expression was 
examined, a significant (p=0.009) downregulation of PDGFB gene expression was 
observed in CTRL cultures treated with +BDNF when compared to the untreated 
CTRL (Fig. 7-56C). No change in PDGFB expression was demonstrated in CTRL 
cultures treated with +PDGF when compared to untreated CTRL (Fig. 7-56C). 
Treatment of GPC1KD cultures with +BDNF or +PDGF did not significantly alter 
PDGFB expression when compared to untreated GPC1KD cultures, although slightly 
increased PDGFB expression was observed in GPC1KD+BDNF cultures when 
compared to untreated GPC1KD cultures Fig. 7-56C). In contrast, GPC4KD cultures 
treated with +BDNF and +PDGF exhibited a highly significantly reduced level 
(p<0.0001) of PDGFB when compared to the untreated GPC4KD cultures (Fig. 7-
56C). PDGFRβ expression was not shown to be significantly altered in any of the 
cultures (CTRL, GPC1KD and GPC4KD) following the addition of +BDNF and 
+PDGF to the cultures. This is, however, likely due to high level of variability in 
gene expression observed in the cultures (Fig. 7-56D). However, a common trend 
between all cultures was demonstrated for the +PDGF treated cultures with increased 
PDGFRβ expression observed when compared to the untreated cultures (Fig. 7-56D). 
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Figure 7-56: PDGF pathway expression following glypican 1 and glypican 4 knockdown in 
hNSC H9 cells. Relative gene expression of A) PDGFB and B) PDGFRβ in control (CTRL) hNSC 
H9 cultures and following glypican 1 (GPC1) and glypican 4 (GPC4) knockdown (KD). Changes in 
relative expression of C) PDGFB and D) PDGFRβ in CTRL, GPC1KD and GPC4KD cultures 
following treatment of the cultures with BDNF or PDGF (Error bars= SD for GPC4KD+BDNF and 
GPC4+PDGF, other error bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** p<0.001). 
 
The effect of GPC1KD and GPC4KD and subsequent +BDNF and +PDGF 
treatments on neuronal lineage marker expression was then examined. As previously 
demonstrated (Chapter 5) GPC1KD in basal hNSC H9 cultures (GeltrexTM matrix, 
culture medium supplemented with +FGF-2 and +EGF) resulted in significantly 
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decreased expression of TUBB3 and NEFM with GPC4KD also resulting in the 
significantly reduced expression level of NEFM. When neuronal marker expression 
was examined in GPC1KD and GPC4KD cultures under neuronal differentiation 
mimicking conditions (as previously described in section 3.5.2) a highly altered 
neuronal marker expression profile was observed with the majority of the markers 
downregulated when compared to the CTRL cultures (Fig. 7-57). TUBB3 gene 
expression was observed to be decreased following GPC1KD and GPC4KD when 
compared to CTRL cultures, however this was not demonstrated to be significant 
(Fig. 7-57A). In contrast, MAP2 expression was highly significantly downregulated 
in both GPC1KD (p=0.007) and GPC4KD (p<0.0001)) cultures when compared to 
CTRL (Fig. 7-57B). Similar to previous results (Chapter 5) GPC1KD cultures 
exhibited a significantly decreased (p=0.04) gene expression level of NEFM (Fig. 7-
57C). Consistent with the other examined neuronal markers, DCX was significantly 
downregulated following GPC1KD (p=0.007) and GPC4KD (p=0.03) when 
compared to CTRL cultures (Fig. 7-57D). 
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Figure 7-57: Neuronal marker expression following glypican 1 and glypican 4 knockdown in 
hNSC H9 cells. Relative gene expression of neuronal markers A) βIII-tubulin (TUBB3), B) 
microtubule-associated protein 2 (MAP2), C) medium molecular-weight neurofilament (NEFM) and 
D) doublecortin (DCX) in control (CTRL) hNSC H9 cultures and following glypican 1 (GPC1) and 
glypican 4 (GPC4) knockdown (KD) (Error bars = SEM, statistical significance: * p<0.05, ** p<0.01, 
*** p<0.001). 
 
Similar to the BDNF and PDGF pathways, changes in neuronal marker expression in 
response to +BDNF or +PDGF treatments in all the cultures conditions was 
examined. The gene expression of TUBB3 was shown to be significantly upregulated 
(p=0.04) in CTRL cultures treated with +PDGF when compared to untreated CTRL 
cultures (Fig. 7-58A). In the GPC1KD and GPC4KD cultures no change in TUBB3 
gene expression was observed following treatment of the cultures with +BDNF or 
+PDGF (Fig. 7-58A). When the expression of MAP2 was examined, no significant 
change in its level of gene expression was observed following treatment of the CTRL 
cultures with +BDNF or +PDGF (Fig. 7-58A). In contrast, distinct changes in MAP2 
expression in GPC1KD and GPC4KD cultures following treatment with +BDNF and 
+PDGF was observed. GPC1KD cultures treated with +PDGF exhibited a 
significantly downregulated (p=0.04) MAP2 gene expression when compared to the 
untreated GPC1KD cultures (Fig. 7-58B). Similarly, GPC4KD cultures treated with 
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+BDNF (p<0.0001) and +PDGF (p=0.0001) expressed a highly significantly 
downregulated MAP2 gene expression when compared to the untreated GPC4KD 
cultures (Fig. 7-58B). When the gene expression of NEFM was examined, CTRL 
cultures treated with +BDNF and +PDGF maintained a similar level of NEFM 
expression when compared to the untreated CTRL cultures while GPC1KD cultures 
treated with +BDNF expressed a significantly upregulated (p=0.002) level of NEFM 
when compared to untreated GPC1KD cultures (Fig. 7-58C). Similarly, GPC4KD 
cultures treated with +PDGF expressed a significantly upregulated (p=0.02) level of 
NEFM when compared to the untreated GPC4KD cultures (Fig. 7-58C). When the 
gene expression of DCX in all culture conditions was examined, no significant 
changes were observed following the addition of +BDNF or +PDGF to the cultures 
(Fig. 7-58D). However, it was clear from the gene expression results that GPC1KD 
and GPC4KD cultures expressed a lower level of DCX than observed in the 
untreated or +BDNF/+PDGF treated CTRL cultures (Fig. 7-58D). 
 
 
Figure 7-58: Neuronal marker expression in response to BDNF and PDGF in control hNSC H9 
cultures and following glypican 1 and glypican 4 knockdown. Changes in relative gene expression 
in of neuronal markers A) βIII-tubulin (TUBB3), B) microtubule-associated protein 2 (MAP2), C) 
medium molecular-weight neurofilament (NEFM) and D) doublecortin (DCX) in control (CTRL) 
hNSC H9 cultures and following glypican 1 (GPC1) and glypican 4 (GPC4) knockdown (KD) 
following treatment of the cultures with BDNF or PDGF. (Error bars= SD for GPC4KD+BDNF and 
GPC4KD+PDGF; other error bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** p<0.001). 
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7.5.4 Inhibition of BDNF and PDGF pathways in hNSC H9 cells 
 
With an altered response to the addition of BDNF and PDGF to hNSC H9 cells 
identified following GPC1 and GPC4 KD, the effect of BDNF and PDGF pathway 
inhibition on BDNF and PDGF response in the cells was then examined. hNSC H9 
cells were exposed to specific inhibitors blocking Trkb and PDGFRβ signalling. For 
the inhibition of Trkb and PDGFRβ signalling hNSC H9 cells were cultured under 
neuronal differentiating culture conditions in medium supplemented with 10 µM of 
either the Trkb inhibitor ANA-12 or the PDGFRβ inhibitor Tyrphostin AG-1295 
(AG-1295) for 72h. Results are presented as untreated and DMSO (0.001%) treated 
conditions averaged as a control (=CTRL). The effect of BDNF and PDGF pathway 
inhibition on hNSC H9 cell number, viability and gene expression profile was 
examined and any statistically significant differences determined using Student’s t-
test.  
 
A similar cell number was observed in the CTRL, ANA-12 and AG-1295-treated 
cultures when examined after 72h (Fig. 7-59A). In addition, treatment of CTRL 
cultures with +BDNF and +PDGF shown to significantly increase (p<0.0001) cell 
number when compared to the untreated CTRL condition (Fig. 7-59A).  Similar to 
this, a significant increase (p=0.001) in cell number in the ANA-12-treated cultures 
following +BDNF treatment was observed with +PDGF-treatment of AG-1295-
cultures demonstrating an increase in cell number, however this was not shown to be 
significant when compared to AG-1295-only treated cultures (Fig. 7-59A). The 
viability of the cultures was shown to be maintained at 64% in the CTRL cultures 
with ANA-12 treated cultures exhibiting a slightly lower viability (57%) and AG-
1295-treated cultures exhibiting a slightly higher viability (74%) than the CTRL 
cultures (Fig. 7-59A). Treatment of CTRL cultures with +BDNF and +PDGF 
increased cell viability in the cultures to 75% and 85%, respectively (Fig. 7-59A).  A 
clear increase in cell viability in the ANA-12-treated cultures was observed 
following +BDNF addition (86%) (Fig. 7-59A) with the viability of AG-1295-treated 
cultures shown to be slightly increased (79%) following the addition of +PDGF to 
the cultures (Fig. 7-59A).  Similar to observations in the siRNA KD cultures, the 
proportion of Ki67+ cells following Trkb and PDGFRβ inhibition was also examined 
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with CTRL, ANA-12 and AG-1295 treated cultures (Fig. 7-59B).  When the 
proportion of Ki67+ nuclei was quantitated, approximately 76% positive cells were 
observed in the CTRL cultures, 83% in the ANA-12 treated cultures and 88% in the 
AG-1295 treated cultures (Fig. 7-59C).  Interestingly, following the addition of 
BDNF or PDGF to the cultures, a decreased proportion of Ki67+ cells was observed 
in the cultures (Fig. 7-59C).  CTRL cultures treated with +BDNF or +PDGF 
exhibited 56% and 64% Ki67+ cells respectively, with the proportion of Ki67+ 
nuclei observed to be 42% in the ANA-12+BDNF-treated cultures (Fig. 7-59C).  
Interestingly, the proportion of Ki67+ cells in the AG-1295+PDGF treated cultures 
was shown to be 48%, significantly lower (p=0.009) that the level observed in the 
AG-1295 only (88%) treated cultures (Fig. 7-59C).   
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Figure 7-59: Cell number, viability and Ki67 expression following Trkb and PDGFRβ inhibition 
in hNSC H9 cultures. A) Cell number (x105 cells/mL) and viability (%) in control (CTRL), ANA-12- 
and AG-1295-treated hNSC H9 cultures without or with BDNF (CTRL and ANA-12) or PDGF 
(CTRL and AG-1295) treatments. Red line indicates cell number in untreated CTRL cultures. B) 
Immunofluorescence of Ki67 (Cy3/yellow) along with DAPI counterstain (blue) (20X magnification, 
scale bar 130 μM) in CTRL, ANA-12- and AG-1295-treated cultures. C) Quantitation of Ki67-
positive (Ki67+) nuclei in CTRL, ANA-12- and AG-1295- treated cultures without or with BDNF or 
PDGF treatments. (Statistical significance: ** p<0.01, *** p<0.001). 
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When the expression of BDNF pathway genes following Trkb inhibition was 
examined, cultures treated with ANA-12-treated demonstrated significantly higher 
(p=0.003) gene expression of BDNF when compared to CTRL cultures (Fig. 7-60A).  
Following supplementation of CTRL and ANA-12 cultures with +BDNF, an increase 
in BDNF expression was observed. However, this increase was only significant 
(p=0.006) in the CTRL condition (Fig. 7-60A). The expression of Trkb was observed 
to be similar between CTRL and ANA-12 treated cultures with +BDNF 
supplementation resulting in a significant increase in Trkb expression in CTRL 
(p=0.0002) and ANA-12 treated (p=0.005) cultures (Fig. 7-60B). This suggests that 
ANA-12-treated cultures did not exhibit an altered response to BDNF treatment 
when compared to CTRL cultures. 
 
When the PDGF pathway was examined in CTRL and AG-1295 treated cultures, a 
similar level of PDGFB expression was observed in the two culture conditions (Fig. 
7-60C). Supplementation of CTRL cultures with +PDGF resulted in a significant 
decrease (p=0.01) of PDGFB expression (Fig. 7-60C).  Interestingly, the opposite 
effect was observed in AG-1295 treated cultures where +PDGF treatment resulted in 
higher expression of PDGFB than in the AG-1295 only treated cultures, with the 
difference in expression level not shown to be significant (Fig. 7-60C). PDGFRβ 
expression was observed to be lower in the AG-1295 treated cultures when compared 
to CTRL cultures, however the difference was not shown to be significant (Fig. 7-
60D). Interestingly, although not shown to be significant, the addition of +PDGF to 
the CTRL cultures resulted in increased PDGFRβ expression (Fig. 7-60D). Notably 
this effect was not observed following +PDGF treatment of the AG-1295 treated 
cultures (Fig. 7-60D). These results indicate an altered response to PDGF treatment 
following PDGF pathway inhibition of the cultures, however, no uniform pattern of 
expression was observed.  
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Figure 7-60: BDNF and PDGF pathway expression following Trkb and PDGFRβ inhibition in 
hNSC H9 cultures. Relative gene expression of A) BDNF and B) Trkb in control (CTRL) and ANA-
12-treated hNSC H9 cultures without or with BDNF treatment. Relative gene expression of C) 
PDGFB and D) PDGFRβ in CTRL and AG-1295-treated hNSC H9 cultures without or with PDGF 
treatment.  (Error bars= SD for AG1295 and AG1295+PDGF, other error bars = SEM, statistical 
significance: * p<0.05, ** p<0.01, *** p<0.001). 
 
Following examination of BDNF and PDGF pathway gene expression in the ANA-
12 and AG1295-treated cultures, the expression of neuronal lineage markers was 
then examined. The expression of TUBB3 and DCX was shown to be maintained at a 
similar level between CTRL and ANA-12 treated cultures, however, the expression 
of MAP2 (p=0.01) and NEFM (p=0.0003) was shown to be significantly upregulated 
in ANA-12 treated cultures when compared to CTRL cultures (Fig. 7-61). The 
expression of TUBB3, NEFM and DCX was observed to be similar between CTRL 
and AG-1295 treated cultures, however, in contrast to the ANA-12 treated cultures, 
AG1295 treated cultures exhibited a significant decrease (p<0.0001) in expression of 
MAP2 when compared to CTRL cultures (Fig. 7-61). 
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Figure 7-61: Neuronal marker expression following Trkb and PDGFRβ inhibition in hNSC H9 
cultures. Relative gene expression of neuronal markers A) βIII-tubulin (TUBB3), B) microtubule-
associated protein 2 (MAP2), C) medium molecular-weight neurofilament (NEFM) and D) 
doublecortin (DCX) in control (CTRL), ANA-12- and AG-1295-treated hNSC H9 cultures. (Error 
bars = SEM, statistical significance: * p<0.05, ** p<0.01, *** p<0.001). 
 
Neuronal marker expression following inhibition of Trkb signalling through ANA-12 
or inhibition of PDGFRβ through AG-1295 in the presence of BDNF or PDGF, 
respectively, was then examined. CTRL and ANA-12 treated cultures responded 
similarly to the addition of BDNF, suggesting ANA-12 treated cultures did not 
exhibit an altered BDNF response (Fig. 7-62). TUBB3 expression was shown to be 
significantly downregulated in the CTRL cultures treated with +BDNF (p<0.0001) 
when compared to untreated CTRL cultures, which was also observed in the ANA-
12 treated cultures where +BDNF supplementation resulted in the significantly 
reduced (p=0.005) expression of TUBB3 when compared to ANA-12 only treated 
cultures (Fig. 7-62A). Similarly, NEFM expression was shown to be significantly 
reduced following treatment of CTRL (p=0.009) and ANA-12 (p=0.003) cultures 
with +BDNF when compared to the untreated conditions (Fig. 7-62C). MAP2 and 
DCX expression was not altered following treatment of CTRL or ANA-12 treated 
cultures with +BDNF (Fig. 7-62B and 7-62D). AG-1205 treated cultures 
demonstrated an altered PDGF response when compared to the CTRL cultures. The 
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expression of TUBB3 was highly significantly downregulated (p<0.0001) following 
treatment of CTRL cultures with +PDGF when compared to untreated CTRL 
cultures (Fig. 7-62A). TUBB3 expression was also shown to be reduced in the AG-
1295+PDGF treated cultures when compared to AG-1295 only cultures, however, 
this was not demonstrated to be significant (Fig. 7-62A). The expression of MAP2 
expression was observed to be altered differently between CTRL and AG-1295 
treated cultures supplemented with +PDGF. CTRL cultures treated with +PDGF 
expressed a significantly lower (p=0.04) level of MAP2 when compared to the 
untreated CTRL cultures, while AG-1295 treated cultures supplemented with 
+PDGF expressed a significantly induced (p=0.01) level of MAP2 when compared to 
AG-1295 only treated cultures (Fig. 7-62B). In addition, differences in the 
expression levels of NEFM and DCX was observed between CTRL and AG-1295 
cultures treated with +PDGF. The expression of NEFM was slightly reduced and the 
expression of DCX remained at a similar level following treatment of CTRL cultures 
with +PDGF when compared to untreated CTRL (Fig. 7-62C and 7-62D). In 
contrast, the expression of NEFM and DCX appeared to increase following +PDGF 
supplementation of AG-1295, suggesting an altered response to PDGF in the AG-
1295 treated cultures when compared to CTRL cultures in expression of these 
neuronal markers (Fig. 7-62C and 7-62D). 
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Figure 7-62: Neuronal marker expression in response to BDNF and PDGF following Trkb and 
PDGFRβ inhibition in hNSC H9 cultures. Relative gene expression of neuronal markers A) βIII-
tubulin (TUBB3), B) microtubule-associated protein 2 (MAP2), C) medium molecular-weight 
neurofilament (NEFM) and D) doublecortin (DCX) in control (CTRL), ANA-12- and AG-1295-
treated hNSC H9 cultures without or with BDNF or PDGF treatment. (Error bars = SEM, statistical 
significance: * p<0.05, ** p<0.01, *** p<0.001). 
 
Expression of GPC1 and GPC4 in the ANA-12 and AG-1295 treated neuronal 
cultures was then examined. Interestingly, while ANA-12-treated cultures 
maintained a similar level of GPC1 and GPC4 expression when compared to CTRL 
cultures, the AG1295-treated cultures were shown to express a significantly 
downregulated level of GPC1 (p=0.006) and GPC4 (p<0.0001) when compared to 
the CTRL cultures (Fig. 7-63A and 7-63B). In CTRL cultures, treatment with 
+BDNF or +PDGF highly significantly (p<0.0001) downregulated the expression of 
GPC1 (Fig. 7-63A). No change in GPC1 gene expression was observed between the 
ANA-12 and ANA-12+BDNF cultures with GPC1 expression increased, although 
not significantly, in AG-1295 cultures supplemented with +PDGF (Fig. 7-63C). 
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Similar to GPC1, GPC4 expression was also significantly downregulated in CTRL 
cultures treated with +BDNF (p=0.04) and +PDGF (p<0.0001) when compared to 
untreated CTRL (Fig. 7-63D). No significant difference in GPC4 expression was 
observed following treatment of the ANA-12 treated cultures with +BDNF, with a 
similar trend of expression to the CTRL cultures observed with slightly reduced 
expression of GPC4 in ANA-12+BDNF cultures when compared to ANA-12 only 
cultures (Fig. 7-63D).  AG-1295 treated cultures supplemented with +PDGF 
exhibited a similar level of GPC4 expression to the level observed in the AG-1295 
only cultures (Fig. 7-63D). 
 
 
 
Figure 7-63: Glypican 1 and 4 expression following Trkb and PDGFRβ inhibition in hNSC H9 
cultures. Relative gene expression of A) glypican 1 (GPC1) and B) glypican 4 (GPC4) in control 
(CTRL), ANA-12- and AG-1295-treated hNSC H9 cultures.  Changes in relative expression of C) 
GPC1 and D) GPC4 in CTRL, ANA-12- and AG-1295 treated cultures following treatment of the 
cultures with BDNF or PDGF (Error bars=  SEM, statistical significance: * p<0.05, ** p<0.01, *** 
p<0.001).  
 
 
 
 
 340 Chapter 7: Unravelling mechanisms of HSPG-mediated control of human neurogenesis 
7.6 SUMMARY AND DISCUSSION OF PART B 
 
The results of this Chapter provide show evidence that GPC1 and GPC4 are neuronal 
proteins, expressed in the neurites and cell bodies of differentiating human neurons. 
Similarly to neuronal proteins, including TUBB3 and MAP2 examined in this study, 
GPC1 and GPC4 were shown to localise along the neuronal protrusions of 
differentiating hNSC-derived neurons. Interestingly, although GPC1 and GPC4 both 
appeared to demonstrate ubiquitous expression in the examined neuronal cultures, 
their localisation pattern differed with numerous areas observed to express one of 
these GPCs with the other on absent. These results suggest that GPC1 and GPC4 are 
key neural proteins with likely specific and differential functions in the human 
neurons. Structurally GPCs are cell surface proteins, attached to the cell membrane 
via a glycosylphosphatidylinositol (GPI)-anchor known to preferably interact with 
extracellular signalling molecules that are close to the cell surface, including 
receptors (Fico et al., 2011; Filmus et al., 2008). It is thought that the GPC-receptor 
interaction modulates the downstream activity of various signalling pathways, 
including growth factor and morphogen pathways (Fico et al., 2011; Filmus et al., 
2008). The differential localisation pattern of GPC1 and GPC4 observed in the 
differentiating neuronal cultures suggests that GPC1 and GPC4 may interact with 
different membrane proteins to drive neuronal lineage commitment or to activate 
specific signaling pathways required for the maintenance of mature neurons. 
Supporting the importance of GPCs in neuronal cell function arises from a study by 
Hill et al. who showed that GPC administration into a rat stroke model improved the 
functional outcome of the animals (Hill et al., 2012). Although it was not specified 
which GPC was tested in this study, the results demonstrated that GPC treatment 
improved behaviour of the animals, upregulated the expression of MAP2 and 
improved neurite outgrowth in rat cortical neuron cultures (Hill et al., 2012).  These 
results correlate with the findings of this Chapter that GPC1 and GPC4 gene 
expression directly correlates with neuronal marker (MAP2 and DCX) gene 
expression. This suggests that a normal level of GPC1 and GPC4 expression is 
required for a normal level of neuronal marker expression, thus these GPCs likely 
have critical roles in mediating the development and function of human neurons.  
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In addition to GPC1 and 4, BDNF and PDGF pathway components, including their 
ligands and receptors, were shown to be expressed within hNSC-derived 
differentiating neuronal cultures. Interestingly, the BDNF receptor Trkb was clearly 
localised on the cell surface or in the cytoplasm of the cultures with PDGFRβ 
observed to be predominantly expressed in the nucleus. The high expression level of 
Trkb observed at the gene expression and cellular level in all the neuronal culture 
conditions highlights the importance of the activity of this signalling pathway during 
hNSC neuronal differentiation. Interestingly, when examined at the protein level, 
Trkb exhibited three protein bands of approximately 40 kDa, 55 kDa and 100 kDa in 
size, all previously described in the literature with the two smaller bands (40 and 55 
kDa) corresponding to a truncated Trkb isoform. (Wessels et al., 2014). The full 
length Trkb and the truncated Trkb are abundantly expressed in the brain with the 
full-length Trkb reported to be mainly involved in BDNF-mediated cell survival 
(Fenner, 2012). The truncated Trkb is a dominant-negative receptor that inhibits the 
function of the full-length Trkb with the truncated form of Trkb previously identified 
to stimulating neurite outgrowth and synapse and neurotransmitter function (Fenner, 
2012). The expression of the different Trkb isoforms in the hNSC-derived neuronal 
cultures suggests that all the Trkb isoforms have importance during human 
neurogenesis.  Interestingly, when Trkb expression was examined via confocal 
microscopy, a similar expression pattern to GPC1 and GPC4 was observed with Trkb 
largely localising along the cell bodies and neurites of the cells within the cultures. 
Localisation of Trkb expression within human neuronal axons and dendrites has 
previously been reported (Fenner et al., 2014), supporting the findings of this study. 
With Trkb demonstrating a similar localisation pattern to GPC1 and GPC4, it is 
possible that these HSPGs directly interact with Trkb mediating its activity. To 
further examine this, a co-stain and confocal imaging of these surface proteins would 
be interesting to identify any co-localisation. In the current literature, no studies have 
yet examined the interaction of GPC1 or GPC4 with Trkb, an interesting avenue of 
further research to increase our understanding of HSPG-mediated regulation of 
human neurogenesis.  
 
Interestingly, the expression and localisation of PDGFRβ in the neuronal cultures 
was observed to be vastly different to that of Trkb. The gene expression levels of the 
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PDGFB ligand and the PDGFRβ receptor were clearly lower than the expression 
levels of the BDNF pathway components, suggesting the activity of the PDGF 
pathway is less important during human neurogenesis. In addition, when examined 
via confocal microscopy PDGFRβ was shown to be predominantly localised to the 
nucleus, suggesting that due to its nuclear localisation, the interaction of PDGFRβ 
with GPCs is less likely. Interestingly, PDGFRβ demonstrated a largely 
heterogeneous expression pattern, with its expression not detected in the nuclei of all 
cells. In addition, at the D40 timepoint in the untreated and heparin treated neuronal 
cultures several non-neuronal-like cells demonstrated ubiquitous cell surface or 
cytoplasmic localisation of PDGFRβ. These observations suggest that hNSC-derived 
neuronal cultures have heterogeneous PDGFRβ expression with PDGFRβ-positive 
cells likely representing a pool of cells with a differential differentiation status. With 
the glial lineages, including astrocytes and oligodendrocytes generally observed to 
express PDGFRα and neurons to express PDGFRβ (Funa & Sasahara, 2014), the 
PDGFRβ-positive cells observed within the cultures may represent a pool of more 
mature neurons. Alternatively, PDGFRβ has been reported to have a role in 
mediating mouse NSC self-renewal (Xu et al., 2013), thus the non-neuronal 
PDGFRβ positive cells observed in the D40 untreated and heparin treated neuronal 
cultures may represent a pool of self-renewing cells. Investigating the specific roles 
or differentiation status of the PDGFRβ-positive and PDGFRβ-negative cells within 
the neuronal cultures may provide an additional marker of characterisation of 
neuronal lineage specificity.  
 
GPC1 and GPC4 along with BDNF and PDGF pathway components were shown to 
be altered in expression in response to treatment with heparin and growth factors, 
suggesting the expression of GPC1 and GPC4 and BDNF and PDGF pathway 
components responded to these treatments. Interestingly, when examined at the D60 
timepoint, both GPC1 and GPC4 gene expression was observed to correlate with 
Trkb gene expression, with all genes downregulated in expression following 
treatment of the cultures with +PDGF and the combination of +BDNF+PDGF with 
and without heparin. These results suggest that there may be a correlation with these 
GPCs and the BDNF pathway. Providing further support to the potential interaction 
between the BDNF and PDGF pathways, downregulation of GPC1 and GPC4 in 
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hNSC H9 cells cultured under neuronal differentiating conditions resulted in altered 
BDNF and PDGF pathway expression. Interestingly, downregulation of GPC4 
resulted in the upregulated expression of Trkb and PDGFRβ. A similar trend in 
expression was observed following GPC1 KD although this was not shown to be 
significant. These observed results may be due to a compensatory response to 
reduced Trkb signalling in the cultures as a result of reduced GPC expression. In 
addition, the effect of BDNF and PDGF treatments was altered following GPC1 and 
GPC4 KD. In the control cultures, BDNF and PDGF supplementation elicited 
changes in gene expression that were not observed following GPC1 or GPC4 KD. 
Most notably, the positive effect of BDNF and PDGF supplementation on BDNF 
ligand and Trkb receptor gene expression was lost following GPC1 and GPC4 KD, 
suggesting that the BDNF and PDGF ligands are not able to exert their full effects 
with reduced GPC1 and GPC4.  
 
Supporting previous findings in this study (Chapter 5, (Oikari et al., 2016b)), 
downregulation of GPC1 and GPC4 expression in hNSC H9 cells cultured under 
neuronal differentiating conditions resulted in a significantly downregulated 
expression of the majority of neuronal markers studied, including MAP2, NEFM and 
DCX. This confirms the associative relationships of these GPCs along with neuronal 
marker expression, which has been demonstrated multiple times throughout this 
study (Chapters 4 to 6, Oikari et al., 2016a; Oikari et al., 2016b)). The decreased 
neuronal marker expression in cultures following GPC1 and GPC4 KD also suggests 
that GPC1 and GPC4 expression is required for full neuronal differentiation potential 
within the cultures with reduced GPC1/4 expression preventing the cells from 
committing efficiently to the neuronal lineage. In addition, supplementation of the 
GPC1 and GPC4 KD cultures with BDNF and PDGF elicited effects on neuronal 
marker expression not observed in the control cultures. These results indicate that the 
loss of GPC1 and GPC4 alters the ability of the cells to respond to exogenous BDNF 
and PDGF with GPC1 and GPC4 potentially playing a role in fine-tuning the BDNF 
and PDGF signal. Although these results are preliminary, they indicate that neuronal 
differentiating hNSC H9 cells lacking GPC1 or GPC4 expression have an altered 
ability to respond to BDNF or PDGF.  
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This study also investigated the effect of Trkb and PDGFRβ pathway inhibition on 
neuronal commitment of hNSC H9 cells with the aim of identifying correlations to 
the results observed following GPC1 and GPC4 KD. When hNSC H9 cells under 
neuronal differentiating conditions were exposed to the Trkb inhibitor ANA-12, it 
was not evident from the data that BDNF pathway inhibition was achieved. This was 
indicated by a similar level of Trkb expression and a similar response to BDNF 
treatment observed in the ANA-12 treated and control cultures, opposite to the 
results expected (Cazorla et al., 2011). Interestingly, however, the neuronal markers 
MAP2 and NEFM were observed to be upregulated in cultures threated with ANA-
12 when compared to control cultures, suggesting that ANA-12 exposure may 
modulate neuronal lineage specificity. In contrast, the results of this study suggest 
that AG-1295 may have inhibited the PDGFRβ pathway. This was indicated by the 
lower expression level of PDGFRβ in AG-1295 treated cultures when compared to 
control cultures with PDGF treatment of control and AG-1295 treated cultures 
eliciting opposing effects in these cultures. PDGF supplementation in control 
cultures resulted in the decreased gene expression of MAP2, while in the AG-1295 
treated cultures an upregulated MAP2 expression was observed following PDGF 
treatment. Interestingly AG-1295 treated cultures were also observed to express a 
decreased level of GPC1 and GPC4 genes when compared to control cultures, 
suggesting that decreased PDGFRβ signalling may result in decreased GPC 
expression. In addition, the BDNF and PDGF supplementation of control cultures 
resulted in decreased GPC1 and GPC4 expression, with this effect not seen in AG-
1295 treated cultures.  These preliminary results indicate that GPC expression may 
be modulated through PDGF with the specific mechanisms behind this requiring 
more investigation.  
 
Overall, these results suggest that neuronal potential of hNSCs is mediated through 
GPC1 and GPC4 potentially via a BDNF- or PDGF-mediated mechanism. The 
results presented here are preliminary with more research required to elucidate the 
relationship between these GPCs and the BDNF and PDGF pathways. The 
generation of a stable knockout of GPC1 and GPC4 in hNSCs followed by extended 
neuronal differentiation is needed to reveal if GPC1 or GPC4 are required for human 
neurogenesis. In addition, optimising ANA-12 and AG-1295 concentrations and 
  
Chapter 7: Unravelling mechanisms of HSPG-mediated control of human neurogenesis 345 
exposure time is required for the effective inhibition of these pathways to further 
investigate their role in hNSC neurogenesis.  
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Chapter 8: Discussion and Future 
Directions 
 
8.1 HSPGS ARE NOVEL MARKERS OF SELF-RENEWING HUMAN 
NEURAL STEM CELLS AND LINEAGE-SPECIFIC NEURAL CELLS 
 
8.1.1 Characterisation of hNSCs in vitro 
 
Self-renewing and multipotent neural stem cells (NSCs) provide an important cell 
model to study the processes of human neurogenesis in vitro and these cells also 
have tremendous potential in the regenerative treatment of central nervous system 
(CNS) injuries. Understanding the mechanisms that regulate NSC expansion, self-
renewal and differentiation is critical for the improved use of these cells for various 
applications. The extracellular microenvironment is known to contribute to the 
regulation of stem cell fate, i.e. the maintenance of self-renewal or lineage-specific 
differentiation (Kazanis & ffrench-Constant, 2011;  Oikari et al., 2016b). Heparan 
sulfate proteoglycans (HSPGs), including syndecans (SDCs) and glypicans (GPCs), 
are key contributors to the extracellular space and play roles in mediating cell 
proliferation, migration and differentiation (Choi et al., 2011; Dreyfuss et al., 2009; 
Filmus et al., 2008). In addition, HSPGs are expressed in neural tissue and they 
interact with a wide variety of neuroregulatory signalling molecules to mediate 
neural cell function (Dreyfuss et al., 2009;  Oikari et al., 2016b). As such, HSPGs are 
likely key regulators of NSC behaviour, however, limited studies examining HSPGs 
in NSC regulation, specifically in human NSC (hNSC) regulation, have to date been 
performed. To expand our knowledge of the function of HSPGs in the hNSC niche, 
this study investigated the roles of HSPGs during hNSC in vitro expansion and 
differentiation. The aim of this study was to examine the roles of HSPGs as 
regulators of hNSC fate and their potential as novel markers of lineage identification 
and specification.  
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In this study human embryonic stem cell-derived NSCs (hNSC H9 cells), cultured as 
an adherent monolayer, were utilised as a model of self-renewing and multipotent 
hNSCs. While these cells are not directly derived from brain tissue, they exhibit the 
classical characteristics of NSCs, including the expression of the NSC self-renewal 
markers nestin and SOX2 and the ability to generate cells of the neuronal, astrocyte 
and oligodendrocyte lineages. This study demonstrated that hNSC H9 cells were able 
to be expanded for over 100 days in culture, during which the cells were shown to 
maintain self-renewal and multi-lineage differentiation capacity (Chapter 4: sections 
4.3.1 and 4.3.2, (Oikari et al., 2016b)). The maintenance of self-renewal capacity 
within hNSC H9 cultures was indicated by the continued high level of cellular 
homogeneity as well as the retained expression of NSC self-renewal markers, 
including nestin, SOX1, SOX2 and musashi-1 (MSI1) along with the pluripotency 
marker human telomerase (hTERT) (Chapter 4: sections 4.3.1 and 4.3.2, (Oikari et 
al., 2016b)). The expanded hNSC H9 cells also continued to express a wide variety 
of multi-lineage markers, including neuronal, astrocyte and oligodendrocyte lineage 
markers indicative of multi-lineage differentiation capacity of the cultures (Chapter 
4: section 4.3.2, (Oikari et al., 2016b)). Several previous studies have reported the 
challenges associated with human brain-derived NSCs, which are cultured as free-
floating neurosphere aggregates. These cultures are generally highly heterogeneous 
and exhibit limited expansive potential during extended culture resulting in an 
increased proportion of glial progenitors at the cost of neuronal progenitors 
(Anderson et al., 2007; Conti et al., 2005; Wright et al., 2006). While increased glial 
marker expression was observed in the hNSC H9 cultures in this study during 
expansion, this did not appear to be at the cost of self-renewal or neuronal lineage 
markers, which were shown to be maintained at a high level within the cultures 
(Chapter 4: section 4.3.2, (Oikari et al., 2016b)). 
 
These results demonstrate that hNSC H9 cells provide an excellent model of NSC 
self-renewal and that these cells are suitable for extended in vitro expansion, during 
which they maintain their multi-lineage potential, features that are beneficial when 
large numbers of cells are required for downstream applications. However, it is 
important to note that hNSC H9 cells exhibited several differences in comparison to 
in vivo NSCs, demonstrating distinctions between the two models. The expression of 
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lineage-specific markers in undifferentiated in vivo NSCs is less commonly 
documented, suggesting this is a characteristic of in vitro expanded hNSCs. The 
expression of lineage markers in undifferentiated hNSCs likely reflects the 
heterogeneity of the cell population, containing both pools of self-renewing as well 
spontaneously differentiating cells, as has been reported in mouse ESC cultures (Nair 
et al., 2014). It has also been documented that when expanded in vitro, NSCs derived 
both from the brain or ESCs exhibit other differences to their in vivo counterparts, 
including the absence of a fate-regulating niche, loss of transcriptional regulators and 
a limited ability to generate specialised neuron types (comprehensively reviewed in 
(Conti & Cattaneo, 2010)). Adding to the complexity of modelling NSC behaviour in 
vitro is the existence of multiple in vivo NSC lineages that largely differ in their 
marker profile and behaviour (Conti & Cattaneo, 2010; Chaker et al., 2016). It is 
important to note that in vivo NSCs cannot be fully replicated in vitro, thus an in 
vitro NSC model that captures the majority of key characteristics of in vivo NSCs, is 
a key aim of in vitro NSC research. With hNSC H9 cells largely exhibiting central 
characteristics of in vivo NSCs, including self-renewal capacity (nestin and SOX2 
expression) and neural lineage potential (neural lineage marker expression), this 
supports their use as an in vitro model of hNSCs. 
 
8.1.2 HS synthesising enzymes and cell surface HSPGs are expressed in 
undifferentiated hNSCs 
 
Along with providing a comprehensive characterisation of hNSC H9 cells during 
extended in vitro expansion, this study is the first to extensively characterise the 
expression of HS biosynthesis enzymes and HSPG core protein SDCs and GPCs in 
hNSC H9 cells. This study provides key evidence that HSPGs are expressed in 
hNSCs, supporting their role as regulators of the hNSC niche. The expression of 
central HS side chain synthesising and modifying enzymes, EXT1, NDST1 and 
HS2ST1 indicated continued HS synthesis in basal hNSC H9, which was confirmed 
by localised expression of HS chains (10E4) within the cells (Chapter 4: section 
4.3.3, (Oikari et al., 2016b)). This data suggests that hNSC H9 cells require and 
synthesise HS, which is supported by previous studies in human and mouse ESCs 
models, where HS has been shown to be involved in ESC fate regulation (Gasimli et 
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al., 2014; Pickford et al., 2011). The varying levels of expression of the HS 
modifying (NDST1-4) and 6-O-sulfation catalysing enzymes (HS6ST1-3) in basal 
hNSC H9 cells suggest specific HS chain modifications likely contribute to the 
maintenance and/or neural lineage fate programs of these cells (Chapter 4: section 
4.3.3, (Oikari et al., 2016b)). A key characteristic of HS chains is their ability to bind 
various extracellular signalling molecules, including growth factors, with the binding 
sites modified through these various HS chain modifications (Brickman et al., 1998; 
Gasimli et al., 2014; Johnson et al., 2007). Thus, the changes observed in HS side 
chain modification enzyme expression during hNSC H9 expansion suggests altered 
growth factor binding abilities of the cells, reflecting altered growth factor 
requirements for the cells within their local microenvironment. Evidence for this is 
supported in the literature in numerous models and systems. In particular, the 
interaction of FGF family members with specific HS chain sulfation sites is well 
characterised (Ashikari-Hada et al., 2004; Esko & Selleck, 2002), thus, with FGFs 
key regulatory proteins of NSC maintenance, altered FGF requirements likely occur 
during hNSC H9 cell expansion.  
 
This study is the first to demonstrate that the two main HSPG superfamilies, the 
SDCs and GPCs, are expressed in basal hNSC H9 cells and their expression is 
maintained during in vitro expansion, suggesting they provide new and novel 
markers of hNSC characterisation (Chapter 4: section 4.3.3, (Oikari et al., 2016b)). 
Of the HSPGs studied, SDC1, SDC2, SDC3, GPC1 and GPC4 were shown to be 
highly expressed in basal hNSC H9 cultures, suggesting they are characteristic of 
self-renewing hNSCs (Chapter 4: section 4.3.3, (Oikari et al., 2016b)). Findings of 
this study in hNSC H9 cells correlate with previous studies in the rodent model, 
where SDC1, GPC1 and GPC4 have been shown to be expressed in mouse ESC and 
neural progenitor cells (NPCs) and required for stem cell maintenance (Abaskharoun 
et al., 2010; Fico et al., 2012; Wang et al., 2012). These results suggest that 
specifically SDC1, GPC1 and GPC4 may provide markers of self-renewal and that 
there are similarities between the human and rodent models. In addition, SDC2 and 
SDC3 have previously been reported to be enriched in rodent neural tissue, 
indicating they may have a similar expression pattern in the human (Ford-Perriss et 
al., 2003; Hienola et al., 2006; Hsueh & Sheng, 1999). This is supported by RNA-
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sequencing (RNAseq) analysis performed on human outer subventricular zone (SVZ) 
NSCs, which revealed high expression of SDC3 in these cells (Pollen et al., 2015). 
These findings suggest that SDC3 is a component of the hNSC niche, both in vitro 
and in vivo. Finally, the expression of several HSPGs, SDC2, SDC3, GPC2 and 
GPC4, correlated with several markers defining NSC self-renewal (SOX2), neuronal 
(TUBB3, MAP2) and glial (S100B, Olig1, Olig2) lineages suggesting there is a 
potential association between HSPGs and neural marker expression, supporting the 
use of HSPGs as additional markers of human neural cells (Chapter 4: sections 4.3.2 
and 4.3.3, (Oikari et al., 2016b)).  
 
Interestingly, the expression level of SDCs was observed to be higher than the GPCs 
in basal hNSC H9 cells, suggesting SDCs may have a specific role in mediating the 
continued undifferentiated state of hNSCs (Chapter 4: section 4.3.3 (Oikari et al., 
2016b)). SDCs have been shown to contribute to cell adhesion due to their 
interaction with integrins and the actin cytoskeleton (Couchman et al., 2015). With 
changes in cell adhesion an important phenomenon during in neuronal differentiation 
(Wojcik-Stanaszek et al., 2011), SDCs may play a role in cell adhesion or cell-cell 
contact regulation to mediate hNSC maintenance and subsequent migration 
associated with lineage specification. Further elucidation of the roles of key SDCs 
and GPCs in undifferentiated hNSCs in vivo will enable the better understanding of 
the roles of these HSPGs within the hNSC niche. 
 
8.1.3 hNSC to hNPC lineage progression is associated with correlated changes 
in lineage marker and HSPG core protein expression 
 
To understand the potential importance of HSPGs during hNSC lineage commitment, 
the cell marker and HSPG profiles of hNSC H9 cells were compared to the more 
lineage-restricted normal human progenitor cells (nhNPCs). nhNPCs were cultured 
as neurospheres, which contain pools of NSCs, neuronal and glial progenitor cells as 
well as lineage committed neural cells (Piao et al., 2006), providing a model of NSC 
lineage commitment. In addition, the nhNPCs examined in this study were derived 
from the human foetal cortex (Lonza), providing a cell model of endogenous hNPCs 
in comparison to the hESC-derived hNSC H9 cells. Interestingly, the comparison of 
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hNSC H9 cells and nhNPCs revealed that these cell types are vastly different in their 
neural marker and HSPG profiles (Chapter 4: section 4.3.4, (Oikari et al., 2016a)).  
Confirming that hNSC H9 cells harbour a higher self-renewal potential than 
nhNPCs, markers denoting NSC self-renewal, including nestin, SOX2, MSI1 and 
vimentin were shown to be more highly expressed in hNSC H9 cells than nhNPCs 
(Chapter 4: section 4.3.4, (Oikari et al., 2016a)). In contrast, lineage-specific markers 
(neuronal and glial) were more highly expressed in nhNPCs than hNSC H9 cells 
indicating a higher proportion of lineage-committed cells within the nhNPC cultures 
(Chapter 4: section 4.3.4, (Oikari et al., 2016a)). A surprising finding of this study 
was the higher expression of pluripotency markers OCT4 and Nanog in nhNPCs 
when compared to hNSC H9 cells. Interestingly, these findings are consistent with 
several previous studies, which have reported high OCT4 and Nanog expression in 
human neurospheres (Ilieva & Dufva, 2013; Sundberg et al., 2011). The observed 
high levels of expression of the pluripotency markers within neurospheres have been 
hypothesised to be due to the presences of a maintained pool of stem cells within the 
neurosphere core or due to the upregulation of these markers is a result of 3D 
clustering of neurospheres (Ilieva & Dufva, 2013). As neurosphere clustering of 
NPCs is an in vitro phenomenon, the in vivo relevance of the observed upregulation 
of pluripotency markers is not clear. Further examination of these markers is needed 
to better understand their role in the regulation of human neural cell behaviour in 
vitro.” 
 
In addition to the distinctly different neural lineage marker profiles between hNSC 
H9 cells and nhNPCs, the HSPG profile of the two cell types was also clearly 
different, suggesting a potential role for HSPGs in hNSC to hNPC progression. 
Consistent with previous studies, SDC1 and GPC4, which have been associated with 
ESC or NPC maintenance in the mouse model (Fico et al., 2012; Wang et al., 2012), 
were more highly expressed in hNSC H9 cells when compared to nhNPCs (Chapter 
4: section 4.3.5, (Oikari et al., 2016a)). Importantly, the expression of these “NSC 
HSPGs” correlated with the expression of NSC self-renewal markers nestin, SOX2 
and vimentin, reinforcing their function as markers of unspecified hNSCs (Chapter 4: 
sections 4.3.4 and 4.3.5, (Oikari et al., 2016a)).  Interestingly, all other syndecans 
(SDC2, SDC3 and SDC4) and glypicans (GPC1-3, -5 and -6) were observed to be 
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more highly expressed in nhNPCs when compared to hNSC H9 cells with their 
expression correlating with neuronal and glial lineage marker expression. These 
results suggest that hNSCs and hNPCs can be characterised based on their HSPG 
profile (Chapter 4: section 4.3.5 (Oikari et al., 2016a)), an important finding 
considering the known difficulty in distinguishing these lineages from each other 
based on current available markers (De Filippis & Binda, 2012; Seaberg & van der 
Kooy, 2003).   
 
In addition, as discussed in the context of pluripotency markers, the 2D and 3D 
culture structure of hNSC H9 cells and nhNPCs, respectively, may contribute to the 
observed differences in the HSPG profile of the cells. It is possible that HSPGs have 
distinct roles in the formation of cell-cell or cell-substrate connections or enabling 
cell interaction with signalling molecules in the extracellular space, with these likely 
differentially accessible within the two cell culture systems (Couchman et al., 2015; 
Fico et al., 2011). Similar to the brain, the nhNPCs represent a 3D structure 
(Hodberg et al., 2013), thus the high expression of HSPGs within these cells may be 
required for the 3D formation of these cultures. The analysis of more human neural 
cell lines would provide the opportunity to better identify whether the expression of 
HSPGs is related to hNSC lineage progression or to 3D cell formation. For example, 
similar to nhNPCs, ReN CX cells (Merck Millipore) are an hNPC line derived from 
human foetal cortex, but in contrast to nhNPCs they are cultured as an adherent 
monolayer, providing a 2D hNPC model. In contrast, examination of human ESCs or 
induced pluripotent stem cells (hiPSCs) during neural differentiation as they proceed 
through the neurosphere-like aggregate phase (D’Aiuto et al., 2014), would provide 
an additional 3D model to examine ESC-derived NSCs. To fully understand the 
specific roles of HSPGs in hNSC and hNPC regulation requires further research, 
however, these results strongly suggest a key contribution for HSPGs in the hNSC 
niche and the potential to use them as markers to characterise hNSC to hNPC 
progression. 
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8.1.4 hNSCs readily differentiate toward the neuronal lineage in vitro with glial 
differentiation achieved at a lower efficiency  
 
During basal expansion, neuronal marker expression was observed to be higher than 
glial marker expression in hNSC H9 cells indicating that the cells exhibited higher 
neuronal than glial lineage differentiation potential (Chapter 4: section 4.3.2, (Oikari 
et al., 2016b)). This observation was further supported during examination of the 
cells under neuronal and astrocyte differentiating culture conditions, where hNSC H9 
cells readily committed to the neuronal lineage while astrocyte lineage specification 
was associated with a high level of heterogeneity.   
 
To assess neuronal lineage commitment of hNSC H9 cells, four commonly used 
neuronal lineage markers, including βIII-tubulin (TUBB3), microtubule-associated 
protein 2 (MAP2), medium molecular weight neurofilament (NEFM) and 
doublecortin (DCX) were examined (Chapter 5: section 5.3.1, (Oikari et al., 2016b)). 
Neuronal differentiating hNSC H9 cells were examined and extensively 
characterised for neuronal marker expression between 14 to 40 days of culture. 
Following 14-18 days in culture under neuronal differentiating conditions, a level of 
hNSC H9 neuronal lineage commitment was observed, indicated by an upregulation 
of several neuronal markers studied (Chapter 5: section 5.3.1, (Oikari et al., 2016b)). 
However, when differentiation time was increased to 40 days, neuronal lineage 
commitment was clearly enhanced, indicated by the high upregulation of all neuronal 
markers studied and the distinctly neuronal morphology of the cells (Chapter 6: 
section 6.3.2). These observations supported previous studies reporting that 
approximately 28 to 56 days is required to yield functional neurons from various 
human stem cell types (Hu et al., 2010; Hu et al., 2016; Schulz et al., 2004; 
Swistowski et al., 2010; Zhang & Zhang, 2010).  
 
Astrocyte and oligodendrocyte lineage differentiation of hNSC H9 cells was 
achieved at a lower efficiency than neuronal differentiation. The oligodendrocyte 
lineage was not studied, primarily due to lack of lineage specificity and low viability 
of oligodendrocyte differentiating cultures. The differentiation protocol used in this 
study for oligodendrocyte differentiation was obtained from Thermo Fisher Scientific 
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and further optimisation of the conditions is likely required for the more efficient 
oligodendrocyte derivation from hNSC H9 cells. The differentiation of human 
pluripotent stem cells to oligodendrocytes has been reported to be time consuming, 
requiring up to 9 months, and the use of additional growth factors and morphogens, 
including Sonic hedgehog (Shh), platelet-derived growth factor-AA (PDGF-AA), 
insulin growth factor and neurotrophin-3 is likely required for efficient 
oligodendrocyte generation (Tabar & Studer, 2014; Wang et al., 2013) 
 
Astrocyte differentiating hNSC H9 cells grew well under the used culture conditions, 
however, upregulation of astrocyte marker expression was achieved at a 
comparatively lower level than neuronal marker expression following neuronal 
differentiation. Identified as a consistent marker of hNSC H9-derived astrocyte 
differentiating cultures was S100B, which was upregulated in expression already 
following 14-18 days of cultures (Chapter 5: section 5.3.1 (Oikari et al., 2016b)) and 
maintained at a high level when examined following 40 days of astrocyte 
differentiation (Chapter 6: section 6.3.1). Similar to observations in the neuronal 
lineage cultured cells, extending the astrocyte differentiation time to 40 days 
enhanced astrocyte lineage specificity with the astrocyte marker GFAP also highly 
upregulated when compared to basal hNSC H9 cells (Chapter 6: section 6.3.2).  
Interestingly, when examined following 40 days of differentiation via 
immunofluorescence (IF), S100B and GFAP demonstrated distinct filamentous 
expression pattern within the astrocyte cultures, with this not observed in neuronal 
differentiating cultures (Chapter 6: section 6.3.2). This expression pattern of S100B 
and GFAP resembled characteristic astrocyte processes as has been demonstrated in 
vitro and in vivo (Kirwan et al., 2015; Srinivasan et al., 2016). This observed 
upregulation in astrocyte lineage markers following 40 days of differentiation 
supports previous reports identifying the requirement of extended differentiation time 
to enable efficient astrocyte differentiation of human stem cells (Haidet-Phillips et 
al., 2014; Palm et al., 2015; Zhang et al., 2016). Further optimisation of the astrocyte 
differentiation protocol will likely enhance astrocyte lineage commitment of hNSC 
H9 cells. During astrocyte differentiation, passaging of cells was not performed, 
which resulted in high cell density, potentially preventing efficient astrocyte lineage 
commitment, due to cell density and contact inhibition. In addition, supplementation 
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of astrocyte differentiating cultures with key growth factors, such as bone 
morphogenetic protein (BMP) and ciliary neurotrophic factor (CNTF) (Shaltouki et 
al., 2013) may result in improved astrocyte differentiation of hNSC H9 cells. In 
addition, the investigation of functional attributes such as glutamate uptake will 
unravel in more detail the efficiency of the astrocyte differentiation protocol 
(Kleiderman et al., 2016; Tyzack et al., 2016). With the acknowledged heterogeneity 
of astrocytes in vivo (Sofroniew & Vinters, 2010; Sosunov et al., 2014), investigation 
of the subtype of astrocytes generated from hNSC H9 cells would provide important 
information for correlation between the in vitro findings and an in vivo system.  
 
8.1.5 Heterogeneous expression of neural lineage markers during in vitro 
differentiation of hNSCs – specificity or cell type? 
 
Interestingly, this study identified several NSC and neural lineage markers 
demonstrating heterogeneity in their expression profile, indicative of a lack of 
specificity for these markers or heterogeneity of cells in the cultures. Nestin and 
SOX2 are well established markers for the characterisation of NSC self-renewal and 
would be expected to diminish during lineage differentiation (Christie & Turnley, 
2013; Ramasamy et al., 2013). However, expression of these markers was 
maintained at a high level in neuronal and astrocyte differentiation cultures (Chapter 
6: section 6.3.2 and Chapter 7: section 7.3.5). When examined via IF, nestin 
expression was discretely localised to cell bodies and the cellular protrusions 
observed in neuronal and astrocyte differentiating hNSC H9 cells, providing key 
evidence that the expression of this protein is maintained during hNSC in vitro 
differentiation. Supporting a role for nestin as a neuronal protein, there are an 
increasing number of studies that have demonstrated nestin expression in a subtype 
of mature neurons in the adult mouse, rat and human brain (Clingman et al., 2014; 
Farzanehfar et al., 2017; Hendrickson et al., 2011; Kuwako et al., 2010). These in 
vivo findings demonstrate that nestin expression is not only a marker of in vitro NSC 
neuronal differentiation, indicating it may have a functional role as a neuronal 
protein. Nestin is a member of the intermediate filament proteins (Ramasamy et al., 
2013), potentially required for structural support of neurons similar to other neuronal 
proteins TUBB3, MAP2 and NEFM. Interestingly, recent reports have emerged of 
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nestin expression localised to astrocytes in vivo, specifically in reactive astrocytes 
generated in response to brain injury (Cho et al., 2013; Shimada et al., 2012). The 
authors hypothesise that nestin is required for the morphological changes occurring 
in the cells during reactive astrocytosis (Cho et al., 2013). These results suggest that 
nestin may have a wider expression profile in the CNS that is not specific only in the 
characterisation of NSC self-renewal. Further investigation of nestin function in 
human neurons and astrocytes will likely reveal novel functions for this protein.  
 
Surprisingly SOX2, a marker highly associated with NSC self-renewal (Zhang & 
Cui, 2014), was also maintained in the differentiating hNSC H9 cultures (Chapter 6: 
section 6.3.2). Following 40 days of differentiation, pools of SOX2 expressing cells 
were clearly evident in the sphere structures within astrocyte differentiating cultures 
(Chapter 6: section 6.3.9), likely reflecting a maintained pool of self-renewing cells 
and heterogeneity within these cultures. Long-term maintenance of self-renewal is a 
characteristics of in vitro expanded NSCs (Conti & Cattaneo, 2010), which may also 
explain the high proportion of SOX2-expressing cells observed in the cultures.  
Interestingly, SOX2 gene expression was also identified in hNSC H9-derived 
neuronal cultures at D60 of differentiation. It is important to note, however, that 
while SOX2 gene expression was observed at D60 of neuronal differentiation, the 
level of protein expression was not examined in these cultures, thus the expression of 
a functional SOX2 protein cannot be confirmed. Low levels of SOX2 expression in 
some neuron types have been previously reported (Puligilla et al., 2010; Thomson et 
al., 2011), confirming the plausibility of maintained SOX2 expression in hNSC H9-
derived neuron cultures. These results indicate that similar to nestin, SOX2 has a 
wider expression profile than previously identified and which may be specific to in 
vitro cultured neural cells. 
 
In addition to NSC markers, several neural lineage markers also demonstrated 
unexpected expression patterns. CD44, which is considered a marker of fibrous 
astrocytes both in the human and mouse brain (Naruse et al., 2013; Sosunov et al., 
2014), was found to be more highly expressed in hNSC H9-derived neuronal cultures 
than in the astrocyte differentiating cultures following 14-18 days of culture (Chapter 
5: section 5.3.1). Interestingly, CD44 expression has previously been reported in 
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some neuron subtypes (Dzwonek & Wilczynski, 2015; Naruse et al., 2013), 
indicating the neuron cultures generated in the conditions used in this study resemble 
these CD44 expressing neurons. In contrast, the astrocytes generated in this study do 
not resemble CD44-expressing astrocytes confirming CD44 is not specific as a 
marker of in vitro differentiated astrocytes.  
 
Perhaps most interestingly, all neuronal markers studied demonstrated upregulated 
expression following astrocyte differentiation when compared to basal hNSC H9 
cultures (Chapter 6: section 6.3.2). While the protein level expression of TUBB3 was 
clearly higher in the neuronal lineage cultures when compared to the astrocyte 
differentiating hNSC H9 cultures, the astrocyte lineage cultures maintained a high 
and homogeneous gene expression of TUBB3 that was also confirmed via IF 
(Chapter 6: section 6.3.2). This data strongly suggests that neuronal markers are 
maintained to some extent in hNSC H9-derived astrocytes, and is supported by 
previous studies where high levels of TUBB3 expression was observed in human 
foetal astrocyte cultures (Draberova et al., 2008). Similar to the expression of nestin, 
neuronal lineage markers, including MAP2, have been identified in reactive 
astrocytes (Khakh & Sofroniew, 2015), suggesting the astrocyte cultures derived 
from hNSC H9 cells may exhibit a reactive astrocyte phenotype. Expression of other 
neuronal lineage markers, including NEFM and DCX would be expected to diminish 
during astrocyte lineage commitment of the cultures. Their observed upregulation in 
gene expression when compared to basal hNSC H9 cells suggests a high level of 
heterogeneity within the hNSC H9-derived astrocyte cultures. This is likely due to 
the high level of neuronal differentiating progenitors within the cultures, resulting 
from a higher neuron versus glial differentiation potential of the hNSC H9 cells. 
Overall, these results demonstrate that NSC and neural lineage markers have a wider 
expression profile than previously identified, specifically in vitro. As a result, many 
of these markers are not adequate for lineage characterisation when used 
independently and the identification of appropriate combinations, rather than the use 
of single markers, is crucial for adequate cell characterisation.  
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8.1.6 In vitro neuronal differentiation of hNSCs is associated with highly 
upregulated HSPG expression with fewer changes observed following 
astrocyte differentiation 
 
Similarly to the observed differences in HSPG expression between hNSC H9 and 
nhNPCs cultures, neuronal differentiation of hNSC H9 cells significantly altered the 
HSPG profile of the cells (Chapter 5: sections 5.3.2 and 5.3.3 (Oikari et al., 2016b)). 
Several HSPGs, including SDC4, GPC1, GPC2, GPC4 and GPC6 were identified as 
markers of neuronal differentiating cells following 14 to 18 days of differentiation 
(Chapter 5: section 5.3.3 (Oikari et al., 2016b)). Interestingly, when the neuronal 
differentiation time was increased to 40 days, more changes in the HSPG prolife of 
the cells was observed when compared to basal hNSC H9 cultures, with SDC1, 
SDC4, GPC1, GPC2, GPC3, GPC4 and GPC6 identified to be neuronal lineage 
specific (Chapter 6: section 6.3.3).  These results demonstrate that induced HSPG 
gene expression is associated with human neurogenesis, suggesting HSPGs are key 
mediators of this process. Additionally, upregulated HSPG expression correlated 
with upregulated neuronal marker expression, suggesting HSPGs can be used as 
novel markers of human neuron characterisation in combination with neuronal 
markers, including TUBB3, MAP2, NEFM and DCX.   
 
Interestingly, this study found SDC1 and SDC4 to be highly expressed in hNSC H9 
neuronal cultures, although these HSPGs are not commonly identified as neuron 
specific. Several studies have identified SDC1 to be associated with NSC 
maintenance as it has been shown to be important in mouse NPC self-renewal and 
proliferation and its expression in the developing rodent brain is generally associated 
with areas of undifferentiated neuroepithelial cells (Ford-Perriss et al., 2003; Wang et 
al., 2011). In addition, SDC4 in the rodent has been identified to be glial-specific 
with its expression associated with astrocytes (Avalos et al., 2009; Hsueh & Sheng, 
1999). Thus, the upregulated expression of SDC1 and SDC4 during hNSC H9 
neurogenesis support that these HSPGs are also important in developing human 
neurons, which is an interesting and novel finding. In support of this, Murakami et 
al. reported in two separate studies that SDC1 expression is induced in mouse 
peripheral motor neurons and primary sensory neurons following nerve injury, 
suggesting a role for SDC1 in nerve regeneration (Murakami et al., 2015; Murakami 
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& Yoshida, 2012). Murakami et al. also reported functional roles for SDC1 in 
mediating neurite outgrowth in mice (Murakami et al., 2015), indicating SDC1 may 
also have this role in human neurons. In mice, SDC4 expression has been shown to 
be required for neuron-mediated adhesion of astrocytes and it has also been reported 
to mediate mouse dorsal root ganglion neuron adhesion (Avalos et al., 2009; Lin et 
a., 2015), suggesting SDC4 may have similar adhesion-mediating roles in 
differentiating human neurons. As SDCs mediate cell adhesion, the expression of 
SDC1 and SDC4 may be required for their cell adhesion and migration modulatory 
effects during neurogenesis (Murakami et al., 2015). In contrast to SDC1 and SDC4, 
the two other SDCs, SDC2 and SDC3 previously associated with neuronal specificity 
in the rodent (Ford-Perriss et al., 2003; Hienola et al., 2006; Hsueh & Sheng, 1999), 
were not upregulated during hNSC H9 neuronal differentiation and thus, not 
identified in this study as markers of human neuronal lineage. As discussed 
previously (section 8.1.2), SDC2 and SDC3 may play a role in hNSC maintenance 
rather than neuronal differentiation.  These results also demonstrate that the rodent 
and human nervous system biology may differ in key features and highlighting the 
importance of human-based research.  
 
This study identified GPCs to be key markers of human neurogenesis with all the 
studied GPCs upregulated in expression during hNSC H9 in vitro neuronal 
differentiation. Supporting the importance of GPCs during human neurogenesis was 
the consistent upregulation of GPC core protein gene expression following 14 to 18 
and 40 days of hNSC H9 neuronal differentiation (Chapter 5: section 5.3.3 and 
Chapter 6: section 6.3.3 (Oikari et al., 2016b)). A number of previous studied have 
reported the importance of GPCs in neuronal cells by demonstrating that these 
proteins interact with axon guidance and synaptic proteins mediating axon guidance 
or synaptic development in C. elegans and the rodent (Allen et al., 2012; Blanchette 
et al., 2015; de Wit et al., 2013; Ko et al., 2015; Ronca et al., 2001). Thus, based on 
the high gene expression levels of GPCs in neuronal differentiation hNSCs, the 
results suggest that GPC expression may be required for the development of axons 
and synapses. This hypothesis is supported for several GPCs, with GPC1, GPC2 and 
GPC4 expression shown to localise to rodent neurons (Bloechlinger et al., 2004; de 
Wit et al., 2013; Ford-Perriss et al., 2003; Ivins et al., 1997; Jen et al., 2009; 
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Murakami et al., 2015). In addition, specifically GPC4 has been shown to interact 
with synaptic proteins and is required for synaptic activity (Allen et al., 2012; de Wit 
et al., 2013; Ko et al., 2015). Interestingly, fewer reports exist in the literature 
describing neuronal specificity for GPC3 and GPC6, which were also upregulated 
following neuronal differentiation of hNSC H9 cells. However, a number of studies 
support their importance within the neuronal lineage. For example, in humans GPC3 
expression has been reported to localise within spinal cord neurons and dorsal root 
ganglia during foetal development (Iglesias et al., 2008). In addition, in the rodent 
model GPC6 together with GPC4 has been shown to be important in astrocyte-
mediated synaptic development (Allen et al., 2012). Importantly, GPC3, GPC4 and 
GPC6 have been demonstrated to mediate key neuroregulatory signalling pathways, 
including Wnt and Shh (Capurro et al., 2008; Capurro et al., 2014; Fico et al., 2012; 
Sakane et al., 2012). As these pathways play key roles during neuronal development, 
these GPCs are likely important in modulating the activity of these pathways during 
human neurogenesis.  
 
Interestingly, the results of this study indicate that hNSC astrocyte differentiation is 
not associated with increased HSPG expression. When the astrocyte differentiating 
cultures were examined following 40 days of differentiation, the expression of the 
majority of the SDCs and GPCs studied was not altered or was significantly 
downregulated in expression when compared to basal hNSC H9 and neuronal 
differentiating cultures (Chapter 6: section 6.3.3). It appears that as hNSCs commit to 
the astrocyte lineage, they lose their requirement for HSPG expression. With the 
known roles of SDCs and GPCs in axon and synaptic regulation, it is likely that they 
are not required in the astrocyte lineage.  Interestingly, one HSPG, GPC4, which was 
highly upregulated following hNSC H9 neuronal differentiation, also demonstrated 
specificity for the astrocyte lineage. GPC4 was shown to be upregulated in astrocyte 
differentiating cultures following 14-18 days of differentiation with its high 
expression maintained following 40 days of differentiation (Chapter 5: section 5.3.3, 
Chapter 6: section 6.3.3 (Oikari et al., 2016b)). These results suggest that GPC4 
likely has a key role in astrocytes, which is supported by a previous study by Allen et 
al. who reported GPC4 to be a key regulator of astrocyte-mediated synaptic function 
in rodents (Allen et al., 2012). It is, thus possible, that GPC4 expression is required 
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in astrocytes to mediate neuron function. The study by Allen et al. also reported 
GPC6 to have a similar function to GPC4 (Allen et al., 2012). In this study, GPC6 
expression was shown to be induced in astrocyte differentiating cultures during the 
early stages of differentiation (14 to 18 days) (Chapter 5: section 5.3.3, (Oikari et al., 
2016b)), however, following 40 days of differentiation the upregulated expression of 
GPC6 in the astrocyte cultures was lost. This data indicates that GPC6 may 
contribute to the specification of the human astrocyte lineage, however the 
contribution of GPC6 to the process of differentiation is required at a lower level 
than GPC4. Interestingly, GPC4 and GPC6 are structurally homologous and 
functionally redundant (Allen et al., 2012), suggesting high expression of GPC4 may 
result in decreased expression of GPC6. Overall, co-expression of GPC4 with S100B 
and GFAP will likely provide an efficient combination of markers for more specific 
astrocyte lineage characterisation.  
 
Data presented here demonstrate that hNSC-derived neuronal and astrocyte cultures 
can be distinguished from undifferentiated hNSCs based on their HSPG profile. 
Specifically, SDC1, SDC4, GPC1, GPC2, GPC3, GPC4 and GPC6 provide novel 
markers for neuronal lineage characterisation to be used in combination with other 
neuronal markers, including TUBB3, MAP2, NEFM and DCX. In addition, hNSC-
derived astrocytes can be distinguished from undifferentiated hNSCs and neuronal 
lineage cells based on their downregulated HSPG expression profile, but maintained 
GPC4, in combination with S100B and GPC4. Importantly, due to their cell surface 
localisation, GPCs provide excellent targets for cell isolation, characterisation and 
cell fate control for neural cell based applications. Further investigation of the 
specific functions of each GPC pose an interesting avenue of novel research and will 
increase our understanding of human neural cell biology and the factors controlling 
these cells. This could be done by editing or deleting HSPG genes within the hNSC 
genome using stable methodology, such as CRISPR/Cas9 (Yang & West, 2016), 
which will likely reveal cues whether HSPGs are involved in mediating hNSC fate 
determination. In addition, examination of HSPG expression in vivo is important to 
confirm the in vitro roles of HSPGs, however, it is important to acknowledge that in 
vivo research remains challenging in the human system. Finally, other PG 
superfamilies, including chondroitin sulfate PGs (CSPGs) may play a more important 
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role in hNSC-derived astrocytes than HSPGs. For example, injury induced reactive 
astrocytes express high levels of CSPGs to form a glial scar, suggesting a larger role 
for these PGs in the astrocyte lineage (Farhy Tselnicker et al., 2014). Further 
investigation of human astrocyte-specific PGs will contribute to the better 
understanding of the biology of these cells and likely aid in their more efficient 
isolation and expansion.  
 
8.1.7 HS chain modifications likely play a key role during hNSC differentiation 
 
SDCs and GPCs carry HS side chains, synthesised post-translationally via a co-
ordinated temporal action of multiple biosynthesis enzymes (Maeda et al., 2011; 
Oikari et al., 2016b). The HS biosynthesis enzymes consist of HS chain elongating 
(EXT1 and EXT2), modifying (NDST1-4, C5-EP) and 2-O- and 6-O-sulfation 
catalysing enzymes (HS2ST1, HS6ST1-3), which generate a heterogeneous 
collection of HS chains that vary in length and sulfation pattern (Maeda et al., 2011; 
Oikari et al., 2016b). The HS chain length along with the sulfation pattern is critical 
in determining, which signalling molecules, including growth factors and 
morphogens, HSPGs are able to interact with and mediate the activity of, which is a 
central characteristic of HSPG function (Jastrebova et al., 2010; Maeda et al., 2011;  
Oikari et al., 2016b; Okolicsanyi et al., 2014a).  
 
A key finding of this study was that in vitro differentiation of hNSC H9 cells 
distinctly altered HS biosynthesis enzyme gene expression profile of the cells, 
suggesting altered HS side chain synthesis and modification during lineage 
commitment (Chapter: sections 4.3.3 and 4.3.5, Chapter 5: section 5.3.2 and Chapter 
6: section 6.3.3 (Oikari et al., 2016b)). A central discovery was that lineage 
commitment of hNSCs was associated with decreased HS synthesis and subsequent 
2-O-sulfation. This was indicated following comparison of basal hNSC H9 cells with 
nhNPCs as well as neuronal and astrocyte differentiating cultures, with the more 
lineage-committed cell types demonstrating decreased gene expression levels of key 
HS chain synthesising EXT1/EXT2 and HS-2-O-sulfation catalysing HS2ST1 when 
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compared to basal hNSC H9 cells (Chapters 4: section 4.3.5, Chapter 5: section 5.3.2 
and Chapter 6: section 6.3.3 (Oikari et al., 2016a; Oikari et al., 2016b)). In addition, 
the findings of this study strongly suggest that hNSC lineage differentiation is 
associated with an altered HS chain N- and 6-O-sulfation profile, indicated by vastly 
altered N-deacetylation/N-sulfation catalysing NDST, and 6-O-sulfation catalysing 
HS6ST, gene expression (Chapter 6: section 6.3.3).  Interestingly, following neuronal 
and astrocyte differentiation of hNSC H9 cells opposing changes in NDST and 
HS6ST gene expression were observed, suggesting differential HS side chain 
modifications during differentiation of these lineages.  
 
Interestingly, when the N-deacetylation/N-sulfation catalysing NDSTs were 
examined,  neuronal differentiation of hNSC H9 cells was specifically associated 
with increased NDST1 and NDST4 gene expression while, in contrast, astrocyte 
differentiation was associated with decreased NDST1, NDST2 and NDST4 gene 
expression. Thus, the NDST enzyme activity differs between differentiation of the 
two neural cell lineages. Interestingly, however, a similarity between both neuronal 
and astrocyte differentiation was the associated increase in NDST3 gene expression, 
suggesting NDST3 activity has general importance during hNSC in vitro lineage 
specification (Chapter 6: section 6.3.3).  NDST3 expression in the mouse has been 
reported to be brain-specific, with its activity in the brain appearing to be region 
specific (Aikawa et al., 2001; Pallerla et al., 2008). In addition, in humans variations 
in the NDST3 gene have been associated with schizophrenia (Lencz et al., 2013). 
These reports suggest that NDST3 expression likely has a role in the CNS with its 
activity possibly important in mediating hNSC lineage commitment. The N-
deacetylation/N-sulfation properties differ between the NDSTs, with for example 
NDST3 reported to have high N-deacetylation and low N-sulfation properties with 
the properties of NDST4 the opposite to NDST3 (Aikawa et al., 2001). These 
differences between NDSTs likely give NDSTs their unique roles with the 
differential N-sulfation pattern of  HS-chains likely required for  lineage-specific 
hNSC differentiation.  
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Similar to the N-sulfation pattern, the changes in the expression of HS O-
sulfotransferases observed in this study suggest an altered HS-chain O-sulfation 
pattern during hNSC in vitro differentiation. Specifically, increased HS chain 6-O 
sulfation appears to be key feature of hNSC neuronal differentiation, as all the 
HS6ST enzymes were observed to be highly upregulated during hNSC H9 neuronal 
differentiation (Chapter 4: section 4.3.5, Chapter 5: section 5.3.2 and Chapter 6: 
section 6.3.3 (Oikari et al., 2016a; Oikari et al., 2016b)). These results indicate that 
during neuronal lineage commitment, hNSCs develop an increased requirement for 
6-O-sulfation sites rather than 2-O-sulfation sites. As 2-O-sulfation sites are 
generally associated with FGF-2 binding, a decreased requirement for FGF-2 during 
lineage commitment is suggested (Jung et al., 2016). In contrast, the cells develop a 
preference for growth factors that bind to 6-O-sulfation sites, for example other FGF 
family members, including FGF-4, FGF-7 or FGF-10 (Ashikari-Hada et al., 2004; 
Sugaya et al., 2008). In addition, the increased HS6ST expression may indicate 
altered Wnt signalling, as HS6ST1 expression has been shown to be required for 
Wnt2 signalling (Habuchi et al., 2007). Finally, FGF1 and glial cell-derived 
neurotrophic factor have been reported to have high affinity for 6-O-sulfated sites 
(Shah et al., 2011), suggesting these growth factors may also have importance during 
hNSC neurogenesis. The shift to 6-O-sulfation of HS chains has been previously 
reported during differentiation of other stem cell types, including rat mesenchymal 
stem cell (MSCs) osteogenic differentiation (Zhao et al., 2015), mouse ESC neuronal 
differentiation (Johnson et al., 2007; Nairn et al., 2007) and hESC splanchnic 
mesoderm differentiation (Gasimli et al., 2014), further supporting the importance of 
6-O-sulfation during stem cell differentiation. Interestingly, increased 6-O-sulfation 
did not appear to be a key feature of gliogenesis as an increase in HS6STs was not 
observed in astrocyte differentiating cultures. This supports the reduced importance 
of HSPG-mediated signalling during astrogliosis as discussed in the previously 
(section 8.1.6). These results provide evidence that during hNSC in vitro 
differentiation, HS- chains within the cells are extensively modified to allow the 
chains to interact with the changing local signalling environment. The interactions 
between HS-chains and the environment are likely different to those required for 
hNSC H9 cell maintenance. An interesting future direction would be to characterise 
the HS chain-growth factor interactions that occur during hNSC in vitro 
differentiation and modulate these interactions using, i.e. specific HS digesting 
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enzymes such as heparinase (Ghadiali et al., 2016; Holley et al., 2011) to guide 
lineage progression.  
 
8.2 DIFFERENTIATION OF HUMAN NEURAL STEM CELLS CAN BE 
MODULATED THROUGH HEPARAN SULFATE AND HS-BINDING 
GROWTH FACTORS  
 
With results clearly demonstrating that hNSCs express HSPGs and that the HSPG 
profile of these cells is distinctly altered following in vitro lineage differentiation, the 
addition of exogenous HS and its effect on modulating hNSC lineage specificity was 
examined. Heparin, a highly sulfated analogue of HS was used as an exogenous HS 
supplement. Heparin supplementation to the cell culture medium has been shown in 
several studies to promote the survival, proliferation and differentiation of various 
cell and stem cell types (Furue et al., 2008; Okolicsanyi et al., 2014b; Pickford et al., 
2011; Simann et al., 2015; Yamasaki et al., 2013). The actions of heparin are thought 
to be achieved through its ability to bind heparin-binding molecules both in the 
extracellular space (i.e. FGFs) and on the cell surface (i.e. FGFR), which results in 
enhanced downstream signalling (Forsten et al., 2000). Reports of heparin 
supplementation on the promotion of neural differentiation are currently 
contradictory. In the mouse model heparin supplementation has been reported to 
promote neural differentiation of iPSCs or ESCs in the presence of FGF-2 or in the 
presence of B-27- and N2-supplements, respectively (Pickford et al., 2011; Yamasaki 
et al., 2013). Conversely, in the human model, heparin in the presence of FGF-2 has 
been shown to promote hESC maintenance or stemness (Furue et al., 2008). 
However, in a protocol described by Zhang et al.  heparin supplementation in 
combination with N-2 supplement has been used for neural induction of hESCs, 
however, addition of heparin to the cultures is not continued during neural 
differentiation of the cells (Zhang & Zhang, 2010).  
 
With the effects of heparin appearing to be ligand-dependent, key neuroregulatory 
growth factors - brain-derived neurotrophic factor (BDNF) and PDGF – were used in 
this study alone and in combination with heparin to investigate their ability to 
mediate hNSC lineage fate. BDNF and PDGF have previously been shown to have a 
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positive effect on neuronal survival or neural cell type proliferation in both human 
and rodent models (D'Aiuto et al., 2014; Liu et al., 2014; Wei et al., 2015; Yang et 
al., 2013; Yao et al., 2012). In addition, these growth factors have been reported to 
bind HS (Abramsson et al., 2007; Kanato et al., 2009; Sasisekharan et al., 2002)..  
 
Preliminary results examining the efficiency of lineage differentiation of hNSCs in 
the presence of BDNF and PDGF and heparin in this study demonstrated the 
modulatory effects of heparin, BDNF and PDGF on neuronal and astrocyte 
differentiating hNSC H9 cultures when exposed for 40 days (Chapter 6: sections 
6.3.4 to 6.3.10). While BDNF clearly supported the growth and survival of neuronal 
differentiating cultures, PDGF supplementation, interestingly, induced the expression 
of neuronal lineage markers, along with HS biosynthesis and HSPG core protein 
genes within the astrocyte cultures (Chapter 6: sections 6.3.4 to 6.3.10). These results 
demonstrated the ability promote neuronal growth and survival using BDNF and 
steering astrocyte differentiating cultures toward a neuronal phenotype in the 
presence of PDGF. Thus, based on these observations, the ability to use these 
supplements to modulate human neurogenesis in vitro was then examined. To do 
this, hNSC H9 cells were differentiated toward the neuronal lineage in the presence 
of heparin, BDNF and PDGF. In addition, due to the beneficial effects of BDNF on 
neuronal cell growth and the neuromodulatory effects of PDGF, the combined 
treatment of BDNF+PDGF was also trialled. All growth factor conditions were 
performed in the presence and absence of heparin supplementation to examine any 
HS-growth factor interactions. To ensure enhanced neuronal lineage commitment 
with neuronal functionality, neuronal differentiating cultures were examined 
following long-term differentiation of 40 and 60 days. Although patch-clamp 
analysis was not used in this study to test neuronal functionality, confirmation that 60 
days in culture increased the presence of functioning cells was indicated by an 
increase in the proportion of cells generating spontaneous Ca2+ signal spikes at D60 
(50%) when compared to D40 (25%).  
 
Following neuronal differentiation of hNSC H9 cells in the presence of the discussed 
in vitro modulations, the cultures were examined for differences in morphology, 
viability, proliferation, marker expression, heterogeneity and functional activity to 
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compare the treatments on neuronal specification. The results demonstrated that 
supplementing hNSC-derived neuronal differentiating cultures with heparin, BDNF 
and PDGF resulted in the generation of phenotypically different neuron populations 
that demonstrated distinct differences in multiple characteristics examined.  An 
important finding was that the various treatments used in this study clearly altered 
gene expression of the cells, an important consideration when using these 
supplements in neuronal differentiation protocols. The effects of each of the 
supplements examined are discussed below.  
 
Heparin 
This study demonstrated that heparin supplementation of neuronal differentiating 
hNSC cultures promoted the presence of proliferating cells within the cultures and 
altered neuronal marker expression without increasing culture heterogeneity (Chapter 
7: sections 7.3.3 to 7.3.5).  The presence of proliferating cells was identified via the 
proliferation marker Ki67 with heparin treated neuronal cultures exhibiting a higher 
percentage of Ki67-positive (Ki67+) cells following 60 days of differentiation than 
observed in the untreated neuronal differentiating cultures (Chapter 7: section 7.3.3).  
These results support the cell proliferation stimulating effects of heparin, observed 
previously in basal hNSC H9 cells (Chapter 3: section 3.4.1), and other human cell 
types (Furue et al., 2008; Okolicsanyi et al., 2014b; Simann et al., 2015; Yamasaki et 
al., 2013). Interestingly, heparin supplementation of the neuronal cultures altered 
neuronal lineage specificity, indicated by altered neuronal marker expression. 
Specifically, when examined following 60 days of differentiation, cultures treated 
with heparin exhibited upregulation of TUBB3 and DCX gene expression and MAP2 
protein expression when compared to the untreated neuronal cultures (Chapter 7: 
section 7.3.4). MAP2 and DCX are commonly used markers for neuronal lineage 
characterisation, with DCX specifically considered to be a marker of new neurons 
(Ansorg et al., 2012; Ernst et al., 2014). The upregulated expression of these markers 
together with the observed increase in proliferation suggests enhanced neurogenesis 
in the heparin treated cultures when compared to untreated neuronal cultures. 
Importantly, heparin supplementation did not increase culture heterogeneity i.e. the 
expression of NSC self-renewal or astrocyte markers when examined following 60 
days of culture under neuronal differentiation culture conditions (Chapter 7: section 
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7.3.5). Interestingly, although heparin appeared to stimulate neurogenesis it did not 
increase the number of cells generating spontaneous Ca2+ signals when compared to 
untreated neuronal cultures at D60. This suggested heparin did not promote 
spontaneous activity of neurons (Chapter 7: section 7.3.6). In this study a 
concentration of 10 μg/mL of heparin was used, found to elicit the highest 
proliferative response in basal hNSC H9 cells when compared to other tested heparin 
concentrations (2.5 or 5 μg/mL) (Chapter 3: section 3.4.1). However, lower 
concentrations (2-5 μg/mL) of heparin have been previously described in the 
literature to induce neural differentiation of mouse and human ESCs (Forsberg et al., 
2012; Pickford et al., 2011; Zhang & Zhang, 2010). Heparin concentrations as low as 
10-100 ng/ml have been shown to elicit a differentiation response in mouse ESCs 
and muscle satellite cells, suggesting the effectiveness of low concentrations of 
heparin in modulating stem cell differentiation (Ghadiali et al., 2016; Holley et al., 
2011). It is conceivable that the higher concentration of heparin used in this study 
may promote proliferation with the lower heparin concentration to more effectively 
induce neuronal specification of hNSCs. This examination of the effects of heparin 
over a wider concentration range than used in this study, may identify more optimal 
concentrations for the stimulation of hNSC neurogenesis. The results of this study 
do, however, support the use of heparin as a supplement in neuronal differentiation 
protocols of hNSCs with positive effects observed on cell proliferation and neuronal 
marker expression.  
 
BDNF and BDNF+heparin 
The most notable effect of BDNF and BDNF+heparin supplementation on neuronal 
differentiating hNSC H9 cultures was the increase in cell number when compared to 
cultures without BDNF (Chapter 7: section 7.3.1). The increased cell number was 
evident throughout the differentiation process (Fig. G2 Appendix G), supporting the 
well-documented neuronal survival promoting effects of BDNF (Fenner, 2012; Liu et 
al., 2014).  When examined following 60 days of culture, BDNF supplementation 
with and without heparin also appeared to increase the number of sphere formations 
identified within the neuronal cultures when compared to untreated neuronal 
cultures, suggesting a positive effect for BDNF in the formation of these structures 
(Chapter 7: section 7.3.1). BDNF has reported modulatory effects on rodent neuron 
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morphology, including dendritic spine maturation and axonal branching (Chapleau et 
al., 2008; Danzer et al., 2002; Kellner et al., 2014), suggesting BNDF is important 
for neuronal maturation. The observed sphere structures were not, however, larger in 
diameter than those observed in the untreated neuronal cultures, contradicting 
previous reports in the rat model, where BDNF supplementation was reported to 
result in increased neurosphere diameter (Li et al., 2009). The observed effects of 
BDNF on neurosphere diameter may have been due to a different concentration (40 
ng/mL) of BDNF in comparison to the concentration used in this study (10 ng/mL). 
Interestingly, BDNF and BDNF+heparin treated cultures were observed to contain a 
significantly higher proportion of viable cells (>80%) when examined at D40 of 
differentiation (Chapter 7: section 7.3.2). Similarly, a significantly increased 
percentage of proliferating cells (Ki67+ cells) was observed within the BDNF and 
BDNF+heparin supplemented cultures when compared to untreated neuronal 
cultures. These results suggested a beneficial effect of BDNF on neuronal viability 
and growth (Chapter 7: section 7.3.3). Interestingly, combining BDNF with heparin 
further stimulated cell proliferation within these cultures, demonstrated by the higher 
percentage of Ki67+ cells when compared to BDNF only cultures (Chapter 7: section 
7.3.3). This supports an interaction of heparin with BDNF and their combined use 
induce the signalling effects of BDNF. Surprisingly, when the effect of BDNF 
supplementation on neuronal specificity (i.e. neuronal marker expression) was 
examined the effects were not as expected from previous studies. Several previous 
reports in the rodent model have reported BDNF treatment to induce the expression 
of neuronal markers, including TUBB3, MAP2 and NEFM (Cardenas-Aguayo et al., 
2013; Li et al., 2009), however, in this study the effect was not seen. In contrast, 
neuronal differentiating cultures exposed to BDNF were generally shown to express 
a significantly lower level of the studied neuronal markers when compared to the 
untreated cultures (Chapter 7: section 7.3.4). Interestingly, when examined at the 
D40 timepoint, the combination of BDNF+heparin increased the gene expression of 
TUBB3 and DCX when compared to the BDNF only cultures, supporting the 
stimulatory effect when combining heparin with BDNF (Chapter 7: section 7.3.4). 
Although BDNF and BDNF+heparin treated cultures appeared to express a 
decreased level of neuronal marker genes, these cultures did not exhibit increased 
culture heterogeneity, i.e. NSC or astrocyte marker expression, when compared to 
the untreated neuronal cultures following 60 days of culture (Chapter 7: section 
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7.3.5). Thus, it is likely that the decreased neuronal marker expression is due to the 
development of a different subtype of neurons than in the absence of BDNF. This is 
supported by work by Silva et al. who reported that exposing mouse brain-derived 
neurospheres to BDNF promoted the generation of γ-aminobutyric acid 
(GABA)ergic neurons (Silva et al., 2009). Similarly, BDNF has been shown to 
promote GABAergic neuronal differentiation from hMSCs further supporting its 
stimulatory effect on the specification of this neuron subtype (Hu et al., 2014). The 
examination of more specific neuronal subtype markers would reveal differences in 
neuronal cell composition between the untreated and BDNF treated neuronal 
differentiating cultures and confirm the presence of lineage subtypes.  When 
examined at D60 of culture, the addition of BDNF and BDNF+heparin to the 
cultures did not positively affect the generation of spontaneous Ca2+ signals within 
the cultures when compared to untreated neuronal cultures (Chapter 7: section 7.3.6). 
However, neuronal cultures treated with the combination of BDNF+heparin were 
shown to contain a higher number of Ca2+ signal generating cells than BDNF only 
treated cultures, again supporting the stimulatory effects of combining heparin with 
BDNF to promote neurogenesis (Chapter 7: section 7.3.6). Overall, these results 
support the use of BDNF as a supplement in hNSC neuronal differentiating cultures 
to promote cell survival and proliferation. In addition, combining BDNF with 
heparin enhances the neuronal viability and proliferation stimulating effects of 
BDNF, supporting their use in combination. However, BDNF did not induce 
neuronal marker expression or spontaneous activity in hNSC H9-derived neuronal 
cultures, suggesting this growth factor may promote the generation of a different 
neuron subtype with reduced spontaneous activity. The BDNF concentration used in 
this study (10 ng/ml) is commonly described in human stem cell neuronal 
differentiation protocols (D'Aiuto et al., 2014; Miura et al., 2015; Palm et al., 2015), 
however, higher concentrations of BDNF (40-50 ng/ml) may further increase 
neuronal specification (Li et al., 2009; Zhang et al., 2011).  Based on these results, 
BDNF supplementation may be most beneficial when used at the early stage of 
neuronal culture to promote cell growth and survival and then withdrawn to drive 
neuron lineage specification. For example, increased neuronal lineage differentiation 
may be achieved when BDNF supplementation is used for example, up to 40 days in 
culture, and then withdrawn to yield a higher proportion of neuron marker 
expressing, spontaneously active cells. 
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PDGF and PDGF+heparin 
Unlike BDNF, PDGF supplementation is not commonly used as a supplement in 
neuron differentiation protocols. Interestingly, however, this study identified PDGF 
supplementation to positively stimulate neuronal lineage differentiation of hNSC H9 
cells. When examined at early stages of differentiation, PDGF supplementation did 
not have similar beneficial effects on cell number as observed for BDNF, however, 
following 60 days of differentiation, a high cell number along with the presence of 
extensive neuronal connections was observed within the PDGF and PDGF+heparin 
treated cultures (Chapter 7: section 7.3.1) (Fig. G3 Appendix G). These observations 
support a role for the PDGF pathway on regulating neuron morphology, previously 
reported in the rodent model (Shioda et al., 2012), indicating a role for PDGF in 
neuron maturation. When examined following 40 days of culture, PDGF and 
PDGF+heparin treated cultures exhibited higher viability when compared to 
untreated neuronal cultures, however, following 60 days of culture, this effect was 
lost (Chapter 7: section 7.3.2). In addition, PDGF alone and PDGF+heparin 
supplementation did not increase the number of proliferative cells within the 
neuronal cultures when compared to untreated neuronal cultures (Chapter 7: section 
7.3.3). These results suggest that in contrast to BDNF, PDGF signalling does not 
promote neuronal viability and proliferation. Interestingly, however, PDGF 
supplementation had differential effects to BDNF on neuronal marker expression 
with PDGF treated neuronal cultures expressing a higher level of the studied 
neuronal marker genes than observed in the BDNF treated cultures (Chapter 7: 
sections 7.3.4 and 7.3.5). Neuronal cultures supplemented with PDGF exhibited 
increased TUBB3 expression at both the D40 and D60 differentiation timepoints 
(Chapter 7: section 7.3.4), consistent with previous reports in the rat model (Yang et 
al., 2015). Importantly, the increased expression of neuronal markers in PDGF-
treated cultures did not correlate with increased heterogeneity (NSC or astrocyte 
marker expression), suggesting the effects of PDGF were neuronal lineage promoting 
(Chapter 7: section 7.3.5). An interesting observation was that structurally PDGF 
treated cultures appeared more “neuron-like” when compared to the other neuronal 
cultures, indicated by thin and highly elongated cell bodies (Chapter 7: section 
7.3.4). Importantly, when examined at D60 of culture, PDGF and PDGF+heparin 
treated neuronal cultures contained the highest proportion (85% and 65%) of 
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spontaneous Ca2+ signal generating cells when compared to the other culture 
conditions, indicating high spontaneous activity (Chapter 7: section 7.3.6). The 
results presented here strongly suggest the beneficial effects of PDGF stimulation on 
hNSC in vitro neurogenesis. The effects of PDGF on hNSC neurogenesis are 
sparsely investigated in the human model, however a number of reports in the rodent 
model have described neuronal differentiation stimulating effects of PDGF (Yang et 
al., 2013; Yang et al., 2015; Yao et al., 2012). Interestingly, in contrast to BDNF, 
combining heparin with PDGF did not augment the effects of PDGF, suggesting the 
combination of these two factors does not provide additional benefit to the effects of 
PDGF alone. With the PDGF treatment not significantly stimulating viability or the 
presence of proliferating cells within the cultures, the use PDGF may be most 
beneficial when combined with BDNF in a sequential manner, i.e. administering 
hNSC-derived cultures first with BDNF+heparin for enhanced survival and 
proliferation, and then switching the supplementation to PDGF to yield a pure, 
spontaneously active neuron population. 
 
BDNF+PDGF and BDNF+PDGF+heparin 
This study also investigated the potential beneficial effects of BDNF+PDGF co-
treatment on hNSC neurogenesis, however, no added benefit was found in this study 
for the use of these two growth factors together. Similarly to BDNF only treated 
cultures, BDNF+PDGF treated neuronal differentiating cultures exhibited a higher 
cell number when compared to culture conditions containing no BDNF, however, the 
administration of BDNF+PDGF or BDNF+PDGF+heparin did not increase neuronal 
culture viability or proliferation beyond to those observed in BDNF or PDGF only 
treated cultures (Chapter 7: sections 7.3.1 to 7.3.3). In addition, the combined 
treatment of BDNF+PDGF and BDNF+PDGF+heparin appeared to reduce neuronal 
lineage specificity as indicated by the decreased neuronal marker and increased NSC 
marker gene expression observed when compared to the untreated neuronal cultures 
(Chapter 7: sections 7.3.4 and 7.3.5). When examined following 60 days of culture, 
neuronal cultures treated with BDNF+PDGF and BDNF+PDGF+heparin were not 
demonstrated to contain a higher proportion of spontaneous Ca2+ signal generating 
cells when compared to the untreated neuronal cultures (Chapter 7: section 7.3.6). 
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These results suggest that the combined use of BDNF and PDGF does not support 
enhanced hNSC neurogenesis.  
 
8.3 GPC1 AND GPC4 ARE NEURONAL PROTEINS AND ARE LIKELY 
INVOLVED IN BDNF- AND PDGF-MEDIATED NEURAL LINEAGE 
SPECIFICATION OF HUMAN NEURAL STEM CELLS 
 
This study is the first to demonstrate the localised expression of GPC1 and GPC4 in 
hNSC-derived neuronal differentiating cells following long-term culture (60 days) 
(Chapter 7: section 7.5.1). The high level of expression of GPC1 and GPC4 within 
hNSC-derived neuronal cultures provides evidence that these HSPGs are key 
proteins of the hNSC in vitro microenvironment and likely of human neurogenesis. 
GPC1 and GPC4 clearly localised along the neurites and within cell bodies of 
differentiating hNSC-derived neurons similar to other neuronal proteins, including 
TUBB3 and MAP2. The highly interesting observation was that in many areas of the 
examined neuronal cultures GPC1 and GPC4 demonstrated a largely differential and 
discreet localisation pattern, with many areas identified to express only one of these 
GPCs (Chapter 7: section 7.5.1). These results strongly suggest that GPC1 and GPC4 
have distinct roles within differentiating neuronal cultures. With both GPC1 and 
GPC4 reported to have roles in the rodent mediating synaptic function (de Wit et al., 
2013; Ko et al., 2015; Ronca et al., 2001), it is likely these two proteins have similar 
roles in human neurons. Alternatively, GPCs are known mediators of multiple 
neuroregulatory signalling pathways, including those mediated by FGFs, Wnts and 
Shh (Fico et al., 2011; Filmus et al., 2008; Hu et al., 2016; Iwata & Hevner, 2009; 
Lie et al., 2005).  Thus the high expression of GPC1 and GPC4 in hNSC-derived 
neuronal cultures suggest these GPCs may also have roles in mediating the activity 
of various signalling pathways to modulate human neurogenesis.  
 
The results of this study also demonstrated that GPC1 and GPC4 mediate hNSC 
neuronal differentiation lineage potential.  Downregulation of GPC1 and GPC4 gene 
expression under basal and neuronal differentiating hNSC H9 cultures resulted in the 
downregulated expression of neuronal lineage markers, including TUBB3, MAP2, 
NEFM and DCX (Chapter 5: section 5.3.4 and Chapter 7: section 7.5.3, (Oikari et al., 
  
Chapter 8: Discussion and Future Directions 375 
2016b)). As such these results confirm the associative relationship of GPC1 and 
GPC4 with neuronal markers and suggest that these HSPGs are required for neural 
lineage commitment hNSCs. Likely, GPC1 and GPC4 expression is required for 
human neurogenesis, revealing important regulatory mechanisms of human nervous 
system biology.  
 
Along with GPC1 and GPC4 expression, the results of this study also demonstrate 
that the BDNF receptor Trkb and the PDGF receptor PDGFRβ are expressed in 
hNSC-derived neuronal cultures displaying very different expression patterns 
(Chapter 7: sections 7.5.2.1 and 7.5.2.2). Interestingly, Trkb was shown to be highly 
expressed in hNSC H9-derived neuronal cultures, demonstrating a similar 
localisation pattern to GPC1 and GPC4 (Chapter 7: section 7.5.2.1). With the known 
roles of GPCs functioning as co-receptors (Fico et al., 2011; Filmus et al., 2008), it is 
plausible that there is direct interaction between GPC1/4 and Trkb in these cells. 
Interestingly, the hNSC H9-derived neuronal cultures demonstrated heterogeneous 
PDGFRβ expression, with its expression not detected in all examined cells (Chapter 
7: section 7.5.2.2). It is thus likely that the activity of Trkb signalling is more 
important in hNSC-derived neuronal differentiating cultures, with PDGFRβ+ cells 
likely representing their own specific pool of cells, possibly exhibiting a differential 
differentiation status to the PDGFRβ-negative cells. Interestingly, two types of 
PDGFRβ+ cells were observed in the hNSC H9-derived neuronal cultures, with the 
majority of these cells appearing morphologically neuron-like (nuclear PDGFRβ 
expression) and others appearing non-neuron like (cell surface/cytoplasmic PDGFRβ 
expression) (Chapter 7: section 7.5.2.2). The neuron-like PDGFRβ+ cells likely 
represent neuronal cells of a different maturity status with the non-neuron-like cells 
potentially representing the pool of self-renewing cells (Funa & Sasahara, 2014; G. 
Xu et al., 2013).  
 
The results of this study suggest a potential interaction between GPC1 and GPC4 and 
the BDNF and PDGF pathways. This is supported by evidence of altered BDNF and 
PDGF signalling following GPC1 and GPC4 knockdown (KD) in hNSC H9 cells, 
suggesting GPC1 and GPC4 are required for fully activated BDNF and PDGF 
signalling (Chapter 7: section 7.5.3). Interestingly, downregulation of GPC1 and 
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GPC4 resulted in the upregulated expression of both Trkb and PDGFRβ, which may 
be a compensatory response by the cells to reduced activity of these pathways as a 
result of reduced GPC expression (Chapter 7: section 7.5.3).  Most notably, 
following GPC1 and GPC4 KD the stimulatory effects of BDNF and PDGF 
supplementation on the BDNF ligand and Trkb receptor gene expression was lost, 
suggesting the BDNF and PDGF ligands are not able to exert their full effects 
without basal levels of GPC1 and GPC4 expression (Chapter 7: section 7.5.3).  In 
addition, BDNF and PDGF supplementation elicited effects on neuronal marker 
expression in GPC1 and GPC4 KD cultures that were not observed in control 
cultures (Chapter 7: section 7.5.3), suggesting basal GPC1 and GPC4 expression is 
also required for modulating the effects of BDNF and PDGF on the cells.  
 
To further elucidate the importance of the BDNF and PDGF pathways during hNSC 
neuronal lineage commitment, with possible correlations to the GPC1 and GPC4 KD 
experiments, neuronal differentiating hNSC H9 cells were also examined in the 
presence of a Trkb inhibitor ANA-12 and PDGFRβ inhibitor Tyrphostin AG-1295 
(Chapter 7: section 7.5.4). The results obtained, however, indicated that the 
inhibition of Trkb signalling was not achieved through ANA-12, thus these results 
could not be reliably analysed (Chapter 7: section 7.5.4), however, the obtained 
results do suggest that AG-1295 may have inhibited the PDGFRβ pathway, indicated 
by altered PDGF signalling (Chapter 7: section 7.5.4). Of interest, the PDGFRβ 
inhibition resulted in decreased GPC1, GPC4 and MAP2 gene expression with a 
similar trend also observed for DCX expression, correlating with results observed 
following GPC1 and GPC4 KD (Chapter 7: sections 7.5.3 and 7.5.4). This data 
suggests that reduced PDGFRβ signalling results in decreased GPC expression along 
with an altered neuronal differentiation potential of hNSCs. As these results are 
preliminary, more investigation is required to unravel the specific mechanisms 
behind the PDGF-GPC axis mediating hNSC neuronal commitment. Further 
optimisation of ANA-12 and AG-1295 inhibitor concentrations and timing is 
required to elicit full inhibition of BDNF and PDGF signalling and confirm any 
associative relationship with GPC1 and GPC4.  
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8.4 FUTURE DIRECTIONS 
 
This study successfully examined hNSCs during in vitro basal expansion as well as 
during neuronal lineage differentiating conditions and identified that HSPGs are 
associated with basal hNSCs and lineage committing neural cells, proposing several 
HSPGs as novel markers of human neural cell characterisation. To examine whether 
HSPGs are involved in hNSC lineage fate regulation, generating stable knockouts of 
key HSPGs in several hNSC lines (hNSC H9, ReN CX and nhNPCs) using CRISPR 
or lentiviral transfection will identify whether HSPG depletion will allow the cells 
proceed down neural cell lineages (Yang & West, 2016). In addition, although 
neuronal differentiation of hNSC H9 cells was achieved at a desirable level, the 
efficiency of astrocyte lineage differentiation remains questionable and the astrocyte 
lineage differentiation protocol used in this study requires further optimisation. As 
discussed previously (section 8.2.3), during astrocyte differentiation, passaging of 
cells was not performed, resulting in a very high cell density within the cultures. This 
may have contributed to the observed inefficient astrocyte differentiation. Passaging 
of cells along with the use of key astrocyte differentiation stimulatory growth factors, 
such as bone BMP and CNTF (Shaltouki et al., 2013) will likely improve hNSC H9 
astrocyte differentiation. In addition, the investigation of functional attributes of the 
hNSC H9-derived astrocyte cultures, including glutamate uptake (Kleiderman et al., 
2016; Tyzack et al., 2016), will be critical to confirm astrocyte lineage commitment 
of the cells. Finally, examining the subtypes of neurons and astrocytes generated 
under the conditions used in this study is critical to gain more in-depth insight into 
the neural cell lineages examined in this study and correlate the findings to in vivo 
environment. 
 
This study identified that the N- and 6-O-sulfation pattern of HS chains is likely 
important during hNSC neural differentiation, however, the role of these 
modifications during hNSC in vitro differentiation was not investigated. Further 
biochemical examination of the length and sulfation profile of HS chains produced 
by the cells during lineage-specific differentiation would reveal the exact chain 
composition associated with hNSC lineage specification. To exploit the HSPG side 
chain sulfation further, identification of the specific signalling molecules that bind to 
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these sites would be crucial and enable the more efficient control of hNSC 
differentiation, critical for downstream applications. For example, first identifying 
the sulfation sites that BDNF and PDGF preferably bind to, then generating them and 
exposing hNSCs to these HS chains could be used to enhance the downstream 
signalling activity of BDNF and PDGF to achieve more efficient lineage 
differentiation. In support of this, the requirement for N-sulfation sites for effective 
PDGF-BB signalling in the mouse model has been demonstrated (Abramsson et al., 
2007). Generating key HS-chains with a specific length and sulfation pattern could 
then potentially be applied to an in vivo system, i.e. along with hNSC transplantation, 
to enhance neurogenesis and cell survival of transplanted NSCs. In addition, 
examination of the key HSPGs of hNSC self-renewal and lineage commitment 
identified in this study in another model of human neurogenesis, including hiPSCs or 
hMSCs, would provide further confirmation of the roles of these HSPGs during 
human stem cell neurogenesis.  
 
To gain the optimal effects of heparin, BDNF and PDGF supplementation to 
modulate human neurogenesis, identifying key concentrations and timing of these 
treatments is required. A concentration of 10 μg/mL of heparin was used in this 
study, however, several studies in the human and mouse systems have described the 
use of a lower concentrations of heparin (10-100 ng/ml to 2-5 μg/mL) to induce stem 
cell differentiation (Forsberg et al., 2012; Ghadiali et al., 2016; Holley et al., 2011; 
Pickford et al., 2011; Zhang & Zhang, 2010). In addition, a concentration of 10 
ng/mL of BDNF and PDGF was used, which has previously been described in the 
literature to elicit neural responses (D'Aiuto et al., 2014; Hermann et al., 2004; Miura 
et al., 2015). However, some studies suggest that a higher concentration (40 – 100 
ng/mL) of these growth factors is required to elicit beneficial effects on neuronal 
differentiation (Fujii et al., 2015; Li et al., 2009; Wei et al., 2015; Yang et al., 2015; 
Yao et al., 2012). A more detailed dose-response experiment on neuronal 
differentiating hNSC H9 cells testing various concentrations of these growth factors 
would identify the optimal concentration for improved neuronal differentiation in 
these cells. In addition, the results of this study suggest that the timing of 
administration of these growth factors is likely critical. As discussed previously 
(section 8.3), BDNF supplementation may be more beneficial when administered at 
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the early stages of neuronal differentiation to promote neuronal survival. However, 
as BDNF does not appear to enhance neuronal lineage specificity, its withdrawal 
following induction of differentiation will likely result in a more homogeneous 
neuronal population. Additionally, only four neuronal lineage markers (TUBB3, 
MAP2, NEFM and DCX) were examined in this study. The incorporation of other 
neuron subtype-specific markers, i.e. dopaminergic, GABAergic or glutamatergic 
markers will enable the identification of the neuron subtype composition of the 
hNSC H9-derived neuronal cultures. This is critical when the aim is to establish 
protocols for neuron subtype-specific differentiation. In addition, this study 
examined neuronal functionality via the examination of spontaneous Ca2+ signals 
within the cultures, previously shown to occur in the rodent model (Hemstapat et al., 
2004; Pacico & Mingorance-Le Meur, 2014). However, using the “gold standard” 
method, patch-clamp assay, in addition to monitoring the Ca2+ signals in the cultures 
to assess the functionality will more accurately identify the presence of action 
potential evoking neurons within hNSC H9-derived neuronal cultures. The 
examination of Ca2+ signalling in astrocytes is also crucial to confirm that the signals 
generated in hNSC H9-derived neuronal cultures are neuron-lineage specific and not 
associated with hNSC differentiation in general. 
 
With promising and interesting results gained in this study regarding GPC1 and 
GPC4 as key proteins of human neurons, identification of their specific roles within 
these cells will markedly increase our understanding of human neural cell biology. In 
addition, to further examine if GPC1 and GPC4 are required for human 
neurogenesis, the generation of a stable knockout of GPC1 and GPC4 in hNSCs, as 
discussed in an earlier paragraph, followed by extended neuronal differentiation 
would enable the investigation if these HSPGs are indeed mediators of hNSC 
neurogenesis. In addition, an interesting avenue of further research would be the 
identification of GPC1 and GPC4 interaction with BDNF and PDGF or their 
receptors and subsequent modulation of the activity of these pathways. Studies to 
examine the co-localisation of GPC1/4 along with Trkb and PDGFR would reveal 
potential interactions. In addition, complete BDNF and PDGF pathway inhibition 
through specific inhibitors (ANA-12 and AG-1295) was not successfully achieved in 
this study. Further optimisation of the specific concentrations and timing of ANA-12 
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and AG-1295 exposure is critical to successfully elicit the inhibition of these 
pathways to enable further investigation of their roles in hNSC neurogenesis and any 
correlations with GPC1 and GPC4 KD.  
 
This study demonstrated the importance of HSPGs as regulators and novel markers 
of hNSCs and neural lineage specificity, and the establishment of methods targeting 
HSPGs to enhance hNSC control is a key area of novel research. Due to their 
localisation within the cell microenvironment, HSPGs may provide an easy-to-access 
target for translational purposes. This may include their use in the more efficient 
isolation of hNSCs or lineage-specific neural cells or by enhancing growth factor 
signalling through HSPG-growth factor interactions. The cell line used in this study, 
hNSC H9, is not suitable for cell transplantation, due to its derivation from ESCs, 
however, it provides a key model of human stem cells and their therapeutic potential. 
These include hiPSCs or hMSCs, which can be derived from the patient and as such 
can be used for autologous transplantation.  The hNSC H9 model established in this 
study provides a basis for understanding HSPG regulation in the human neural niche 
which can be applied to the development of cell transplantation techniques for the 
treatment of brain damage. 
 
8.5 SUMMARY  
 
The aim of this project was to investigate the roles of proteoglycans, specifically 
HSPGs, in mediating hNSC maintenance and lineage specification. The results of 
this project demonstrate that hESC-derived NSCs (hNSC H9 cells) provide an 
excellent in vitro model of self-renewing and multipotent NSCs. Their high 
expansive and neuronal differentiation potential make them an excellent model to 
investigate the processes of self-renewal and neurogenesis. Importantly, this study 
demonstrated that HSPGs function as novel markers of basal and lineage 
differentiating hNSCs with these cell types distinguishable from each other based on 
their combined marker and HSPG profile. HSPGs, specifically GPCs, not only 
function as markers of neural cells but also mediate neuronal differentiation potential 
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of hNSC. In addition, differences in the N- and 6-O-sulfation pattern of HS chains 
appear to be critical during hNSC neuronal differentiation. 
 
This study demonstrated that hNSC H9 neuronal differentiation can be modulated 
through the addition of exogenous HS in the form of heparin and key 
neuroregulatory signalling molecules, including BDNF and PDGF. In addition, the 
actions of BDNF are enhanced when combined with heparin. This study 
demonstrated, that approximately 60 days of hNSC H9 neuronal differentiation is 
required for the generation of functioning neurons as indicated by the occurrence of 
spontaneous Ca2+ signals in these cultures. BDNF and BDNF+heparin have positive 
effects on the survival of neuronal differentiating hNSC H9 cultures with PDGF 
having a positive effect on neuronal specificity. The sequential administration of 
these growth factors may be beneficial for optimal efficiency of neurogenesis.  
 
GPC1 and GPC4 are human neuronal proteins expressed along the neurites and cell 
bodies of developing human neurons. GPC1 and GPC4 demonstrate an associative 
relationship with the expression of neuronal lineage markers, indicating they are 
required for full neuronal lineage differentiation potential of hNSCs. In addition, 
GPC1 and GPC4 likely play a role in modulating BDNF and PDGF signalling during 
human neurogenesis. Further investigation of the mechanisms behind these 
interactions will provide novel targets for enhanced control hNSC lineage specificity. 
The findings of this study have improved our understanding of human neural cell 
regulation and the role of HSPGs in mediating numerous neural events, including 
self-renewal and lineage specification. This knowledge will benefit the field of 
human stem cells, HSPGs and human neurogenesis and provide targets and novel 
approaches to enable the development of improved hNSC-related applications, 
including cell therapy. 
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Appendices 
 
APPENDIX A: CELL CULTURE MEDIA RECIPES 
 
Table A1: Neural stem cell serum free medium (NSC SFM) 
Component Concentration Amount 
KnockOutTM DMEM/F-12* 1X 500 mL 
GlutaMAXTM-I Supplement* 2 mM 5 mL 
bFGF* 20 ng/mL 10 µg 
EGF* 20 ng/mL 10 µg 
StemPro® Neural Supplement* 2% 10 mL 
*Obtained from Thermo Fisher Scientific 
 
Table A2: Neural progenitor maintenance media  (NPMMTM) 
Component Concentration Amount 
NP Basal Medium* 1X 200 mL 
rh-FGF*  0.4 mL 
rh-EGF*  0.4 mL 
Neural Survival Factor-1*   
Gentamicin/Amphotericin*   
*Obtained from Lonza 
 
Table A3: hNSC H9 neuronal differentiation medium 
Component Concentration Amount 
Neurobasal® Medium* 1X 500 mL 
GlutaMAXTM-I Supplement* 2 mM 5 mL 
B-27 Serum-Free Supplement* 2% 10  mL 
*Obtained from Thermo Fisher Scientific 
 
Table A4: hNSC H9 astrocyte differentiation medium 
Component Concentration Amount 
DMEM* 1X 500 mL 
GlutaMAXTM-I Supplement* 2 mM 5 mL 
N-2 Supplement* 2% 10 mL 
Fetal bovine serum (FBS)** 1% 5 mL 
*Obtained from Thermo Fisher Scientific 
** Obtained from  
 
Table A5: hNSC H9 oligodendrocyte differentiation medium 
Component Concentration Amount 
Neurobasal® Medium* 1X 500 mL 
GlutaMAXTM-I Supplement* 2 mM 5 mL 
B-27 Serum-Free Supplement* 2% 10  mL 
T3** 30 ng/mL 0.5 mL of 1000x stock 
*Obtained from Thermo Fisher Scientific 
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*Obtained from Sigma 
 
Table A6: Accell siRNA Delivery Media for hNSC H9 maintenance 
Component Concentration Amount 
Accell siRNA Delivery Medium* 1X  
bFGF** 20 ng/mL  
EGF** 20 ng/mL  
StemPro® Neural Supplement** 2%  
siRNA* 1 µM  
* Obtained from GE Dharmacon  
** Obtained from Thermo Fisher Scientific 
 
Table A7: Accell siRNA Delivery Media for hNSC H9 neuronal differentiation 
Component Concentration Amount 
Accell siRNA Delivery Medium* 1X  
B-27   
   
 2  
siRNA* 1 µM  
* Obtained from GE Dharmacon  
** Obtained from Thermo Fisher Scientific 
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APPENDIX B : RNA EXTRACTION (DIRECT-ZOLTM RNA MINIPREP KIT, 
ZYMO RESEARCH) AND IN-COLUMN DNASE TREATMENT 
 
Perform all centrifugation steps at 10,000 x g unless stated otherwise. 
 
1. Add one volume 100% ethanol to one volume of sample homogenate (1:1) in 
TRIzol Reagent. Mix well by vortexing.  
2. Load the mixture into a Zymo-SpinTM IIC Column in a collection tube and 
centrifuge for 1 min. Transfer the column into a new collection tube and 
discard the collection and the flow-through. 
3. Add 400 µL RNA Wash Buffer to the column and centrifuges for 1 min. 
Discard the flow-through. 
4. Prepare the DNase I cocktail: 
 
Old recipe:    Individual reaction: 
DNase I (250 U/vial; lyophilized) 5 µL 
10X DNase I Reaction Buffer 8 µL 
DNase/RNase-Free Water  3 µL 
RNA Wash Buffer   64 µL 
 
New recipe:    Individual reaction: 
DNase I (250 U/vial; lyophilized) 5 µL 
DNA Digestion Buffer  75 µL 
 
5. Add 80 µL of the DNase I cocktail directly to the matrix of the column and 
incubate at room temperature for 15 min. Then centrifuge for 30s. 
6. Add 400 µL of RNA PreWash Buffer to the column and centrifuge for 1 
min. Discard the flow-through. Repeat this step.  
7. Add 700 µL of RNA Wash Buffer to the column and centrifuge for 1 min. 
Discard the flow-through. Centrifuge the column for an additional 2 min in an 
emptied collection tube to ensure complete removal of the wash buffer.  
8. Transfer the column into an Eppendorf Tube and add 30 µL of 
DNase/RNase-Free Water directly to the column matrix and centrifuge at 
max speed for 1 min.  
9. Transfer the RNA to an O-ring tube for storage and store at -80°C. Measure 
quality and quantity or RNA by NanoDrop. 
 
 
 
  
 408 Appendices 
APPENDIX C: PRIMER SEQUENCES 
 
Table C1: Primer sequences of neural genes 
* Wu et al. (2012) Regulation of glioblastoma multiforme stem-like cells by inhibitor of DNA binding 
proteins and oligodendroglial lineage-associated transcription factors. Cancer Sci, 103(6): 1028-37 
** Samsonraj et al. (2013) Telomere length analysis of human mesenchymal stem cells by 
quantitative PCR. Gene.  519(2): 348-55. 
*** Ovchinnikov et al.(2013) Transgenic human ES and iPS reporter cell lines for identification and 
selection of pluripotent stem cells in vitro. Stem Cell Res. 12(2):251-61. 
 
Gene Symbol Forward primer Reverse primer RefSeq 
18S Ribosomal  5 RNA 18S TTCGAGGCCCTGTAATTGGA GCAGCAACTTTAATATACGC
TATTGG 
NR_003286.2 
CD44 CD44 AGCAACTGAGACAGCAACCA 
 
AGACGTACCAGCCATTTGTG
T 
 
NM_000610.3 
Doublecortin Dcx TATGCGCCGAAGCAAGTCTC TACAGGTCCTTGTGCTTCCG NM_178152.2 
Enolase 2 ENO2 TGCACAGGCCAGATCAAGAC ACAGCACACTGGGATTACG
G 
NM_001975.2 
Forkhead box A2 FOXA2 CTGGTCGTTTGTTGTGGCTG GGAGGAGTAGCCCTCGG NM_021784.4 
*Galactosylceramidase GalC GCCAAGCGTTACCATGATTT TTTCACTCGCTGGAGACCTT NM_001201402.1 
Glial Fibrillary Acidic 
Protein 
GFAP GAGGTTGAGAGGGACAATCTGG GTGGCTTCATCTGCTTCCTG
TC 
NM_002055.4 
**Human telomerase hTERT GACGTGGAAGATGAGCGTG 
 
GACGACGTACACACTCATC 
 
NM_001193376.1 
NM_198253.2 
Microtubule 
Associated Protein 2 
MAP2 GACTGCAGCTCTGCCTTTAG AAGTAAATCTTCCTCCACTG
TGAC 
NM_002374.3 
Mushahi I MSI I TGACCAAGAGATCCAGGGGT CGATTGCGCCAGCACTTTAT NM_002442.3 
Nanog homeobox NANOG ACCTCAGCTACAAACAGGTGAA AAAGGCTGGGGTAGGTAGG
T 
NM_024865.2 
Nestin NES CTCAGCTTTCAGGACCCCAA GTCTCAAGGGTAGCAGGCA
A 
NM_006617.1 
Neurofilament M NEFM TGCAGTCCAAGAGCATCGAG GGATGGTGTCCTGGTAGCTG NM_005382.2 
Neurogenin 2 NEURO
G2 
AGAGCCAACTAAGATGTTCGTC
A 
CGATCCGAGCAGCACTAAC
A 
NM_024019.3 
*Oligodendrocyte 
transcription factor 1 
OLIG1 GTCATCCTGCCCTACTCAGC CTGCCCAGCAGTAGGATGT
AG 
NM_138983.2 
*Oligodendrocyte 
transcription factor 2 
OLIG2 GACAAGCTAGGAGGCAGTGG CGGCTCTGTCATTTGCTTCT NM_005806.3 
POU Class 5 
homeobox 1 (OCT3/4) 
OCT3/4 ATCTTCAGGAGATATGCAAAGC
AGA 
TGATCTGCTGCAGTGTGGGT NM_002701.4 
SRY box 1 SOX1 CAACCAGGACCGGGTCAAAC CCTCGGACATGACCTTCCAC NM_005986.2 
*SRY box 2 SOX2 CCACCTACAGCATGTCCTACTC
G 
 
GGGAGGAAGAGGTAACCAC
AGG 
 
NM_003106.3 
S100 Calcium binding 
protein B 
S100B TTCTGGAAGGGAGGGAGACA CTCCTGCTCTTTGATTTCCTC
T 
NM_006272.2 
Vimentin VIM GGACCAGCTAACCAACGACAAA 
 
CGCATTGTCAACATCCTGTC
TG 
 
NM_003380.3 
 
βIII Tubulin TUBB3 GGCCAAGTTCTGGGAAGTCAT CTCGAGGCACGTACTTGTGA NM_06086.3 
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Table C2: Primer sequences of proteoglycan-associated genes 
Gene Symbol Forward primer Reverse primer RefSeq 
Aggrecan AGG TGCATTCCACGAAGCTAACCTT CGCCTCGCCTTCTTGAAATGT NM_001135 
C5-Epimerase C5-EP AGCTGTCAAGCCAACCAAAATA
A 
CTTACTAGCCAATCACTAGCA
GCAA 
AY635582 
carbohydrate 
(chondroitin 6) 
sulfotransferase 3 
CHST3 GGTTTTTGTGGTGATAGTTTTTG
TCTT 
GCTGGGTCGGTGCTGTTG NM_004273 
carbohydrate 
(chondroitin 4) 
sulfotransferase 11 
CHST11 CTGCTGGAAGTGATGAGGATGA GATGTCCACACCAAAGGGATT
C 
NM_018413 
Decorin DCN TCCTGATGACCGCGACTT GAGTTGTGTCAGGGGGAAGA NM_001920.3 
Exostose 1 EXT1 TGACAGAGACAACACCGAGTAT
GA 
GCAAAGCCTCCAGGAATCTGA
AG 
NM_000127.2 
Exostose 2 EXT2 CAGTCAATTAAAGCCATTGCCC
TG 
GGGATCAGCGGGAGGAAGAG NM_000401 
Glypican 1 GPC1 GGACATCACCAAGCCGGACAT GTCCACGTCGTTGCCGTTGT NM_002081 
Glypican 2 GPC2 TGATCAGCCCCAACAGAGAAA CCACTTCCAACTTCCTTCAAACC NM_152742 
Glypican 3 GPC3 GATACAGCCAAAAGGCAGCAA GCCCTTCATTTTCAGCTCATG NM_004484. 
Glypican 4 GPC4 GGTGAACTCCCAGTACCACTTTACA 
GCTTCAGCTGCTCCGTATACT
TG NM_001448 
Glypican 5 GPC5 GCTCACCTCAATGGACAAAAATT GTTGGCAAGCGTCTCTTCACT NM_004466 
Glypican 6 GPC6 CAGCCTGTGTTAAGCTGAGGTTT 
GATGTGTGTGCGTGGAGGTAT
GT NM_005708. 
Heparanase HPSE TCACCATTGACGCCAACCT CTTTGCAGAACCCAGGAGGAT NM_006665.5 
Heparan sulfate 2-O 
sulfotransferase 1 
HS2ST1 TCCCGCTCGAAGCTAGAAAG CGAGGGCCATCCATTGTATG NM_012262 
Heparan sulfate 6-O 
sulfotransferase 1 
HS6ST1 AGCGGACGTTCAACCTCAAGT GCGTAGTCGTACAGCTGCATG
T 
NM_004807 
Heparan sulfate 6-O 
sulfotransferase 2 
HS6ST2 TCTGGAAAGTGCCAAGTCAAAT
C 
ATGGCGAAATAAAGTTCATGT
TGAA 
NM_147175 
Heparan sulfate 6-O 
sulfotransferase 3 
HS6ST3 ACATCACGCGGGCTTCTAACGT GGCGGTCCCTCTGGTGCTCTA NM_153456 
N-deacetylase/N-
sulfotransferase 1 
NDST1 TGGTCTTGGATGGCAAACTG CGCCAAGGTTTTGTGGTAGTC NM_001543 
N-deacetylase/N-
sulfotransferase 2 
NDST2 CCTATTTGAAAAAAGTGCCACC
TACT 
GCAGGGTTGGTGAGCACTGT NM_003635 
N-deacetylase/N-
sulfotransferase 3 
NDST3 ACCCTTCAGACCGAGCATACTC CCCGGGACCAAACATCTCTT NM_004784 
N-deacetylase/N-
sulfotransferase 4 
NDST4 ATAAAGCCAATGAGAACAGCTT
ACC 
GGTAATATGCAGCAAAGGAG
ATTGA 
NM_022569 
Perlecan PER TGGACACATTCGTACCTTTCTGA CCTCGGACACCTCTCGAAACT NM_005529 
Syndecan 1 SDC1 CTGGGCTGGAATCAGGAATATT
T 
CCCATTGGATTAAGTAGAGTT
TTGC 
BC008765.2 
Syndecan 2 SDC2 AGCTGACAACATCTCGACCACT
T 
GCGTCGTGGTTTCCACTTTT NM_002998.3 
Syndecan 3 SDC3 CTTGGTCACACTGCTCATCTATC
G 
GCATAGAACTCCTCCTGCTTG
TC 
AF248634 
Syndecan 4 SDC4 CCACGTTTCTAGAGGCGTCACT CTGTCCAACAGATGGACATGC
T 
BC030805.1 
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Versican  VCN TGGAATGATGTTCCCTGCAA AAGGTCTTGGCATTTTCTACA
ACAG 
NM_004385.4 
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APPENDIX D: WESTERN BLOTTING BUFFERS AND ASSAY PROTOCOL 
 
Table D1: Protein lysis buffer (50 mL) 
Component Concentration Amount 
Hepes 20 mM 100 µL of 0.1 M Stock 
Glycerol 25% 12.5 mL 
MgCl2 1.5 mM 750 µL of 0.1 M Stock 
NaCl 420 mM 21 mL of 1 M Stock 
DTT 0.5 mM 250 µL of 0.1 M Stock 
EDTA 0.2 mM 100 µL of 0.1 M Stock 
Igepal 0.5 % 250 µL 
PMSF 1:100 500 µL in 50 mL lysis buffer 
Na3VO4 0.2 mM 100 µL of 0.1 M Stock 
H2O  To 50 mL (~ 15 mL) 
Note: proteinase/phosphatase inhibitors to be added prior use 
 
Table D2: 6X SDS loading dye 
Component Concentration Amount 
Tris-HCL, pH 6.8 0.5 M 7 mL 
SDS 10% 1 G 
Glycerol 28% 3 mL 
Bromophenol blue  1.2 mG 
β-Mercaptoethanol  6 mG 
 
Table D3: 10X Running buffer (1 litre) 
Component Amount 
Glycine 144g 
SDS 10 G 
Tris-Base 30 G 
H2O To 1 litre 
 
Table D4: 5X Transfer buffer (2 litres) 
Component Amount 
Glycine 150g 
Tris-Base 30 G 
H2O To 2 litres 
Add 20% MeOH to working solution (1/5 transfer buffer, 1/5 MeOH and 3/5 H2O). 
 
Table D5: Protein stripping buffer (500 mL) 
Component Amount 
Glycine 7.5 G 
SDS 0.5 G 
Tween-20 5 mL 
H2O To 500 mL 
Instructions: bring volume to 400 mL with H2O, bring pH to 2.2 with HCL, bring 
final volume to 500 mL with H2O. 
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Table D6: 10X TBS (Tris-buffered saline) (1 litre) 
Component Amount 
Tris-Base 24 G 
NaCl 88 G 
Instructions: dissolve in 900 mL H2O, bring pH to 7.6, bring final volume to 1 litre 
with H2O. 
 
Table D7: 1X TBST 
Component Concentration Amount 
10X TBS 1/10 100 mL 
H2O 9/10 900 mL 
Treen-20 0.1% 1 mL 
 
Protein sample preparation: 
1. Lyse cell pellet sample in protein lysis buffer (Table. X) 
2. Vortex samples 3X 15s. Rest samples on ice between vortexing. 
3. Sonicate samples 30s ON/30s OFF on HIGH for 5 cycles. 
4. Centrifuge samples at max speed for 20 min at 4°C. 
5. Quantitate protein concentration.  
 
BCA protein concentration assay (Pierce): 
1. Prepare diluted Albumin (BSA) standards in PBS: 
A. 2 mg/ml 
B. 1.5 mg/ml 
C. 1 mg/ml 
D. 0.75 mg/ml 
E. 0.5 mg/ml 
F. 0.25 mg/ml 
G. 0.125 mg/ml 
H. 0.025 mg/ml 
I. 0 mg/ ml (blank=PBS) 
2. Pipette 25 μL of each standard or unknown sample in replicates into a 96-
well plate (if sample size is limited, 10 μL of standard and sample can be 
used). 
3. Add 200 μL of the working reagent (WR) into each well. To prepare WR, 
mix 50 parts of BCA Reagent A and 1 part of Reagent B (50:1, A:B).  
4. After adding WR to wells, mix plate thoroughly, cover plate and incubate at 
37°C for 30 min.  
5. Cool plate to RT and measure absorbance at 562 nm on a plate reader or 
NanoDrop.  
 
SDS-PAGE: 
1. Combine 20 – 50 μG of protein sample with 1:6 6X loading dye and boil 
sample for 5 min at 95°C. Spin down. 
2. Assemble gel tank and fill it with 1X running buffer. Load 5 uL of protein 
ladder (PageRuler Plus Prestained Protein Ladder from Thermo Fisher 
Scientific) and  all of protein sample into a 12% Mini-PROTEAN®TGX™ 
gel (Bio-Rad). 
3. Run gel at constant V (150 V) until loading dye has run off the edge of gel 
(approx. 1 – 1.5 h).  
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Protein transfer: 
1. Transfer protein onto a PVDF membrane (0.2 μM) using Bio-Rad Trans-Blot 
system (e.g. 1.5 mm gel, 10 min program). 
2. Pre-pack transfer pack: follow instructions on packet how to assemble 
transfer “sandwich”. Carefully place gel onto membrane and remove air 
bubbles. 
3. Self-made transfer packs: 
i) “Activate” PVDF membrane for 20s in MeOH, rinse in for 2min in Milli-
Q-H2O 
ii) Soak filter papers and membrane for 5-10min in 1X transfer buffer 
iii) Rinse gel quickly in transfer buffer 
iv) Assemble: filter paper + membrane + gel + filter paper in transfer system 
 
Blocking and blotting membrane (complete steps on plate shaker): 
1. After transfer, carefully cut off excess parts of membrane and transfer 
membrane into a 50 ml Falcon tube or staining dish. Quickly rinse membrane 
with TBST or PBST (TBS or PBS + 0.1 – 0.5 % Tween) 
2. Block membrane for 1h at RT with 5% non-fat milk or 5% BSA made in 
TBST or PBST. If using BSA, filter it before use. 
3. Add 1° antibody in appropriate concentration (usually 1:500 – 1:1000) in 5 % 
milk or 5% BSA in TBST or PBST and incubate over night at 4°C. After use, 
antibody dilutions can be collected, stored in -20 °C and used again. 
4. The following day remove 1° antibody and wash membrane 3X 5 min with 
TBST or PBST 
5. Add 2° antibody in appropriate concentration (1:3000 – 1:5000) in 5% milk 
or 5% BSA in TBST or PBST and incubate for 2 h at RT 
6. Wash membrane 3 x 5 min with TBST or PBST and do a final 5 min wash 
with TBS or PBS (no Tween  less background).  
7. Detect membrane using ECL reagent and Fusion Fx Spectra 
chemiluminescence system. 
 
Detection of loading control: 
1. Strip membrane if necessary: 
i) Add 5 ml stripping buffer and incubate for 5 min, repeat this step 
ii) Wash membrane 3X 5 min with TBST or PBST 
iii) Block membrane for 20 min with 5% milk or 5% BSA 
2. Add 1° Ab (e.g. GAPDH) and incubate for 45 – 60 min at RT  
3. Wash membrane 3X 5 min with TBST or PBST 
4. Add 2 °Ab and incubate for 45 – 60 min at RT 
5. Wash membrane 3 X5 min with TBST or PBST 
6. Detect 
 
Loading control antibody concentrations vary. For Cell Signaling 1:1000 dilutions 
for both 1° and 2° antibodies work well. Some loading control antibodies require a 
1:10000 dilutions as they come up very strongly. If using HRP-conjugated β-actin 
loading control, no 2° antibody incubation is necessary. 
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Figure D1: PageRuler Plus Prestained Protein Ladder. Image obtained from 
www.thermofisher.com 
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Figure D2: Representative Western blot images indicating size of proteins studied in hNSC H9 
cells. Western blot analysis of A) SOX2 (40 kDa), B) TUBB3 (55 kDa), C) CD44 (60 kDa),  D) 3G10 
(70 kDa, 35 kDa and 15 kDa), E) MAP2 (90 kDa), F) GAPDH (35 kDa), G) Trkb (100 kDa, 55 kDa 
and 40 kDa) and H) S100B (11 kDa). PageRuler Plus Prestained Protein Ladder (Thermo Fisher 
Scientific) used as a reference. 
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APPENDIX E: IMMUNOFLUORESCENCE AND CONFOCAL 
MICROSCOPY PROTOCOL AND NEGATIVE CONTROLS 
 
Immunocytochemistry  
 
1. Culture cells on CC2-coated chamber slides or 24- or 48-well plates with or 
without cover slips. 
2. Aspirate growth medium and rinse cells with PBS containing Ca2+ and Mg2+. 
3. Fix cells with 2.5 – 4% PFA for 30 min at RT. 
4. Block cells for 1 – 2h at RT with blocking solution. 
 
Permeabilising blocking solution: 
Normal Donkey Serum 5% 
BSA      1% 
Triton-X     0.1% 
made in PBS containing Ca2+ and Mg2+ 
 
Non-permeable blocking solution: 
            Normal Donkey Serum 5% 
BSA      1% 
made in PBS containing Ca2+ and Mg2+ 
 
5. Remove blocking solution and incubate primary antibodies diluted in 
blocking solution over night at 4°C. 
6. The following day remove primary antibodies and rinse cells 3X 5 min with 
PBS containing Ca2+ and Mg2+. 
7. Add secondary antibodies diluted in blocking solution and incubate for 1 – 2h 
at room temperature in the dark. 
8. Rinse cells 3X 5min with PBS containing Ca2+ and Mg2+. 
9. Mount cells with DAPI and place coverslips on cells. 
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Figure E1: Representative immunofluorescence images of isotype negative controls in hNSC H9 
P5 cultures.  Phase-contrast (10X magnification, scale bar 140 μM), DAPI counterstain (blue) and 
immunofluorescent detection of A) mouse IgG (MIgG) (FITC/green), B) rabbit IgG (RIgG) 
(Cy3/yellow) and C) mouse IgM (MIgM) (AF594/red).  
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Figure E2: Representative immunofluorescence images of secondary antibody only negative 
controls in hNSC H9 P5 cultures.  Phase-contrast (10X magnification, scale bar 140 μM), DAPI 
counterstain (blue) and immunofluorescent detection of A) FITC (green), B) Cy3 (yellow) and C) 
AF594 (red).  
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Figure E3: Representative confocal images of secondary antibody only negative controls in 
hNSC H9 P5 neuronal cultures. DAPI counterstain (blue), secondary antibody-only stain and merge 
phase-contrast image (63X magnification, scale bar 50 μM) of A) FITC, B) Cy3 and C) AF594.  
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APPENDIX F: FLUO-4 CALCIUM ASSAY PROTOCOL 
 
Kit: Fluo-4 DirectTM calcium assay starter pack (Thermo Fisher Scientific 
cat#F10471) 
Materials required but not provided: 
o Poly-D-Lysine or Poly-L-ornithine/laminin coated 96-well plates 
o For high-throughput kit:  
 1X HBSS (Invitrogen cat#14025-092) 1.5 l 
 I M HEPES (Invitrogen cat# 15630-106) 
Notes: 
o Prepare reagents on the day you perform the assay. Ensure that 
components A and B are completely dissolved when making the 
reagent solutions. 
o The quantity of component A is enough for 2 microplates at a time 
o When following the directions below the calcium assay reagent 
solution is at 2X concentration (add to culture medium 1:1). If you 
plan to remove culture medium completely, dilute the calcium assay 
reagent to 1X with culture medium or assay buffer.  
o Fluo-4 calcium assay reagent solution made from component A can 
be frozen for up to 7 days at -20 °C. 
 
Experimental protocol for adherent cells: 
o Culture adherent cells in a 96- or 384-well plate to near confluence.  
 
Preparing reagents: 
1. Prepare 250 mM stock solution of probenecid by adding 1 mL of 
Fluo-4 DirectTM calcium assay buffer (component C) to each of the 77 
mg vial of water-soluble probenecid (component B). Vortex until 
dissolved. Unused stock solution can be stored at -20 °C for up to 6 
months.  
2. Prepare the 2X Fluo-4 DirectTM calcium reagent for the starter pack 
(cat# FI0471) as follows: Add 10 mL of Fluo-4 DirectTM calcium 
assay buffer (component C) OR low MgCl2 HBSS (HBSS containing 
2 mM CaCl2, 0.1 mM MgCl2 and 20 mM Hepes), and 200 ul of 250 
mM probenecid stock solution to one bottle Fluo-4 DirectTM calcium 
reagent (component A). This solution is sufficient for 2 microplates.  
3. If needed, prepare solutions of the receptor ligands in Fluo-4 DirectTM 
calcium assay buffer (component C) without probenecid. 
 
Performing the assay: 
1. Remove cells from the incubator and add an equal volume of 2X 
Fluo-4 DirectTM calcium reagent directly to wells containing cells in 
culture medium (or remove culture medium and add 1X Fluo-4 
DirectTM calcium reagent to cells). E.g. add 50 ul of Fluo-4 DirectTM 
calcium reagent to 50 ul of growth medium per well in a 96-well 
plate.  
2. Incubate plates at 37 °C for 60 min. Allow plates to cool down to 
room temperature before imaging (in Pacico et al. 2014 Fluo-4 was 
removed before imaging and replaced by HBSS (with or without CaCl 
and MgCl) for imaging) 
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Imaging on the plate reader (from Pacico & Mingorancel 2014 ) 
• Temperature: 24 °C 
• Wavelengths: excitation 485 nm, emission 525 nm (note: protocol provided with 
the kit recommends 494 nm excitation). Cut off at 515 nm.  
• Recording time: 600 s with intervals of 0.8 s.  
• Photomultipliers set at high and 6 reads per well (allowing for recording of 4 
wells (in one column) at a time).  
• Fluorescence intensity measurements every 0.8 s can be transferred to GaphPad 
Prism for presentation.  
Imaging on a fluorescent microscope (Olympus IX81 fluorescent microscope with a 
Hamamatsu C10600-10B camera) 
• Use 20X objective 
• Detect using the FITC (excitation: 490 nm, emission: 530 nm) 
• Capture images for 200 s at 0.8 s intervals (1.25 timepoints per second) 
• Obtain fluorescence intensity values using Volocity® v.6.3 software (Perkin 
Elmer) 
 
*Pacico & Mingorance-Le Meur (2014). New in vitro phenotypic assay for epilepsy: fluorescent 
measurement of synchronized neuronal calcium oscillations. PLoS One, 9(1), e84755. 
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APPENDIX G: PHASE-CONTRAST IMAGES OF hNSC H9 NEURONAL 
DIFFERENTIATING CULTURES 
 
 
Figure G1: Representative phase-contrast images of hNSC H9 P5 neuronal differentiating cells 
with or without heparin treatment. Phase-contrast images acquired at day 14 (10X magnification), 
day 36, day 50 and day 60 (4X magnification) in A) untreated and B) heparin treated neuronal 
differentiating cultures (scale bar scale bar 90 μM).  
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Figure G2: Representative phase-contrast images of hNSC H9 P5 neuronal differentiating cells 
treated with BDNF or BDNF+heparin. Phase-contrast images acquired at day 14 (10X 
magnification), day 36, day 50 and day 60 (4X magnification) in A) BDNF- and B) BDNF+heparin 
treated neuronal differentiating cultures (scale bar scale bar 90 μM).  
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Figure G3: Representative phase-contrast images of hNSC H9 P5 neuronal differentiating cells 
treated with PDGF or PDGF+heparin. Phase-contrast images acquired at day 14 (10X 
magnification), day 36, day 50 and day 60 (4X magnification) in A) PDGF- and B) PDGF+heparin 
treated neuronal differentiating cultures (scale bar scale bar 90 μM).  
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Figure G4: Representative phase-contrast images of hNSC H9 P5 neuronal differentiating cells 
treated with BDNF+PDGF or BDNF+PDGF+heparin. Phase-contrast images acquired at day 14 
(10X magnification), day 36, day 50 and day 60 (4X magnification) in A) BDNF+PDGF- and B) 
BDNF+PDGF+heparin treated neuronal differentiating cultures (scale bar scale bar 90 μM).  
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